WTC 2025

World Transplant Congress

San Francisco, USA | August 2-6

AST AMERICAN SOCIETY OF TRANSPLANTATION

ASTS American Society of Transplant Surgeons

TTS The Transplantation Society

WTC2025.ORG

2025 DIGITAL PROGRAM

Thank You to Our Partners

Diamond Level

natera™ CareDx®

Platinum Level

TransMedics® Veloxis® PHARMACEUTICALS an Asahi Kasei company

Gold Level

Bristol Myers Squibb Eledon Pharmaceuticals

eurofins | Transplant sanofi Takeda

Silver Level

ALEXION AstraZeneca Rare Disease Alnylam Apellis Biogen BRIDGE TO LIFE™ CUSTODIOL®

MERCK PARAGONIX A Getinge company Pierre Fabre Pharmaceuticals Inc. New ways to care ThermoFisher SCIENTIFIC United Therapeutics A PUBLIC BENEFIT CORPORATION XVIVO

Bronze Level

als advanced life solutions astellas CSL Vifor CTI diatiro DONOR NETWORK WEST eurobiogendx HANSA BIOPHARMA HISTOSONICS

IGL kamada EACH LIFE IS UNIQUE medsleuth NATIONAL KIDNEY FOUNDATION 75 YEARS iMDx OrganOx Organ Recovery systems PIRCHE

NORA NORTHERNMOST Northwestern Medicine Stanford MEDICINE UNOS VALIANT AI VERICI Dx Xena MediCardia

Table of Contents

4 **Welcome Letter**

5 **About WTC**

6 **WTC 2025 Committees**

Venue Floorplan
7 Exhibit Hall Level
8 Upper Mezzanine Level, Lobby Level
9 Level 3, Level 2

10 **Program at a Glance**

12 **Plenary Sessions & Speakers**

17 **Host Society Events**

20 **Networking Events**

22 **WTC Awards**

Exhibitor Information
23 Exhibit & Poster Hall Floorplan
24 Exhibitor Listing

26 **Industry Supported Symposia**

44 **Theater Presentations**

46 **Pre-Congress Workshops**

Detailed Program
52 Saturday, August 2
52 Sunday, August 3
84 Monday, August 4
109 Tuesday, August 5
142 Wednesday, August 6

169 **Poster Numbering Format Guide**

170 **Poster Presentation Times for Each Topic**

Poster Listing
171 Sunday, August 3
198 Monday, August 4
223 Tuesday, August 5

249 **General Information**

Welcome Letter

On behalf of the American Society of Transplantation, the American Society of Transplant Surgeons, and The Transplantation Society, I am honored to welcome you to the World Transplant Congress 2025.

This once-in-a-decade gathering in San Francisco marks the first time since 2014 that our three societies have come together to present a truly global congress. The program you are about to experience is the result of a remarkable international collaboration, representing the collective expertise, dedication, and innovation of the global transplantation community.

This year's agenda highlights cutting-edge science and technology, explores emerging therapies and clinical practices, and addresses critical challenges across the transplant continuum. Equally important, it offers a powerful forum for connection and collaboration, strengthening partnerships across disciplines, institutions, and countries.

As we look ahead to a future full of opportunity and innovation, we are especially proud to gather in a spirit of unity, discovery, and shared purpose. We hope this week inspires meaningful dialogue, fosters new ideas, and deepens your commitment to advancing transplantation worldwide.

Now more than ever, we celebrate our global partnership and look forward to sharing science, practice and fellowship in the beautiful city of San Francisco.

A warm welcome,

Emily A. Blumberg, MD
Congress Chair



About WTC

The World Transplant Congress (WTC) is a significant event in the field of organ transplantation, organized jointly by the American Society of Transplant Surgeons (ASTS), the American Society of Transplantation (AST), and The Transplantation Society (TTS). The event serves as a platform for experts from around the globe to meet and share research, discuss advancements, and address challenges in organ transplantation.

WTC 2025 event highlights the three main elements below:

- **Scientific Sessions:** presenting cutting-edge research and clinical practices in transplantation lead by renowned keynote speakers
- **Educational Workshops:** providing updates on the latest in transplant medicine and practical skills in the field
- **Networking Opportunities:** facilitating networking, collaborations and partnerships among transplant professionals and experts

The WTC will harness our global collective intelligence to address the human challenges of end stage organ failure. We will:

- Share global expertise in clinical and scientific knowledge
- Address key clinical issues across the continuum of care, from access to long-term follow-up
- Examine new technologies impact and utility
- Promote guidance, based upon best evidence
- Consider global challenges addressed by local innovation
- Foster collaboration in an environment promoting interaction and teamwork irrespective of geographic, economic, cultural, clinical and academic barriers

WTC 2025 Committees

The success of WTC 2025 in San Francisco is made possible by the dedication and expertise of our Organizing Committees. Comprising a diverse team of healthcare professionals, event specialists, and passionate volunteers, the Committees are at the heart of bringing this global Congress to life.

Our Committees are committed to creating a memorable and enriching experience for all attendees. With a deep understanding of organ transplantation's pivotal role in healthcare, our Committees are working tirelessly to ensure that WTC 2025 exceeds your expectations.

Executive Committee

Emily Blumberg
Congress Chair
AST

Marcelo Cantarovich
TTS

John Gill
AST

Kim Olthoff
ASTS

Tim Pruett
ASTS

Stefan Tullius
TTS

Program Committee

Tim Pruett
Program Committee Chair
ASTS

Curie Ahn
TTS

Ala Ali
TTS

Carla Baan
TTS

Yanik Bababekov
ASTS

Dempsey Hughes
AST

Deepali Kumar
AST

Jonathan Maltzman
AST

Peter Stock
ASTS

Finance Committee

Marcelo Cantarovich
Finance Chair
TTS

Anil Chandraker
AST

William Chapman
ASTS

Rich Formica
AST

John Fung
TTS

Elizabeth Pomfret
ASTS

Staff Committee

Robert Colarusso
TTS Staff

Jen Gillespie
AST Staff

JoAnn Gwynn
AST Staff

Marcelle McPhaden
TTS Staff

Diane Mossholder
ASTS Staff

Denise Rainville
TTS Staff

Tracy Reynolds
ASTS Staff

Venue Floorplan

Exhibit Hall Level

- **Exhibit + Poster Hall**
- **Session Rooms** 4, 8, 9-12, 20-25



Venue Floorplan

Upper Mezzanine Level

- **Session Rooms** 153, 154, 155



Lobby Level

- **Registration**
- **Speaker Ready Room**
  Room 101



Access to Esplanade Ballroom from Upper Mezzanine

Venue Floorplan

Level 3

Industry Supported Symposia Session Rooms
Rooms 303, 305, 307



Level 2

Plenary Session Room
San Francisco Ballroom

Town Hall Room
Room 201



Program at a Glance

SATURDAY August 2	SUNDAY August 3	MONDAY August 4
REGISTRATION 7:30 AM - 6:30 PM	**REGISTRATION** 7:00 AM - 5:00 PM	**REGISTRATION** 7:00 AM - 5:00 PM
SPEAKER READY ROOM 8:00 AM - 5:00 PM	**SPEAKER READY ROOM** 7:00 AM - 5:00 PM	**SPEAKER READY ROOM** 7:00 AM - 5:00 PM
EXHIBIT + POSTER HALL 5:30 PM - 7:00 PM	**EXHIBIT + POSTER HALL** 9:30 AM - 4:30 PM	**EXHIBIT + POSTER HALL** 9:30 AM - 4:30 PM
	CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS 7:00 AM - 8:00 AM ★ **EARLY CAREER BREAKFAST** 7:00 AM - 8:00 AM	**INDUSTRY SYMPOSIA** 7:00 AM - 8:00 AM
	CONCURRENT SYMPOSIA 8:15 AM - 9:30 AM	**CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS** 8:15 AM - 9:30 AM
	AM COFFEE & TEA BREAK 9:30 AM - 10:00 AM	**AM COFFEE & TEA BREAK** 9:30 AM - 10:00 AM
	KEYNOTE 2 & PLENARY ABSTRACTS 1 10:00 AM - 11:30 AM	**KEYNOTE 3 & PLENARY ABSTRACTS 2** 10:00 AM - 11:30 AM
	AST PRESIDENTIAL ADDRESS & SOCIETY AWARDS 11:30 AM - 12:45 PM	**ASTS PRESIDENTIAL ADDRESS & SOCIETY AWARDS** 11:30 AM - 12:45 PM
	LUNCH BREAK 12:45 PM - 2:15 PM **INDUSTRY SYMPOSIA** 1:00 PM - 2:00 PM	**LUNCH BREAK** 12:45 PM - 2:15 PM **INDUSTRY SYMPOSIA** 1:00 PM - 2:00 PM
★ **PRE-CONGRESS WORKSHOPS** 1:00 PM - 4:00 PM	**CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS** 2:15 PM - 3:30 PM	**CONCURRENT SYMPOSIA** 2:15 PM - 3:30 PM
	PM BREAK & POSTER RECEPTION (Diversity, Equity & Inclusion Reception) 3:30 PM - 4:30 PM	**PM BREAK & POSTER RECEPTION** 3:30 PM - 4:30 PM
OPENING CEREMONY & KEYNOTE 1 4:30 PM - 5:30 PM	**CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS** 4:30 PM - 5:45 PM	**CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS** 4:30 PM - 5:45 PM
WELCOME RECEPTION 5:30 PM - 7:00 PM	**TTS TOWN HALL** 6:00 PM - 7:30 PM	**AST TOWN HALL** 6:00 PM - 7:30 PM
★ **WHCOP & WIT RECEPTION** 7:00 PM - 8:30 PM		

★ Advanced Sign Up Required

Program at a Glance

TUESDAY August 5

REGISTRATION
7:00 AM - 5:00 PM

SPEAKER READY ROOM
7:00 AM - 5:00 PM

EXHIBIT + POSTER HALL
9:30 AM - 4:30 PM

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
7:00 AM - 8:00 AM

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
8:15 AM - 9:30 AM

AM COFFEE & TEA BREAK 9:30 AM - 10:00 AM

KEYNOTE 4 & PLENARY ABSTRACTS 3
10:00 AM - 11:30 AM

TTS PRESIDENTIAL ADDRESS & SOCIETY AWARDS
11:30 AM - 12:45 PM

LUNCH BREAK
12:45 PM - 2:15 PM

INDUSTRY SYMPOSIA
1:00 PM - 2:00 PM

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
2:15 PM - 3:30 PM

PM BREAK & POSTER RECEPTION
3:30 PM - 4:30 PM

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
4:30 PM - 5:45 PM

ASTS TOWN HALL
6:00 PM - 7:30 PM

WEDNESDAY August 6

REGISTRATION
7:00 AM - 12:00 PM

SPEAKER READY ROOM
7:00 AM - 11:00 AM

EXHIBIT + POSTER HALL
N/A

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
7:00 AM - 8:00 AM

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
8:15 AM - 9:30 AM

AM COFFEE & TEA BREAK 9:30 AM - 10:00 AM

CONCURRENT SYMPOSIA AND ORAL ABSTRACT SESSIONS
10:00 AM - 11:15 AM

CLOSING PLENARY
11:30 AM - 12:30 PM

CLOSING CEREMONY 12:30 PM - 1:00 PM

Plenary Sessions & Speakers

Opening Ceremony & Keynote 1: From Liver Transplant to Olympic Podium

Chris Klug

Saturday, August 2, 2025
4:30 PM - 5:30 PM
Moscone South – San Francisco Ballroom

Olympic medalist and the first athlete to compete in the Olympics after an organ transplant, he is a liver transplant recipient and a passionate advocate.

In 2004, he shared his inspiring journey in his book *To the Edge and Back*.

Chris Klug will share his inspiring journey and unique perspective as a transplant recipient. Just 18 months after his surgery, Chris made history by winning a bronze medal in snowboarding at the 2002 Winter Olympics – the first transplant recipient to ever medal at the Games. Today, he continues to inspire through his athletic achievements, advocacy, and commitment to transplant awareness.

Chris Klug Foundation is a supporter of the Living Donor Circle of Excellence, an initiative recognizing employers who provide salary support for living organ donors.

Plenary Sessions & Speakers

Keynote 2: The Health Misinformation Crisis!

Timothy Caulfield

Sunday, August 3, 2025
10:00 AM - 10:30 AM
Moscone South – San Francisco Ballroom

Timothy Caulfield is a Professor in the Faculty of Law and the School of Public Health, and Research Director of the Health Law Institute at the University of Alberta. He was the Canada Research Chair in Health Law and Policy for over 20 years (2002 – 2023). His interdisciplinary research on topics like stem cells, genetics, research ethics, the public representations of science, and public health policy has allowed him to publish almost 400 academic articles. He has won numerous academic, science communication, and writing awards, and is a Member of the Order Canada and a Fellow of the Royal Society of Canada, the Canadian Academy of Health Sciences, and the Committee for Skeptical Inquiry. He contributes frequently to the popular press and is the author of national bestsellers, including: The Cure for Everything: Untangling the Twisted Messages about Health, Fitness and Happiness (Penguin 2012); Is Gwyneth Paltrow Wrong About Everything?: When Celebrity Culture and Science Clash (Penguin 2015), and Relax, Dammit!: A User's Guide to the Age of Anxiety (Penguin Random House, 2020). His most recent book, a #1 national bestseller, is The Certainty Illusion: What You Don't Know and Why It Matters (Penguin Random House, 2025). Caulfield is also the co-founder of the science engagement initiative #ScienceUpFirst and has written, hosted and produced documentaries, including the award-winning TV show, A User's Guide to Cheating Death, which has been shown in over 60 countries, including streaming on Netflix in North America.

Plenary Sessions & Speakers

Keynote 3: Transplant Under Stress: Operating in a Warzone

Dr. Borys Todurov

Monday, August 4, 2025
10:00 AM - 10:30 AM
Moscone South – San Francisco Ballroom

With over 35 years of experience, Dr. Borys Todurov has revolutionized cardiac surgery in Ukraine, leading his transplant team to perform hundreds of successful surgeries, including:

- First Heart Transplant in Ukraine (2001)
- First Pediatric Heart Transplant (2023)
- First Heart-Lung Complex Transplant (2023)
- His visionary leadership at the Kiev Heart Institute has elevated it to a center of excellence in cardiac care, performing Ukraine's first LVAD implantation (2016) and pioneering numerous complex surgical procedures, including the first-ever thrombectomy with nephrectomy and thoracoscopic surgery for congenital heart disease.

Dr. Todurov has carried out over 500 successful operations for wounded soldiers during Ukraine's ongoing conflict, providing critical care and evacuation to the frontlines. He also lead international humanitarian missions to provide heart surgery in countries like Egypt, Iraq, Azerbaijan, and many more.

Plenary Sessions & Speakers

Keynote 4: Stem Cell Derived Beta Cell Clusters and Successful Allotransplantation

Dr. Hongkui Deng

Tuesday, August 5, 2025
10:00 AM - 10:30 AM
Moscone South – San Francisco Ballroom

Dr. Deng is a Professor at Pekin University – a leading stem cell researcher known for pioneering chemical reprogramming of somatic cells. He earned his Ph.D. from UCLA, contributed to HIV research, and held roles at ViaCell and NYU. He has received multiple honors and serves on top journal editorial boards. Hongkui Deng received his B.Sc. in Cell Biology from Wuhan University and went on to earn a Ph.D. in Immunology from the University of California, Los Angeles.

- From 1995 to 1997, he completed a postdoctoral fellowship as an Aaron Diamond Fellow in Dan R. Littman's lab at the Skirball Institute, NYU School of Medicine, where he played a key role in identifying major co-receptors involved in HIV cell entry.
- Between 1998 and 2000, Deng served as Director of Molecular Biology at ViaCell Inc., focusing on the ex vivo expansion of human hematopoietic stem cells.
- In 2000, he was honored with the Cheung Kong Scholarship and, the following year, joined Peking University as a professor.
- Since 2013, Professor Deng has led the Peking University Stem Cell Research Center. His research centers on somatic cell reprogramming and lineage-specific differentiation of human pluripotent stem cells. His lab also pioneers chemical biology strategies to control cell fate and function, including being the first to report a purely chemical method for inducing pluripotent stem cells.

Professor Deng's contributions have been recognized with numerous honors, including the Tan Jiazhen Life Science Award and the Wu Jieping–Paul Janssen Medical & Pharmaceutical Award. He also serves on the editorial boards of leading journals such as Cell, Cell Stem Cell, Stem Cell Reports, and Cell Research. He was elected to the ISSCR Board of Directors in 2010 and reappointed for a second term in 2013.

Plenary Sessions & Speakers

Dr. Ala Ali
TTS, Iraq

Dr. Dempsey Hughes
AST, USA

Dr. Yanik Bababekov
ASTS, USA

Closing Plenary: WTC 2025: Reflections, Revelations, and the Road Ahead

Wednesday, August 6, 2025
11:30 AM - 12:30 PM
Moscone South – San Francisco Ballroom

Host Society Events

AST Presidential Address

- 11:30 AM - 12:45 PM
- Moscone South – San Francisco Ballroom
- Complimentary for all registered attendees

The AST Presidential Address offers a look back at the Society's milestones over the past year and a vision for the future. Hear from AST President Dr. Jon Kobashigawa as he reflects on his term. This is a special moment to honor progress and set the tone for what's ahead in transplantation.

AST | AMERICAN SOCIETY OF® TRANSPLANTATION

TTS Town Hall

- 6:00 PM - 7:30 PM
- Moscone South – Room 201
- Complimentary for all registered attendees

Join us for the TTS Town Hall for a reception where attendees will hear about how TTS and its World Health Organization projects are helping to expand access to transplantation, and its vision for global data harmonization into the future.

TTS The Transplantation Society

THE TRANSPLANTATION SOCIETY • SOCIÉTÉ DE TRANSPLANTATION • 1966

Host Society Events

ASTS Presidential Address

- 11:30 AM - 12:45 PM
- Moscone South – San Francisco Ballroom
- Complimentary for all registered attendees

Hear Dr. Ginny Bumgardner speak about her term as president of ASTS and the challenges currently facing the field of transplantation.

ASTS
American Society of Transplant Surgeons

AST Town Hall

- 6:00 PM - 7:30 PM
- Moscone South – Room 201
- Complimentary for all registered attendees

Join us for the AST Town Hall to hear important Society updates, learn the results of the Board of Directors election, and celebrate key accomplishments across the transplant community. This session provides an opportunity to connect with AST leadership and acknowledge the outstanding work of your colleagues.

AST | AMERICAN SOCIETY OF TRANSPLANTATION

Host Society Events

TTS Presidential Address

- 11:30 AM - 12:45 PM
- Moscone South – San Francisco Ballroom
- Complimentary for all registered attendees

Join us for TTS' Presidential Address to hear about TTS' recent achievements, including the fight against organ trafficking and an exciting announcement of a new major endowed award recognizing excellence in transplantation.

TTS
The Transplantation Society

THE TRANSPLANTATION SOCIETY
SOCIÉTÉ DE TRANSPLANTATION
1966

ASTS Town Hall

- 6:00 PM - 7:30 PM
- Moscone South – Room 201
- Complimentary for all registered attendees

Join us for the ASTS Town Hall, where attendees will hear and discuss recent developments in the field of transplantation, in addition to conducting society business.

ASTS
American Society of Transplant Surgeons

Networking Events

Welcome Reception

- 5:30 PM - 7:00 PM
- Moscone South – Exhibit Hall AB
- Complimentary for all registered attendees. Tickets required for guests.

Join us for the Welcome Reception immediately following the Opening Ceremony & Keynote 1 to kick off an exciting lineup of networking events and scientific programming at WTC 2025!

Sponsored by

Pierre Fabre Pharmaceuticals Inc.
New ways to care

WHCOP & WIT Reception

- 7:00 PM - 8:30 PM
- Moscone South – Room 201
- Complimentary – Pre-Registration required.

This session will feature a keynote speech, panel discussion and moderated Q&A addressing barriers and facilitators in the ascent to academic and professional leadership as women and underrepresented minorities in transplant. This empowering session will include shared experiences and strategies for navigating macro and micro aggressions. Together with audience participation, we will discuss tools at the individual and programmatic level for overcoming these barriers as we strive to advance our careers and to promote diversity and inclusion in our respective workplace and professional societies.

Following the session, there will be a networking reception to foster ongoing networking and small round table conversations, including wine and light appetizers. To enhance the networking experience, AST Women's Health Community of Practice (WHCOP) and Women in Transplantation (WIT – an Initiative of The Transplantation Society (TTS)) members will be available to foster ongoing small group conversions, to further the session discussion during this networking reception.

Sponsored by

CareDx®

Networking Events

Early Career Networking Event

Breakfast Bites & Barriers: A Peer Discussion of How to Overcome Hurdles in the Early Career Stage in Transplantation

- 7:00 AM - 8:00 AM
- Moscone South – Room 156
- Complimentary – Pre-Registration required.

This complimentary, one-hour in-person event is open to congress registrants and offers an excellent opportunity for medical students, postdocs, trainees, and early-career faculty (within three years in the field of transplantation) to connect and engage with their future colleagues over breakfast.

Diversity, Equity, and Inclusion Reception

(held in conjunction with the 1st Poster Reception)

- 3:30 PM - 4:30 PM
- Moscone South – Exhibit Hall AB
- Complimentary for all registered attendees.

All are welcome to join this reception highlighting diversity, equity, and inclusion (DEI) within the field of transplantation. Learn more about the three societies' activities for both patient care and professionals. There will be opportunity to engage with ambassadors from each society to find out more, network with colleagues, and get involved.

WTC Awards

Young Investigator Award Winners

Nadim Al Rahy
USA

Sara Alibrandi
USA

Madonna Rica Anggelia
Taiwan

Laura Batista de Oliveira
USA

Roni Bitterman
Canada

Maogen Chen
China

Po-Yu (Teresa) Chiang
USA

Peter Chin
USA

Avery Fortier
USA

Alessia Giarraputo
France

Valentin Goutaudier
France

Masaaki Hirata
USA

Avery Koi
USA

Masaki Komatsu
USA

Hwan Lee
South Korea

Sabrina Leo
Canada

Rikako Oki
USA

Nithye Parvathy
India

Marc Raynaud
France

Harry Robertson
Australia

Carolyn Smullin
USA

Xiaojun Su
USA

Justin Wang
USA

Chase Wehrle
USA

Karolien Wellekens
Belgium

Christine Wolesensky
USA

Chao Yang
China

Francesca Zanoni
Italy

Haoming Zhou
China

WTC 2025 Student Ambassadors

Aleksandra Frankowska
Poland

Angela Gascon
Philippines

David Chen
USA

Patricia Viana
Brazil

Rohan Bhattacharjya
Australia

Sarah Fatukasi
Nigeria



Exhibitor Information

Exhibit & Poster Hall Floorplan



Exhibit & Poster Hall

Moscone South – Exhibit Hall AB

Saturday, August 2	5:30 PM - 7:00 PM (Welcome Reception)
Sunday, August 3	9:30 AM - 4:30 PM 3:30 PM - 4:30 PM (Poster & DEI Reception)
Monday, August 4	9:30 AM - 4:30 PM 3:30 PM - 4:30 PM (Poster Reception)
Tuesday, August 5	9:30 AM - 4:30 PM 3:30 PM - 4:30 PM (Poster Reception)

Medical Affairs Meeting Rooms

Alexion Medical Affairs	**12**	Merck & co.	**3**
Apellis Pharmaceuticals	**8**	Natera	**1**
Astellas Pharma Europe Ltd.	**13**	Pierre Fabre	**11**
Biogen	**14-15**	Sanofi	**9**
Bridge to Life	**10**	Takeda US	**2**
Bristol-Myers Squibb	**6**	Takeda Medical	**7**
CareDx	**4**	Veloxis Pharmaceuticals, Inc.	**5**

Exhibitor Information

Exhibitor Listing

Advanced Life Solutions 322
Alexion, AstraZeneca Rare Disease 809
Alnylam Pharmaceutical 724
American Association of Kidney Patients (AAKP) 1102
American Board for Transplant Certification (ABTC®) 114
American Journal of Transplantation 1142
American Kidney Fund 125
American Society of Transplant Surgeons (ASTS) 601
American Society of Transplantation (AST) 600
Amgen Rare Disease 1307
Apellis Pharmaceuticals – Medical 714
Apellis Pharmaceuticals 715
Associates Of Cape Cod, Inc. 221
Association for Multicultural Affairs in Transplantation 1206
Astellas Pharma Europe Ltd. 423
Automated Medical Products Corp. 633
Baskent University 101
Biogen 912
BIOHOPE 1104
BioMatrix Specialty Infusion Pharmacy 302
Bridge to Life 814
Buckeye Transplant 1321
Calliditas Therapeutics 506
CareDx, Inc. 701
Carenostics 1315
CDRG Transplant 231
Clix Therapy 130
CompuMed 1204
CSL Vifor 930
CTI Clinical Trial and Consulting Services 1201
Decima 107
Designs for Vision, Inc. 401
Diatiro 200
Donate Life America (DLA) 1208
Donor Network West 116
DTI Foundation 121
Eledon Pharmaceuticals 710
Essential Pharmaceuticals (Custodiol HTK) 306
Eurofins Transplant 821
Evidently 1222
Geister Medizintechnik 427
GenDx 1010
Gift of Life 105
Global Transplant Solutions 328
Glycorex Transplantation 109
Gold Standard Preservation 831
Hansa Biopharma 321
HLM - Explore Transplant and Living Donation 123
Heartbeat Perfusion Solutions 1224
Helinet Aviation Services 1209
HistoSonics 1114
InBody BWA 533
IIAM 103
InVita Healthcare Technologies / iTransplant 111
INVIVYD 534
Kamada 430
Lazarus 3D 634
Luminodx 1303
Lyfebulb 1203
Mallinckrodt Pharmaceuticals ..... 1028 / 1313
MedSleuth 530
Melinta Therapeutics 1116
Merck & Co., Inc. 1015
Methodist Le Bonheur Healthcare 1309
MezLight 433
MiraVista Diagnostics, LLC 225
Mirum Pharmaceuticals 132
Mobile Network 24 120

Exhibitor Information

Exhibitor Listing

Natera 1002
National Kidney Donation Organization (NKDO) 129
National Kidney Foundation (NKF) 1101
National Labs 1134
Nebraska Medicine 229
New England Donor Services 1124
Nationwide Organ Recovery Transport Alliance (NORA) 222
Northernmost 631
Northwestern Medicine 509
Nova Biomedical 117
Novartis Medical Affairs 1202
OKEIRO 1230
Oncocyte 324
Organ Donation & Transplantation Alliance (The Alliance) 126
Organ Perfusion and Cellular Services 1216
Organ Recovery Systems 630
OrganOx 220
Paragonix 314
patients.app 1232
Perfusion Solution Inc. 131
perfusionX 115
PIRCHE 1110
PLEXISION,INC 827
ProCure On-Demand 215
QuidelOrtho 213
QUOD Biobank 1128
Ready Transplant 127
Sanofi 622
Scanlan International 201
Scripps Clinic Biorepository 119
Specialist Direct 1233
SpecialtyCare 1033
Stanford Medicine 1024
Statline 733
Sutter Health CPMC 113
Takeda 512
Tampa General Hospital Transplant Institute 1215
The Legacy Gift Solutions 932
The Strength Of My Scars 1301
The Transplantation Society (TTS) 801
Thermo Fisher Scientific 915
Thompson Retractor 325
Transmedics 612
Transonic 334
Travere Therapeutics 1323
Trinity Medical Solutions 102
United Network for Organ Sharing (UNOS) 1022
Valiant 434
Veloxis Pharmaceuticals, Inc. 501
Verici Dx 330
Vizlitics 1214
Waters Medical Systems (an IGL Company) 830
Werfen 226
Xena Medical Technologies Inc 729
X-Therma 1130
XVIVO 722
Zambon USA Ltd. 1210

Industry Supported Symposia

ISS 1 – NATERA

Beyond Biopsy: Cell-Free DNA Use Not Just For Ruling Out Rejection

Sunday, August 3, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 307

Description:

Hear our discussion on the latest use cases of Prospera cell-free DNA to measure treatment response, further risk stratify, and inform immunosuppression dialing.

Agenda:

- **PEDAL Study: Prospera dd-cfDNA use in post-rejection monitoring**
  Nicolae Leca, MD
  UW Medicine

- **ProActive Study: Prospera monitoring to further risk stratify kidney recipients**
  Anthony J. Langone, MD
  Vanderbilt University Medical Center

- **Clinical Experience: Prospera immunosuppression treatment protocol**
  Alex W. Rogers, PharmD, BCTXP
  Houston Methodist Hospital

- **Study Announcement: Prospera to inform immunosuppression dialing**
  Gaurav Gupta, MD
  Virginia Commonwealth University Health

Eledon Pharmaceuticals

ISS 2 – ELEDON

What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?

Sunday, August 3, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 305

Description:

This dynamic and thought-provoking symposium brings together leading international experts in transplantation to explore a fundamental question: how should we define success in transplant outcomes? Traditionally, acute rejection has served as the cornerstone endpoint in clinical trials and transplant evaluation. However, with advancing science and emerging clinical insights, this session challenges that narrow focus—urging a broader, more holistic view that considers long-term graft survival, patient comorbidities, and overall quality of life.

Instead of traditional slide presentations, the session will feature a dynamic panel discussion shaped around four key questions:

1. How impactful is acute rejection in the first year?
2. How important is eGFR at 12 months, and are there better predictors of long-term allograft function?
3. What other factors affect long-term patient and allograft survival?
4. What does the ideal immunosuppression regimen look like?

Panelists will share diverse clinical and research perspectives from across regions, encouraging open dialogue and active audience participation. Attendees can expect to leave with new insights on the future direction of transplant science, clinical practice, and how we define meaningful success for both patients and the broader community.

Agenda:

3-5 Minutes: Opening Remarks and Context
- Welcome by facilitator
- Overview of session objectives and structure. Explanation of format and how panelists will respond
- The facilitator introduces the four guiding questions

Background Presentations (2-3 minutes each)
Question 1: How impactful is acute rejection in the first year?
Presenter: **John Gill**

Question 2: How important is eGFR at 12 months and are there better predictors of long-term allograft function?
Presenter: **Alex Loupy**

Question 3: What other factors affect long-term patient and allograft survival?
Presenter: **Deirdre Sawinski**

Question 4: What does the ideal immunosuppression regimen look like?
Presenter: **Oriol Bestard**

35-40 minutes: Open table discussion (all faculty)
- Facilitator/Moderator: Dr. Allan Kirk
  Panelists: Dr. John Gill, Dr. Deirdre, Dr. Oriol Bestard, Dr. Alexandre Loupy
- Discussion structured around four key themes (as stated in description)
- Audience engagement woven throughout (Q&A encouraged by facilitator)

8 minutes: Summary and Takeaways
- Panelists share final thoughts or key take-home messages
- Highlight emerging consensus or ongoing tensions in the field

2 minutes: Closing remarks
- Facilitator thanks speakers and audience

ISS 3 – MERCK

Considerations for CMV Disease Prevention in Kidney Transplantation

Sunday, August 3, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 303

Description:

- Discuss the burden of CMV infection and disease in kidney transplantation
- Review current AST guideline (2019) recommendations for CMV prevention in adult kidney transplant patients
- Review clinical data for an option to help prevent CMV disease in high-risk adult kidney transplant recipients

Speaker:

Kyle Molina, PharmD is a board-certified infectious disease pharmacist and a board-certified HIV pharmacist. He is an Infectious Diseases and Antimicrobial Stewardship Clinical Specialist at Scripps Green Hospital; La Jolla, CA. Dr. Molina received his Doctor of Pharmacy from the Midwestern University College of Pharmacy – Glendale, AZ. He then completed a PGY-1 Pharmacy Residency at Scripps Mercy Hospital – San Diego, CA and a PGY-2 Infectious Diseases Pharmacy Residency at the University of Colorado Anschutz Medical Campus, Aurora, CO. Dr. Molina is a member of the Society of Infectious Diseases Pharmacists (SIDP), Mountain Plains Regional Disaster Health Response (MPRDHRS) and multiple other committees. He also has numerous publications as well as abstracts.

sanofi

ISS 4 – SANOFI

Striving to Advance Kidney Utilization: The Power of Collaboration

Sunday, August 3, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom B

Description:

1. Identify current obstacles in the utilization of deceased donor kidneys
2. Examine diverse strategies to enhance kidney utilization across different levels: patient, center, OPO, and system
3. Assess the potential effects of various methods aimed at improving kidney utilization

Moderator:

Dr. Dorry L Segev, MD, PhD, FACS, New York University, New York, USA

Panelists:

1. **Dr. Anthony Watkins**, MD, FACS Tampa General Hospital, Tampa FL
2. **Andrea Tietjen**, CPA, MBA Cooperman Barnabas Medical Center, Livingston NJ
3. **Dorrie Dils**, BSN, MHA Gift of Life Michigan, Ann Arbor, MI
4. **Kevin Longino**, MBA NKF, New York, New York

ThermoFisher SCIENTIFIC

ISS 5 – THERMO FISHER SCIENTIFIC

From Risk Assessment to Advanced Diagnostics: The Role of PTRA, CXCL10, MMDx®, and TTv

Sunday, August 3, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom C

Description:

Monitoring tools for kidney transplants are essential for ensuring the success and longevity of the graft. Our presenters will discuss the benefits and implementation of the Thermo Fisher Scientific Transplant Diagnostic portfolio, which includes several key assays: the blood-based Pre-transplant Risk Assessment assay, the urine based CXCL10 test, and the tissue-based Molecular Microscope Diagnostic System. Together, these tools can help improve the management of kidney transplant patients, potentially enhancing long-term outcomes and reducing the risk of graft loss. We will also introduce the Torque Teno virus assay (not yet commercially available).

Agenda:

1:00 PM - 1:05 PM: Introduction
Richard Knight, MD

1:05 PM - 1:15 PM: Presenter #1
Sanjeev Kumar Akkina, MD

1:15 PM - 1:25 PM: Presenter #2
Tom Blydt-Hansen, MD, PhD

1:25 PM - 1:35 PM: Presenter #3
Dhiren Kumar, MD

1:35 PM - 1:45 PM: Presenter #4
Richard Knight, MD

1:45 PM - 2:00 PM: Q&A and Closing

Industry Supported Symposia

BRIDGE TO LIFE™

ISS 6 – BRIDGE TO LIFE

Hypothermic Oxygenated Perfusion (HOPE): From Science to Clinical Impact

Monday, August 4, 2025
7:00 AM - 8:00 AM
Moscone Center – Room 307

Description:

This symposium will highlight the science behind Hypothermic Oxygenated Perfusion and its clinical relevance. The presenters will focus on outcomes, including data on the Bridge to HOPE trial conducted in the US, ease of use, cost analysis and viability assessment during HOPE.

Agenda:

- **Chair/Moderator** - Introductions and Symposium Overview (5min)
- **David Foley** - Hypothermic Oxygenated Perfusion Clinical Evidence: Bridge to HOPE Trial (15 min)
- **David Axelrod** - Economic Impact of Hypothermic Oxygenated Liver Perfusion (15 min)
- **Andrea Schlegel** - Viability Assessment in HOPE (15 min)
- **Discusssion (10 min)**

Industry Supported Symposia

ALEXION®
AstraZeneca Rare Disease

ISS 7 – ALEXION
Conundrums in Kidney Transplantation

Monday, August 4, 2025
7:00 AM - 8:00 AM
Moscone Center – Room 303

Description:

This symposium will cover kidney transplantation challenges, including delayed graft function, antibody-mediated rejection, and sensitized patients. Topics include the complement system's role in post-transplant outcomes, current treatments, and ongoing clinical studies. We will also address highly sensitized patients who need new therapies to achieve transplantation and prevent rejection. A Q&A session will follow.

Speakers:

Dr. Robert Montgomery (chair): NYU Langone Transplant Institute, NYU Langone Health, New York, NY

Dr. Jean Francis: Renal Section, Department of Medicine, Boston Medical Center, Boston University Chobanian and Avedisian School of Medicine, Boston, MA

Agenda:

- **1. Introduction from chair**
  (Montgomery, 5 minutes)
- **2. The role of complement in kidney transplantation**
  (Francis, 20 minutes)
- **3. Sensitized patients in kidney transplantation**
  (Montgomery, 20 minutes)
- **4. Audience Q&A (15 minutes)**

Industry Supported Symposia

ISS 8 – CAREDX

Transforming Transplant Management with Precision Molecular Intelligence

Monday, August 4, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 307

Description:

Hear from leaders advancing the paradigm of precision medicine in transplant, and explore the range of clinical contexts where they leverage AlloSure's molecular insights to improve patient management.

Speakers:

- **Dr. Nicole Ali**, MD, Medical Director, Kidney and Pancreas Transplant Program at NYU Langone
- **Dr. Dhiren Kumar**, MD, Co-Medical Director, Kidney/Pancreas Transplant Program at VCU
- **Marta Sablik**, PhD Candidate, Paris Institute for Transplantation and Organ Regeneration
- **Dr. Alexandre Loupy**, MD, PhD, Paris Institute for Transplantation and Organ Regeneration

Industry Supported Symposia

TransMedics®

ISS 9 – TRANSMEDICS

TransMedics Next Generation of Transplant Innovations

Monday, August 4, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 305

Description:

Join us for a forward-looking symposium that unveils the next generation of transplant innovations from TransMedics, the leader in normothermic organ perfusion technology. This session will explore how TransMedics' multi-organ Organ Care System (OCS) platform is revolutionizing the field of transplantation—redefining what's possible for liver, heart and lung recovery and preservation, with a preview into the future of kidney normothermic machine perfusion.

Designed to preserve organs in a functioning, near-physiologic state, the OCS platform is enabling dynamic organ assessment, optimization, and logistical flexibility never seen before. Learn how these innovations are dramatically increasing donor organ utilization, improving clinical outcomes and setting a new standard of care across the globe.

Agenda:

1:00 PM - 1:15 PM: Farhan Zafar:
- OCS Heart & Lung: Next-gen heart and lung clinical programs – going beyond preservation
- OCS Kidney (Coming Soon): A glimpse into TransMedics' development of kidney perfusion technology and its potential to disrupt static cold storage in renal transplantation

1:15 PM - 1:30 PM: Magdy Attia:
- OCS Liver: "Clinical Impact of the OCS Liver: Normothermic Machine Perfusion in 7,000 Liver Transplants and counting"

1:30 PM - 1:45 PM: Malcolm MacConmara:
- OCS Kidney: "OCS Kidney: Developing the Next Frontier for Donor Kidney Preservation and Assessment"

1:45 PM - 2:00 PM: Open Discussion & Q&A

Industry Supported Symposia

Bristol Myers Squibb

ISS 10 – BRISTOL MYERS SQUIBB

Advances in Post-Kidney Transplant Immunosuppression: Applying the Latest CNI-Sparing Strategies to Optimize Long-Term Outcomes

Monday, August 4, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 303

Description:

While calcineurin inhibitors (CNIs) have long served as the cornerstone of maintenance immunosuppression following kidney transplantation, a growing body of evidence supports the use of alternative regimens that include co-stimulation blockade or mTOR inhibitors, to reduce adverse events and improve long-term graft function in select patients.

Join us for this dynamic symposium featuring two renowned kidney transplant experts. Together they will discuss how to individualize maintenance immunosuppression regimens and apply the latest CNI-sparing strategies in practice. This highly interactive session will spotlight complex cases and practical tools, including a new expert-developed clinical resource, for using alternative regimens to optimize outcomes following kidney transplant. Don't miss this opportunity to learn from top thought leaders and leave with real-world strategies for use in your own clinical practice.

Agenda:

- **I. Immunosuppression and Long-Term Outcomes: Key Determinants and Challenges**
- **II. Identifying Patients for CNI-Sparing or CNI-Minimizing Regimens**
- **III. Evaluating the Evidence on Alternative Maintenance Immunosuppression Regimens**
- **IV. Strategies for Individualizing Maintenance Immunosuppression Regimens**

Notes: Interactive polling with leaderboard will be utilized throughout the presentation

XVIVO

ISS 11 – XVIVO

Unlock The Power of HOPE – Advancing Organ Preservation with Hypothermic Oxygenated Perfusion

Monday, August 4, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom B

Description:

As waiting lists for liver and kidney transplantation continue to grow, there is an increasing reliance on older and higher risk donor organs, underscoring the critical importance of optimizing organ preservation and selection.

Hypothermic Oxygenated Perfusion (HOPE) represents a significant advancement in organ preservation, combining the advantages of cold storage with continuous perfusion and active oxygenation. The benefits of HOPE in solid organ transplantation have been extensively proven, particularly for liver and kidney grafts. Patients receiving donor organs preserved with HOPE have better chances of long-term graft survival and lower risk of transplant related complications.
In this symposium we will explore how HOPE mitigates the detrimental effects of ischemia-reperfusion injury and review the expanding body of scientific evidence supporting its use. We will also discuss the possibility of organ assessment during hypothermic perfusion and the role of renal resistance as a viability tool.

Join us to explore how the future of organ preservation is being reshaped - the power of HOPE is in your hands!

Agenda:

1. The concept and application of cold perfusion in liver and kidney transplantation
- **Prof. Andrea Schlegel** (MD, MBA), Cleveland Clinic (USA)

2. Warm or cold perfusion for liver and kidney: where is the evidence?
- **Prof. Colin Wilson**, (MD, PhD), Newcastle University (UK)

3. Organ assessment during hypothermic kidney perfusion – should we trust renal resistance as a viability tool?
- **Prof. Rutger Ploeg** (MD, PhD), University of Oxford (UK)

Industry Supported Symposia

powered by cea

ISS 12 – CLINICAL CARE OPTIONS

Navigating Complex Refractory CMV Cases in SOT Recipients: Expert Approaches

Monday, August 4, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom A

Description:

Explore approaches to optimizing antiviral treatment of refractory CMV in SOT recipients.

This activity is intended for physicians, nurses, and clinical pharmacists, including transplant, infectious diseases, nephrology, and internal medicine specialists who care for SOT recipients with CMV infections.

Agenda:

- Welcome, Introduction, and Baseline Assessment (5 min)
- Soundings: Understanding and Identifying Refractory CMV Infections in Transplant Settings (15 min)
- Charting the Course: Antivirals for Refractory CMV Infections (20 min)
- Deep Dive: Complex Clinical Scenarios Involving Refractory CMV Infections (15 min)
- Closing Remarks, Post-Activity Polling, Final Question and Answer Session (10 min)

Apellis

ISS 13 – APELLIS

A Closer Look at Two Rare Glomerular Diseases: C3G and Primary IC-MPGN

Monday, August 4, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom C

Description:

This presentation outlines the clinical and pathological landscape of C3 glomerulopathy (C3G) and primary IC-MPGN, two rare kidney diseases driven by complement system overactivation. These conditions can lead to progressive kidney damage and are known to recur even after transplantation, often resulting in allograft loss.

Diagnosis relies on renal biopsy and immunofluorescence to detect C3 and immunoglobulin deposits. Risk factors for recurrence include genetic mutations, disease severity, and age at diagnosis. Management typically involves supportive therapies such as antihypertensives, immunosuppressants, and dietary adjustments.

Agenda:

1:00 PM - 1:50 PM
- A Closer Look at Two Rare Glomerular Diseases: C3G and Primary IC-MPGN

1:50 PM - 2:00 PM
- Question & Answer Session

Industry Supported Symposia

eurofins | Transplant

ISS 14 – EUROFINS

Challenges in Post Transplant Care: CMV, Immunosuppression Management, Rejection and More

Tuesday, August 5, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 307

Agenda:

1:00 PM - 1:15 PM
- Introduction
  Dr. John Friedewald

1:15 PM - 1:35 PM
- IS Management & Rejection
  Dr. Wojciechowski

1:35 PM - 1:55 PM
- Navigating CMV in Solid Organ Transplantation
  Dr. Kotton

Industry Supported Symposia

PARAGONIX®

A Getinge company

ISS 15 – PARAGONIX

Preservation Innovations Propelling Abdominal Transplantation Forward

Tuesday, August 5, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 303

Description:

This session will provide a comprehensive overview of the latest findings from the GUARDIAN-Liver Registry, along with case studies showcasing innovative applications of Paragonix Advanced Donor Liver Preservation technology. Additionally, learn how KidneyVault's portable hypothermic perfusion technology is changing what is possible in kidney transplantation.

Join leading experts as they explore current trends in advanced organ preservation and transplantation, highlighting groundbreaking techniques designed to enhance organ viability and improve patient outcomes.

Discover what's next in the field as experts share their vision for the future of abdominal preservation and its role in expanding access to life-saving transplants.

Agenda:

Introduction - 5 min
- Welcome by **Lisa Anderson**, PhD, President, Paragonix Technologies

Introduction of Panel – 1 min
- **Jake Miles**, MD, Medical Director, Paragonix Technologies

Speaker Talk 1 - 15 minutes
- Improved Outcomes Utilizing Hypothermic Liver Preservation: Real World Evidence from the GUARDIAN-Liver Registry
- Speaker: **Jean Botha**, MD, Intermountain Health

Speaker Talk 2 - 15 minutes
- Bridging Distance and Donor Complexity: Advancing Liver Transplantation with Controlled Hypothermic Preservation
- Speaker: **Kiran Dhanireddy**, MD, FACS, Tampa General Hospital

Speaker Talk 3 - 15 minutes
- Revolutionizing Hypothermic Perfusion for the Next Era of Kidney Transplantation
- Speaker: **Sherry Quire**, RN, MBA, BSN, Director, Organ Services, Indiana Donor Network

5-10 Min Q&A

Industry Supported Symposia

ISS 16 – BIOGEN

AMR Pathogenesis of the Kidney: The Central Role of CD38+ Cells

Tuesday, August 5, 2025
1:00 PM - 2:00 PM
Moscone Center – Room 305

Description:

This symposium will review the following topics around antibody-mediated rejection of the kidney:

- 1. Treatment landscape & unmet need
- 2. AMR disease state, with a focus on how CD38+ cells might contribute to AMR pathogenesis
- 3. Targeting of CD38+ cells in AMR
- 4. Molecular impact of felzartamab, an investigational anti-CD38 monoclonal antibody, in AMR

Agenda:

- **Welcome, treatment landscape, unmet need - 5 min**
  Matthew Cooper, MD
- **AMR disease state and the central role of CD38+ cells - 10 min**
  Yasir Qazi, MD
- **Phase 2 study of felzartamab, an investigational anti-CD38 monoclonal antibody, in AMR - 10-15 min**
  Georg Bohmig, MD
- **Molecular effect of anti-CD38 treatment in AMR - 10-15 min**
  Phillip Halloran, MD
- **Q&A and concluding remarks - 5-10 min**
  Matthew Cooper, MD

Industry Supported Symposia

Veloxis® PHARMACEUTICALS
an Asahi Kasei company

ISS 17 – VELOXIS

Kidney Transplantation Outcomes: Looking Forward by Looking Back

Tuesday, August 5, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom B

Description:

Kidney transplantation is currently the gold standard of care and provides patients with end-stage kidney disease the best chance for long-term, dialysis-free survival, but in addition to challenges regarding organ availability is the challenge of optimizing allograft survival over time. Join our expert panel as they review the long-term challenges of graft survival in kidney transplant recipients and the importance of achieving better long-term outcomes.

Agenda:

12:30 PM
- Lunch and Registration

1:00 PM - Welcome and Introductions
- **Alexander Wiseman**, MD

1:05 PM - Unmet Needs in Transplantation
- **Alexander Wiseman**, MD; **Leonardo V. Riella**, MD, PhD; **Deirdre L. Sawinski**, MD

1:15 PM - Recommendations on Maintenance Immunosuppression
- **Alexander Wiseman**, MD; **Leonardo V. Riella**, MD, PhD; **Deirdre L. Sawinski**, MD

1:25 PM - Future of Immunosuppression: Emerging Targets and Evolving Endpoints
- **Alexander Wiseman**, MD; **Leonardo V. Riella**, MD, PhD; **Deirdre L. Sawinski**, MD

1:45 PM - Concluding Remarks
- **Alexander Wiseman**, MD

1:50 PM - Audience Q&A
- All Panel

Industry Supported Symposia

powered by cea

ISS 18 – CLINICAL CARE OPTIONS

From All Angles: Minimizing CMV in High-Risk Kidney Transplant Recipients

Tuesday, August 5, 2025
1:00 PM - 2:00 PM
InterContinental Hotel – Grand Ballroom A

Description:

Learn how to individualize CMV prevention in high-risk kidney transplant recipients, including selecting optimal antivirals and designing antiviral regimens to optimize patient outcomes.

This activity is intended for transplant and infectious diseases specialists, including physicians, nurses, pharmacists, and other healthcare professionals, who care for patients at risk for CMV following kidney transplantation.

Agenda:

- Welcome, Introduction, and Baseline Assessment (5 min)
- The Viral Angle: CMV in Kidney Transplantation (15 min)
- The Antiviral Angle: Leveraging the Full Armamentarium (15 min)
- The Patient Angle: Individualized Approaches (15 min)
- Closing Remarks, Postactivity Polling, Final Question and Answer Session (10 min)

Product Theater Presentations

natera™

American Kidney Fund®
FIGHTING ON ALL FRONTS

Presented by: Natera & American Kidney Fund

Understanding Post-transplant Surveillance Through Patient Eyes

Sunday, August 3, 2025
9:35 AM - 10:00 AM
Moscone Center – Exhibit Hall AB

Moderator:

Gates Colbert, Nephrologist, Kidney and Hypertension Associates of Dallas

Panelists:

Jen Benson
Kidney and Pancreas Transplant Recipient and Advocate

JoDee DeVillier
Parent Caregiver and Advocate

Daniel DeVillier
Pediatric Kidney Transplant Recipient

Product Theater Presentations

Alnylam®

Presented by: Alnylam

OXLUMO® (lumasiran) for the Treatment of Primary Hyperoxaluria (PH1): Case Studies

Monday, August 4, 2025
9:35 AM - 10:00 AM
Moscone Center – Exhibit Hall AB

Speakers:

Dr. Michael J. Somers, M.D.
Attending, Division of Nephrology; Director, Clinical Services, Division of Nephrology; Medical Director, Renal Dialysis Unit

Associate Professor of Pediatrics, Harvard Medical School

Boston Children's Hospital, Boston, Massachusetts

Pre-Congress Workshops

Saturday, August 2

WS01 - Keys to Success in Your Academic Transplant Career (Ticketed Session)

- 1:00 PM - 4:00 PM
- Moscone South – Room 8
- Organ Inclusive
- CME Accredited

Moderators: Arpan Arun Patel, USA and Michael Englesbe, USA and Karen Ladin, USA and Nuria Montserrat, Spain and Chris Johnston, UK and Dimitrios Raptis and Valeria Mas, USA and Heidi Yeh, USA

1:00 PM Welcome & Introduction: How to Pursu Academic Professional Development: Creating a Niche
Arpan Arun Patel, USA
Michael Englesbe, USA

1:00 PM WS01.1 - Medical Student Perspective
Anna Ha, USA

1:15 PM WS01.2 - Resident Perspective
Chase Wehrle, USA

1:30 PM WS01.3 - Mentor Perspective
Michael Englesbe, USA

1:45 PM Panel Discussion

2:00 PM Introduction: Pearls and Pitfalls of Getting Your Paper Published: Ask the Editors
Karen Ladin, USA and Nuria Montserrat, Spain
Christine Haugen, USA

2:00 PM Panelists
Stefan Tullius, USA
Sandy Feng, USA

2:20 PM Break

2:30 PM Introduction: Climbing the Ladder in Academic Transplantation
Chris Johnston, UK
Dimitrios Raptis

2:30 PM WS01.6 - How to Prepare and Present Slides
Marcelo Cantarovich, Canada

2:38 PM WS01.7 - How to Prepare for an Academic Job Interview (Interviewee Perspective)
Christina Papachristou, Greece

2:46 PM WS01.8 - How to Create a Research Plan as a Clinician. How to Be in Two Places at Once: Building a Career as a Physician-Scientist
Elizabeth Sonnenberg, USA

2:54 PM Panel Discussion

3:00 PM Introduction: How to Get a Grant: If at First You Don't Succeed, Try Again
Valeria Mas, USA
Heidi Yeh, USA

3:00 PM WS01.9 - Early Career - Emphasis on Training Plan
Joshua Weiner, USA

3:15 PM WS01.10 - Mid Career - Emphasis on Independent Investigation
Xunrong Luo, USA

3:30 PM WS01.11 - Learning from Common Mistakes in Grant Writing
Lisa VanWagner, USA

3:45 PM WS01.12 - Putting It All Together- The Importance of Peer Networks
Juliet Emamaullee, USA

WS02 - Allied Health Professionals Around the World (Ticketed Session)

- 1:00 PM - 4:10 PM
- Moscone South – Room 9
- APP
- CME Accredited

Moderators: Chantal Wiggins, Canada and Julie Corkrean, USA and Hazel Domingo, USA and Sharon Klarman, USA and JoLynn Shinsako, USA and Dana Jakoubek, USA

1:00 PM Welcome and Introduction: How We Built It: Administrative Pearls to Team Success
Chantal Wiggins, Canada
Julie Corkrean, USA

1:00 PM WS02.1 - Integrating Data Management & Quality Metrics into Clinical Practice
Julie Prigoff, USA

1:15 PM WS02.2 - Developing an AHP Program - A Case Study from the First Generation of Advanced Practice Nursing in France
Brigitte Ursini, France

1:30 PM WS02.3 - Addressing Financial Challenges in Transplantation
Luke Preczewski, USA

1:45 PM Panel Discussion

2:00 PM Introduction: Clinical Innovation: AHPs on the Frontline
Hazel Domingo, USA
Sharon Klarman, USA

2:00 PM WS02.4 - Forward Progress: Prehabilitation and Rehabilitation - The Effectiveness and Accessibility of Programs Tailored to Transplant Patients Developed by Physiotherapists
Hannah ML Young, UK

2:12 PM WS02.5 - Innovating for Tomorrow: Allied Health-Led Quality Improvement Initiatives PACU Extended Stay Program for Transplant Recipients
JoLynn Shinsako, USA

2:24 PM WS02.6 - The Power of Partnerships: To Innovate and Save Lives Through Organ DonationThe Power of Partnerships: To Innovate and Save Lives Through Organ Donation
Jennifer Prinz, USA

2:36 PM WS02.7 - Looking to the Future: Can Frailty Be Reversed in Transplant Patients?
Brooke Chapman, Australia

2:48 PM Panel Discussion

3:00 PM Break

3:15 PM Introduction to Part 3
JoLynn Shinsako, USA
Dana Jakoubek, USA

3:15 PM WS02.8 - The Value of Allied Health Professionals in Research
Elaina Weldon, USA

3:30 PM WS02.9 - The Evolving Role of Pharmacists in Transplant Centers Around the Globe
Barrett Crowther, USA

3:45 PM WS02.10 - The AHP Transplant Pipeline: How to Inspire and Train the Next Generation
Sharon Klarman, USA

4:00 PM Panel Discussion

WS03 - Transplant ID 2025: Global Insights, Experience, and Innovation (Ticketed Session)

1:00 PM - 4:30 PM
Moscone South – Room 23
Infectious Disease
CME Accredited

Moderators: Wanessa Trindade Clemente, Brazil and Cameron Wolfe, USA and Lara Danziger-Isakov, USA and Deepali Kumar, Canada and Sarah Longworth, USA

1:00 PM Welcome & Introduction: Cases in Transplant ID Syndromes: Expert Evaluation and Management
Wanessa Trindade Clemente, Brazil
Cameron Wolfe, USA

1:00 PM WS03.1 - Fevers and Cytopenias - When the Blood Runs Thin
Daniel Santos, Brazil

1:15 PM Q&A

1:18 PM WS03.2 - CNS Infections - The Patient Is Confused, but What About Their Doctor?
Tan Ban Hock, Singapore

1:33 PM Q&A

1:36 PM WS03.3 - Pneumonia - Just Breathless in Anticipation
Andre Kalil, USA

1:51 PM Q&A

1:54 PM WS03.4 - Diarrhea - Trying to Tame the Torrent
Christopher Saddler, USA

2:09 PM Q&A

2:12 PM WS03.5 - Rash Syndromes for the Transplant Clinician
Adela Cardones, USA

2:27 PM Q&A

Pre-Congress Workshops

Saturday, August 2

2:30 PM Introduction: Emerging Problems Migrating to Your Neighborhood
Lara Danziger-Isakov, USA

2:30 PM WS03.6 - Asia Vector Borne Infections
Jackrapong Bruminhent, Thailand

2:40 PM Q&A

2:42 PM WS03.7 - Oceania Organism
Tina Marinelli, Australia

2:52 PM Q&A

2:54 PM WS03.8 - Latin America: Changin Epidemiology of Parasites
Wanessa Trindade Clemente, Brazil

3:04 PM Q&A

3:06 PM WS03.9 - North America: MDROs
Maricar Malinis, USA

3:16 PM Q&A

3:18 PM WS03.10 - Europe: Fungal Infections
Alessandra Mularoni, Italy

3:28 PM Q&A

3:30 PM Introduction: Teaching Transplant ID to Trainees - How Do We Get Better?
Deepali Kumar, Canada
Sarah Longworth, USA

3:30 PM WS03.11 - Successful Models for Training
Aruna Subramanian, USA

3:45 PM WS03.12 - Having an Online Presence in Order to Teach
Courtney Harris, USA

4:00 PM WS03.13 - Building Your NIH Funded and/or Industry Engaged Career
Michael Ison, USA

4:15 PM Q&A

WS04 - Xenotransplantation – Regulatory Challenges and Clinical Implementation (Ticketed Session)

1:00 PM - 4:00 PM
Moscone South – Room 11
Basic Science
CME Accredited

Moderators: Andrew Adams, USA and Alexandra Glazier, USA

1:00 PM Welcome & Introduction
Andrew Adams, USA
Alexandra Glazier, USA

1:00 PM WS04.1 - History and Challenges in Xenotransplantation
David K. Cooper, USA

1:20 PM WS04.2 - Regulatory Aspects in the US
Vijay Kumar, USA

1:40 PM WS04.3 - Regulatory Aspects Outside the US
Wayne Hawthorne, Australia

2:00 PM WS04.4 - Ethical Issues
Laura Kimberly, USA

2:20 PM Break

2:30 PM WS04.5 - Updates and Outlooks from Clinical Trials: Kidney
Robert Montgomery, USA

2:45 PM WS04.6 - Updates and Outlooks from Clinical Trials: Heart
Muhammad Mohuiddin, USA

3:00 PM WS04.7 - Updates and Outlooks from Clinical Trials: Kidney
Leonardo Riella, USA

3:15 PM WS04.8 - Updates and Outlooks from Clinical Trials: Liver
Abraham Shaked, USA

3:30 PM Panel Discussion

Pre-Congress Workshops

Saturday, August 2

WS05 - Tolerance — Toward the Elusive Promise of Clinical Tolerance (Ticketed Session)

- 1:00 PM - 4:00 PM
- Moscone South — Room 21
- Basic Science
- CME Accredited

Moderators: Stuart Knechtle, USA and Qizhi Tang, USA

1:00 PM Welcome & Introduction
Stuart Knechtle, USA
Qizhi Tang, USA

1:00 PM WS05.1 - Different Approaches - Barriers and Opportunities
Fadi Lakkis, USA

1:15 PM Q&A

1:20 PM WS05.2 - Ethical and Regulatory Issues of Tolerance Trials
Stephan Busque, USA

1:35 PM Q&A

1:40 PM WS05.3 - Cellular Therapies to Achieve Tolerance
Elmar Jaeckel, Canada

1:55 PM Q&A

2:00 PM WS05.4 - Combined Thymus/Organ Approach
Megan Sykes, USA

2:15 PM Q&A

2:20 PM WS05.5 - How Stable Is Tolerance: Experimental and Clinical Data
Maria-Luisa Alegre, USA

2:35 PM Q&A

2:40 PM WS05.6 - Tissue Modification to Avoid Immune Rejection
Sonja Schrepfer, USA

2:55 PM Q&A

3:00 PM WS05.7 - Patient Perspective
Peggy Bradbury, Canada

3:15 PM Q&A

3:20 PM Panel Discussion

WS06 - Obesity Management in Transplant Recipients and Donors (Kidney and Liver) (Ticketed Session)

- 1:00 PM - 4:00 PM
- Moscone South — Room 20
- Organ Inclusive
- CME Accredited

Moderators: Adnan Sharif, UK and Pratima Sharma, USA and Harini Chakkera, USA and Saleh Alqahtani, USA and Atsushi Yoshida, USA and Chandra Bhati, USA

1:00 PM Welcome & Introduction: Managing Obesity and Cardiometabolic Disease Before and After Transplant
Adnan Sharif, UK and
Pratima Sharma, USA

1:00 PM WS06.1 - Selecting Weight Loss Strategies for Kidney Transplant Candidates
Babak Orandi, USA

1:12 PM WS06.2 - Cardiovascular Disease and Diabetes Management in Kidney Transplants Before and After Transplant
Vikas Sridhar, Canada

1:24 PM WS06.3 - Epidemiology of Obesity and Cardiometabolic Disease in Liver Transplant Candidates and Impact on Clinical Outcomes
Lisa VanWagner, USA

1:36 PM WS06.4 - Use of Anti-obesity Pharmacotherapy in Liver Transplant Recipients Including Updates from Clinical Trials
Juan Pericas, Spain

1:48 PM Q&A

2:00 PM Introduction: Managing Obesity in Transplant Donors
Harini Chakkera, USA
Saleh Alqahtani, USA

2:00 PM WS06.5 - Methods and Ethics of Obesity Management of Living Donors in Kidney Transplantation
Dorry Segev, USA

2:15 PM WS06.6 - Impact of Machine Perfusion on Liver Graft Steatosis
Andrea Schlegel, USA

Pre-Congress Workshops

2:30 PM Obesity Management in Living Donors for Liver Transplant
Saleh Alqahtani, USA

2:45 PM Q&A

3:00 PM Introduction: Robotic Kidney Transplant Surgery for High BMI Recipients: Tips and Tricks From Around the World
Atsushi Yoshida, USA
Chandra Bhati, USA

3:00 PM WS06.7 - How I Do It: Middle East
Yaser Elsheikh, Saudi Arabia

3:15 PM WS06.8 - How I Do It: North America
Mario Spaggiari, USA

3:30 PM WS06.9 - How I Do It: Asia
Pranjal Modi, India

3:45 PM Panel Discussion

WS07 - Improving the Care and Follow-Up of Living Organ Donors (Ticketed Session)

12:00 PM - 4:00 PM
Moscone South – Room 10
Organ Inclusive
CME Accredited

Moderators: Hassan Ibrahim, USA and Krista Lentine, USA and Elizabeth Pomfret, USA and Kim Olthoff, USA and Arthur Matas, USA and Vivekanand Jha, India and John Gill, Canada and Vineeta Kumar, USA

12:00 PM Welcome & Introduction: Living Kidney Donation
Hassan Ibrahim, USA
Krista Lentine, USA

12:00 PM WS07.1 - Debate: PRO: Non-transplant Nephrology Evaluation of Potential Donors
Martina McGrath, USA

12:10 PM WS07.2 - Debate: CON: Non-transplant Nephrology Evaluation of Potential Donors
Melanie Wyld, Australia

12:20 PM WS07.3 - Maximizing the Efficiency of the Living Donor Evaluation Process
Deirdre Sawinski, USA

12:30 PM Panel Discussion

1:00 PM Introduction: Living Liver Donation
Elizabeth Pomfret, USA
Kim Olthoff, USA

1:00 PM WS07.5 - Recruitment of Directed and Altruistic Donors
TBC

1:10 PM WS07.6 - Logistics and Practicalities of Living Liver Donor Swaps
Arvinder Soin, India

1:20 PM WS07.7 - Medical and Psychological Care of the Declined Donor
Peter Reese, USA

1:30 PM Panel Discussion

2:00 PM Introduction: Global Perspectives on Post Donation Follow Up
Arthur Matas, USA
Vivekanand Jha, India

2:00 PM WS07.8 - Global Practice of Living Kidney Donor Follow-up
Ngan Lam, Canada

2:10 PM WS07.9 - Global Practice of Living Liver Donor Follow-up
Mohamed Rela, India

2:20 PM WS07.10 - Care of Donors Who Travel
Sanjay Nagral, India

2:30 PM WS07.11 - When Donors Get Old
Robert Steiner, USA

2:40 PM Panel Discussion

3:15 PM Introduction: Strategies to Obtain Long-Term Data and Improve the Long-Term Care of Donors
John Gill, Canada
Vineeta Kumar, USA

3:15 PM Roundtable Discussion
Allyson Hart, USA
John Lake, USA
Betsy King, USA

Pre-Congress Workshops

Saturday, August 2

WS08 - Frontiers in Transplant Medication Management in a Technological Revolution (Ticketed Session)

- 1:00 PM - 4:00 PM
- Moscone South – Room 22
- Pharmacy
- CME Accredited

Moderators: Nicole Pilch, USA and Paula Krzos, USA

1:00 PM Welcome & Introduction
Nicole Pilch, USA
Paula Krzos, USA

1:00 PM WS08.1 - Introduction to AI: A Bootcamp for the Transplant Pharmacists and Clinicians
Mamatha Bhat, Canada

1:30 PM WS08.2 - Ethical Implications of Artificial Intelligence and Regulatory Considerations in Transplant Medicine
Lisiane Pruinelli, USA

2:00 PM WS08.3 - Use of Generative AI in the Medication Management of the Transplant Recipient
Aaron Boussina, USA

2:30 PM WS08.4 - Medical Education in the Age of AI: Skill Augmentation or Atrophy?
Alicia Lichvar, USA

3:00 PM Break

3:15 PM Ask the Experts Panel Discussion

WS09 - Global Perspective for Improving Organ Donation and Transplantation for Indigenous People (Ticketed Session)

- 1:00 PM - 3:30 PM
- Moscone South – Room 12
- Organ Inclusive
- CME Accredited

Moderator: Caroline Tait, Canada

1:00 PM Welcome & Introduction
Caroline Tait, Canada

1:00 PM WS09.1 - Framing the Conversation: Advancing Indigenous Priorities in Donation and Transplantation Medicine
Caroline Tait, Canada

1:10 PM WS09.2 - The Reality of Organ Donation in Aotearoa: Experience of Māori and Pasifika People
Merryn Jones, New Zealand

1:25 PM WS09.3 - Displacement in Care: The Northern and Indigenous Experience in Transplant Medicine
Veronica McKinney, Canada

1:40 PM WS09.4 - Inequities in Kidney Transplantation: Systemic Barriers for Aboriginal and Torres Strait Islander Peoples and Transplant Outcomes
Samantha Bateman, Australia

1:55 PM Q&A

2:10 PM WS09.5 - The National Indigenous Kidney Transplantation Taskforce: Changing Systems to Achieve Equitable Access to Kidney Transplantation
Kelli Owen, Australia

2:25 PM WS09.6 - Working with Indigenous People in Transplant Medicine - The BRIDGE to Transplant Initiative
Jagbir Gill, Canada

2:40 PM WS09.7 - Making it Work: Implementing Kidney Transplant Interventions to Improve Access for Indigenous Peoples in the US Southwest
Larissa Myaskovsky, USA

2:55 PM WS09.8 - Creating a culture of donation in Indigenous communities in Canada
Caroline Tait, Canada

3:10 PM WS09.9 - Partnerships to Advance Health Equity: Innovating with Rural and Northern Indigenous Communities
Anurag Singh, Canada

3:30 PM Q&A

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

Saturday, August 2

KN01 - Opening Ceremony & Keynote - From Liver Transplant to Olympic Podium - Chris Klug

4:30 PM - 5:30 PM
Moscone South – San Francisco Ballroom
Not For CME Credit

Moderator: Emily Blumberg, USA

04:30 PM Welcome & Introduction
Emily Blumberg, USA

5:00 PM **KN01.1** - From Liver Transplant to Olympic Podium
Chris Klug, USA

Welcome Reception
5:30 PM – 7:00 PM
Exhibit & Poster Hall, Exhibit Hall AB
Refreshments Provided

Sunday, August 3

IVS001 - Eplet Matching: Hype or the Way to the Transplant Lasting a Lifetime – A Debate

7:00 AM - 8:00 AM
Moscone South – Room 11
Basic Science
CME Accredited

Moderators: Howie Gebel, USA

7:00 AM Welcome & Introduction
Howie Gebel, USA

7:00 AM **IVS001.1** - Pro
Peter Nickerson, Canada

7:30 AM **IVS001.2** - Con
Anat Tambur, USA

IVS002 - Stopping the Inevitable? Approaches to Respiratory Viruses

7:00 AM - 8:00 AM
Moscone South – Room 25
Infectious Disease
CME Accredited

Moderators: Wanessa Trindade Clemente, Brazil and Andrew Karaba, USA

7:00 AM Welcome & Introduction
Wanessa Trindade Clemente, Brazil
Andrew Karaba, USA

7:00 AM **IVS002.1** - Pre-Exposure and Post-Exposure Prophylaxis for Respiratory Viruses
Nancy Law, USA

7:15 AM **IVS002.2** - Exploring the Therapeutic Pipeline for Respiratory Viruses
Michael Ison, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:30 AM **IVS002.3** - Update on Vaccinations to Prevent Respiratory Viral Infections
Victoria Hall, Canada

7:45 AM Q&A

IVS003 - Recurrent Glomerular Disease Post Kidney Transplant: Navigating the New Landscape, New Frontiers in FSGS, and Membranous Nephropathy, Session I

7:00 AM - 8:00 AM
Moscone South – Room 4
Kidney
CME Accredited

Moderators: Francesca Zanoni, Italy and Nada Alachkar, USA

07:00 AM Welcome & Introduction
Francesca Zanoni, Italy
Nada Alachkar, USA

07:00 AM **IVS003.1** - The Changing Landscape and Understanding of Recurrent Glomerular Disease After Kidney Transplantation
Leonardo Riella, USA

07:15 AM **IVS003.2** - FSGS-Recurrence: Latest Advances in Genetic Screening, Novel Immunosuppressive Strategies, Precision Approaches
Nada Alachkar, USA

07:30 AM **IVS003.3** - Membranous Nephropathy Post Kidney Transplant
Mireille El Ters, USA

07:45 AM Q&A

IVS004 - Overcoming Structural and Societal Barriers to Organ Donation

7:00 AM - 8:00 AM
Moscone South – Room 155
Public Policy
CME Accredited

Moderators: Axel Rahmel, Germany and Rudolf Garcia-Gallont, Guatemala

7:00 AM Welcome & Introduction
Axel Rahmel, Germany
Rudolf Garcia-Gallont, Guatemala

7:00 AM **IVS004.1** - What Steps Need to Be Taken to Advance Equitable Deceased Donor Transplant in India?
Sanjay Nagral, India

07:15 AM **IVS004.2** - Deceased and Living Donation in Europe - which countries are making progress and why?
Axel Rahmel, Germany

7:30 AM **IVS004.3** - Travelling for Transplant - How to Provide Care for Recipients and Donors Who Travel for Transplantation
Elmi Muller, South Africa

7:45 AM Q&A

IVS005 - Tell Me More About That: How to Do Qualitative Research in Transplantation

7:00 AM - 8:00 AM
Moscone South – Room 10
Organ Inclusive
CME Accredited

Moderators: Olivia Kates, USA and Catherine Butler, USA

7:00 AM Welcome & Introduction
Olivia Kates, USA
Catherine Butler, USA

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:00 AM **IVS005.1** - Best Papers in Transplant Qualitative Research
Elisa Gordon, USA

7:15 AM **IVS005.2** - Designing, Conducting, and Publishing Qualitative Interview Studies
Karen Vanterpool, USA

7:30 AM **IVS005.3** - The Future of Qualitative Research in the Era of AI
Rachel Patzer, USA

7:45 AM **Q&A**

IVS006 - Exploring the Immune Impact of Frailty and Aging on Solid Organ Transplant Recipients

7:00 AM - 8:00 AM
Moscone South – Room 22
Basic Science
CME Accredited

Moderators: Brittany Schreiber, USA and Laurie Snyder, USA

7:00 AM Welcome & Introduction
Brittany Schreiber, USA
Laurie Snyder, USA

7:00 AM **IVS006.1** - Effect of Physical Frailty and Aging on Recipient Outcomes in Solid Organ Transplantation
Jennifer Lai, USA

7:15 AM **IVS006.2** - Frailty and Its Association with Immune Dysfunction in Transplant Recipients
Joanna Schaenman, USA

7:30 AM **IVS006.3** - Impact of Immune Aging and Senescence on the Generation of the Alloimmune Response of Solid Organ Transplant Recipients
Stefan Tullius, USA

7:45 AM Q&A

IVS007 - Highway Guardrails: Organ Transplantation with Kidney Safety Net

7:00 AM - 8:00 AM
Moscone South – Room 154
Organ Inclusive
CME Accredited

Moderators: Richard Formica, USA and Jayme Locke, USA

7:00 AM Welcome & Introduction
Richard Formica, USA
Jayme Locke, USA

7:00 AM **IVS007.1** - Preventing Highway Robbery: Kidney Transplant Perspective on Safety Nets
Giselle Guerra, Brazil

7:15 AM **IVS007.2** - Highway to Heaven: Kidney Utilization and Outcome after Liver Transplant
Mark Russo, USA

7:30 AM **IVS007.3** - On the Road Again: The Journey of Heart Kidney Transplant and Safety Net Timing
Shelley Hall, USA

7:45 AM Q&A

IVS008 - Ancestry-Specific Variation in the Apolipoprotein L1 Gene (APOL1) and Kidney Transplant Outcomes

7:00 AM - 8:00 AM
Moscone South – Room 24
Kidney
CME Accredited

Moderators: Winfred Williams, USA and Neil Powe, USA

7:00 AM Welcome & Introduction
Winfred Williams, USA
Neil Powe, USA

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:00 AM **IVS008.1** - Overview of the Current Status of the NIH Study 7 Years Later
Barry Freedman, USA

7:20 AM **IVS008.2** - Exploring Solutions to Ethical Challenges of APOL-1 Testing
Krista Lentine, USA

7:30 AM **IVS008.3** - Living Donor Extended Time Outcomes (LETO Study)
Chi-Yuan Hsu, USA

7:40 AM **IVS008.4** - APOL1 Bi and Monoallelic Variants and Chronic Kidney Disease in West Africans
Akinlolu Ojo, USA

7:50 AM Q&A

IVS009 - Current Status of Uterus Transplantation

7:00 AM - 8:00 AM
Moscone South – Room 9
VCA
CME Accredited

Moderators: Paige Porrett, USA and Kim Olthoff, USA

7:00 AM Welcome & Introduction
Paige Porrett, USA
Kim Olthoff, USA

7:00 AM **IVS009.1** - Uterus Transplantation - Current State and Future Application
Liza Johannesson, USA

7:15 AM **IVS009.2** - Cost-Effectiveness of Uterine Transplant Versus Other Pathways to Parenthood
Kathleen O'Neill, USA

7:30 AM **IVS009.3** - Unique Aspects of the Immune Response in Uterus Transplantation
Giuliano Testa, USA

07:45 AM Q&A

LOA01 - Transplantation: Patient Access and Provider Perceptions

7:00 AM - 8:00 AM
Moscone South – Room 21
Organ Inclusive
Not For CME Credit

Moderators: Carrie Thiessen, USA and Daniel Borja-Cacho, USA

7:00 AM Welcome & Introduction
Carrie Thiessen, USA
Daniel Borja-Cacho, USA

7:02 AM **LOA01.1** - Recovery Without Equity: The Complex Post-COVID Landscape of Transplantation in Mexico
Marco Arizmendi, Mexico

7:09 AM Q&A

7:11 AM **LOA01.2** - Analysis of Kidney and Liver Exchange Transplantation in India (2000-2025): A Multicentre, Retrospective Cohort Study
Vivek Kute, India

7:18 AM Q&A

7:20 AM **LOA01.3** - Strategic Insights into Organ Donation: Analyzing Perceptions, Attitudes, and Disincentive Removal Effects
Marco Arizmendi, Mexico

7:27 AM Q&A

7:29 AM **LOA01.4** - Consent and Complexity: Organ Donation Decisions in a Multicultural UAE Organ Donation Program HAYAT
Lijamol Joseph, United Arab Emirates

7:36 AM Q&A

7:38 AM **LOA01.5** - When Biology Meets Bureaucracy: Organ Waiting Times of Deceased Donor Organ Transplantation. 13 Years of Transplants in Mexico
Javier Sanchez Maldonado, Mexico

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:45 AM Q&A

7:47 AM **LOA01.6** - Transplant Professionals perception towards age and solid organ transplant: Survey results
Manpreet Samra, USA

7:54 AM Q&A

7:56 AM Closing Remarks

RF01 - Fundamentals of Transplantation Science

7:00 AM - 8:00 AM
Moscone South – Room 12
Basic Science
Not For CME Credit

Moderators: Peter Heeger, USA and Brendan Keating, USA

7:00 AM Welcome & Introduction
Peter Heeger, USA
Brendan Keating, USA

7:02 AM **RF01.1** - Use of BMT CTN 1202 Study Samples to Identify Prognostic Biomarkers for Chronic Graft-versus-Host Disease with Peripheral Blood Hematopoietic Cell Transplant Recipients
Joseph Douglas, USA

7:07 AM Q&A

07:09 AM **RF01.2** - Integrated Multi-Omics and Murine Models Identify CSF1 as a Therapeutic Target in Chronic Allograft Rejection Following Kidney Transplantation
Chao Yang, China

7:14 AM Q&A

7:16 AM **RF01.3** - Single-Cell RNA/TCR Sequencing: Do Urinary CD8+ T Cell Populations Accurately Reflect Transcriptional Profiling of Allograft Infiltrating CD8⁺ T Cell Populations?
Ramiah Caine, USA

7:21 AM Q&A

7:23 AM **RF01.4** - Genetic Polymorphisms of LILRB3 Drive Monocyte-Mediated Inflammation in Acute Kidney Injury
Chengguo Wei, USA

7:28 AM Q&A

7:30 AM **RF01.5** - Exogenous Mitochondrial Therapy during Machine Perfusion Restores the Function of Livers Donated After Circulatory Death A Cross-Circulation Evaluation for Clinical Transplantability
Gabriel Oniscu, Sweden

7:35 AM Q&A

7:37 AM **RF01.6** - Synergistic Effects of MKK4 Inhibitor and Ex Vivo Gene Therapy on Liver Regeneration in a Porcine Model of FAH Deficiency: Progress Towards Human Liver Production in Chimeric Pigs
Sara Kazeminia, USA

7:42 AM Q&A

7:44 AM **RF01.7** - The Use of Nanocomposite Materials Tagged with Deferoxamine to Facilitate Iron Chelation and Mitigation of Ferroptosis and Ischemia Reperfusion Injury of Livers Using Novel Normothermic Perfusion Pump
Mustafa Nazzal, USA

7:49 AM Q&A

7:51 AM Closing Remarks

RF02 - Hot Topics in Heart Transplantation

7:00 AM - 8:00 AM
Moscone South – Room 20
Heart
Not For CME Credit

Moderators: Eman Hamad, USA and Anne Dipchand, Canada

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:00 AM Welcome & Introduction
Eman Hamad, USA
Anne Dipchand, Canada

7:02 AM **RF02.1** - A Novel Donor-Recipient Risk Index to Predict Short-Term Outcomes in Pediatric Heart Transplantation
Jeremy Birkmire, USA

7:07 AM Q&A

7:09 AM **RF02.2** - Long-Term Outcomes of Total Lymphoid Irradiation (TLI) Following Pediatric Heart Transplantation
Peter Chin, USA

7:14 AM Q&A

7:16 AM **RF02.3** - Does the Binding Strength of Multiple Donor Specific Antibodies Crossed at the Time of Heart Transplant Impact Post-Transplant Outcomes?
David Chang, USA

7:21 AM Q&A

7:23 AM **RF02.4** - Heart Transplantation from Donation After Circulatory Death Donors: Comparison of the OCS Heart and Non-OCS Methods
David D'Alessandro, USA

7:28 AM Q&A

7:30 AM **RF02.5** - Over 1,000 Heart Transplants Using Donation After Circulator Death (DCD) Donors: Real-World Experience with the Organ Care System (OCS) Heart
Yasuhiro Shudo, USA

7:35 AM Q&A

7:37 AM **RF02.6** - Large Heart Transplant Meta-Analysis Reveals Several New Genetic Associations with Post-Transplant Outcomes
Vincent Mauduit, USA

7:42 AM Q&A

7:44 AM **RF02.7** - Outcomes of C1q Positive De Novo Donor-Specific Antibodies Following Heart Transplantation
Achilles Aiken, USA

7:49 AM Q&A

7:51 AM **RF02.8** - Evaluation of the Long-Term Outcomes of Hypomagnesemia Post Heart Transplantation
Morgan Baughman, USA

7:56 AM Q&A

7:58 AM Closing Remarks

RF03 - Graft Under Pressure: Navigating BK Virus

7:00 AM - 8:00 AM
Moscone South – Room 23
Infectious Disease
Not For CME Credit

Moderators: Hans Hirsch, Switzerland and Shweta Anjan, USA

7:00 AM Welcome & Introduction
Hans Hirsch, Switzerland
Shweta Anjan, USA

7:02 AM **RF03.1** - Molecular and Histological Insights into BK Virus-Associated Nephropathy in Kidney Transplant Recipients
Ambreen Azhar, USA

7:07 AM Q&A

7:09 AM **RF03.2** - RNASeq Changes Associated with Polyomavirus-Associated Nephropathy: From Pathophysiology to Drug Repurposing
Alexis Piedrafita, France

7:14 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:16 AM **RF03.3** - Adding on mTOR Inhibitors May Help Reducing Viral Load in BK Polyomavirus Infection After Kidney Transplantation
Sy-Yuan Chen, Taiwan

7:21 AM Q&A

7:23 AM **RF03.4** - Immune Predictors of BK Viremia Clearance: Role of BK Virus-Specific T-Cell Immunity in Kidney Transplant Recipients
Ambreen Azhar, USA

7:28 AM Q&A

7:30 AM **RF03.5** - Comparative Analysis of Immunosuppressant Adjustments in BK Viremia Management: Sirolimus, Leflunomide, and MMF Tapering
Hye Eun Kwon, South Korea

7:35 AM Q&A

7:37 AM **RF03.6** - Intravenous Immunoglobulin as Adjunctive Treatment for BK DNAemia
Matthew D'Costa, Singapore

7:42 AM Q&A

7:44 AM **RF03.7** - Changes in the Duration and Severity of BK Viral Load May as a Surrogate Outcome in Trials to Advance New Therapeutics for BK Virus
Ross Doyle, Canada

7:49 AM Q&A

7:51 AM **RF03.8** - The Risk Factors Developing BK Viraemia and Its Viral Kinetics in Kidney Transplant Recipients
Nicole Clarke, USA

7:56 AM Q&A

7:58 AM Closing Remarks

RF04 - Deceased Donor Kidney Allocation

7:00 AM - 8:00 AM
Moscone South – Room 153
Kidney
Not For CME Credit

Moderators: Jean Tchervenkov, Canada and Jeffrey Stern, USA

7:00 AM Welcome & Introduction
Jean Tchervenkov, Canada
Jeffrey Stern, USA

7:02 AM **RF04.1** - Obesity and Access to Out-of-Sequence Deceased Donor Kidney Transplantation
John Montgomery, USA

7:07 AM Q&A

7:09 AM **RF04.2** - Pretransplant Virtual Epitope-Based Crossmatch is Associated with Worse Outcomes After Kidney Transplantation
Tainá Freitas, Brazil

7:14 AM Q&A

7:16 AM **RF04.3** - CPRA Sensitization Priority: The Need to Recalculate After Implementation of 250 nm Sharing Circles
Kenneth Andreoni, USA

7:21 AM Q&A

7:23 AM **RF04.4** - Plasma Uromodulin Dynamics in Deceased Donors: A Marker of Tubular Integrity for Post-Transplant Kidney Function
Ioannis Michelakis, United Kingdom

7:28 AM Q&A

7:30 AM **RF04.5** - Hypothermic Machine Perfusion Parameters Are Associated with Donor Characteristics and Post-Transplant Outcomes in Deceased Donor Kidney Transplant
Jennifer Philip, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:35 AM Q&A

7:37 AM **RF04.6** - A Pilot Randomized Trial of Approaches to Deceased Donor Kidney Procurement Biopsies: Operational Challenges and Lessons Learned
Krista Lentine, USA

7:42 AM Q&A

7:44 AM **RF04.7** - Taking One for the Team, Should the Time Limit for Reinstatement of Waiting Time After Early Graft Loss Be Extended?
Douglas Keith, USA

7:49 AM Q&A

7:51 AM Closing Remarks

RF05 - Kidney: Cardiometabolic Issues

7:00 AM - 8:00 AM
Moscone South – Room 8
Kidney
Not For CME Credit

Moderator: Vikas Sridhar, Canada

7:00 AM Welcome & Introduction
Vikas Sridhar, Canada

7:02 AM **RF05.1** - Association of Right Ventricular Strain with Cardiovascular Outcomes in Kidney Transplant Recipients
Cayden Lawrence, USA

7:07 AM Q&A

7:09 AM **RF05.2** - Interplay of Inflammation, Dysregulated Angiogenesis, and Coronary Microvascular Dysfunction Among Patients Being Evaluated for Kidney Transplant
Daniel Huck, USA

7:14 AM Q&A

7:16 AM **RF05.3** - Pre-Transplant Revascularization Reduces Post-Kidney Transplant Major Adverse Cardiovascular Events
Khang Nguyen, USA

7:21 AM Q&A

7:23 AM **RF05.4** - The Effect of Kidney Allograft Rejection on Post-Transplant Cardiovascular Complications
Suwasin Udomkarnjananun, Thailand

7:28 AM Q&A

7:30 AM **RF05.5** - Tolerability of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) in Kidney Transplant Recipients with Diabetes
Vineeta Kumar, USA

7:35 AM Q&A

7:37 AM **RF05.6** - The Impact of Anticoagulation on Post-Transplant Complications - Impact on Deceased Donor Recipients
Julio Cisneros Correa, USA

7:42 AM Q&A

7:44 AM **RF05.7** - The Impact of Obesity and Health Insurance on Kidney Transplantation and Waiting List Mortality
Tatenda Mupfudze, USA

7:49 AM Q&A

7:51 AM **RF05.8** - Preeclampsia in Kidney Transplant Recipients during Pregnancy and Its Impact on Graft Survival
Ophelia Yin, USA

7:56 AM Q&A

7:58 AM Closing Remarks

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS010 - Transplant Oncology: Challenges and Innovation

8:15 AM - 9:30 AM
Moscone South – Room 23
Organ Inclusive
CME Accredited

Moderators: John Fung, USA and Ala Ali, Iraq

8:15 AM Welcome & Introduction
John Fung, USA
Ala Ali, Iraq

8:15 AM IVS010.1 - Transplant Oncology - Liver: Challenges and Strategies to Advance the Field
Anjana Pillai, USA

8:30 AM IVS010.2 - Challenges and Innovation of Transplant Onconephrology
Naoka Murakami, USA

8:45 AM IVS010.3 - Challenges and Opportunities in Thoracic Transplant Oncology
Ankit Bharat, USA

9:00 AM IVS010.4 - Panel Discussion

IVS011 - An Update from TPAC (Transplant Pharmacy Adherence Consortium) on Transplant Adherence Sharing Published Experiences and Lessons Learned

8:15 AM - 9:30 AM
Moscone South – Room 10
Pharmacy
CME Accredited

Moderators: Helen Sweiss, USA and Matt Harris, USA

8:15 AM Welcome & Introduction
Helen Sweiss, USA
Matt Harris, USA

8:15 AM IVS011.1 - TRAMM Tool 2.0: Tips for Practice Utilization and EMR Integration
Ann Kataria, USA

8:35 AM IVS011.2 - Share Strategies to Implement the Newly Developed Transplant Medication Adherence Videos Within Your Clinical Practice
Krysta Walter, USA

8:55 AM IVS011.3 - Technology-Based Adherence Solutions
Tiffany Kaiser, USA

9:15 AM Q&A

IVS012 - Cell Therapy – Novel Approaches to Refine Immunosuppression and Immunity

8:15 AM - 9:30 AM
Moscone South – Room 22
Basic Science
CME Accredited

Moderators: Heth Turnquist, USA and Megan Sykes, USA

8:15 AM Welcome & Introduction
Heth Turnquist, USA
Megan Sykes, USA

8:15 AM IVS012.1 - OX40l CAR-Directed Treg: Biology and Clinical Implications
Leslie Kean, USA

8:33 AM IVS012.2 - Translating TIRC7 Expressing Treg to the Clinic
Nalan Utku, Germany

8:51 AM IVS012.3 - Using DC Regulatory Cells in Humans
Angus Thomson, USA

9:09 AM IVS012.4 - Adoptive Cell Therapy for Viral Infection in Transplant Recipients
Susan Prockop, USA

9:27 AM Q&A

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS013 - Multi-drug-resistant Organisms: Challenging Cases

8:15 AM - 9:30 AM
Moscone South – Room 154
Infectious Disease
CME Accredited

Moderators: Ghady Haidar, USA and Tina Marinelli, Australia

8:15 AM Welcome & Introduction
Ghady Haidar, USA
Tina Marinelli, Australia

8:15 AM Panelists
Paolo Grossi, Italy
Priscilla Rupali, India
Ghadeer Al-Ahmadi, Saudi Arabia
Saima Aslam, USA

IVS014 - Multiorgan Transplantation in Pediatrics

8:15 AM - 9:30 AM
Moscone South – Room 12
Organ Inclusive
CME Accredited

Moderators: Amy Bobrowski, USA and Carlos Esquivel, USA

8:15 AM Welcome & Introduction
Amy Bobrowski, USA
Carlos Esquivel, USA

8:15 AM IVS014.1 - Indications/Outcomes/Future Directions of Pediatric Multiorgan Transplant
Armando Ganoza, USA

8:30 AM IVS014.2 - Simultaneous Peds Heart/Kidney - When to Pull the Trigger
Swati Choudhry, USA

8:45 AM IVS014.3 - Combined Liver/Kidney Transplantation for Children
Lars Pape, Germany

9:00 AM IVS014.4 - Ethical Considerations fo Multiorgan Transplantation in Children
Anji Wall, USA

9:15 AM Q&A

IVS015 - International Selection Panel for Lung Transplant

8:15 AM - 9:30 AM
Moscone South – Room 11
Lung
CME Accredited

Moderators: Deborah Levine, USA

8:15 AM Welcome & Introduction
Deborah Levine, USA

8:15 AM Panel Discussion
Jasleen Kukreja, USA
Robin Vos, Belgium
Marie Budev, USA
Maryam Valapour, USA
Konrad Hoetzenecker, USA

IVS016 - The Global Perspective on Organ Donation

8:15 AM - 9:30 AM
Moscone South – Room 153
Organ Inclusive
CME Accredited

Moderators: Philip O'Connell, Australia and Alex Capron, USA

8:15 AM Welcome & Introduction
Philip O'Connell, Australia
Alex Capron, USA

8:15 AM IVS016.1 - Deceased Organ Donation
Axel Rahmel, Germany

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:30 AM **IVS016.2** - Living Kidney Donation
Vivekanand Jha, India

8:45 AM **IVS016.3** - Living Liver Donation
Mohamed Rela, India

9:00 AM **IVS016.4** - Donor Care Centers
Emily Vail, USA

9:15 AM Q&A

IVS017 - Clinical Trials: How Do We Promote Innovation?

8:15 AM - 9:30 AM
Moscone South – Room 25
Organ Inclusive
CME Accredited

Moderators: Roy Bloom, USA and Germaine Wong, Australia

8:15 AM Welcome & Introduction
Roy Bloom, USA
Germaine Wong, Australia

8:15 AM **IVS017.1** - Faster Cheaper Better Trials
Michael Collins, Australia

8:30 AM **IVS017.2** - Industry Perspective / Precision Medicine-Based Trials
Amit Sharma, USA

8:45 AM **IVS017.3** - Innovative Trial Designs
Laura Esserman

9:00 AM **IVS017.4** - PROMs
Roshan George, USA

9:15 AM Q&A

IVS018 - Role of Robotics in Transplantation: Are We Ready for Prime Time?

8:15 AM - 9:30 AM
Moscone South – Room 21
Organ Inclusive
CME Accredited

Moderators: Adeel Khan, USA and Danielle Haakinson, USA
8:15 AM Welcome & Introduction
Adeel Khan, USA
Danielle Haakinson, USA

8:15 AM **IVS018.1** - Advances in Robotic Liver Transplantation: The Donor
Yee Lee Cheah, USA

8:30 AM **IVS018.2** - Advances in Robotic Liver Transplantation: The Recipient
Dieter Broering, Saudi Arabia

8:45 AM **IVS018.3** - Advances in Robotic Kidney Transplantation: The Donor
Jesse Davidson, USA

9:00 AM **IVS018.4** - The Next Frontiers in Minimally Invasive Surgery for Transplantation: The Recipient
Phillipe Abreu, USA

9:15 AM **IVS018.5** - The Next Frontiers in Minimally Invasive Surgery for Transplantation
Pier Giulianotti, USA

IVS019 - Prehabilitation: A Proactive Approach to Improving Transplant Outcomes

8:15 AM - 9:30 AM
Moscone South – Room 20
Organ Inclusive
CME Accredited

Moderators: Markus Quante, Germany and Tania Janaudis Ferreira, Canada

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:15 AM Welcome & Introduction
Markus Quante, Germany
Tania Janaudis Ferreira, Canada

8:15 AM **IVS019.1** - Perioperative Considerations in Older Recipients
Babak Orandi, USA

8:27 AM **IVS019.2** - Anesthetic Considerations to Optimize Post-transplant Recovery
Jan Larmann, Germany

8:39 AM **IVS019.3** - Updates in Innovations in Prehabilitation for Solid Organ Transplant Recipients
Tania Janaudis Ferreira, Canada

8:51 AM **IVS019.4** - Frailty in Kidney Transplant Recipients
Christine Liu, USA

9:03 AM Q&A

IVS020 - Making It Easier: Removing Disincentives and Barriers from Live Donation

8:15 AM - 9:30 AM
Moscone South – Room 155
Public Policy
CME Accredited

Moderators: Didier Mandelbrot, USA and Anju Yadav, USA

8:15 AM Welcome & Introduction
Didier Mandelbrot, USA
Anju Yadav, USA

8:15 AM **IVS020.1** - Living Donor Protection Act
Dempsey Hughes, USA

8:30 AM **IVS020.2** - Improving the Efficiency of Living Donor Process
Deirdre Sawinski, USA

8:45 AM **IVS020.3** - Financial Neutrality for Living Donors - NLDAC, LDCOE and Other Governmental Programs
Syed Husain, USA

9:00 AM **IVS020.4** - Crowdfunding for Living Donors?
Carrie Thiessen, USA

9:15 AM Q&A

IVS021 - Manipulation of Organs During Machine Perfusion

8:15 AM - 9:30 AM
Moscone South – Room 24
Organ Inclusive
CME Accredited

Moderators: Chris Johnston, UK and Abraham Shaked, USA

8:15 AM Welcome & Introduction
Chris Johnston, UK
Abraham Shaked, USA

8:15 AM **IVS021.1** - Mending Broken Hearts: Organ Reconditioning for Transplantation Using siRNA-based Therapies During Ex Vivo Machine Perfusion
Seyed Alireza Rabi, USA

8:30 AM **IVS021.2** - Ex Vivo Lung Reconditioning: Xenotransplantation of Mitochondria
Sandra Lindstedt, Sweden

8:45 AM **IVS021.3** - Opportunities to Optimize Livers During Perfusion: The Role of Sequential Perfusion Technology
Rohit Gaurav, UK

9:00 AM **IVS021.4** - Ex Vivo Kidney Modulation: Opportunities for Drug Delivery and Organ Repair
Leonie van Leeuwen, USA

9:15 AM Q&A

Detailed Program

Sunday, August 3

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS022 - Harnessing AI for Efficiency and Precision in Transplantation

8:15 AM - 9:30 AM
Moscone South – Room 8
Organ Inclusive
CME Accredited

Moderators: Lisiane Pruinelli, USA and Ashley Spann, USA

8:15 AM Welcome & Introduction
Lisiane Pruinelli, USA
Ashley Spann, USA

8:15 AM IVS022.1 - AI: How it Started
Antony Attia, UK

8:30 AM IVS022.2 - AI: How It's Going: Clinical Decision Making
Mamatha Bhat, Canada

8:45 AM IVS022.3 - AI: How It's Going: Transplant Health Systems
Leyla Warsame, USA

9:00 AM IVS022.4 - AI: Where It Could Lead Us
Allan Kirk, USA

9:15 AM Q&A

IVS023 - Current Status of Hand and Face Transplantation

8:15 AM - 9:30 AM
Moscone South – Room 9
VCA
CME Accredited

Moderators: Matthew Levine, USA and Sue Valerie McDiarmid, USA

8:15 AM Welcome & Introduction
Matthew Levine, USA
Sue Valerie McDiarmid, USA

8:15 AM IVS023.1 - Hand Transplantation - Past, Present, and Future - Is It Time for Standard of Care?
Scott Levin, USA

8:30 AM IVS023.2 - Face Transplantation - Past Present and Future
Laurent Lantieri, France

8:45 AM IVS023.3 - The Role of NASEM in Validating Hand and Face Transplant in the USA
Linda Cendales, USA

9:00 AM IVS023.4 - Unique Aspects of Immunosuppression in Face and Hand Transplant
Bruce Gelb, USA

9:15 AM Q&A

IVS024 - Innovations to Expand Living Kidney Donation

8:15 AM - 9:30 AM
Moscone South – Room 4
Kidney
CME Accredited

Moderators: Hatem Amer, USA and Lloyd Ratner, USA

8:15 AM Welcome & Introduction
Hatem Amer, USA
Lloyd Ratner, USA

8:15 AM IVS024.1 - Kidney Paired Donation
Matthew Cooper, USA

8:27 AM IVS024.2 - Advanced Donation and Reciprocity-Based Strategies
Justin Gill, Canada

8:39 AM IVS024.3 - Elimination of Financial Disincentives / Incentives
Elisa Gordon, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:51 AM **IVS024.4** - From Stagnation to Transformation: A Multisystem Strategy for Growth
James Rodrigue, USA

9:03 AM Q&A

KN02 - The Health Misinformation Crisis! - Timothy Caulfield

10:00 AM - 10:30 AM
Moscone South – San Francisco Ballroom
Not for CME Credit

Moderators: Ginny Bumgardner, USA and James Markmann, USA

10:00 AM Welcome & Introduction
Ginny Bumbgardner, USA
James Markmann, USA

10:00 AM **KN02.1** - The Health Misinformation Crisis!
Timothy Caulfield, Canada

PL01 - Plenary Abstracts 1

10:30 AM - 11:30 AM
Moscone South – San Francisco Ballroom
Not for CME Credit

Moderators: Ginny Bumgardner, USA and James Markmann, USA

10:30 AM Welcome & Introduction
Ginny Bumbgardner, USA
James Markmann, USA

10:30 AM **PL01.2** - Longest Surviving Recipient of a Xenotransplant: Allo-Sensitized Patient Receiving a 10 Gene-Edited Pig Kidney
Robert Montgomery, USA

10:42 AM Q&A

10:45 AM **PL01.3** - Burdens of Therapy: AST's National Patient Survey of Unmet Immunosuppressant Needs
David Taber, USA

10:57 AM Q&A

11:00 AM **PL02.2** - Virus-Inclusive Single-Cell RNA Sequencing Reveals Broad Cellular Tropism and Common Pathway Dysfunctions Linked to Cytomegalovirus Infection in Organ Transplant Recipients
Victor Ferreira, Canada

11:12 AM Q&A

11:15 AM **PL01.5** - Ischemia-Free Procedure Reshapes the Local and Systemic Immunity in Liver Transplantation
Zhiyong Guo, China

11:27 AM Q&A

IVS025 - How to Optimise a More Global Research Infrastructure Redefining the Clinical and Scientific Landscape in the Era of AI

2:15 PM - 3:30 PM
Moscone South – Room 8
Organ Inclusive
CME Accredited

Moderators: Rutger Ploeg, UK and Timothy Pruett, USA

2:15 PM Welcome & Introduction
Rutger Ploeg, UK
Timothy Pruett, USA

2:20 PM **IVS025.2** - Fingerprinting the Donor and Organ Quality Predicting Post Transplant Outcomes
Maria Kaisar, UK

2:35 PM **IVS025.3** - Genetic and Other Recipient Factors Impacting Success in Transplantation
Brendan Keating, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:50 PM **IVS025.4** - A Robust Snapshot of Relevant Donor and Recipients Factors in Kidney Transplantation
TBC

3:05 PM Panelists Plus 1 Minute Vision Statement

IVS025.5 - Role and Vision of NIH of Integrated Bioresources and AI
Anthony Langone, USA

IVS025.6 - Platform Development and Collaboration (QUOD Perspective)
Maria Kaisar, UK

IVS025.7 - Integrated Bioresources and AI - iGeneTRAIN Perspective
Brendan Keating, USA

IVS025.8 - Integrated Bioresources and AI - KIT-GENIE Perspective
Chris Jaynes, USA

IVS026 - Mechanisms of Antibody Mediated Rejection

2:15 PM - 3:30 PM
Moscone South – Room 12
Basic Science
CME Accredited

Moderators: Scott Krummey, USA and Carrie Schinstock, USA

2:15 PM Welcome & Introduction
Scott Krummey, USA
Carrie Schinstock, USA

2:15 PM **IVS026.1** - Intra-Graft B Cell Populations After Heart Transplantation
Emmanuel Zorn, USA

2:29 PM Q&A

2:33 PM **IVS026.2** - Control of Antibody Mediated Rejection by CD4+ Follicular T Populations
Peter Sage, USA

2:47 PM Q&A

2:51 PM **IVS026.3** - Identification of Epitopes Associated with Indirect Alloreactivity
Christian Larsen, USA

3:05 PM Q&A

3:09 PM **IVS026.4** - Formation and Maintenance of Graft-Specific Plasma Cells
David Allman, USA

3:23 PM Q&A

IVS027 - Empowering Care Teams: Allied Health-Led Multidisciplinary Clinics for Transplant Patients

2:15 PM - 3:30 PM
Moscone South – Room 10
APP
CME Accredited

Moderators: Eliana Agudelo, USA and Hazel Domingo, USA

2:15 PM Welcome & Introduction
Eliana Agudelo, USA
Hazel Domingo, USA

2:15 PM **IVS027.1** - Decoding the Tower of Babel in Rejection: APP-Led Initiative in Complex Immunologic Cases
Staci McKean, USA

2:30 PM **IVS027.2** - Breaking Boundaries: APP-Led Specialty Clinic for ABO Incompatible and HIV-Positive Transplant Patients
Darnell Mompoint-Williams, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:45 PM **IVS027.3** - Guardians of Immunity: Pharmacy-Led CMV Stewardship for Transplant Recipients
Jillian Fose, USA

3:00 PM **IVS027.4** - Too Sweet: Pharmacy-Led Post-Transplant Diabetes Management Clinic
Janice Kerr, USA

3:15 PM Q&A

IVS028 - Heart Transplant Selection Criteria: Urban Legends, Myths, and Lies (Where's the Data?)

2:15 PM - 3:30 PM
Moscone South – Room 155
Heart
CME Accredited

Moderators: Monica Colvin, USA and Jeffrey Teuteberg, USA

2:15 PM Welcome & Introduction
Monica Colvin, USA
Jeffrey Teuteberg, USA

2:15 PM Panelists
Eileen Hsich, USA
Shelley Hall, USA
Seyed Alireza Rabi, USA
Anne Dipchand, Canada
Pedro Catarino, USA

IVS029 - The ABCs of CMV

2:15 PM - 3:30 PM
Moscone South – Room 24
Infectious Disease
CME Accredited

Moderators: Camille Kotton, USA and Helio Tedesco Silva, Brazil

2:15 PM Welcome & Introduction
Camille Kotton, USA
Helio Tedesco Silva, Brazil

2:15 PM **IVS029.1** - Introduction to the New International Consensus Guidelines
Camille Kotton, USA

2:20 PM **IVS029.2** - CMV Prophylaxis vs Pre-emptive Therapy
Atul Humar, Canada

2:40 PM **IVS029.3** - New Approaches for Treatment
Raymund Razonable, USA

3:00 PM **IVS029.4** - Moving Forward with CMV Cell-mediated Immunity
Deepali Kumar, Canada

3:20 PM Q&A

IVS030 - Update on OPTN in the USA

2:15 PM - 3:30 PM
Moscone South – Room 25
Public Policy
CME Accredited

Moderators: Nicole Turgeon, USA and Henry Randall, USA

2:15 PM Welcome & Introduction
Nicole Turgeon, USA
Henry Randall, USA

2:15 PM **IVS030.1** - The History of the OPTN and its Accomplishments
Jeffrey Crippin, USA

2:30 PM **IVS030.2** - Don't Throw the Baby Out with the Bathwater
Richard Formica, USA

2:45 PM **IVS030.3** - HRSA Perspective for the Future
Raymond Lynch, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

3:00 PM IVS030.4 - Patient Perspectives from Within the Field
Silke Niederhaus, USA

3:15 PM Q&A

IVS031 - Nonutilization: How Do We Flip the Switch to Increase Utilization?

2:15 PM - 3:30 PM
Moscone South – Room 154
Organ Inclusive
CME Accredited

Moderators: Ty Dunn, USA and Sumit Mohan, USA

2:15 PM Welcome & Introduction
Ty Dunn, USA
Sumit Mohan, USA

2:15 PM IVS031.1 - Is Non-use Mainly a US Problem?
Peter Reese, USA

2:30 PM IVS031.2 - Factors Contributing to Nonuse in the US
Darren Stewart, USA

2:45 PM IVS031.3 - Perspective on Utilization from Other Parts of the World
Axel Rahmel, Germany

3:00 PM Panel Discussion: Which of These Policies Should Be Promoted or Abandoned? Multiple Listing, Out of Sequence Offers, Incorporating Patient Choice In Organ Allocation, Preemptive Transplant of High KDPI Kidneys?

IVS032 - Non-invasive Biomarkers for Monitoring Kidney Transplant Recipients

2:15 PM - 3:30 PM
Moscone South – Room 4
Kidney
CME Accredited

Moderators: Carla Baan, Netherlands and Jennifer Li, Australia

2:15 PM Welcome & Introduction
Carla Baan, Netherlands
Jennifer Li, Australia

2:15 PM IVS032.1 - Clinical Utility of Donor-Derived Cell-Free DNA Monitoring After Kidney Transplant
Klemens Budde, Germany

2:30 PM IVS032.2 - Comparison of Different Blood Transcriptomics for Rejection or Immune Quiescence
Enver Akalin, USA

2:45 PM IVS032.3 - Urinary Exosomes and Transcriptomics for Diagnosis of Rejection
Jamil Azzi, USA

3:00 PM IVS032.4 - The IBOX Prognostication System
Alexandre Loupy, France

3:15 PM Q&A

IVS034 - Intestinal Transplantation Around the World: Updates and Perspectives

2:15 PM - 3:30 PM
Moscone South – Room 23
Intestine
CME Accredited

Moderators: Joshua Weiner, USA and Maria Segovia, USA

2:15 PM Welcome & Introduction
Joshua Weiner, USA
Maria Segovia, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:15 PM **IVS034.1** - North America
Cal Matsumoto, USA

2:25 PM **IVS034.2** - South America
Gabriel Gondolesi, USA

2:35 PM **IVS034.3** - Europe
Francisco Hernandez Oliverios, Spain

2:45 PM **IVS034.4** - Middle East
Ehab Abufarhaneh, Saudi Arabia

2:55 PM **IVS034.5** - Asia
Guosheng Wu, China

3:05 PM **IVS034.6** - Oceania
Adam Testro, Australia

3:15 PM Q&A

IVS035 - Working Beyond Borders: It Takes an International Village

2:15 PM - 3:30 PM
Moscone South – Room 21
Organ Inclusive
CME Accredited

Moderators: Philip O'Connell, Australia and Michelle Josephson, USA

2:15 PM Welcome & Introduction
Philip O'Connell, Australia
Michelle Josephson, USA

2:15 PM **IVS035.1** - The Pharmaceutical Industry's Role in Expanding Global Health Initiatives
Stefano M. Bertozzi, USA

2:30 PM **IVS035.2** - Developing Deceased Organ Donation in Africa
David Thomson, South Africa

2:45 PM **IVS035.3** - How Can Developed Countries Best Help Developing Countries?
Jeffrey Punch, USA

3:00 PM **IVS035.4** - Beyond Who: Enabling Global Capacity and Expertise
Vivekanand Jha, India

3:15 PM Panel Discussion

IVS036 - Sex in Transplantation

2:15 PM - 3:15 PM
Moscone South – Room 11
Basic Science
CME Accredited

Moderators: Melanie Wyld, Australia and Anette Melk, Germany

2:15 PM Welcome & Introduction
Melanie Wyld, Australia
Anette Melk, Germany

2:15 PM **IVS036.1** - Sex Differences in Immune Responses
Shannon Dunn

2:30 PM Q&A

2:35 PM **IVS036.2** - Impact of Hormones and Hormonal Receptors on Autoimmunity
Friederike Martin, USA

2:50 PM Q&A

2:55 PM **IVS036.3** - Loss of Y: Implications for Transplantation
Andrew Malone, Ireland

3:10 PM Q&A

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS037 - Debrief of the First Annual DEI in Transplant Conference: Charting the Path Toward Equity in Transplantation

2:15 PM - 3:15 PM
Moscone South – Room 20
Organ Inclusive
CME Accredited

Moderators: Cynthia Tsien, Canada and Nazia Selzner, Canada

2:15 PM Welcome & Introduction
Cynthia Tsien, Canada
Nazia Selzner, Canada

2:15 PM IVS037.1 - Transforming Healthcare Systems to Support Transplant Professionals
Nigel Girgrah, USA

2:30 PM IVS037.2 - Gender, Racial, and Age Disparities Amongst Solid Organ Transplant Recipients
Lisa McElroy, USA

2:45 PM IVS037.3 - Gift of Life: Navigating the Journey to Find a Live Donor
Heather Badenoch, Canada

3:00 PM Q&A

IVS038 - Mens Sana in Corpore Sano - The Underappreciated Issues of Mental Health in Transplant

2:15 PM - 3:15 PM
Moscone South – Room 22
Psychosocial & Ethics
CME Accredited

Moderators: Max Weder, USA and Jody Jones, USA

2:15 PM Welcome & Introduction
Max Weder, USA
Jody Jones, USA

2:15 PM IVS038.1 - Incorporating Tools to Assess Mental Health and Cognitive Function in the Transplant Evaluation
Paula Zimbrean, USA

2:30 PM IVS038.2 - Assessing and Managing Post-transplant Delirium
Makayla Cordoza, USA

2:45 PM IVS038.3 - Caregiver Fatigue and Burnout
Ken Lotherington, Canada

3:00 PM Q&A

LOA02 - Liver Transplantation and Machine Perfusion

2:15 PM - 3:30 PM
Moscone South – Room 9
Liver
Not for CME Credit

Moderators: Aleah Brubaker, USA and Shennen Mao, USA

2:15 PM Welcome & Introduction
Aleah Brubaker, USA
Shennen Mao, USA

2:17 PM LOA02.1 - Normothermic Machine Perfusion Equalizes Graft Survival in DCD and DBD Liver Transplantation
Michelle Nguyen, USA

2:24 PM Q&A

2:26 PM LOA02.2 - Are the Flows Sufficient? Potential of Oxygen Extraction Ratio during Normothermic Machine Perfusion of Human Liver Grafts as a Marker of Perfusion Quality.
Khaled Ali, USA

2:33 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:35 PM **LOA02.3** - Low Bile Output During Normothermic Machine Perfusion Is Not Predictive of Poor Graft Outcomes
Stephanie Ohara, USA

2:42 PM Q&A

2:44 PM **LOA02.4** - The Impact of Routine Application of Normothermic Machine Perfusion in Liver Transplantation: Making the Unacceptable Acceptable
Valberto Sanha, USA

2:51 PM Q&A

2:53 PM **LOA02.5** - Donor Time to Death and DCD Liver Transplant Outcomes: Challenging the Dogma that Shorter is Better
Dharesh Raj Amarnath, UK

3:00 PM Q&A

3:02 PM **LOA02.6** - Normothermic Machine Perfusion of Moderately Steatotic Livers
Alissa Cutrone, USA

3:09 PM Q&A

3:11 PM **LOA02.7** - Novel Approach to Viability Assessment of Split Liver Grafts Using Hypothermic Oxygenated Perfusion
Geofia Crasta, USA

3:18 PM Q&A

3:20 PM **LOA02.8** - Clinical and Logistical Impact of Machine Perfusion in a Low Volume Liver Transplant Center
Marco Maria Pascale, Italy

3:27 PM Q&A

3:29 PM Closing Remarks

OA01 - Next-Gen Biomarkers

4:30 PM - 5:45 PM
Moscone South – Room 9
Basic Science
Not for CME Credit

Moderators: Khodor Abou-Daya, USA and Marie-Josée Hébert, Canada

4:30 PM Welcome & Introduction
Khodor Abou-Daya, USA
Marie-Josée Hébert, Canada

4:32 PM **OA01.1** - Cellular Deconvolution of Microarray Data from Transplant Biopsies Predicts a Central Role for CD3/CD28 Stimulated CD4 Memory T Cells in Human T Cell-Mediated Rejection in All Organ Transplants
Patrick Gauthier, Canada

4:39 PM Q&A

4:41 PM **OA01.2** - Innate-Like CD8 T Cell Response to Kidney Graft: A Multimodal Profiling Study of Transplant Rejection
Kevin Louis, France

4:48 PM Q&A

4:50 PM **OA01.3** - Circulating, Cell-Free Methylated DNA Indicates Cellular Sources of Allograft Injury After Liver Transplant
Alexander Kroemer, USA

4:57 PM Q&A

4:59 PM **OA01.4** - Early Reporting of Transplant Rejection: Genetically Engineered 'Smart-Organs' Featuring Diagnostic Capabilities
Raphaela Bento, USA

5:06 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:08 PM **OA01.5** - Metabolomic Signatures of Perfused Livers Reveal Early Evaluation May Be Superior
Avery Fortier, USA

5:15 PM Q&A

5:17 PM **OA01.6** - Urinary and Blood mRNA Biomarkers for Detecting Kidney Allograft Rejection (The KTD-Innov Study: NCT03582436)
Valentin Goutaudier, France

5:24 PM Q&A

5:26 PM **OA01.7** - Immune-Metabolism in Acute Heart Transplant Rejection: A Metabolomics Approach to Biomarker Identification in Mice
Sarah Tsou, USA

5:33 PM Q&A

5:35 PM Closing Remarks

OA02 - Xenotransplantation: Pushing Boundaries

4:30 PM - 5:45 PM
Moscone South – Room 24
Basic Science
Not for CME Credit

Moderators: Abraham Shaked, USA and Jayme Locke, USA

4:30 PM Welcome & Introduction
Abraham Shaked, USA
Jayme Locke, USA

4:32 PM **OA02.1** - Longitudinal Multi-Omics Profiling Reveals Molecular Responses in a Living Human Receiving a Gene-Edited Pig Kidney Xenograft
Qian Guo, USA

4:39 PM Q&A

4:41 PM **OA02.2** - Incompatibility of Porcine Endothelial Cell-Derived Extracellular Vesicles and Human Endothelial Cells
Shu Li, USA

4:48 PM Q&A

4:50 PM **OA02.3** - Comprehensive Long-Read Whole Genome Sequencing in 7 Human Xenotransplant Recipients
Kiana Moi, USA

4:57 PM Q&A

4:59 PM **OA02.4** - GLP Preclinical Trial of Pig-to-Baboon Thymokidney Xenotransplantation Using Inbred GalT-KO Miniature Swine Donors
M. Esad Gunes, USA

5:06 PM Q&A

5:08 PM **OA02.5** - Blockade of CD40 with or without CD11b versus CD154 Blockade in GTKO and hCD55 Transgenic Pig-to-Macaque Kidney Xenotransplantation
Bryar Hansen, USA

5:15 PM Q&A

5:17 PM **OA02.6** - Spatial Multimodal Characterization of Long-Term Immune Response After Pig-to-Human Kidney Xenotransplantation
Valentin Goutaudier, France

5:24 PM Q&A

5:26 PM **OA02.7** - Urinary Single-Cell RNA Sequencing from a Pig Kidney to Living Human Xenotransplantation Reveals Dynamic Cellular Changes
Mercy Rophina, USA

5:33 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:35 PM **OA02.8** - Systemic Transfer of Endothelial Molecules of Recipient Origin to Pig Kidney Xenograft Endothelium
Ivy Rosales, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA03 - The Current Heart Allocation System: Wins and Losses

4:30 PM - 5:45 PM
Moscone South – Room 20
Heart
Not for CME Credit

Moderators: Shelley Hall, USA and Josef Stehlik, USA

4:30 PM Welcome & Introduction
Shelley Hall, USA
Josef Stehlik, USA

4:32 PM **OA03.1** - Analysis of Time Waiting by Adult Heart Candidates Listed with an LVAD
Alina Martinez, USA

4:39 PM Q&A

4:41 PM **OA03.2** - Low Rates of Dischargeable Left Ventricular Assist Device Placement Following Temporary Non-Surgical Mechanical Circulatory Support Among Status 2 Heart Transplant Candidates
Daniel Ahn, USA

4:48 PM Q&A

4:50 PM **OA03.3** - Early versus Late Postoperative Renal Replacement Therapy and Associated Outcomes Following Combined Heart-Kidney Transplantation: A UNOS National Database Analysis
Rachel Holstein, USA

4:57 PM Q&A

4:59 PM **OA03.4** - Mortality and Acute Renal Failure Following Simultaneous Heart-Kidney Transplantation (SHK) vs. Heart Transplant Alone (HAT) in Recipients with Moderate to Severe Renal Dysfunction in the USA
Dhirisha Bhatt, USA

5:06 PM Q&A

5:08 PM **OA03.5** - Illness Severity Among Heart Transplant Recipients Following 2018 Allocation Change
Alyssa Mezochow, USA

5:15 PM Q&A

5:17 PM **OA03.6** - Waitlist Mortality Risk (US-CRS Score) Distribution Among Status 1 and 2 Adult Heart Transplant Candidates with Exceptions
Najiya Fatma, USA

5:24 PM Q&A

5:26 PM **OA03.7** - Practice Changes at Transplant Centers 5 Years After 2018 US Heart Allocation Policy Change
Stratton Tolmie, USA

5:33 PM Q&A

5:35 PM **OA03.8** - Short and Long Term Outcomes Across All Three Heart Transplant Allocation Eras
Amit Alam, USA

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA04 - Cytomegalovirus: Antivirals and Immune Defense

- 4:30 PM - 5:45 PM
- Moscone South – Room 4
- Infectious Disease
- Not for CME Credit

Moderators: Ajit Limaye, USA and Rebecca Kumar, USA

4:30 PM Welcome & Introduction
Ajit Limaye, USA
Rebecca Kumar, USA

4:32 PM OA04.1 - 6-Month Outcomes of a Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
H Culpepper, USA

4:39 PM Q&A

4:41 PM OA04.2 - Risk Factors and Real-World Implications of CMV Resistance Mutations After Treatment with Maribavir or Foscarnet for Resistant and Refractory CMV
Chelsea Morinishi, USA

4:48 PM Q&A

4:50 PM OA04.3 - Pre-Viremic, Multi-Omic Immune Signatures of Cytomegalovirus Infection in Kidney Transplant Recipients
Harry Pickering, USA

4:57 PM Q&A

4:59 PM OA04.4 - CMV T-Cell Immunity Assay Based Guidance to Interrupt Prophylaxis in Intermediate Risk Kidney Transplant Patients
Irfan Moinuddin, USA

5:06 PM Q&A

5:08 PM OA04.5 - Impaired CMV-Specific CD8+ T Cell Responses Correlate with Increased CMV Viremia in Kidney Transplant Recipients: A Comparative Analysis of Adult and Pediatric Patients
Bongha Shin, USA

5:15 PM Q&A

5:17 PM OA04.6 - Prevention of CMV and BKV in De Novo Kidney Transplant Recipients Immunosuppressed with the Combination of Low Dose Tacrolimus and Everolimus
Patrizia Sivestri, Italy

5:24 PM Q&A

5:26 PM OA04.7 - Low-Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant
Kennedy Concannon, USA

5:33 PM Q&A

5:35 PM OA04.8 - Effect of Secondary Prophylaxis on the Risk of Recurrent Cytomegalovirus Infection Among Solid Organ Transplant Recipients
Zachary Yetmar, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA05 - Deceased Donor Selection/Utilization

- 4:30 PM - 5:45 PM
- Moscone South – Room 25
- Kidney
- Not for CME Credit

Moderators: José Pestana, Brazil and TBC

4:30 PM Welcome & Introduction
TBC
José Pestana, Brazil

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:32 PM **OA05.1** - Changes in Donor Quality and Discards OVER Time: Analysis of Kidney Procurement and Transplantation over the Last 20 Years in the USA
Douglas Keith, USA

4:39 PM Q&A

4:41 PM **OA05.2** - Older Donor Age in Transplanted Kidneys Adversely Impacts the Response to Injury, Increasing Failed Repair
Philip Halloran, Canada

4:48 PM Q&A

4:50 PM **OA05.3** - Archetypal Analysis of Deceased Donor Kidneys: A Molecular Approach for Posttransplant Outcomes
Petra Hruba, Czech Republic

4:57 PM Q&A

4:59 PM **OA05.4** - Molecular Injury in Deceased-Donor Kidneys at Kidney Removal is Associated with Donor Age, KDPI and with Future Kidney Function (Serum Creatinine)
Martina Mackova, Canada

5:06 PM Q&A

5:08 PM **OA05.5** - Predictors of Kidney Graft Outcomes in Transplants from Acute Kidney Injury Donors - AKI Donor Graft Outcomes Study (ADOPT)
Hemant Sharma, UK

5:15 PM Q&A

5:17 PM **OA05.6** - Defining Hard-to-Place Kidney Donors
Thomas Dolan, USA

5:24 PM Q&A

5:26 PM **OA05.8** - The Impact of Pre-Transplant Biopsy on Kidney Graft Selection: A Comparative Study in High KDPI Patients
Jimena Alaniz, USA

5:33 PM Q&A

5:35 PM Closing Remarks

OA06 - Kidney: Hot Topics

4:30 PM - 5:45 PM
Moscone South – Room 154
Kidney
Not for CME Credit

Moderators: Charles Rickert, USA and David Wojciechowski, USA

4:30 PM Welcome & Introduction
Charles Rickert, USA
David Wojciechowski, USA

4:32 PM **OA06.1** - Stop Calling Us!: Preemptive Identification of Kidneys with Virtually Zero Chance of Acceptance
Po-Yu (Teresa) Chiang, USA

4:39 PM Q&A

4:41 PM **OA06.2** - Evaluating Outcomes of Preemptive Kidney Transplant in Patients over 65 Using High-KDPI Kidneys Compared to Non-Preemptive Recipients
Reza Saidi, USA

4:48 PM Q&A

4:50 PM **OA06.3** - Global Survey on Access to Transplantation: Knowledge and Comfort Gaps in the Acceptance of Kidneys from Deceased Donors
Marcelo Cantarovich, Canada

4:57 PM Q&A

4:59 PM **OA06.4** - Eplet Matching Using a Novel Imputational Algorithm Predicts Long-Term Outcomes in Deceased Donor Kidney Transplantation
Abraham Matar, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:06 PM Q&A

5:08 PM **OA06.5** - Delayed Graft Function After Kidney Transplant: Unwanted Complication or Metric of Center Excellence?
Lauren Matevish, USA

5:15 PM Q&A

5:17 PM **OA06.6** - Association Between Out of Sequence Allocation and Deceased Donor Kidney Non-Utilization Across Organ Procurement Organizations
David Cron, USA

5:24 PM Q&A

5:26 PM **OA06.7** - Development and Validation of a Non-Invasive Urinary Metabolite Signature to Differentiate Stable Graft from Graft Injury in Large Scale Multi-Center Study
Elizabeth O'Day, USA

5:33 PM Q&A

5:35 PM **OA06.8** - Performance of Computable Phenotypes for Identification of Immunosuppression Related Complications in Kidney Transplant Recipients within the Patient-Centered Clinical Research Network
Joshua Kettelkamp, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA07 - Kidney: Surgical Innovation and Organ Assessment

4:30 PM - 5:45 PM
Moscone South – Room 155
Kidney
Not for CME Credit

Moderators: Ricardo Ribas, Brazil and Jeffrey Stern, USA

4:30 PM Welcome & Introduction
Ricardo Ribas, Brazil
Jeffrey Stern, USA

4:32 PM **OA07.1** - Optimizing Outcomes in 2200 Pure-Laparoscopic Living Donor Kidney Transplants: The Largest Single-Center Analysis of Single vs. Multiple Renal Arteries
Sarbpreet Singh, India

4:39 PM Q&A

4:41 PM **OA07.2** - Robotic versus Laparoscopic Living Donor Nephrectomy: Advancing Minimally Invasive Techniques for Optimized Donor Outcomes
Simone Santoro Angelo Zaragoza, USA

4:48 PM Q&A

4:50 PM **OA07.3** - Comparative Outcomes of Single-Port vs. Multi-Port Robotic Kidney Transplantation for Living and Deceased Donor
Hafiz Umair Siddiqui, USA

4:57 PM Q&A

4:59 PM **OA07.4** - Identifying Early Injury Biomarkers in Living Donor Kidney Perfusion Fluid: Unveiling the Role of Tissue-Resident Immune Cells
Ashish Sharma, India

5:06 PM Q&A

5:08 PM **OA07.5** - The Evolution of Kidney Auto-Transplant: Single-Center Experience Transitioning from Open to Single-Port Robotic Approach and Impact on Perioperative Outcomes
Dylan Isaacson, USA

5:15 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:17 PM **OA07.6** - The Effect of Modified vs Conventional ERAS on Clinical and Graft Outcomes in Kidney Transplant Recipients: Preliminary Results of Randomized Controlled Trial
Manjunath Pol, India

5:24 PM Q&A

5:26 PM **OA07.7** - Early Experience with AWAKE Kidney Transplantation
Vinayak Rohan, USA

5:33 PM Q&A

5:35 PM **OA07.8** - Renal-Agent: The First Artificially Intelligent Autonomous Agent for Renal Pathology
Harry Robertson, Australia

5:42 PM Q&A

5:44 PM Closing Remarks

OA08 - Recurrent Disease and Genetics

4:30 PM - 5:45 PM
Moscone South – Room 21
Kidney
Not for CME Credit

Moderators: Sami Alasfar, USA and Nancy Rodig, USA

4:30 PM Welcome & Introduction
Sami Alasfar, USA
Nancy Rodig, USA

4:32 PM **OA08.1** - Pegcetacoplan for Posttransplant Patients with Complement 3 Glomerulopathy or Primary (Idiopathic) Immune-Complex Membranoproliferative Glomerulonephritis
Eli Khankin, USA

4:39 PM Q&A

4:41 PM **OA08.2** - Impact of APOL1 Risk Alleles on HIV+ to HIV+ Kidney Transplant Outcomes in South Africa and the USA
Moreno Rodrigues, USA

4:48 PM Q&A

4:50 PM **OA08.3** - Development of a Novel Mouse Model of Focal Segmental Glomerulosclerosis Recurrence Post-Kidney Transplantation Mediated by Anti-Nephrin Antibodies
Marie-Camille Lafargue, USA

4:57 PM Q&A

4:59 PM **OA08.4** - Recurrence of C3GN and DDD After Kidney Transplantation: TANGO Consortium
Frank Hullekes, USA

5:06 PM Q&A

5:08 PM **OA08.5** - Polygenic Risk Score Predicts IgA Nephropathy Recurrence and Graft Failure in Kidney Transplant Recipients
Francesca Zanoni, Italy

5:15 PM Q&A

5:17 PM **OA08.6** - Daratumumab in Recurrent FSGS After Kidney Transplantation
Parthenopi Avaniadi, Germany

5:24 PM Q&A

5:26 PM **OA08.7** - Genetic Determinants of Kidney Transplant Outcomes: A Large-Scale Multi-Ancestry GWAS Meta-Analysis
Francesca Zanoni, Italy

5:33 PM Q&A

5:35 PM **OA08.8** - LIMS1 rs893403-GG Genotype and Its Impact on Recurrent/De Novo Glomerulonephritis in Kidney Transplant Recipients
Yasar Caliskan, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:42 PM Q&A

5:44 PM Closing Remarks

OA09 - Innovation in Pediatric Liver Transplant

4:30 PM - 5:45 PM
Moscone South – Room 10
Liver
Not for CME Credit

Moderators: Carlos Esquivel, USA and Sang-Mo Kang, USA

4:30 PM Welcome & Introduction
Carlos Esquivel, USA
Sang-Mo Kang, USA

4:32 PM OA09.1 - Age Matching Improves Graft Survival in Adolescent Liver Transplantation
Toshihiro Nakayama, USA

4:39 PM Q&A

4:41 PM OA09.2 - Functional Phenotypic Diversity of Regulatory T Cells in Pediatric Liver Transplantation
Udeme Ekong, USA

4:48 PM Q&A

4:50 PM OA09.3 - Health Outcomes in Children of Liver Transplant (LT) Recipients
Sarah Maxwell, USA

4:57 PM Q&A

4:59 PM OA09.4 - Split Liver Transplantation Using Machine Perfusion in Pediatric Recipients
Amanda Jensen, USA

5:06 PM Q&A

5:08 PM OA09.5 - Disparities in Pediatric Liver Transplantation Based on Limited English Proficiency: Trends over 20 Years
Nensi Ruzgar, USA

5:15 PM Q&A

5:17 PM OA09.6 - Consensus Treatment Plans: A Novel Collaborative Effort to "Right Size" Immunosuppression After Pediatric Liver Transplant
Jennifer Halma, USA

5:24 PM Q&A

5:26 PM Closing Remarks

OA10 - Post Liver Transplant Complications

4:30 PM - 5:45 PM
Moscone South – Room 153
Liver
Not for CME Credit

Moderators: Ian Currie, UK and Adeel Khan, USA

4:30 PM Welcome & Introduction
Ian Currie, UK
Adeel Khan, USA

4:32 PM OA10.1 - Vascularized Liver Tissueoid-on-a-Chip: An In Vitro Model for Studying Allograft Rejection
Abdul Rahim Chethikkattuveli Salih, USA

4:39 PM Q&A

4:41 PM OA10.2 - Molecular Signatures of Rejection in Liver Transplant Biopsies Using the Banff Human Organ Transplant Consensus Gene Panel
Zeynep Demir, France

4:48 P Q&A

4:50 PM OA10.3 - Single-Cell and Spatial Genomics Reveal T-Cell Priming, Spatially Differentiated Networks and Novel Drug Targets in Early T-Cell-Mediated Liver Transplant (TCMR, LT) Rejection
Rakesh Sindhi, USA

4:57 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:59 PM **OA10.4** - Clinical Impact of Desensitization in HLA-Incompatible Liver Transplantation: A Propensity Score-Matched Multicenter Analysis
Min Kyoung Kim, South Korea

5:06 PM Q&A

5:08 PM **OA10.5** - Major Adverse Cardiovascular Events After Liver Transplantation: An English Population Cohort Analysis
Fatima Malik, UK

5:15 PM Q&A

5:17 PM **OA10.6** - Impact of Pre-Liver Transplant Hepatic Encephalopathy and Post-Liver Transplant Altered Mental Status on Post-Transplant Outcomes
Richard Mangus, USA

5:24 PM Q&A

5:26 PM **OA10.7** - Ischemia-Free Liver Transplantation Alleviates Post-Transplant Myocardial Injury and Pulmonary Complication: A Post Hoc Analysis from IFLT-DBD Trial
Zhiyong Guo, China

5:33 PM Q&A

5:35 PM **OA10.8** - Preventing Alcohol Relapse in High-Risk Liver Transplant Recipients: Evaluation of a Multi-Disciplinary Post-Transplant Clinic
Brooke Rice, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA11 - New Frontiers in Lung Transplantation

4:30 PM - 5:45 PM
Moscone South – Room 22
Lung
Not for CME Credit

Moderators: Stephen Juvet, Canada and Jianing Fu, USA

4:30 PM Welcome & Introduction
Stephen Juvet, Canada
Jianing Fu, USA

4:32 PM **OA11.1** - Immunogenomic Landscape of T Cell Repertoires After Human Lung Transplantation and Its Clinical Significance
Jianing Fu, USA

4:39 PM Q&A

4:41 PM **OA11.2** - Lung Xenotransplantation Outcomes Using Multi-Gene Edited Pigs: In Vivo Transplant and Ex Vivo Human Xenoperfusion
Sho Takemoto, USA

4:48 PM Q&A

4:50 PM **OA11.3** - T-Cell Receptor Repertoire Diversity and Change are Associated with Response to Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction
Rashmi Prava Mohanty, USA

4:57 PM Q&A

4:59 PM **OA11.4** - Banff Human Organ Transplant Panel for Detecting Acute Cellular Rejection in Lung Transplant Biopsies
Marta Sablik, France

5:06 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:08 PM **OA11.5** - In Vitro Characterization of Pro-Inflammatory LILRB2+ and Pro-Fibrotic SPP1+ Pulmonary Macrophages in Chronic Lung Allograft Dysfunction
Allen Duong, Canada

5:15 PM Q&A

5:17 PM **OA11.6** - Airway Epithelial P53 Expression is a Molecular Driver of Chronic Lung Allograft Dysfunction
Bhavya Kapse, USA

5:24 PM Q&A

5:26 PM **OA11.7** - Molecular Diagnosis of Rejection in Lung Transplant Mucosal Biopsies
Patrick Gauthier, Canada

5:33 PM Q&A

5:35 PM **OA11.8** - Trifecta-Lung Study: dd-cfDNA Correlates with T Cell-Mediated Rejection and Parenchymal Injury in Mucosal Biopsies of Lung Transplants
Patrick Gauthier, Canada

5:42 PM Q&A

5:44 PM Closing Remarks

OA12 - Artificial Intelligence and Complex Analytics

4:30 PM - 5:45 PM
Moscone South – Room 11
Organ Inclusive
Not for CME Credit

Moderators: Lisiane Pruinelli, USA and Henry Randall, USA

4:30 PM Welcome & Introduction
Lisiane Pruinelli, USA
Henry Randall, USA

4:32 PM **OA12.1** - Machine Learning-Based Risk Prediction of Allograft Rejection within One-Year Post-Transplant for Kidney Transplant Patients
Tambi Jarmi, USA

4:39 PM Q&A

4:41 PM **OA12.2** - Development and Validation of a Prediction Model for Risk of Death in Kidney Transplant Recipients (Mortality Box)
Marc Raynaud, France

4:48 PM Q&A

4:50 PM **OA12.3** - On Interpretable Heart Transplant Mortality Prediction and Benchmarking
Yingtao Luo, USA

4:57 PM Q&A

4:59 PM **OA12.4** - A New Prediction Model for Waitlist Survival in Kidney Transplant Candidates
Piyawat Kantagowit, USA

5:06 PM Q&A

5:08 PM **OA12.5** - Optimization of a Model for Predicting Renal Function After Living Kidney Transplantation Using Computed Tomography Volumetry
Yu Kijima, Japan

5:15 PM Q&A

5:17 PM **OA12.6** - Development and Validation of a Machine Learning Model to Reduce Futile Donation After Circulatory Death Procurements in Liver Transplantation
Kazunari Sasaki, USA

5:24 PM Q&A

5:26 PM **OA12.7** - Development of a HIPAA Compliant Cloud-Based Donor Liver Biopsy Steatosis Assessment Tool Using Artificial Intelligence Technology
Kenji Okumura, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:33 PM Q&A

5:35 PM **OA12.8** - Impact of Missing Data Imputation Strategies on Performances of Kidney Allograft Failure Prediction Models
Marc Raynaud, France

5:42 PM Q&A

5:44 PM Closing Remarks

OA13 - Organ Donation

4:30 PM - 5:45 PM
Moscone South – Room 8
Organ Inclusive
Not for CME Credit

Moderators: James Rodrigue, USA and Alin Gragossian, USA

4:30 PM Welcome & Introduction
James Rodrigue, USA
Alin Gragossian, USA

4:32 PM **OA13.1** - Cross-Border Organ Donationand Transplantation: The UAE Experience inRegional Collaboration with Saudi Arabia and Kuwait
Maria Paula Gomez, United Arab Emirates

4:39 PM Q&A

4:41 PM **OA13.2** - Exploring New Ways to Increase Organ Donation Rate, the First Museum of Donation and Transplantation in the World
Ernesto Duarte Tagles, Mexico

4:48 PM Q&A

4:50 PM **OA13.3** - The Impact of a Merit Point Incentive System on the Willingness to Donate Among Non-Registered Individuals
Mustafa Nazzal, USA

4:57 PM Q&A

4:59 PM **OA13.4** - From Clicks to Compassion: Social Media Use Significantly Drives Altruistic Living Organ Donations in Liver and Kidney Transplantation
Marissa Di Napoli, USA

5:06 PM Q&A

5:08 PM **OA13.5** - Effectively Engaging High School Students About Organ Donation and Transplantation: An Updated on the High School Outreach Initiative Experience
Kate Rokoss, Canada

5:15 PM Q&A

5:17 PM **OA13.6** - Asymmetric Parallelism - The Positive Impact of Transplant Procurement Management Training Programs on Deceased Donation Activity Worldwide
Chloë Balleste, Spain

5:24 PM Q&A

5:26 PM **OA13.7** - A Novel Comprehensive Assessment of Transplant Center Offer Acceptance Practices
Molly White, USA

5:33 PM Q&A

5:35 PM **OA13.8** - Why Fly When You Can Drive! - Utilizing Controlled Hypothermic Preservation to Facilitate Long Distance Ground Transportation
Vijay Subramanian, USA

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA14 - Islet

4:30 PM - 5:45 PM
Moscone South – Room 12
Pancreas
Not for CME Credit

Moderators: Trevor Reichman, Canada and Piotr Witkowski, USA

4:30 PM Welcome & Introduction
Trevor Reichman, Canada
Piotr Witkowski, USA

4:32 PM OA14.2 - Clinical Scale Cryopreservation of Human Deceased Donor Islet and Stem Cell-Derived Beta Clusters by Vitrification for Allotransplantation in Type I Diabetes
Joseph Sushil Rao, USA

4:39 PM Q&A

4:41 PM OA14.3 - Development of Non-Human Primate Stem Cell-Derived Islets for Allogeneic Transplantation
Ji Lei, USA

4:48 PM Q&A

4:50 PM OA14.4 - Generation of Functional Islet Cell Organoids from Adult Multipotent Islet Progenitor Cells Captured during Islet Cell Isolation Procedures
Jayachandra Kuncha, USA

4:57 PM Q&A

4:59 PM OA14.5 - Evaluation of Optimal Engraftment Sites for Human Stem Cell-Derived Islets in a Non-Human Primate Model
Ji Lei, USA

5:06 PM Q&A

5:08 PM OA14.6 - Simultaneous Islet-Kidney Transplantation as an Alternative for Patients Ineligible for Pancreas Transplant: Initial Experience at a North American Transplant Center
Catherine Parmentier, Canada

5:15 PM Q&A

5:17 PM OA14.7 - A Comparison of Depletional Induction Strategies on Non-Human Primate Islet Xenotransplantation Outcomes
Meghan Hu, USA

5:24 PM Q&A

5:26 PM Closing Remarks

OA15 - Psychosocial

4:30 PM - 5:45 PM
Moscone South – Room 23
Psychosocial & Ethics
Not for CME Credit

Moderators: Amy Waterman, USA and Daniela Ladner, USA

4:30 PM Welcome & Introduction
Amy Waterman, USA
Daniela Ladner, USA

4:32 PM OA15.1 - Health-Related Quality of Life in Kidney Transplant Recipients: Association with Graft Function and Comparison to atients on Dialysis
Jad Fadlallah, Canada

4:39 PM Q&A

4:41 PM OA15.2 - Cognitive Function Impacts Waitlist Mortality Risk for Some but Not All Solid Organ Candidates
Jingyao Hong, USA

4:48 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:50 PM **OA15.3** - Out of Pocket (OOP) Medical Costs for Transplant Recipients Before and After Transplantation
Deena Brosi, USA

4:57 PM Q&A

4:59 PM **OA15.4** - Financial Burden and Social Needs in Solid Organ Transplant Candidates
Nicolas Muñoz, USA

5:06 PM Q&A

5:08 PM **OA15.5** - Associations of Marijuana Use History with Progression from Living Donor Candidate Evaluation to Approval: Analysis of the US SRTR Living Donor Collective
Krista Lentine, USA

5:15 PM Q&A

5:17 PM **OA15.6** - Identifying Risk Factors for Return to Alcohol Use After Liver Transplant
Natalia Rodriguez-Payan, USA

5:24 PM Q&A

5:26 PM **OA15.7** - Validation of the Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) in Brazilian Kidney Transplant Recipients
Juliana Ferreira, Brazil

5:33 PM Q&A

5:35 PM **OA15.8** - PROMETHEUS: Patient Reported Ethics Outcomes Following Transplants from Donors with or without HIV
S. Hussain, USA

5:42 PM Q&A

5:44 PM Closing Remarks

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS039 - Value Based Care in Liver Transplantation: Learning from Global Perspectives to Guide Best Practices

8:15 AM - 9:30 AM
Moscone South – Room 21
Liver
CME Accredited

Moderators: Shennen Mao, USA and Michelle Nguyen, USA

8:15 AM Welcome & Introduction
Shennen Mao, USA
Michelle Nguyen, USA

8:15 AM IVS039.1 - Defining Value and Blueprint to the Future
Madhukar Patel, USA

8:30 AM IVS039.2 - The Pros and Cons of Transplant in a National Payer Model
Abdul Hakeem, UK

8:45 AM IVS039.3 - The Pros and Cons of Transplant in a Private Payer Model
Ashwin Rammohan, India

9:00 AM IVS039.4 - Considerations for Adopting Innovation and Optimizing Education in Value-Based Care Model
Markus Selzner, Canada

9:15 AM Q&A

IVS040 - Extracellular Vesicles - Small but Powerful with Broad Consequences

8:15 AM - 9:30 AM
Moscone South – Room 10
Basic Science
CME Accredited

Moderators: Brittany Schrieber, USA and Sheri Krams, USA

8:15 AM Welcome & Introduction
Brittany Schrieber, USA
Sheri Krams, USA

8:15 AM IVS040.1 - New Insight into the Biology and Function of Extracellular Vesicles in Cancer
Raghu Kalluri, USA

8:30 AM IVS040.2 - Immune Consequences of Apoptosis Generated EVs
Marie-Josée Hébert, Canada

8:45 AM IVS040.3 - Role of EVs in Allotransplantation and Tolerance
Sheri Krams, USA

9:00 AM IVS040.4 - EVs as Biomarkers in Transplantation
Jamil Azzi, USA

9:15 AM Q&A

IVS041 - Hot Topics in Pediatric Transplantation

8:15 AM - 9:30 AM
Moscone South – Room 22
Organ Inclusive
CME Accredited

Moderators: Lars Pape, Germany and Hayley Gans, USA

8:15 AM Welcome & Introduction
Lars Pape, Germany
Hayley Gans, USA

8:15 AM IVS041.1 - Tolerance for Pediatric Transplant Recipients
Stephen Alexander, Australia

8:30 AM IVS041.2 - Update in Pediatric Liver Transplant Allocation
Emily Perito, USA

8:45 AM IVS041.3 - Splitter vs. Lumper: Split Liver Transplantation for Pediatrics
Blayne Amir Sayed, Canada

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

9:00 AM **IVS041.4** - Increasing Pediatric Transplant Participation in Clinical Trials
Kevin Downes, USA

9:15 AM Q&A

IVS042 - Lung Transplant Hot Topic Debate

8:15 AM - 9:30 AM
Moscone South – Room 20
Lung
CME Accredited

Moderators: Carli Lehr, USA and Stephen Juvet, Canada

8:15 AM Welcome & Introduction
Carli Lehr, USA
Stephen Juvet, Canada

8:15 AM **IVS042.1** - Lung Transplant for ARDS - Is it Worth it? Pro
Rade Tomic, USA

8:30 AM **IVS042.2** - Lung Transplant for ARDS - Is It Worth It? CON
Andrew Courtwright, USA

8:45 AM **IVS042.3** - Lung Transplant for Cancer - Should It Be Done? PRO
Ankit Bharat, USA

9:00 AM **IVS042.4** - Lung Transplant for Cancer - Should It Be Done? CON
Konrad Hoetzenecker, USA

9:15 AM Q&A

IVS043 - Living Donor Medical and Surgical Selection

8:15 AM - 9:30 AM
Moscone South – Room 4
Organ Inclusive
CME Accredited

Moderators: Danielle Haakinson, USA and Rahul Mainra, Canada

8:15 AM Welcome & Introduction
Danielle Haakinson, USA
Rahul Mainra, Canada

8:15 AM **IVS043.1** - Kidney Function Assessment
Emilio Poggio, USA

8:30 AM **IVS043.2** - Kidney Function in Older Donors (What Is Normal and Acceptable)
Mona Doshi, USA

8:45 AM **IVS043.4** - The Hypertensive Donor and the Risk of Post-Donation Hypertension
Neetika Garg, USA

9:00 AM **IVS043.5** - The Obese Donor
Babak Orandi, USA

9:15 AM Q&A

IVS044 - Ensuring the Quality and Safety of Deceased Donor Services

8:15 AM - 9:30 AM
Moscone South – Room 23
Organ Inclusive
CME Accredited

Moderators: Jeff Orlowski, USA and Kevin Myer, USA

8:15 AM Welcome & Introduction
Jeff Orlowski, USA
Kevin Myer, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:15 AM **IVS044.1** - Metrics - Beyond Donor Rate per Million and the Critical Pathway
Maria Paula Gomez, United Arab Emirates

8:30 AM **IVS044.2** - Harnessing Big Data to Improve Deceased Donor Management
Darren Malinoski, USA

8:45 AM **IVS044.3** - Ensuring Safety - Biovigilance
Bartira De Aguiar Roza, Brazil

9:00 AM **IVS044.4** - Cultural Safety in Deceased Donation
Clive Callender, USA

9:15 AM Q&A

IVS045 - Global Perspectives on Management of Alcohol-Associated Liver Disease and Alcohol Use Disorder

8:15 AM - 9:30 AM
Moscone South — Room 155
Organ Inclusive
CME Accredited

Moderators: Scott Winder, USA and Nazia Selzner, Canada

8:15 AM Welcome & Introduction
Scott Winder, USA
Nazia Selzner, Canada

8:15 AM **IVS045.1** - AUD Management and Culturally Appropriate Considerations
Yael Belinki, USA

8:30 AM **IVS045.2** - Global Differences in AAH/ALD Management Including Non-Transplant Liver Replacement Therapy
Luis Diaz, USA

8:45 AM **IVS045.3** - LT Recipient Selection for AAH vs AALD
Brian Lee

9:00 AM **IVS045.4** - Post-LT Relapse: Management & Prevention
Kathryn Horwath, USA

9:15 AM Q&A

IVS046 - Stem-Cell Derived Islet Clusters for Diabetes: How Close Is the Future?

8:15 AM - 9:30 AM
Moscone South — Room 9
Pancreas
CME Accredited

Moderators: Hongkui Deng, China and Peter Stock, USA

8:15 AM Welcome & Introduction
Hongkui Deng, China
Peter Stock, USA

8:15 AM **IVS046.1** - Stem-Cell Derived Islets: Status of Clinical Trials
Jon Odorico, USA

8:35 AM **IVS046.2** - Knocking Out the HLA: A Viable Strategy for Making Hypoimmune Islets?
Sonja Schrepfer, USA

8:55 AM **IVS046.3** - Supercooling Stem Cell Derived Islets to Facilitate Clinical Translation
Erik Finger, USA

9:15 AM Q&A

IVS047 - Assessment of Deceased Donor Organ Viability and Longevity

8:15 AM - 9:30 AM
Moscone South — Room 25
Organ Inclusive
CME Accredited

Moderator: Axel Rahmel, Germany

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:15 AM Welcome & Introduction
Susan Orloff, USA
Axel Rahmel, Germany

8:15 AM **IVS047.1** - The Deceased Donor Kidney Biopsy
Maziar Riazy, Canada

8:27 AM **IVS047.2** - Artificial Intelligence Strategies
Darren Stewart, USA

8:39 AM **IVS047.3** - Biomarkers
Lakshman Gunaratnam, Canada

8:51 AM **IVS047.4** - Patient Selection Considerations
Dixon Kaufman, USA

9:03 AM Q&A

9:18 AM Panel Discussion

IVS048 - Recovering from Innovation Stagnation — Leveraging Global Regulatory Pathways for New Therapeutic Approvals in Solid Organ Transplant

8:15 AM - 9:30 AM
Moscone South — Room 24
Public Policy
CME Accredited

Moderators: Roslyn Mannon, USA and Kenneth Newell, USA

8:15 AM Welcome & Introduction
Roslyn Mannon, USA
Kenneth Newell, USA

8:15 AM **IVS048.1** - Transplant Recipient Perspective - Where Are Endpoints and New Therapies Falling Short?
Karin Hehenberger, USA

8:30 AM **IVS048.2** - Kidney NMP and Trial Perspectives and Endpoints
Stefan Schneeberger, Austria

8:45 AM **IVS048.3** - Comparing and Contrasting Expedited Development Pathways in US, EU, and ROW
Bill Fitzsimmons, USA

9:00 AM **IVS048.4** - Strategies for Developing a New Therapeutic in Multinational Trials to Address the Needs of Global Regulators
Timothy Schroeder, USA

9:15 AM Q&A

IVS049 - Xenotransplantation - Basic Mechanisms on the Way to Clinical Success

8:15 AM - 9:15 AM
Moscone South — Room 12
Basic Science
CME Accredited

Moderators: James Markmann, USA and Xian Li, USA

8:15 AM Welcome & Introduction
James Markmann, USA
Xian Li, USA

8:15 AM **IVS049.1** - Innate Immune Infiltration of Xenografts
Paige Porrett, USA

8:30 AM **IVS049.2** - NK Cells in NHP Xenografts
Steven Kim, USA

8:45 AM **IVS049.3** - NK Cells in Human Decedent Model
Brendan Keating, USA

9:00 AM Q&A

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS050 - Fungal Busters: Navigating the Moldy Maze of Antifungals

8:15 AM - 9:15 AM
Moscone South – Room 153
Infectious Disease
CME Accredited

Moderators: Alicia Lichvar, USA and Stephanie Pouch, USA

8:15 AM Welcome & Introduction
Alicia Lichvar, USA
Stephanie Pouch, USA

8:15 AM IVS050.1 - Antifungal Drug Interactions: Management Pearls
Ashley Feist, USA

8:30 AM IVS050.2 - Optimizing Antifungal Durations: Prophylaxis, Pre-emptive, Definitive Treatment
Shahid Husain, Canada

8:45 AM IVS050.3 - Using Novel Antifungals: First Line or Salvage
Shmuel Shoham, USA

9:00 AM Q&A

IVS051 - Recurrent Glomerular Disease Post Kidney Transplant: Navigating New Frontiers in IgA Nephropathy, FSGS, Membranous Nephropathy, and MPGN - Session 2

8:15 AM - 9:15 AM
Moscone South – Room 8
Kidney
CME Accredited

Moderators: Helio Tedesco Silva, Brazil and Paolo Cravedi, USA

8:15 AM Welcome & Introduction
Helio Tedesco Silva, Brazil
Paolo Cravedi, USA

8:15 AM IVS051.1 - Recurrent MPGN and C3 Glomerulopathy: Understanding Recurrence and Complement-Targeted Therapies
Sami Alasfar, USA

8:35 AM IVS051.2 - IgAN-Recurrence: Overview of New Biomarkers, Evolving Diagnostics, Emerging Therapies
Song Ong, USA

8:55 AM Q&A

OA16 - Advances in HLA Research

8:15 AM - 9:30 AM
Moscone South – Room 11
Basic Science
Not for CME Credit

Moderators: Anat Tambur, USA and Caner Suesal, Turkey

8:15 AM Welcome & Introduction
Anat Tambur, USA
Caner Suesal, Turkey

8:17 AM OA16.2 - A 64-Plex Single-HLA Reporter Cell Panel for Characterizing Allo-Specific B-Cell Responses
Emma Fatzaun, USA

8:24 AM Q&A

8:26 AM OA16.3 - Dissecting HLA-DQ Immunogenicity: Validating the Impact of HLA-DQα05 Heterodimer and HLA-DQ Evolutionary Divergent Mismatches in Kidney Transplant Recipients with Two Mismatches yet One Donor-Specific Antibody
Dennis van den Broek, USA

8:33 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:35 AM **OA16.4** - TLR4 Regulates HLA-II Antibody-Mediated P-selectin Expression and Monocyte Capture to Human Endothelial Cells in a Piezo1 Dependent Manner
Yiping Jin, USA

8:42 AM Q&A

8:44 AM **OA16.5** - Development of a Cross-Organ Predictive Model for De Novo Donor-Specific Antibody Based on Differential Risk Assessment of Individual HLA Eplet Mismatches
Masaaki Hirata, Japan

8:51 AM Q&A

8:53 AM **OA16.6** - 2025 Novel Designation of Serologic HLA Antigens, Their Implications in Organ Allocation and Humoral Sensitization Assessment
Kazutoyo Osoegawa, USA

9:00 AM Q&A

9:02 AM **OA16.7** - Virtual Crossmatching: Is Physical Crossmatching Still Necessary?
Katrin Hacke, USA

9:09 AM Q&A

9:11 AM **OA16.8** - Surrogate Crossmatch Verification of De Novo DSA Development to Define the True DSA Incidence
Luis Hidalgo, USA

9:18 AM Q&A

9:20 AM Closing Remarks

OA17 - Deceased Donor Kidney General Outcomes

8:15 AM - 9:30 AM
Moscone South – Room 154
Kidney
Not for CME Credit

Moderators: Sixto Giusti, USA and Douglas Keith, USA

8:15 AM Welcome & Introduction
Sixto Giusti, USA
Douglas Keith, USA

8:17 AM **OA17.1** - Comparable Long-Term Outcomes Between Donation After Circulatory Death versus Neurological Death Donors for Kidney Transplant Recipients: An Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) Study
Alan Xu, Australia

8:24 AM Q&A

8:26 AM **OA17.2** - Outcomes of Hepatitis B Viremic Donor Kidney Transplants in Seronegative Recipients: An Analysis of National Registry Data
James Rogers, USA

8:33 AM Q&A

8:35 AM **OA17.3** - Survival Benefit of Kidney Transplantation in the Modern Era
Joshua Vergin, USA

8:42 AM Q&A

8:44 AM **OA17.4** - Time-Dependent Impact of Deceased-Donor and Graft Risk Factors on Kidney Allograft Survival
Junichiro Sageshima, USA

8:51 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:53 AM **OA17.5** - Equal Clinical Outcomes and Favorable Histopathological Findings in Kidneys from Donors with Acute Kidney Injury
Juan Pablo Huidobro Espinosa, USA

9:00 AM Q&A

9:02 AM **OA17.6** - The Kidney Donor Profile Index (KDPI) is Associated with Kidney Allograft Function (eGFR) at One Year After Transplant but Not with the Subsequent Change in Kidney Allograft Function (eGFR Slope)
John Gill, Canada

9:09 AM Q&A

9:11 AM **OA17.7** - One Year Graft and Patient Outcomes from Deceased Kidney Donors on Dialysis: A Single Center Experience
Anu Murthy, USA

9:18 AM Q&A

9:20 AM **OA17.8** - Prolonged Cold Ischemia Time is a Risk Factor for Delayed Graft Function and Increased Mortality in Kidney Transplant Recipients within the Eurotransplant Senior Program
Laura Matuschik, Germany

9:27 AM Q&A

9:29 AM Closing Remarks

KN03 - Transplant Under Stress: Operating in a Warzone - Borys Todurov

10:00 AM - 10:30 AM
Moscone South — San Francisco Ballroom
Not for CME Credit

Moderators: Jon Kobashigawa, USA and David Foley, USA

10:00 AM Welcome & Introduction
Jon Kobashigawa, USA
David Foley, USA

10:00 AM **KN03.1** - Transplant Under Stress: Operating in a Warzone
Borys Todurov, Ukraine

PL02 - Plenary Abstracts 2

10:30 AM - 11:30 AM
Moscone South — San Francisco Ballroom
Not for CME Credit

Moderators: Jon Kobashigawa, USA and David Foley, USA

10:30 AM Welcome & Introduction
Jon Kobashigawa, USA
David Foley, USA

10:30 AM **PL02.1** - Hypothermic-Oxygenated and Normothermic Machine Perfusion: A Risk-Matched Post-Hoc Comparison of the Bridge to Hope Randomized Trial with Prospectively Collected Institutional Outcomes
Chase Wehrle, USA

10:42 AM Q&A

10:45 AM **PL01.4** - A Phase I/II Trial Investigating Autologous Polyclonal Treg Therapy Together with Donor Bone Marrow Infusion in HLA-Mismatched Kidney Transplantation
Rainer Oberbauer, Austria

10:57 AM Q&A

11:00 AM **PL02.3** - Exosome-Mediated Allorecognition is Complement Dependent
Sara Alibrandi, USA

11:12 AM Q&A

11:15 AM **PL02.4** - A Change of Heart: siRNA-Mediated

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

Gene Silencing and Delivery during Ex Vivo Heart Perfusion for Organ Optimization
Julianna Buchwald, USA

11:27 AM Q&A

IVS052 - Women in Transplantation: Opportunities, Challenges, and Strategies for Advancement and Allyship

- 2:15 PM - 3:30 PM
- Moscone South – Room 154
- Organ Inclusive
- CME Accredited

Moderators: Yolanda Becker, USA and Jolanta Malyszko, Poland

2:15 PM Welcome & Introduction
Yolanda Becker, USA
Jolanta Malyszko, Poland

2:15 PM Panelists
Sarah Tsou, USA
Jasleen Kukreja, USA
Curie Ahn, South Korea
Ligia Pierrotti, Brazil

IVS053 - Long-Term Care of Pancreas Transplant Recipients: What Nephrologists Need to Know

- 2:15 PM - 3:30 PM
- Moscone South – Room 8
- Pancreas
- CME Accredited

Moderators: Ronald Parsons, USA and Ty Dunn, USA

2:15 PM Welcome & Introduction
Ronald Parsons, USA
Ty Dunn, USA

2:15 PM IVS053.1 - Weight Gain After Pancreas Transplantation
Neeraj Singh, USA

2:23 PM IVS053.2 - Type 2 DM / Hyperglycemia in Pancreas Recipients
Meaghan Stumpf, USA

2:31 PM IVS053.3 - Novel Immunosuppression in Pancreas Transplantation
Ty Dunn, USA

2:39 PM IVS053.4 - Alloimmunity: Rejection Monitoring and Treatment
Aleksandra Kukla, USA

2:47 PM IVS053.5 - Autoimmunity: Recurrence of Type 1 DM
George Burke III, USA

2:55 PM IVS053.6 - Reproductive Health: Contraception and Pregnancy After Pancreas Transplantation
Swati Rao, USA

3:03 PM IVS053.7 - Late Surgical Complications
Henry Pleass, Australia

3:11 PM Q&A

IVS054 - Clinical Tolerance - News and Updates on Ongoing Trials

- 2:15 PM - 3:30 PM
- Moscone South – Room 155
- Basic Science
- CME Accredited

Moderators: James Mathew, USA and Stephan Busque, USA

2:15 PM Welcome & Introduction
James Mathew, USA
Stephan Busque, USA

2:15 PM IVS054.1 - Update of Ongoing Clinical Trials in

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

Tolerance
Joseph Leventhal, USA

2:30 PM **IVS054.2** - Use of Anti-CD2 in Tolerance - The PANORAMA Trial
Joshua Weiner, USA

2:45 PM **IVS054.3** - Combining Treg With Bone Marrow Transplantation for Tolerance - TREX001
Rainer Oberbauer, Austria

3:00 PM **IVS054.4** - Predictive Biomarkers in Tolerance
Sandy Feng, USA

3:15 PM Q&A

IVS055 - Healthcare Systems Under Stress: Transplantation in Times of Pandemics, War, and Climate Disasters

2:15 PM - 3:30 PM
Moscone South – Room 25
Organ Inclusive
CME Accredited

Moderators: Tan Ban Hock, Singapore and Fernanda Silveira, USA

2:15 PM Welcome & Introduction
Tan Ban Hock, Singapore
Fernanda Silveira, USA

2:15 PM **IVS055.3** - Hot and Cold: How Climate Impacts Infectious Diseases
Peter Chin-Hong

2:35 PM **IVS055.1** - When Nature Strikes Back: Natural Disasters and Climate Change Impact of Transplant Centers
Steven Wisel, USA

2:55 PM **IVS055.2** - Confronting a Pandemic: Lessons Learned From COVID-19
Maddalena Giannella, Italy

3:15 PM Q&A

IVS056 - Frailty in Thoracic Transplantation

2:15 PM - 3:30 PM
Moscone South – Room 20
Organ Inclusive
CME Accredited

Moderators: Jeffrey Edelman, USA and Josef Stehlik, USA

2:15 PM Welcome & Introduction
Jeffrey Edelman, USA
Josef Stehlik, USA

2:15 PM **IVS056.1** - Defining and Assessing Frailty in Thoracic Transplant
Lianne Singer, Canada

2:30 PM **IVS056.2** - Hot Topic Debate - Should We Be Using Frailty to Make Decisions in Lung Transplant (PRO)
Michaela Anderson, USA

2:45 PM **IVS056.3** - Hot Topic Debate - Should We Be Using Frailty to Make Decisions in Lung Transplant (CON)
Laurie Snyder, USA

3:00 PM **IVS056.4** - Hot Topic Debate - Should We Be Using Frailty to Make Decisions in Heart Transplant (PRO)
Brian Hsi, USA

3:15 PM **IVS056.5** - Hot Topic Debate - Should We Be Using Frailty to Make Decisions in Heart Transplant (CON)
Sean Pinney, USA

IVS057 - Kidney Paired Donation - State of the Art

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:15 PM - 3:30 PM
Moscone South – Room 23
Kidney
CME Accredited

Moderators: Michel Paquet, Canada and Hatem Amer, USA

2:15 PM Welcome & Introduction
Michel Paquet, Canada
Hatem Amer, USA

2:15 PM IVS057.1 - KPD Programs Around the World - Common Elements for Success
Dorry Segev, USA

2:27 PM IVS057.2 - The Importance of a Strong Immunogenetics Lab Partner
Cathi Murphey, USA

2:39 PM IVS057.3 - Inclusion of Donors Who Are Not ABO or HLA Incompatible - NDADs and Compatible Pairs
Toby Coates, Australia

2:51 PM IVS057.4 - International KPD - Dos and Don'ts
Gabriel Danovitch, USA

3:03 PM IVS057.5 - Maximizing the Donor Experience - Donor Safeguards / Cost Minimization
Garet Hil, USA

3:15 PM Q&A

IVS058 - Clinical Trials – How Can We Reinvigorate Transplant Trials?

2:15 PM - 3:30 PM
Moscone South – Room 153
Organ Inclusive
CME Accredited

Moderators: Roslyn Mannon, USA and Daniel Brennan, USA
2:15 PM Welcome & Introduction
Roslyn Mannon, USA
Daniel Brennan, USA

2:15 PM IVS058.1 - Lessons from the Transplant Therapeutics Consortium
Anil Chandrakar, USA

2:30 PM IVS058.2 - Successes and Failures in Advancing Transplant Research
Peter Heeger, USA

2:45 PM IVS058.3 - The ASN Experience in Engaging with Regulators, Funding Bodies, and Industry
Prabir Roy-Chaudhury, USA

3:00 PM IVS058.4 - Patient Engagement in Clinical Trials
Kristi Coldwell, Canada

3:15 PM Q&A

IVS059 - Save My Kidneys! Management of Kidney Disease in Liver Transplant Recipients

2:15 PM - 3:30 PM
Moscone South – Room 11
Kidney
CME Accredited

Moderators: Nicholas Lim, USA and Samy Riad, USA

2:15 PM Welcome & Introduction
Nicholas Lim, USA
Samy Riad, USA

2:15 PM IVS059.1 - Beyond Serum Creatinine: Renal Function Measurement in LT Candidates and Recipients: Role of Cystatin C and Novel Biomarkers
Hassan Ibrahim, USA

2:30 PM IVS059.2 - Kidney or Not: Liver Transplantation in Patients With Acute Kidney Injury
Florence Wong, Canada

2:45 PM IVS059.3 - Role of Immunosuppression and

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

Other Strategies to Preserve Kidney Function in Liver Transplant Recipients
Hani Wadei, USA

3:00 PM Q&A

IVS060 - Cutaneous Malignancies in Solid Organ Transplantation: A New Era with Novel Agents

2:15 PM - 3:30 PM
Moscone South – Room 10
Organ Inclusive
CME Accredited

Moderators: Fiona Zwald and Gina Jamero, USA

2:15 PM Welcome & Introduction
Fiona Zwald
Gina Jamero, USA

2:15 PM IVS060.1 - Risk of Cutaneous Malignancies in Transplant Recipients: Implications for Listing and Screening
Sarah Arron, USA

2:30 PM IVS060.2 - Clinical Considerations for Initiating Immune Checkpoint Inhibitors in Cutaneous Malignancy Treatment Post-transplantation
Christopher Blosser, USA

2:45 PM IVS060.3 - Challenges in Managing Cutaneous Malignancy Post-transplant: Adjusting Maintenance Immunosuppression Strategies
Naoka Murakami, USA

3:00 PM IVS060.4 - Evaluating Recurrence Risk of Cutaneous Malignancies in Transplant Recipients: Implications for Candidacy Assessment
Germaine Wong, Australia

3:15 PM Q&A

IVS061 - The Global Need for Organ Replacement in 2030

2:15 PM - 3:30 PM
Moscone South – Room 24
Public Policy
CME Accredited

Moderators: Steve Chadban, Australia and Elmi Muller, South Africa

2:15 PM Welcome & Introduction
Steve Chadban, Australia
Elmi Muller, South Africa

2:15 PM IVS061.1 - Noncommunicable Disease Burden and Future Management Challenges- Diabetes and Kidney Disease
Marcello Tonelli, Canada

2:30 PM IVS061.2 - Heart Replacement Therapy
Jeff Teuteberg, USA

2:45 PM IVS061.3 - Liver Replacement Therapy
Nancy Ascher, USA

3:00 PM IVS061.4 - Dialysis vs Transplant in Low Income Countries
Benjamin Hippen, USA

3:15 PM Panel Discussion

IVS062 - Updates in Liver Allocation: How Has Policy Impacted Practice in the US?

2:15 PM - 3:30 PM
Moscone South – Room 21
Public Policy
CME Accredited

Moderators: James Pomposelli, USA and John Lake, USA

2:15 PM Welcome & Introduction
James Pomposelli, USA
John Lake, USA

2:15 PM IVS062.1 - MELD 3.0 and the Potential for

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

Continuous Distribution
Allison Kwong, USA

2:30 PM **IVS062.2** - Expedited Liver Offers
Amit Mathur, USA

2:45 PM **IVS062.3** - Allocation Updates Related to Transplant Oncology
Majella Doyle, USA

3:00 PM Q&A

IVS063 - Antibiosis and the Anastomosis: Surgical Considerations for Post-Transplant Infections

2:15 PM - 3:30 PM
Moscone South — Room 22
Infectious Disease
CME Accredited

Moderators: Rachel Miller, USA and Nicolas Mueller, Switzerland

2:15 PM Welcome & Introduction
Rachel Miller, USA
Nicolas Mueller, Switzerland

2:15 PM **IVS063.1** - Global Perspective: Periop Antibacterial and Antifungal Prophylaxis in Liver Transplant
Ankit Mittal, India

2:30 PM **IVS063.2** - Asymptomatic Bacteriuria in Kidney Transplant
Joseph Kim, Canada

2:45 PM **IVS063.3** - Addressing Donor Cultures in the Face of Preservation and Perfusion Technologies
Cameron Wolfe, USA

3:00 PM Q&A

IVS064 - Endothelial Cells

2:15 PM - 3:15 PM
Moscone South — Room 9
Basic Science
CME Accredited

Moderators: David Briscoe, USA and Dan Jane-wit, USA

2:15 PM Welcome & Introduction
David Briscoe, USA
Dan Jane-wit, USA

2:15 PM **IVS064.1** - Targeting Endothelial Cell Il-15 Trans-Presentation
Jordan Pober, USA

2:30 PM **IVS064.2** - Endothelial Cell-Mediated Polarization of Macrophages
Elaine F. Reed, USA

2:45 PM **IVS064.3** - Diagnostic Roles of Endothelial Cells During Antibody-Mediated Rejection
Marion Rabant, France

3:00 PM Q&A

IVS065 - EBV/PTLD: State-of-the-Art Consensus Update

2:15 PM - 3:15 PM
Moscone South — Room 12
Infectious Disease
CME Accredited

Moderators: Masaki Yamada, Japan and Upton Allen, Canada

2:15 PM Welcome & Introduction
Masaki Yamada, Japan
Upton Allen, Canada

2:15 PM **IVS065.1** - IPTA Consensus Update
Michael Green, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:30 PM **IVS065.2** - Biomarkers for PTLD
Olivia Martinez, USA

2:45 PM **IVS065.3** - Treatment of PTLD in 2025
Thomas Gross, USA

3:00 PM Q&A

IVS066 - Beyond Just Survival: Addressing Transplant Recipients' Perspective of Unmet Immunosuppressant Needs: The AST's National Survey of 10,000 Transplant Recipients

2:15 PM - 3:15 PM
Moscone South – Room 4
Pharmacy
CME Accredited

Moderators: Lisa Potter, USA and Marie Chisholm-Burns, USA

2:15 PM Welcome & Introduction
Lisa Potter, USA
Marie Chisholm-Burns, USA

2:15 PM **IVS066.1** - Survey Rationale, Design, and High-Level Findings
David Taber, USA

2:30 PM **IVS066.2** - Response Findings in Pediatrics - Similarities and Differences as Compared to Adults
Roshan George, USA

2:45 PM **IVS066.3** - Comparisons of Finding Across Kidney, Liver, Heart, Lung, Pancreas, Intestine, and VCA Recipients
Larissa Myaskovsky, USA

3:00 PM Q&A

LOA03 - Basic Science Advances in Transplantation: From T Cells to Tolerance

4:30 PM - 5:45 PM
Moscone South – Room 20
Basic Science
Not for CME Credit

Moderators: Maria-Luisa Alegre, USA and Stefen Alexander, Australia

4:30 PM Welcome & Introduction
Maria-Luisa Alegre, USA
Stefen Alexander, Australia

4:32 PM **LOA03.1** - First Evidence of Operational Tolerance in a Rare Case of Pediatric Heart Transplantation
Wai Yen Yim, China

4:39 PM Q&A

4:41 PM **LOA03.2** - Third-Party Haploidentical Bone Marrow Transplantation for the Induction of Transplant Tolerance
Hong Xu, USA

4:48 PM Q&A

4:50 PM **LOA03.3** - Transcription Factor Aiolos Deficiency in CD8+ T Cells Impacts the Development and Cytotoxic Effector Function of Antibody Suppressor CD8+ T Cells
Shane Walters, USA

4:57 PM Q&A

4:59 PM **LOA03.4** - JAK/STAT Pathway Inhibition Facilitates Mixed Chimerism with Reduced Conditioning for Allograft Tolerance
Hong Xu, USA

5:06 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:08 PM **LOA03.5** - Generation of Viable, Immunologically Distinct Intra-Species Chimeric Swine: Potential Implications for Novel Mechanisms of Tolerance
Joshua Weiner, USA

5:15 PM Q&A

5:17 PM **LOA03.6** - Load-Independent Assessment of Ex Situ Donor Hearts to Determine Transplant Suitability
Wyeth Alexander, USA

5:24 PM Q&A

5:26 PM **LOA03.7** - Necroptosis Inhibition in Kidney Ischaemia Reperfusion Injury- a Preclinical Study
Azita Mellati, UK

4:33 PM Q&A

4:35 PM **LOA03.8** - Deciphering the Molecular Crosstalk Between Ferroptosis and Peroxisomes in Macrosteatotic Graft Failure Following Liver Transplantation: A Multi-Omics Perspective
Zhengtao Liu, China

4:42 PM Q&A

4:44 PM Closing Remarks

LOA04 - Late Breaking Studies in Transplant Infectious Diseases

4:30 PM - 5:45 PM
Moscone South — Room 155
Infectious Disease
Not for CME Credit

Moderators: Matthew D'Costa, Singapore and Sara Belga, Canada

4:30 PM Welcome & Introduction
Matthew D'Costa, Singapore
Sara Belga, Canada

4:32 PM **LOA04.1** - HCV Cure Rates in the THINKER-NEXT Trial of Transplanting Kidneys from HCV-Infected Donors into HCV-Negative Recipients
David Goldberg, USA

4:39 PM Q&A

4:41 PM **LOA04.2** - Adjuvanted respiratory syncytial virus (RSV) vaccination in high-risk transplant recipients
Victoria Hall, Canada

4:48 PM Q&A

4:50 PM **LOA04.3** - Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: a Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Nadiesda Costa, USA

4:57 PM Q&A

4:59 PM **LOA04.4** - Developing CD8 T cell mRNA Vaccines Targeting BK Polyomavirus Large T Antigen
Hans Hirsch, Switzerland

5:06 PM Q&A

5:08 PM **LOA04.5** - Early experience with MMR vaccination in pediatric heart transplant recipients
Anne Dipchand, Canada

5:15 PM Q&A

5:17 PM **LOA04.6** - Cytomegalovirus-specific CD40LG-expressing T-cells are present before transplantation in CMV-seronegative recipients and predict early CMV DNAemia.
Lisa Remaley, USA

5:24 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:26 PM **LOA04.7** - Liver and Kidney Transplantation with Organs from Chagas Disease Positive Donors: A Valuable Resource That Requires Close Monitoring
Maria Margarita Anders, Argentina

5:33 PM Q&A

5:35 PM **LOA04.8** - Ex Vivo Targeting of the Latent Cytomegalovirus Reservoir in Human Kidneys to Prevent Virus Reactivation Post Transplantation
Ian McGowan, Denmark

5:42 PM Q&A

5:44 PM Closing Remarks

OA18 - Transplant Administration and Quality

4:30 PM - 5:45 PM
Moscone South – Room 11
Administrative
Not for CME Credit

Moderators: Stacey Doll, USA and Jon Snyder, USA

4:30 PM Welcome & Introduction
Stacey Doll, USA
Jon Snyder, USA

4:32 PM **OA18.1** - Historical Priors for Bayesian Assessment of Transplant Program Performance
Grace Lyden, USA

4:39 PM Q&A

4:41 PM **OA18.2** - Contemporary Practice and Challenges in Managing the Costs of Kidney Paired Donation: A Survey of US Transplant Professionals
Krista Lentine, USA

4:48 PM Q&A

4:50 PM **OA18.3** - Optimizing Readmission Risk Thresholds for Remote Patient Monitoring of Kidney Transplant Recipients A Cost-Benefit Analysis
Amber Paulus, USA

4:57 PM Q&A

4:59 PM **OA18.4** - Impact of Protocol AlloSure on Resource Utilization in Kidney Transplantation
Koren Axelrod, USA

5:06 PM Q&A

5:08 PM **OA18.5** - Changing Dynamics in Liver Allocation: Donor and Recipient Traits Pre- and Post Acuity Circle Implementation
Yichen Fang, USA

5:15 PM Q&A

5:17 PM **OA18.6** - Survival After Listing, a New Metric to Provide Patients with Comparative Information About Patient Experience Across Transplant Centers
Cinthia Lozano, USA

5:24 PM Q&A

5:26 PM **OA18.7** - Assessment of Process Variation in Liver, Kidney, and Pancreas Transplantation Using the Consortium for the Holistic Assessment of Risk in Transplant (CHART)
Alexandra Strauss, USA

5:33 PM Q&A

5:35 PM **OA18.8** - Impact of Current MPSC Program Metrics on Pediatric Solid Organ Transplant Programs
Vikram Raghu, USA

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA19 - Basic Mechanisms of Rejection

- 4:30 PM - 5:45 PM
- Moscone South – Room 12
- Basic Science
- Not for CME Credit

Moderators: Anna Morris, USA and Anat Tambur, USA

4:30 PM Welcome & Introduction
Anna Morris, USA
Anat Tambur, USA

4:32 PM OA19.1 - A T Cell Intrinsic Role for APOL1 Risk Alleles in Allograft Rejection
Madhav Menon, USA

4:39 PM Q&A

4:41 PM OA19.2 - Ebp1 is Required for Maintenance of CD8+ TRM in Transplant Rejection
Khodor Abou-Daya, USA

4:48 PM Q&A

4:50 PM OA19.3 - Mapping Immunodominant Indirect CD4+ T Cell Epitopes Associated with Transplant Rejection
Grace Zhou, USA

4:57 PM Q&A

4:59 PM OA19.4 - Discovery of a Novel Role of CD74 in Alloimmunity through Binding and Stabilizing IFNɣ Receptor on T Cells
Nadim Al Rahy, USA

5:06 PM Q&A

5:08 PM OA19.5 - Modulating Crosstalk Between Macrophages and Renal Tubular Epithelial Cells Improves Kidney Transplant Outcome
Jianye Cai, USA

5:15 PM Q&A

5:17 PM OA19.6 - Intracellular Membrane Attack Complexes Disrupt Proteostasis and Acquire Alarmin-Like Properties during Antibody-Mediated Rejection
Dan Jane-Wit, USA

5:24 PM Q&A

5:26 PM OA19.7 - Allorecognition and Costimulation of Human Endothelium-Derived Extracellular Vesicles in Initiating Allo-Specific CD4 Cell Immune Responses
Shu Li, USA

5:33 PM Q&A

5:35 PM OA19.8 - Leveraging Heterologous Immunity to Provide Insights into Alloreactivity
Ashley Burg, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA20 - Normothermic Machine Perfusion in Clinical Use

- 4:30 PM - 5:45 PM
- Moscone South – Room 24
- Basic Science
- Not for CME Credit

Moderators: Rutger Ploeg, UK and Marty Sellers, USA

4:30 PM Welcome & Introduction
Rutger Ploeg, UK
Marty Sellers, USA

4:32 PM OA20.1 - Secondary Perfusion: Modeling Viability of Organs Declined for Transplant
Avery Fortier, USA

4:39 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:41 PM **OA20.2** - Normothermic Regional Perfusion (NRP) Combined with Hypothermic Oxygenated Machine Perfusion (HMP-O2) Reduces Oxygen Deficit during Preservation in DCD Liver Allografts
Anastasia Xynogala, USA

4:48 PM Q&A

4:50 PM **OA20.4** - Implementation of an OPO-Driven NRP Program: Impact on Abdominal Organ Utilization
Charles Strom, USA

4:57 PM Q&A

4:59 PM **OA20.5** - Initial Experience in a Porcine Autotransplantation Model to Validate Normothermic Ex Vivo Kidney Perfusion
Jean Lee, USA

5:06 PM Q&A

5:08 PM **OA20.6** - Reducing Kidney Discard: Do NMP Parameters Correlate with Post-Transplant Graft Function?
Leonie van Leeuwen, USA

5:15 PM Q&A

5:17 PM **OA20.7** - Largest Real-World Multi-Center Study Outcomes Reported with Controlled Moderate Hypothermic Preservation of Donor Livers
Kiran Dhanireddy, USA

5:24 PM Q&A

5:26 PM **OA20.8** - Donor Liver Weight in Normothermic Ex Situ Machine Perfusion: Do Large Livers Perform Worse?
Braxton Goodnight, USA

5:33 PM Q&A

5:35 PM Closing Remarks

OA21 - Viral Frontlines: Tracking Vaccine-Preventable Viruses

4:30 PM - 5:45 PM
Moscone South – Room 21
Infectious Disease
Not for CME Credit

Moderators: Yoichiro Natori, USA and Natasha Halasa, USA

4:30 PM Welcome & Introduction
Yoichiro Natori, USA
Natasha Halasa, USA

4:32 PM **OA21.1** - Risk of RSV Infection in Solid Organ Transplant Recipients: A Real-World, Propensity Score-Matched Analysis of RSV Vaccination
German Contreras, USA

4:39 PM Q&A

4:41 PM **OA21.2** - Durability of RSV Antibodies Following RSV Vaccination in Solid Organ Transplant Recipients
Andrew Karaba, USA

4:48 PM Q&A

4:50 PM **OA21.3** - International Multicenter Study of the Outcomes of Infection with Neglected Respiratory Viruses in Solid Organ Transplant Recipients
Victoria Hall, Canada

4:57 PM Q&A

4:59 PM **OA21.4** - Early and Long-Term COVID-19 Outcomes in Pediatric Kidney Transplant Recipients: Results from a Brazilian Multicenter Study
Guilherme Sousa Ferreira, Brazil

5:06 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:08 PM **OA21.5** - One-Year Thromboembolic Outcomes in COVID-19+ Solid Organ Transplant Recipients: Comparing Triple-Vaccinated vs. Unvaccinated Patients
Avery Koi, USA

5:15 PM Q&A

5:17 PM **OA21.6** - COVID-19 Infection during Pregnancy in Transplant Recipients
Lisa Coscia, USA

5:24 PM Q&A

5:26 PM **OA21.7** - Seroprevalence and Incidence of Measles, Mumps, and Rubella in Adult Solid Organ Transplant Recipients: A Large Database Analysis
Chia-Yu Chiu, USA

5:33 PM Q&A

5:35 PM **OA21.8** - Risk Factors for Loss of Varicella Immunity After Pediatric Kidney Transplantation
Helen Pizzo, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA22 - Intestinal Transplantation and Rehabilitation

4:30 PM - 5:45 PM
Moscone South — Room 22
Intestine
Not for CME Credit

Moderators: Cal Matsumoto, USA and Douglas Farmer, USA

4:30 PM Welcome & Introduction
Cal Matsumoto, USA
Douglas Farmer, USA

4:32 PM **OA22.1** - The Discarded Donor Intestine: A Review of Donor Criteria, Donor Availability and Usage, and Current Efforts to Expand Donor Access
Carolyn Smullin, USA

4:39 PM Q&A

4:41 PM **OA22.2** - Rituximab Induction Therapy in Intestinal Transplantation: Beneficial Effects on De Novo DSA Development
Mohamed Khalaf, USA

4:48 PM Q&A

4:50 PM **OA22.3** - Normothermic Machine Perfusion Mitigates Allograft Inflammation in Intestinal Transplantation
Liara Gonzalez, USA

4:57 PM Q&A

4:59 PM **OA22.4** - Reconsidering the Immune Pathway of Intestinal Transplant Rejection: Novel Insights from Comparison with Crohn's Disease
Julie Hong, USA

5:06 PM Q&A

5:08 PM **OA22.5** - Establishment of a Large Animal Model for Ischemia-Free Intestine Transplantation
Yuqi Dong, China

5:15 PM Q&A

5:17 PM **OA22.6** - Donor-Derived Cell-Free DNA Analyses in Small Intestine Transplantation: A Multicenter Prospective Observational Study in Japan
Yohei Yamada, Japan

5:24 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:26 PM **OA22.7** - Multivisceral versus Isolated Intestinal Transplantation: A Comparative Analysis of Morbidity, Mortality, and Graft-Related Outcomes
Michael Gianarakis, USA

5:33 PM Q&A

5:35 PM Closing Remarks

OA23 - Kidney Novel Immune Risk Assessment and Monitoring

4:30 PM - 5:45 PM
Moscone South — Room 8
Kidney
Not for CME Credit

Moderators: Aleksandar Senev, Belgium and Giselle Guerra, Brazil

4:30 PM Welcome & Introduction
Giselle Guerra, Brazil
Aleksandar Senev, Belgium

4:32 PM **OA23.1** - Historically Reported Donor Specific Antibodies Rather Than Current Should Be Used to Assess Immunological Risk After Kidney Transplant (KTx)
Friederike Martin, USA

4:39 PM Q&A

4:41 PM **OA23.2** - The Role of Molecular Microscope and Donor Derived Cell Free DNA to Guide Therapy for T-Cell Mediated Rejection in Kidney Transplants
Dhiren Kumar, USA

4:48 PM Q&A

4:50 PM **OA23.3** - Diffusion Kurtosis Imaging Biomarkers Stratify Graft Injury and T Cell-Mediated Rejection in Renal Transplantation: A Multimodal Approach
Jiqiu Wen, China

4:57 PM Q&A

4:59 PM **OA23.4** - Discovering Molecular Signatures in ATMR: Single-Cell RNA-Sequencing Analysis of Human Blood and Tissue Spatial Transcriptomics
Minji Kang

5:06 PM Q&A

5:08 PM **OA23.5** - Transcriptomic Insights into HIV Rejection Profiles in Renal Transplant Recipients
Brenda Ametepe, USA

5:15 PM Q&A

5:17 PM **OA23.6** - PIRCHE-II Scores Correlate with Early Transcriptional Changes in Kidney Transplant Recipients with Antibody Mediated Rejection
Nida Saleem, USA

5:24 PM Q&A

5:26 PM **OA23.7** - Evaluating the Role of Molecular Mismatches in Kidney Graft Survival Using the PIRCHE-II and SNOW Algorithms: A Study from Mayo Clinic
Caroline Jadlowiec, USA

5:33 PM Q&A

5:35 PM **OA23.8** - HLA Eplet (HLAMatchmaker) and T Cell Epitope (PIRCHE) Mismatch and the Risk of Acute Rejection in Kidney Transplant Recipients
Jenny Tran, Canada

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA24 - Advances in Pediatric Kidney Transplant

4:30 PM - 5:45 PM
Moscone South — Room 154
Kidney
Not for CME Credit

Moderators: Lars Pape, Germany and Rouba Garro, USA

4:30 PM Welcome & Introduction
Lars Pape, Germany
Rouba Garro, USA

4:32 PM OA24.1 - Flow Cytometric Crossmatch for Pre-Transplant Immunologic Risk Assessment in Pediatric Kidney Transplant: STILL Not Necessary in Most Cases
Kelley Hitchman, USA

4:39 PM Q&A

4:41 PM OA24.2 - Large Scale Urinary Metabolomic Screening in the Prospective Multicenter VIRTUUS Children's Study
Qian Guo, USA

4:48 PM Q&A

4:50 PM OA24.3 - Antibodies to Angiotensin II Type 1 Receptor and Endothelin Type A Receptor in the First Year Post-Transplant Are Associated with Decline in Renal Function and HLA Donor Specific Antibodies at 5 Years Post-Transplant in Pediatric Kidney Transplant Recipients
Meghan Pearl, USA

4:57 PM Q&A

4:59 PM OA24.4 - Tissue-Based Gene Expression Resolves Ambiguity When Histology is I ndeterminant in Pediatric Kidney Transplant Recipients
Clarkson Crane, USA

5:06 PM Q&A

5:08 PM OA24.5 - Alternative, Low-Cost Monitoring of CD3 Cell Depletion Following Anti-Thymocyte Globulin Induction in Pediatric Renal Transplant Recipients
Samantha Krieger, USA

5:15 PM Q&A

5:17 PM OA24.6 - What is the Immunological Risk Threshold for Steroid-Free Immunosuppression in Pediatric Kidney Transplantation?
Sunil Karhadkar, USA

5:24 PM Q&A

5:26 PM OA24.7 - Impact of Living Donor Age and Sex on Pediatric Kidney Transplant Outcomes
Stella Kilduff, USA

5:33 PM Q&A

5:35 PM OA24.8 - Challenges in Non-Invasive Biomarker Profiling of Subclinical Borderline Rejection in Pediatric Kidney Transplantation
Tom Blydt-Hansen, Canada

5:42 PM Q&A

5:44 PM Closing Remarks

OA25 - Deceased Donor Kidney Allocation

4:30 PM - 5:45 PM
Moscone South — Room 4
Kidney
Not for CME Credit

Moderators: Charles Rickert, USA and Neeraj Singh, USA

4:30 PM Welcome & Introduction
Charles Rickert, USA
Neeraj Singh, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:32 PM **OA25.1** - The Additional Dialysis Time That Would Eliminate the Posttransplant Survival Benefit of a Better Kidney Offer
Maria Masotti, USA

4:39 PM Q&A

4:41 PM **OA25.2** - Association Between Geographic Variation in Kidney Transplant Wait Times and Utilization of Deceased Donor Kidneys in the U.S.
John Gill, Canada

4:48 PM Q&A

4:50 PM **OA25.3** - A Novel Strategy for Prioritizing Closer HLA Matching in Kidney Allocation Policy Would Avoid a Tradeoff of Increased Ethnic Disparity
Loren Gragert, USA

4:57 PM Q&A

4:59 PM **OA25.4** - Outcomes of Deceased Donor Kidney Transplants Allocated out of Sequence in the USA
Anne Huml, USA

5:06 PM Q&A

5:08 PM **OA25.5** - The Rapidly Shifting Calibration Between KDRI, KDPI, and Graft Survival: It's Time to Stop Moving the Goalposts!
Po-Yu (Teresa) Chiang, USA

5:15 PM Q&A

5:17 PM **OA25.6** - Virtual Crossmatch Outcomes Support Using OPTN Match Run as the Final Crossmatch to Improve Kidney Allocation Efficiency
Raja Rajalingam, USA

5:24 PM Q&A

5:26 PM **OA25.7** - Prognosis Matching in the Australian Deceased Donor Kidney Allocation Algorithm
James Hedley, Australia

5:33 PM Q&A

5:35 PM **OA25.8** - The Shift to Acuity Circles: Analyzing Changes in Kidney Transplant Access Across Socioeconomic and Geographic Lines
Justin Weissberg, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA26 - Kidney Rejection

4:30 PM - 5:45 PM
Moscone South – Room 25
Kidney
Not for CME Credit

Moderators: Ahmed Daoud, USA and TBC

4:30 PM Welcome & Introduction
TBC
Ahmed Daoud, USA

4:32 PM **OA26.1** - Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation: The Role of Biopsy-Based Transcript Diagnostics in Differentiating Immune Accommodation from Alloimmune Injury
Kai Castrezana Lopez, Switzerland

4:39 PM Q&A

4:41 PM **OA26.2** - HLA T Cell Epitope Mismatch and the Risk of Acute Rejection Among Participants in the Astellas Double Blind Randomized Early Corticosteroid Cessation Trial
James Lan, Canada

4:48 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:50 PM **OA26.3** - Tocilizumab Stabilizes Kidney Function and Reduce DSA in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection
Johan Noble, France

4:57 PM Q&A

4:59 PM **OA26.4** - Predicting Treatment Resistance at the Time of Diagnosis of Acute T Cell Mediated Rejection
Shana Coley, USA

5:06 PM Q&A

5:08 PM **OA26.5** - Combining PIRCHE-II and dd-cfDNA for Rejection Monitoring in Kidney Transplantation
Aylin Akifova, Germany

5:15 PM Q&A

5:17 PM **OA26.6** - Non-HLA Autoantibodies - Anti-Angiotensin II Type 1 Receptor and Endothelin Type A Receptor Antibodies in the Diagnosis of Antibody-Mediated Rejection: Biopsy-Based Transcript Diagnostics Perspective
Kai Castrezana Lopez, Switzerland

5:24 PM Q&A

5:26 PM **OA26.7** - The Effect of USA Citizenship Status on Black Deceased Donor Kidney Transplant Outcomes
Kofi Atiemo, USA

5:33 PM Q&A

5:35 PM **OA26.8** - Depletion of Senescent Cells Prevents CNI-Induced Nephrotoxicity
Merih Gizlenci, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA27 - Living Donor Kidney Public Awareness and Access

4:30 PM - 5:45 PM
Moscone South – Room 23
Kidney
Not for CME Credit

Moderators: Sunil Shroff, India and Chethan Puttarajappa, USA

4:30 PM Welcome & Introduction
Sunil Shroff, India
Chethan Puttarajappa, USA

4:32 PM **OA27.1** - Bridging the Gap: How Geography and Socioeconomic Factors Shape Access to Living Donor Kidney Transplant
Justin Weissberg, USA

4:39 PM Q&A

4:41 PM **OA27.2** - Are Changing Demographics of Candidates for Kidney Transplant the Reason for Lack of Growth in Living Donor Transplant in the USA?
Douglas Keith, USA

4:48 PM Q&A

4:50 PM **OA27.3** - Living Donor Demographics in Australia and New Zealand: Have Disparities Increased over Time?
Rose Scarlato, Australia

4:57 PM Q&A

4:59 PM **OA27.4** - Impact of a Living Donor Coach on Living Donor Engagement and Racial Disparities in Kidney Transplantation
Amit Tevar, USA

5:06 PM Q&A

5:08 PM **OA27.5** - Social Media & Organ Donation: Mapping Attitudes and Engagement
Rajesh Anumolu, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:15 PM Q&A

5:17 PM **OA27.6** - Effectiveness of a US Media Campaign Targeting the General Public to Increase Pursuit of Living Donation
Amy Waterman, USA

5:24 PM Q&A

5:26 PM **OA27.7** - Potential Living Kidney Donors' Preferences on Who Should Decide Donor Eligibility: Changes over Time
Sierra Auleta, USA

5:33 PM Q&A

5:35 PM **OA27.8** - Low Risk HLAi (LRHLAi) Matching for Highly Sensitized Patients (HSP): A Successful KPD Matching Strategy
Khalid Almeshari, Saudi Arabia

5:42 PM Q&A

5:44 PM Closing Remarks

OA28 - Reduced Sized Grafts, Living and Deceased Livers

4:30 PM - 5:45 PM
Moscone South — Room 10
Liver
Not for CME Credit

Moderators: Mohamed Rela, India and Varvara Kirchner, USA

4:30 PM Welcome & Introduction
Mohamed Rela, India
Varvara Kirchner, USA

4:32 PM **OA28.1** - Robotic Donor Right Hepatectomy is a Safe Operation with a Short Learning Curve: 50 Consecutive Cases from a Single North American Center
Amar Gupta, USA

4:39 PM Q&A

4:41 PM **OA28.2** - Over One Thousand Consecutive Living Donor Hepatectomies over 24 Years at a Single Institution- The Impact of ERAS Protocols on Donor Recovery
Swaytha Ganesh, USA

4:48 PM Q&A

4:50 PM **OA28.3** - QUALITY Score, Development of Integrative Prognostic Index for Living Donor Liver Using Multicentric Registry Data
Deok-Gie Kim, South Korea

4:57 PM Q&A

4:59 PM **OA28.4** - Refining the Prognostic Framework for Small-for-Size Graft Syndrome Grade B After LDLT: A Multicenter Study by the iLDLT Group
Takeo Toshima, Japan

5:06 PM Q&A

5:08 PM **OA28.5** - Shifting Landscape of Adult Liver Transplantation in the USA: Declining Role of Living Donor Transplants?
Shinichiro Yokota, USA

5:15 PM Q&A

5:17 PM **OA28.6** - reduced sized grafts, living and deceased livers
Jessica Singh, Germany

5:24 PM Q&A

5:26 PM **OA28.7** - Graft-to-Spleen Volume Ratio is a New Indicator for Splenectomy in Living Donor Liver Transplantation to Protect Graft Function: Retrospective Analysis and Prospective Validation
Siyuan Yao, Japan

5:33 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:35 PM **OA28.8** - Feasibility and Outcomes of Living-Donor Liver Transplantation in Elderly Patients Aged 70 Years and Older: A Propensity Score-Matched Analysis
Yu Minami, Japan

5:42 PM Q&A

5:44 PM Closing Remarks

OA29 - International Perspectives on Public Policy

4:30 PM - 5:45 PM
Moscone South – Room 9
Public Policy
Not for CME Credit

Moderators: Abdul Hakeem, UK and Curie Ahn, South Korea

4:30 PM Welcome & Introduction
Abdul Hakeem, UK
Curie Ahn, South Korea

4:32 PM **OA29.1** - Exploring Public Attitudes and Views on Xenotransplantation: Results from the First Representative UK Sample Survey
Antonia Cronin, UK

4:39 PM Q&A

4:41 PM **OA29.2** - Kidney Transplantation: Are There Differences in Kidney Donation and Transplantation Rates When Countries Switch from an Opt-In to and Opt-Out System?
Gordon Treacy, Ireland

4:48 PM Q&A

4:50 PM **OA29.3** - Association Between Socio-Economic Factors and Kidney Transplantation Activity Across Muslim Majority Countries
Fatima Malik, UK

4:57 PM Q&A

4:59 PM **OA29.4** - About Time: Improving Equity in Korean Kidney Allocation System through Virtual Crossmatch
John Yang, South Korea

5:06 PM Q&A

5:08 PM **OA29.5** - The Growth and Development of Liver Transplantation in the United Arab Emirates
Giuseppe Iuppa, UAE

5:15 PM Q&A

5:17 PM **OA29.6** - Enhancing Post-Transplant Care in Austria: A Survey of Primary Care Physicians' Needs and the Potential for Integrated Care Software
Angelika Rzepka, Austria

5:24 PM Q&A

5:26 PM **OA29.7** - The Boy Who Saved Thousands of Lives
Reg Green, USA

5:33 PM Q&A

5:35 PM **OA29.8** - Teaching of Organ Donation is Sub-Optimal in English High Schools
Aidan Sharif, UK

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

RF08 - Kidney Transplant Cardiometabolic Risk Assessment and Outcomes

4:30 PM - 5:30 PM
Moscone South — Room 153
Kidney
Not for CME Credit

Moderators: Vikas Sridhar, Canada and Nahel Elias, USA

4:30 PM Welcome & Introduction
Vikas Sridhar, Canada
Nahel Elias, USA

4:32 PM **RF08.1** - GLP-1 Receptor Agonists: Advancing Kidney Transplant Access and Safety in a National ESKD Cohort
Babak Orandi, USA

4:37 PM Q&A

4:39 PM **RF08.2** - SGLT2 Inhbitors Reduce the eGFR Slope in Diabetic and Non-Diabetic Kidney Transplant Recipients
Diana Rodríguez-Espinosa, Spain

4:44 PM Q&A

4:46 PM **RF08.3** - Incorporating Six-Minute Walk Test, Cardio-Pulmonary Exercise Testing and Renal Rehabilitation in Kidney Transplant Candidates: A Descriptive Report
Dhiren Kumar, USA

4:51 PM Q&A

4:53 PM **RF08.4** - Distinct Differences in the Pattern of Major Adverse Cardiac Events Pre- and Post-Kidney Transplantation: The CARSK Study
Steven Chadban, Australia

4:58 PM Q&A

5:00 PM **RF08.6** - The Hidden Threat: Air Pollution Harming Cardiovascular and Cognitive Health in Older Kidney Transplant Recipients
Malika Wilson, USA

5:05 PM Q&A

5:07 PM **RF08.7** - Evidence-Based Population Health Management Program for Diabetes Mellitus Type 2 Management in Kidney Transplant Recipients
Anshul Bhalla, USA

5:12 PM Q&A

5:14 PM **RF08.8** - Electrocardiographic Predictors of Major Adverse Cardiovascular Events in Renal Transplant Recipients
Davy Song, USA

5:19 PM Q&A

5:21 PM Closing Remarks

Detailed Program

Tuesday, August 5

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS067 - Mortality and Cardio-Kidney-Metabolic Complications in Kidney Transplantation: The State of Evidence and the Need for Outcome Trials

7:00 AM - 8:00 AM
Moscone South – Room 25
Kidney
CME Accredited

Moderators: Vikas Sridhar, Canada and Lachlan McMichael, Australia

7:00 AM Welcome & Introduction
Vikas Sridhar, Canada
Lachlan McMichael, Australia

7:00 AM IVS067.1 - Cardiometabolic and Renal (CVRM) Pathways to Post-kidney Transplant Mortality
Shaifali Sandal, Canada

7:15 AM IVS067.2 - The Need For Trials - Novel Trial Endpoints
David Vock, USA

7:30 AM IVS067.3 – SGLT2 Inhibitors in Kidney Transplantation
Martina McGrath, USA

7:45 AM Q&A

IVS068 - Culturally Safe Organ Donation

7:00 AM - 8:00 AM
Moscone South – Room 21
Psychosocial & Ethics
CME Accredited

Moderators: Jagbir Gill, Canada and Sixto Giusti, USA

7:00 AM Welcome & Introduction
Jagbir Gill, Canada
Sixto Giusti, USA

7:00 AM IVS068.1 - Cultural / Religious Barriers to Deceased and Living Donation Among Immigrant Populations
Gurch Randawa, UK

7:12 AM IVS068.2 - Living and Deceased Donation in African Americans
Burnett Kelly, USA

7:24 AM IVS068.3 - Living Donation in Indigenous Populations Around the Globe
Caroline Tait, Canada

7:36 AM IVS068.4 - Living Donation in Poor Populations
Rudolf Garcia-Gallont, Guatemala

7:48 AM Q&A

IVS069 - Best Practices for Transitioning Pediatric Recipients to Adult Transplant Programs

7:00 AM - 8:00 AM
Moscone South – Room 23
Organ Inclusive
CME Accredited

Moderators: Anne Dipchand, Canada and Elaine Ku, USA

7:00 AM Welcome & Introduction
Anne Dipchand, Canada
Elaine Ku, USA

7:00 AM IVS069.1 - Transition in Chronic Illness
Anne Loes van Staa, Netherlands

7:15 AM IVS069.2 - Optimal Practices for Transition
Anne Dipchand, Canada

7:30 AM IVS069.3 - Challenges and Opportunities for Improvement
Megan Kamath, USA

7:45 AM Q&A

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS070 - State-of-the-Art BK Virus

7:00 AM - 8:00 AM
Moscone South – Room 24
Infectious Disease
CME Accredited

Moderators: Hans Hirsch, Switzerland and Daniel Brennan, USA

7:00 AM Welcome & Introduction
Hans Hirsch, Switzerland
Daniel Brennan, USA

7:00 AM IVS070.1 - Overview of the Updated BK Guidelines
Camille Kotton, USA

7:15 AM IVS070.2 - Modulating Immunosuppression to Manage BK
Ilies Benotmane, USA

7:30 AM IVS070.3 - Novel Treatment Paradigms for BK Virus
David Wojciechowski, USA

7:45 AM Q&A

IVS071 - New Frontiers in VCA and Uterus Transplantation

7:00 AM - 8:00 AM
Moscone South – Room 9
VCA
CME Accredited

Moderators: Vijay Gorantla, USA and Nadey Hakim, UK

7:00 AM Welcome & Introduction
Vijay Gorantla, USA
Nadey Hakim, UK

7:00 AM IVS071.1 - Mother and Child: Basic and Translational Research in Uterus Transplantation
Paige Porrett, USA

7:15 AM IVS071.2 - Spatial Transcriptomics and VCA
Fadi Issa, UK

7:30 AM IVS071.3 - Can Nanotechnology revolutionize VCA
Jelena Janjic, USA

7:45 AM Q&A

IVS072 - Why Are Islet Cell Transplants Failing in the US and Thriving in the Rest of the World?

7:00 AM - 8:00 AM
Moscone South – Room 11
Pancreas
CME Accredited

Moderators: Balamurugan Appakalai, USA and Toby Coates, Australia

7:00 AM Welcome & Introduction
Balamurugan Appakalai, USA
Toby Coates, Australia

7:00 AM IVS072.1 - Pancreatic Islet Transplant: A Viable Alternative to Pancreas Transplantation
Trevor Reichman, Canada

7:20 AM IVS072.2 - Challenges in the US Leading To the Demise of Islet Allotx
Piotr Witkowski, USA

7:40 AM Panel Discussion

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS073 - "I'm Bringing Sexy Back": Improving Fellows' Interest in Solid Organ Transplantation

7:00 AM - 8:00 AM
Moscone South – Room 22
Organ Inclusive
CME Accredited

Moderators: Aasim Afzal, USA and Carli Lehr, USA

7:00 AM Welcome & Introduction
Aasim Afzal, USA
Carli Lehr, USA

7:00 AM IVS073.1 - "I'm Loving It": How Do We Increase Exposure for Medical Students, Residents and Fellows
Samira Farouk, USA

7:15 AM IVS073.2 - "What Goes Around, Comes Around": How to Be a Successful Transplantation Mentor
Anjana Pillai, USA

7:30 AM IVS073.3 - "Cry Me a River": Making the Field of Transplantation More Attractive
Jon Kobashigawa, USA

7:45 AM Q&A

IVS074 - Consequences of Pregnancy on Alloimmunity

7:00 AM - 8:00 AM
Moscone South – Room 10
Basic Science
CME Accredited

Moderators: Stephen Alexander, Australia and Cathi Murphey, USA

7:00 AM Welcome & Introduction
Stephen Alexander, Australia
Cathi Murphey, USA

7:00 AM IVS074.1 - Immunological Consequences of Microchimerism in Pregnancy
Ina Stelzer, USA

7:15 AM Q&A

7:20 AM IVS074.2 - Implications of Pregnancy on Immunity
Anita Chong, USA

7:35 AM Q&A

7:40 AM IVS074.3 - Innate Allorecognition and Reproductive Success
Fadi Lakkis, USA

7:55 AM Q&A

IVS075 - Biomarkers - Will We Ever Get Closer to Predicting Outcomes

7:00 AM - 8:00 AM
Moscone South – Room 4
Basic Science
CME Accredited

Moderators: Jamil Azzi, USA and Valeria Mas, USA

7:00 AM Welcome & Introduction
Jamil Azzi, USA
Valeria Mas, USA

7:00 AM IVS075.1 - Pan Organ Biomarkers
Jennifer Li, Australia

7:15 AM Q&A

7:20 AM IVS075.2 - What Is the Next IBox?
Marc Raynaud, France

7:35 AM Q&A

7:40 AM IVS075.3 - A Redox-based Approach for Monitoring T Cell Function in Transplant
Miguel Fribourg-Casajuana, USA

7:55 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS076 - Top Papers in Transplant Infectious Diseases

- 7:00 AM - 8:00 AM
- Moscone South – Room 153
- Infectious Disease
- CME Accredited

Moderators: Atul Humar, Canada and Carlos Cervera, Canada

7:00 AM Welcome & Introduction
Atul Humar, Canada
Carlos Cervera, Canada

7:00 AM IVS076.1 - Top Papers in Viral Infections
Marcus Pereira, USA

7:20 AM IVS076.2 - Top Papers in Bacterial Infections
Nicolas Mueller, Switzerland

7:40 AM IVS076.3 - Top Papers in Fungal Infections
C. Orla Morrissey, Australia

IVS077 - Innovative Tools in Transplant Education

- 7:00 AM - 8:00 AM
- Moscone South – Room 155
- Organ Inclusive
- CME Accredited

Moderators: Cybele Lara Abad, Philippines and Courtney Harris, USA

7:00 AM Welcome & Introduction
Cybele Lara Abad, Philippines
Courtney Harris, USA

7:00 AM IVS077.1 - Developing a Podcast
Sara Dong, USA

7:15 AM IVS077.2 - Gamification as a Learning Tool
Jeremey Walker, USA

7:30 AM IVS077.3 - Tips & Tricks for Patient Webinars
Candice Coghlan, Canada

7:45 AM Q&A

IVS078 - Challenges in the Management of Lung Transplant Recipients

- 7:00 AM - 8:00 AM
- Moscone South – Room 20
- Lung
- CME Accredited

Moderators: Deborah Levine, USA and Andrew Courtwright, USA

7:00 AM Welcome & Introduction
Deborah Levine, USA
Andrew Courtwright, USA

7:00 AM IVS078.1 - Alphabet Soup of Rejection Including Biomarkers: ALAD, BLAD, CLAD
Stephen Juvet, Canada

7:15 AM IVS078.2 - Gastroesophageal Reflux and Management Post-lung Transplant
Matthew Hartwig, USA

7:30 AM IVS078.3 - Difficult to Manage Post-lung Transplant Infections
Erika Lease, USA

7:45 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

LOA05 - Non Immunological Outcomes

7:00 AM - 8:00 AM
Moscone South – Room 154
Kidney
Not for CME Credit

Moderators: Venkatesh Ariyamuthu, USA

7:00 AM Welcome & Introduction
Venkatesh Ariyamuthu, USA

7:02 AM LOA05.1 - Cognitive Outcomes and Quality of Life in Stable Renal Transplant Patients Switched from Twice-Daily Tacrolimus to Envarsus XRTM
Anthony Langone, USA

7:09 AM Q&A

7:11 AM LOA05.2 - Impact of a Multidisciplinary, Holistic Clinic on Kidney-Transplant Recipients with Complex Needs: Twelve-Month Prospective Evaluation
Beatriz Rodriguez-Cubillo, Spain

7:18 AM Q&A

7:20 LOA05.3 - Clinical and Symptom Profile of Kidney Transplant Recipients Flagged by the NECPAL Tool: Cross-Sectional Analysis from a Multidisciplinary Clinic
Beatriz Rodriguez-Cubillo, Spain

7:27 AM Q&A

7:29 AM LOA05.4 - Optimizing Cognitive Risk Assessment to Determine Fitness for Transplant in an Elderly Veteran Population
Hillary Dorman, USA

7:36 AM Q&A

7:38 AM LOA05.5 - The Effect of Adding Dapagliflozin on Chronic Allograft Dysfunction. A Prospective, Randomized, Double-Blind, Placebo-Control Trial
Elias David Neto, Brazil

7:45 AM Q&A

7:47 AM LOA05.6 - Association of Post-Transplant Apolipoprotein A-1 Levels with Cardiovascular Events and Graft Loss in Kidney Transplant Recipients: Results from the KOTRY Study
Hee Jung Jeon, South Korea

7:54 AM Q&A

7:56 AM Closing Remarks

RF06 - Insights from Transplant Science

7:00 AM - 8:00 AM
Moscone South – Room 12
Basic Science
Not For CME Credit

Moderators: Xunrong Luo, USA and Leonie van Leeuwen, USA

7:00 AM Welcome & Introduction
Xunrong Luo, USA
Leonie van Leeuwen, USA

7:02 AM RF06.1 - Graft-Derived Extracellular Vesicles Carry miRNAs That Promote Macrophage M1 Polarization in a Murine Allogeneic Heart Transplant Model
Ashley Haluck-Kangas, USA

7:07 AM Q&A

7:09 AM RF06.2 - Cytomegalovirus-Infected Dendritic Cells Demonstrate Dysregulated Insulin-Like Growth Factor Signaling Associated with Loss of T Cell Anergy
Olivia Fay, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:14 AM Q&A

7:16 AM **RF06.3** - Heterogeneous B Cell Subsets Clonally Expand in Human Lymph Nodes under Immunosuppression
Jasmine Shwetar, USA

7:21 AM Q&A

7:23 AM **RF06.4** - Dual CXCR3 and CD28 Blockade Synergistically Prolongs Graft Survival and Potently Restrains Effector CD8+ T Cells
Scott Krummey, USA

7:28 AM Q&A

7:30 AM **RF06.5** - Graft Survival and Rejection Risk with TNX-1500 as Monotherapy or in Combination with Conventional IS Agents in Nonhuman Primate Heart Transplants
Kohei Kinoshita, USA

7:35 AM Q&A

7:37 AM **RF06.6** - Adjuvant IL15 Blockade Significantly Improves Survival When Combined with a Costimulation-Based Immunosuppression Protocol of Pig-to-Nonhuman Primate Renal Xenotransplantation
James Keiler, USA

7:42 AM Q&A

7:44 AM **RF06.7** - Targeting CD11b - An Alternative Binding Site of CD154 - Increases the Prevalence of Exhausted TEMRA CD8 T Cells in a Nonhuman Primate Model of Renal Allotransplantation
James Keiler, USA

7:49 AM Q&A

7:51 AM **RF06.8** - Dual Blockade of CD154 and CD28 Co-Stimulation Pathways Mitigates Pathogenic Allo-Immunity and Enhances Survival in Cynomolgus Cardiac Transplantation
Kohei Kinoshita, USA

7:56 AM Q&A

7:58 AM Closing Remarks

RF07 - Deceased Donor Kidney Access to Waitlist/Transplant Outcomes

7:00 AM - 8:00 AM
Moscone South – Room 8
Kidney
Not For CME Credit

Moderators: Jesse Schold, USA and Christine Haugen, USA

7:00 AM Welcome & Introduction
Jesse Schold, USA
Christine Haugen, USA

7:02 AM **RF07.1** - Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation: Preliminary Results of the ADAPT Trial
Stuart Knechtle, USA

7:07 AM Q&A

7:09 AM **RF07.2** - Identifying Quality Improvement Opportunities to Increase Early Transplant Preparation and Pursuit of Transplant
Amy Waterman, USA

7:14 AM Q&A

7:16 AM **RF07.3** - National Trends of Sex Disparity over 5 Decades of Living Donor Kidney Transplantation in Singapore
Sobhana Thangaraju, Singapore

7:21 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:21 AM **RF07.4** - Association Between California Kidney Transplant Waitlist and Living Donor Kidney Transplantation
Fawaz Al Ammary, USA

7:28 AM Q&A

7:30 AM **RF07.5** - From Bias to Balance: The Role of Race-Neutral eGFR in African American Transplant Equity
Matthew Pittappilly, USA

7:35 AM Q&A

7:37 AM **RF07.6** - Intersectional Disadvantage and It's Effect on Living Donor Kidney Transplant Access in Australia: A National Cohort Study (2006-2023)
Tennille Vitagliano, Australia

7:42 AM Q&A

7:44 AM **RF07.7** - Disparities in Kidney Transplantation Access and Outcomes Among Native Hawaiians and Pacific Islanders in the USA
Kiyonari Noguchi, USA

7:49 AM Q&A

7:51 AM **RF07.8** - Comprehensive Geriatric Assessment (CGA) and Optimisation Services Prior to Kidney Transplantation in Older Potential Recipients: Results from the First UK-Wide Transplant Centre and Renal Unit Survey Study
Antonia Cronin, UK

7:56 AM Q&A

7:58 AM Closing Remarks

IVS079 - Psychosocial Issues in Living Donation

8:15 AM - 9:30 AM
Moscone South – Room 20
Psychosocial & Ethics
CME Accredited

Moderators: James Rodrigue, USA and Didier Mandelbrot, USA

8:15 AM Welcome & Introduction
James Rodrigue, USA
Didier Mandelbrot, USA

8:15 AM **IVS079.1** - The Psychosocial Risks and Benefits of Living Donation
Martina McGrath, USA

8:30 AM **IVS079.2** - Substance Use in Living Donors
Filza Hussain, USA

8:45 AM **IVS079.3** - The Overwhelmed Donor
AnnMarie Liapakis, USA

9:00 AM **IVS079.4** - Care of the Denied Donor
Peter Reese, USA

9:15 AM Q&A

IVS080 - Challenging Cases World Edition: Transplant ID Experiences Across the Globe

8:15 AM - 9:30 AM
Moscone South – Room 8
Infectious Disease
CME Accredited

Moderators: Aruna Subramanian, USA and Ankit Mittal, India

8:15 AM Welcome & Introduction
Aruna Subramanian, USA
Ankit Mittal, India

8:15 AM Panelists
Marian Michaels, USA
Thuan Tong Tan, Singapore
Ligia Pierrotti, Brazil
Sara Belga, Canada
Ajit Limaye, USA

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS081 - Advanced Practice Providers on the Cutting Edge: Expanding Roles in Surgery and Transplant Research

8:15 AM - 9:30 AM
Moscone South – Room 21
APP
CME Accredited

Moderators: Lindsay Powell, USA and Elaina Weldon, USA

8:15 AM Welcome & Introduction
Lindsay Powell, USA
Elaina Weldon, USA

8:15 AM IVS081.1 - APP-Led Robotics: APPs in Robotic and Minimally Invasive Donor Surgery
Erin Grace Kinsella, USA

8:30 AM IVS081.2 - Lifeline Logistics: APPs on the Frontlines of Organ Procurement
Carlee Komoroski, USA

8:45 AM IVS081.3 - Into the Future: APPs in Research
Kelly Cederquist, USA

9:00 AM IVS081.4 - Guardians of Viability: APPs in Organ Perfusion and Preservation
Georgeine Smith, USA

9:15 AM Q&A

IVS082 - Pediatric Access to Transplantation

8:15 AM - 9:30 AM
Moscone South – Room 12
Organ Inclusive
CME Accredited

Moderators: Ron Shapiro, USA and Sang-Mo Kang, USA

8:15 AM Welcome & Introduction
Ron Shapiro, USA
Sang-Mo Kang, USA

8:15 AM IVS082.1 - Overview of Global Pediatric Access to Transplantation
Jennifer Vittorio, USA

8:30 AM IVS082.2 - How to Increase Deceased Donor Organ Availability for Pediatric Recipients
Emily Perito, USA

8:45 AM IVS082.3 - Dare to Dream - A World Where Every Child in Need Receives a Transplant!
Julie Ingelfinger, USA

9:00 AM IVS082.4 - Role of Philanthropy
Sajid Sultan, Pakistan

9:15 AM Q&A

IVS083 - Innovation in Organ Allocation

8:15 AM - 9:30 AM
Moscone South – Room 155
Public Policy
CME Accredited

Moderators: Dave Foley, USA and Julie Heimbach, USA

8:15 AM Welcome & Introduction
Dave Foley, USA
Julie Heimbach, USA

8:15 AM IVS083.1 - Longevity Matching Revisited
Elizabeth Pomfret, USA

8:27 AM IVS083.2 - Eplet Matching - Is It Feasible and Equitable?
James Lan, Canada

8:39 AM IVS083.3 - Preemptive Transplantation
Deirdre Sawinski, USA

8:51 AM IVS083.4 - Moving Away From Transplanting the Sickest Patients in Liver Transplantation
Elizabeth Verna, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

9:03 AM IVS083.5 - Continuous Distribution
Jon Snyder, USA

9:15 AM Q&A

IVS084 - Transplantation in the Context of Migration and Refugees: An Update of the DICG and TTS Ethics Committee Workshop TTS 2022

- 8:15 AM - 9:30 AM
- Moscone South – Room 10
- Psychosocial & Ethics
- CME Accredited

Moderator: Maria Amalia Matamoros, Costa Rica and Peter Stock, USA

8:15 AM Welcome & Introduction
Maria Amalia Matamoros, Costa Rica
Peter Stock, USA

8:15 AM IVS084.6 - Ethical and Legal Challenges Impacting Refugees and Migrants With ESRD - The Need for International Attention
Frederike Ambagtsheer, Netherlands

8:35 AM IVS084.1 - Access to Dialysis/Transplantation for Syrian Refugees in Türkiye
Rumeyza Kazancioglu, Turkey

8:45 AM IVS084.7 - Transplantation in Ethiopia - The Impact of Internal Conflict
Mekdim Tadesse Siyoum

8:55 AM IVS084.3 - Brief Updates on Report of the DICG/TTS Ethics Committee Workshop From Buenos Aires 2022 Meeting (Poland / Refugees-Migrants From Ukraine)
Jolanta Malyszko, Poland

9:02 AM IVS084.4 - Brief Updates on Report of the DICG/TTS Ethics Committee Workshop From Buenos Aires 2022 Meeting (Colombia / Refugees-Migrants From Venezuela)
Alejandro Nino-Murcia, Colombia

9:09 AM IVS084.2 - Brief Updates on Report of the DICG/TTS Ethics Committee Workshop From Buenos Aires 2022 Meeting (Australia / Refugees From SE Asia, Pacific Islands)
Toby Coates, Australia

9:16 AM IVS084.5 - Brief Updates on Report of the DICG/TTS Ethics Committee Workshop From Buenos Aires 2022 Meeting (USA / Refugees-Migrants From Mexico and Central America)
Peter Stock, USA

9:23 AM Q&A

IVS085 - Donor Follow Up – How Can We Do Better?

- 8:15 AM - 9:30 AM
- Moscone South – Room 154
- Organ Inclusive
- CME Accredited

Moderators: Vineeta Kumar, USA and Melanie Wyld, Australia

8:15 AM Welcome & Introduction
Vineeta Kumar, USA
Melanie Wyld, Australia

8:15 AM IVS085.1 - The Global Status of Post-Donation Follow-Up
Ngan Lam, Canada

8:27 AM IVS085.2 - Living Donor Registry: The South Korean Experience
Hajeong Lee, South Korea

8:39 AM IVS085.3 - Efforts to Establish Follow Up in the US
Ajay Israni, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:51 AM **IVS085.4** - What Do Donors Want?
Sunita Singh, Canada

9:03 AM **IVS085.5** - Engaging Donors in Health Maintenance Post Donation
Emilio Poggio, USA

9:15 AM Q&A

IVS086 - Quality and Value in Organ Donation and Transplantation

8:15 AM - 9:30 AM
Moscone South – Room 23
Organ Inclusive
CME Accredited

Moderators: Ashley Cardenas, USA and Alexander Wiseman, USA

8:15 AM Welcome & Introduction
Ashley Cardenas, USA
Alexander Wiseman, USA

8:15 AM **IVS086.1** - You Know It When You See It - The Elusive Concepts of Quality and Value in Healthcare
Alexandra Glazier, USA

8:27 AM **IVS086.2** - Quality in Organ Donation Services
Rutger Ploeg, UK

8:39 AM **IVS086.3** - Quality in Kidney Transplantation
Greg Knoll, Canada

8:51 AM **IVS086.4** - Measures of What Matters to Patients
Kevin Longino, USA

9:03 AM **IVS086.5** - Quality From the Donor's Perspective: A Past Living Donor's Perspective
Brooke Iarkowski, USA

9:15 AM Q&A

IVS087 - Ethics and Legal Considerations in Deceased Donation

8:15 AM - 9:30 AM
Moscone South – Room 153
Psychosocial & Ethics
CME Accredited

Moderators: Alex Capron, USA and Henry Randall, USA

8:15 AM Welcome & Introduction
Alex Capron, USA
Henry Randall, USA

8:15 AM **IVS087.1** - Ethics of Normothermic Regional Perfusion
Anji Wall, USA

8:30 AM **IVS087.2** - Deceased Donor Intervention Research
Maryl Johnson, USA

8:45 AM **IVS087.3** - Donor Rewards and Recognition: International Perspective
Sanjay Nagral, India

9:00 AM **IVS087.4** - Deceased Donation After Medical Assistance in Dying
Kim Wiebe, Canada

9:15 AM Q&A

IVS088 - From "Good Enough" to "Great": Addressing Barriers to Improving Immunosuppression

8:15 AM - 9:30 AM
Moscone South – Room 24
Organ Inclusive
CME Accredited

Moderators: Roslyn Mannon, USA and Kenneth Newell, USA

8:15 AM Welcome & Introduction
Roslyn Mannon, USA
Kenneth Newell, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:15 AM **IVS088.1** - The (Unspoken) Risks of Over-Immunosuppression
Nithya Santhana Krishnan, UK

8:27 AM **IVS088.2** - Structuring Trials of Novel Agents: Risks and Opportunities
Steve Chadban, Australia

8:39 AM **IVS088.3** - Regulatory Pathways and Barriers to Innovation: Lessons from the EMA
Stefan Schneeberger, Austria

8:51 AM **IVS088.4** - Industry Partners: Friends or Foes?
Ulf Meier Kriesche, USA

9:03 AM **IVS088.5** - Can Technology and Therapeutic Monitoring Strategies Improve the Gap?
Dirk Kuypers, Belgium

9:15 AM Q&A

IVS089 - Innovations in Organ Preservation and Perfusion Strategies

8:15 AM - 9:30 AM
Moscone South — Room 4
Organ Inclusive
CME Accredited

Moderators: Aleah Brubaker, USA and Andrew Butler, UK

8:15 AM Welcome & Introduction
Aleah Brubaker, USA
Andrew Butler, UK

8:15 AM **IVS089.1** - The Evidence for in Situ Versus Ex Situ Perfusion of DCD Donor Organs
Peter Abt, USA

8:30 AM **IVS089.2** - Advancements in Combined Hypothermic and Normothermic Machine Perfusion: Controlled Oxygenated Rewarming
Robert J. Porte, Netherlands

8:45 AM **IVS089.3** - Economic Considerations of Implementing Perfusion Technology: Can We Afford It?
David Axelrod, USA

9:00 AM **IVS089.4** - Cryopreservation, Vitrification, and Nano-Rewarming: The Next Innovation in Organ
Erik Finger, USA

9:15 AM Q&A

IVS090 - Harnessing Social Media for Good

8:15 AM - 9:30 AM
Moscone South — Room 22
Organ Inclusive
CME Accredited

Moderators: Juliet Emamaullee, USA and Burnett Kelly, USA

8:15 AM Welcome & Introduction
Juliet Emamaullee, USA
Burnett Kelly, USA

8:15 AM **IVS090.1** - Spreading the Gospel of Transplant to the Public
Richard Hasz, USA

8:30 AM **IVS090.2** - Creating a Social Profile to Advance Your Science: Pearls and Pitfalls
Juliet Emamaullee, USA

8:45 AM **IVS090.3** - Using Social Media to Increase Organ Donation Awareness and Support
Sunil Shroff, India

9:00 AM **IVS090.4** - Using Social Media to Find a Donor
Macey Levan, USA

9:15 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS117 - Costimulation - from Biology to Clinical Trials

8:15 AM - 9:30 AM
Moscone South – Room 25
Basic Science
CME Accredited

Moderators: Flavio Vincenti, USA and Jonathan Maltzman, USA

8:15 AM Welcome & Introduction
Flavio Vincenti, USA
Jonathan Maltzman, USA

8:15 AM IVS117.1 - Single Cell Analysis of Rejection Under Costimulation Blockade
David Hildeman, USA

8:30 AM IVS117.2 - FIRsT - Anti-CD28 Fabs in Humans (Phase 1/2 study)
Gilles Blancho, France

8:45 AM IVS117.3 - Fgl2/Fcgr2b - The New Kid on the Block
Mandy Ford

9:00 AM IVS117.4 - Blocking CD40/CD40L in Allo and Xenotransplantation
Allan Kirk, USA

9:15 AM Q&A

LOA06 - Liver Transplantation: New Techniques, Immunosuppresion Strategies and Patient Outcomes

8:15 AM - 9:30 AM
Moscone South – Room 11
Liver
Not for CME Credit

Moderators: Amar Gupta, USA and Adeel Khan, USA

8:15 AM Welcome & Introduction
Amar Gupta, USA
Adeel Khan, USA

8:17 AM LOA06.1 - The Bypass Paradox - Frequency and Impact of UNOS Bypass Code 850 on 'Out of Sequence' liver Allocation
Kishore Iyer, USA

8:24 AM Q&A

8:26 AM LOA06.2 - A Stepwise Institutional Progression to Total Robotic Liver Transplantation: Technical Refinements into a Simpler and Reproducible Technique Across Eight Cases
Juan Rocca, USA

8:33 AM Q&A

8:35 AM LOA06.3 - Trends and Recipient Outcomes in Liver Transplants from Hepatitis C Donors: A National Analysis by Donor Age
William Julian, USA

8:42 AM Q&A

8:44 AM LOA06.4 - Total Robotic Living Donor Liver Transplantation: First North American Case
Yuzuru Sambommatsu, USA

8:51 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:53 AM **LOA06.5** - Immunomodulation through Hypothermic Oxygenated Perfusion in Liver Transplantation: Biomarker Analysis in Peripheral Blood
Marco Maria Pascale, Italy

9:00 AM Q&A

9:02 AM **LOA06.6** - Living Liver Donor Intra-operative Analgesia and Day 1 Pain - Insights from the International LDLT Registry
Ilya Kantsedikas, UK

9:09 AM Q&A

9:11 AM **LOA06.7** - Health-Related Quality of Life Improves Rapidly after Liver Transplantation - Findings from the PRO-LT Study
Zachary Dietch, USA

9:18 AM Q&A

9:20 AM Closing Remarks

OA30 - VCA

8:15 AM - 9:30 AM
Moscone South — Room 9
VCA
Not for CME Credit

Moderators: Paige Porrett, USA and Giuliano Testa, USA

8:15 AM Welcome & Introduction
Paige Porrett, USA
Giuliano Testa, USA

8:17 AM **OA30.1** - Myd88-Areg Axis in Regulating Host Responses to Vascularized Composite Allotransplantation
Yinan Guo, USA

8:24 AM Q&A

8:26 AM **OA30.2** - Post-Transplant Malignancy Following Vascularized Composite Allotransplantation
Bruce Gelb, USA

8:33 AM Q&A

8:35 AM **OA30.3** - A First-in-Class Imaging Capable Acellular Oxygen Nanocarrier Perfusate for Extended Machine Preservation of Organs
Jelena Janjic, USA

8:42 AM Q&A

8:44 AM **OA30.4** - Spectrum of Pregnancy Complications Induced by Tacrolimus
Brittney Knott, USA

8:51 AM Q&A

8:53 AM **OA30.5** - Donor-Derived Cell-Free DNA (dd-cfDNA) in Vascularized Composite Allograft Recipients
Daniel Brennan, USA

9:00 AM Q&A

9:02 AM **OA30.6** - Optimizing VCA Donors: Transplant Center Perspective
Elizabeth Stearns, USA

9:09 AM Q&A

9:11 AM **OA30.7** - Sentinel Flaps Reflect Inflammation and Rejection in Human Face Allografts
William Crisler, USA

9:18 AM Q&A

9:20 AM **OA30.8** - First-In-Human Bladder Transplant
Nima Nassiri, USA

9:27 AM Q&A

9:29 AM Closing Remarks

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

KN04 - Stem Cell Derived Beta Cell Clusters and Successful Allotransplantation - Hongkui Deng

10:00 AM - 10:30 AM
Moscone South — San Francisco Ballroom
Not for CME Credit

Moderators: John Fung, USA and Nadey Hakim, UK

10:00 AM Welcome & Introduction
John Fung, USA
Nadey Hakim, UK

10:00 AM **KN04.1** - Stem Cell Derived Beta Cell Clusters and Successful Allotransplantation
Hongkui Deng, China

PL03 - Plenary Abstracts 3

10:30 AM - 11:30 AM
Moscone South — San Francisco Ballroom
Not for CME Credit

Moderators: John Fung, USA and Nadey Hakim, UK

10:30 AM Welcome & Introduction
John Fung, USA
Nadey Hakim, UK

10:30 AM **PL03.1** - Integrated Model-Informed Precision Dosing (MIPD) of Tacrolimus in Organ Transplantation
Dirk Kuypers, Belgium

10:42 AM Q&A

10:45 AM **PL03.2** - Ly6-ChiCD56+ Stem-Like Monocytes Propagate Specific Innate Immune Memory
Khodor Abou-Daya, USA

10:57 AM Q&A

11:00 AM **PL03.3** - First-Year Post-Transplant Respiratory DNA Methylation Profile Predicts Chronic Lung Allograft Dysfunction
Fei-Man Hsu, USA

11:12 AM Q&A

11:15 AM **PL03.4** - High-Resolution Profiling of Immune Responses Following Gene-Edited Pig Kidney Xenotransplantation
Thiago Borges, USA

11:27 AM Q&A

IVS091 - Global Perspectives on Genetic Insights for Optimizing Transplant Success

2:15 PM - 3:30 PM
Moscone South — Room 154
Organ Inclusive
CME Accredited

Moderators: Krista Lentine, USA and Mona Doshi, USA

2:15 PM Welcome & Introduction
Krista Lentine, USA
Mona Doshi, USA

2:15 PM **IVS091.1** - Non-HLA Genetic Factors in Recipient and Donor Compatibility
Madhav Menon, USA

2:30 PM **IVS091.2** - Complex Genetic Conditions, Pharmacogenomics and Polygenic Risk Scores in Kidney Transplantation: A Global Approach
Dirk Kuypers, Belgium

2:45 PM **IVS091.3** - Clinical Use of Genetic Testing for Monogenic Diseases in Transplant Recipients: Regional Applications
Francesca Zanoni, Italy

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

3:00 PM IVS091.4 - Clinical Use of Genetic Testing for Monogenic Diseases in Transplant Recipients: Regional Applications
Yasar Caliskan, USA

3:15 PM Q&A

IVS092 - Xenotransplantation - Clinical Achievements and Next Steps

2:15 PM - 3:30 PM
Moscone South – Room 25
Basic Science
CME Accredited

Moderators: Vineeta Kumar, USA and Tatsuo Kawai, USA

2:15 PM Welcome & Introduction
Vineeta Kumar, USA
Tatsuo Kawai, USA

2:15 PM IVS092.1 - History and Current Status of the Field
Wayne Hawthorne, Australia

2:30 PM IVS092.2 - The Right Patient
Winfred Williams, USA

2:45 PM IVS092.3 - The Right Immunosuppression
Andrew Adams, USA

3:00 PM IVS092.4 - The Right Pig
Alfred Tector, USA

3:15 PM Q&A

IVS093 - Novel Diagnostics in Transplant Infectious Diseases. Some Hope or Just Nope?

2:15 PM - 3:30 PM
Moscone South – Room 23
Infectious Disease
CME Accredited

Moderators: Shahid Husain, Canada and Jason Goldman, USA

2:15 PM Welcome & Introduction
Shahid Husain, Canada
Jason Goldman, USA

2:15 PM IVS093.1 - Microbial cfDNA: Ready for Universal Use (CON)
Kimberly Hanson, USA

2:30 PM IVS093.2 - Microbial cfDNA: Ready for Universal Use (PRO)
Monica Fung, USA

2:45 PM IVS093.3 - Does Galactomannan Change Your Management? (CON)
Sophia Koo, USA

3:00 PM IVS093.4 - Does Galactomannan Change Your Management? (PRO)
John W. Baddley, USA

3:15 PM Q&A

IVS094 - Navigating the Future: Implementation of Patient Navigation Strategies in Organ Transplant Across the Globe

2:15 PM - 3:30 PM
Moscone South – Room 11
APP
CME Accredited

Moderators: Brian Lee, USA and Evi Ruzsicska, USA

2:15 PM Welcome & Introduction
Brian Lee, USA
Evi Ruzsicska, USA

2:15 PM IVS094.1 - Rural & Remote Access to Healthcare for Patients With Chronic Kidney Disease
Nicole Scholes-Robertson, Australia

2:40 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:40 PM IVS094.2 - Equity in Access to Kidney Transplantation
Tanjala Purnell, USA

3:00 PM Q&A

3:05 PM Panel Discussion

IVS095 - Pregnancy in Transplant Recipients: From Preconception to Birth

2:15 PM - 3:30 PM
Moscone South – Room 10
Organ Inclusive
CME Accredited

Moderators: Lisa Coscia, USA and Michelle Josephson, USA

2:15 PM Welcome & Introduction
Lisa Coscia, USA
Michelle Josephson, USA

2:15 PM IVS095.1 - Lessons Learned From Pregnancy Registries Worldwide
Margriet De Jong, Netherlands

2:30 PM IVS095.2 - Preconception Counseling
Silvi Shah, USA

2:45 PM IVS095.3 - Medication Safety During Pregnancy and Breastfeeding
Nicole Alvey, USA

3:00 PM IVS095.4 - Contraception
Monika Sarkar, USA

3:15 PM Q&A

IVS096 - Addressing Disparities in Access to Transplantation

2:15 PM - 3:30 PM
Moscone South – Room 155
Public Policy
CME Accredited

Moderators: Ryutaro Hirose, USA and Rachel Patzer, USA

2:15 PM Welcome & Introduction
Ryutaro Hirose, USA
Rachel Patzer, USA

2:15 PM IVS096.1 - Social Determinants of Health - Measures and Interventions
Lisa McElroy, USA

2:27 PM IVS096.2 - Gender Disparities - Global Perspective
Elizabeth Hendren, Canada

2:39 PM IVS096.3 - Health Literacy
Leigh Anne Dageforde, USA

2:51 PM IVS096.4 - Community Engagement Strategies
Teri Browne, USA

3:03 PM IVS096.5 - Undocumented Persons
Sixto Giusti, USA

3:15 PM Q&A

IVS097 - Wait-List Access and Management

2:15 PM - 3:30 PM
Moscone South – Room 8
Organ Inclusive
CME Accredited

Moderators: Bekir Tanriover, USA and Xingxing Cheng, USA

2:15 PM Welcome & Introduction
Bekir Tanriover, USA
Xingxing Cheng, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:15 PM **IVS097.1** - Mandatory Referral to the Wait-List
Jesse Schold, USA

2:30 PM **IVS097.2** - Screening for CAD
Tracey Ying, Australia

2:45 PM **IVS097.3** - Waitlisting the Patient with Cancer
Germaine Wong, Australia

3:00 PM **IVS097.4** - Should There Be a Standard Approach to Removing Patients from the Waiting List
Adnan Sharif, UK

3:10 PM **IVS097.5** - Patient Representation on WI Selection Committees
Joel Adler, USA

3:20 PM Q&A

IVS098 - Non-HCC Liver Malignancy and Transplantation: Evolving Patient Selection Criteria, Graft Preservation Methods, and Post-transplant Outcomes

2:15 PM - 3:30 PM
Moscone South – Room 22
Liver
CME Accredited

Moderators: Julie Heimbach, USA and Takashi Ito, Japan

2:15 PM Welcome & Introduction
Julie Heimbach, USA
Takashi Ito, Japan

2:15 PM **IVS098.1** - Unresectable Colorectal Liver Metastases: Updates in Recipient Selection, Surgical Techniques and Post-transplant Outcomes
Dong-Sik Kim, South Korea

2:30 PM **IVS098.4** - Advancements in Transplant Oncology for Cholangiocarcinoma
Keri Lunsford, United States

2:45 PM **IVS098.2** - Impact of Donor Characteristics and Graft Preservation Methods on Post-transplant Outcomes
Andrea Schlegel, USA

3:00 PM **IVS098.3** - Biomarkers Predictive of Recurrent Liver Tumors
Laia Aceitunosierra, Canada

3:15 PM Q&A

IVS099 - Artificial Intelligence in Transplantation: From Theory to Practice

2:15 PM - 3:30 PM
Moscone South – Room 4
Organ Inclusive
CME Accredited

Moderators: Carlos Goncalves, USA and Jin Ge, USA

2:15 PM Welcome & Introduction
Carlos Goncalves, USA
Jin Ge, USA

2:15 PM **IVS099.1** - AI: Present and Future: Potential for Solid Organ Transplantation
Mohammed Akhtar, USA

2:30 PM **IVS099.2** - Multi-Omics Integration in Transplantation
Jean Yang, Australia

2:45 PM **IVS099.3** - Integrating Artificial Intelligence into Clinical Decision Making: Promise of a Virtual Biopsy
Alexandre Loupy, France

3:00 PM **IVS099.4** - Role of Generative AI in Transplant Medicine
Aman Sidhu, Canada

3:15 PM Q&A

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS100 - Updates from STAR

2:15 PM - 3:15 PM
Moscone South – Room 9
Basic Science
CME Accredited

Moderators: Annette Jackson, USA and Carrie Schinstock, USA

2:15 PM Welcome & Introduction
Annette Jackson, USA
Carrie Schinstock, USA

2:15 PM IVS100.1 - Updates in the Analytic and Clinical Validity of Non-HLA DSA Testing
Chris Weibe, Canada

2:30 PM Q&A

2:35 PM IVS100.2 - Donor Derived Cell Free DNA: The Path to Clinical Utility
Kelley Hitchman, USA

2:50 PM Q&A

2:55 PM IVS100.3 - Practical Use of Titers to Measure HLA Antibody Reduction
Marlena Habal, USA

3:10 PM Q&A

IVS101 - 70th Anniversary of the First Successful LD Kidney Transplant

2:15 PM - 3:15 PM
Moscone South – Room 24
Organ Inclusive
CME Accredited

Moderators: Elizabeth Pomfret, USA and Gabriel Danovitch, USA

2:15 PM Welcome & Introduction
Elizabeth Pomfret, USA
Gabriel Danovitch, USA

2:15 PM IVS101.6 - The First Transplant in Pictures
Jamil Azzi, USA

2:20 PM IVS101.1 - Remembering the First Kidney Transplant
J. Harold Helderman, USA

2:31 PM IVS101.2 - Surgical Advances Over Time
Lloyd Ratner, USA

2:42 PM IVS101.3 - Evolution of the Understanding of Donor Risk
Arthur Matas, USA

2:53 PM IVS101.4 - The Incompatibility Challenge - Montgomery or Stan Jordan: From Identical Twins to Kidney Paired Donation
Robert Montgomery, USA

3:04 PM IVS101.5 - The Longest Surviving Living Donor Transplant Recipient
Denice Lombard, USA

IVS102 - New Drugs in Pediatric Transplantation

2:15 PM - 3:15 PM
Moscone South – Room 20
Pharmacy
CME Accredited

Moderators: Justin Chen, USA and Mary Chandran, USA

2:15 PM Welcome & Introduction
Justin Chen, USA
Mary Chandran, USA

2:15 PM IVS102.1 - Sglt-2
Rouba Garro, USA

2:30 PM Q&A

2:35 PM IVS102.2 - Glp-1
Carissa Baker-Smith, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:50 PM Q&A

2:55 PM IVS102.3 - Antivirals
Marc Foca, USA

3:10 PM Q&A

OA31 - Global Trends in Donor-Derived Infections

2:15 PM - 3:30 PM
Moscone South – Room 21
Infectious Disease
Not for CME Credit

Moderators: Cameron Wolfe, USA and C. Orla Morrissey, Australia

2:15 PM Welcome & Introduction
Cameron Wolfe, USA
C. Orla Morrissey, Australia

2:17 PM OA31.1 - Trends in Deceased Donor 2020 Public Health Service Guideline Risk Criteria
Dzhuliyana Handarova, USA

2:24 PM Q&A

2:26 PM OA31.2 - Donor-Derived Transmissions 2023: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
Stephanie Marie Pouch, USA

2:33 PM Q&A

2:35 PM OA31.3 - Donor-Derived Infections in Deceased Donor Organ Transplantation in Germany from 2016-2024
Ana Paula Barreiros, Germany

2:42 PM Q&A

2:44 PM OA31.4 - Burden of Infectious Diseases in Potential Organ Donors in Victoria, a Retrospective Audit of All Potential Organ Donors Between 2014-2024
Shanti Narayanasamy

2:51 PM Q&A

2:53 PM OA31.5 - Donor-Derived Hepatitis B Virus (HBV) Infection in Solid Organ Transplant (SOT) Recipients: Report from the Organ Procurement & Transplantation Network Ad Hoc Disease Transmission Advisory Committee (OPTN DTAC)
Cynthia Fisher, USA

3:00 PM Q&A

3:02 PM OA31.6 - Lessons from a Newly Implemented Organ Donor Screening for Human Herpes Virus Type 8 in the UK
Ines Ushiro-Lumb, UK

3:09 PM Q&A

3:11 PM OA31.7 - Impact of Dengue Outbreak on Solid Organ Transplant Programs in an Endemic Region: Devising and Implementation of Risk Mitigation Strategies
José Pestana, Brazil

3:18 PM Q&A

3:20 PM OA31.8 - Trends in Deceased Organ Donor Risk Factors for Bloodborne Infections. A Single-Centre Retrospective Study
Oscar Fernandez Garcia, Canada

3:27 PM Q&A

3:29 PM Closing Remarks

Detailed Program

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA32 - Deceased Donor Kidney Allocation 2

2:15 PM - 3:30 PM
Moscone South – Room 153
Kidney
Not for CME Credit

Moderator: Heidi Yeh, USA

2:15 PM Welcome & Introduction
Heidi Yeh, USA

2:17 PM OA32.1 - Out-of-Sequence Kidney Allocation: Identifying a Subgroup with Superior Outcomes
David Walls, USA

2:24 PM Q&A

2:26 PM OA32.2 - Out-of-Sequence Allocation Allows Increased Utilization of Kidneys While Providing Equivalent Outcomes to Standard Allocation Kidney Transplants
David Walls, USA

2:33 PM Q&A

2:35 PM OA32.3 - Deceased Donor Kidneys Allocated out of Sequence Differ from Kidneys Allocated in Sequence - Do Outcomes Differ?
Keighly Bradbrook, USA

2:42 PM Q&A

2:44 PM OA32.4 - The Current Iteration of Zero HLA Mismatch Priority in KAS is Highly Biased Against Minorities, Shunts Kidneys Away from Blood Type O Recipients, and Has a Marginal Impact on Graft and Patient Outcomes
Douglas Keith, USA

2:51 PM Q&A

2:53 PM OA32.5 - HLA Class I Amino Acid Mismatches That Distinguish Divergent HLA-A Allele Lineages Confer Incremental Risk of Kidney Allograft Failure Independent of Class II Mismatches
Keith McCullough, USA

3:00 PM Q&A

3:02 PM OA32.6 - Improving the Fit: Adding County Deprivation Index to SRTR Graft Outcomes
David Leeser, USA

3:09 PM Q&A

3:11 PM OA32.7 - Kidney Donation: Public Engagement and Readability of Online Resources - An AI-Driven Sentiment and Content Analysis
Benjamin Bizer, USA

3:18 PM Q&A

3:20 PM Closing Remarks

OA33 - Kidney Biomarkers, Imaging, and Engineering

2:15 PM - 3:30 PM
Moscone South – Room 12
Kidney
Not for CME Credit

Moderators: Dirk Van Der Windt, USA and Jesse Davidson, USA

2:15 PM Welcome & Introduction
Dirk Van Der Windt, USA
Jesse Davidson, USA

2:17 PM OA33.1 - Association of Donor-Derived Cell-Free DNA with Microvascular Inflammation Phenotypes in Kidney Allografts
Marta Sablik, France

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

2:24 PM Q&A

2:26 PM **OA33.2** - Characterising Prognostic Complement Biomarkers during Clinical Normothermic Machine Perfusion for Renal Transplantation
John Fallon, UK

2:33 PM Q&A

2:35 PM **OA33.3** - Performance of Integrative dd-cfDNA in Detecting Rejection Based on the Updated Banff 2022 Classification
Romain Brousse, France

2:42 PM Q&A

2:44 PM **OA33.4** - Using Torque Teno Virus as a Serial Monitoring Tool Representing the Net State of Immunosuppression for Kidney Recipients
Akhil Singla, USA

2:51 PM Q&A

2:53 PM **OA33.5** - A Multiclass Machine Learning Model with Allospecific B-Cells and T-Cells Predicts Antibody- and T-Cell-Mediated Rejection (ABMR, TCMR) After Kidney Transplantation (KT)
Bobby Nibhanupudy, USA

3:00 PM Q&A

3:02 PM **OA33.6** - Improving the Prediction of Deceased Donor Allograft Function with Donor Urinary Biomarkers
Chirag Parikh, USA

3:09 PM Q&A

3:11 PM **OA33.7** - Longitudinal Assessment of Alloreactive Memory T and B Cells in the EUTRAIN Kidney Transplant Cohort
Laura Donadeu, Spain

3:18 PM Q&A

3:20 PM **OA33.8** - Early Post-Transplant TTV Load: A Biomarker of Immunosuppression and Infection
Anil Bhalla, India

3:27 PM Q&A

3:29 PM Closing Remarks

OA34 - From Pre-Clinical Studies to First in Human: What's New on the Horizon

4:30 PM - 5:45 PM
Moscone South – Room 12
Basic Science
Not for CME Credit

Moderators: Anette Melk, Germany and Marilia Cascalho, USA

4:30 PM Welcome & Introduction
Anette Melk, Germany
Marilia Cascalho, USA

4:32 PM **OA34.1** - Adaptive Responses within the Graft Endothelial Cell as a Determinant of Long-Term Survival
Masaki Komatsu, USA

4:39 PM Q&A

4:41 PM **OA34.2** - Intrarenal T Follicular Helper Cells Promote Alloimmune Injury and Fibrosis After Kidney Transplantation
Hengcheng Zhang, USA

4:48 PM Q&A

4:50 PM **OA34.3** - An IL-2 Mutein (VIS171) Induces Regulatory T Cells and Prolongs Survival in a Rhesus Kidney Transplant Model
Davide Schiliró, USA

4:57 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:59 PM **OA34.4** - First and Second Genetically Modified Pig Kidney Xenotransplants in Living Human Recipients: Immunological and Physiological Insights
Leonardo Riella, USA

5:06 PM Q&A

5:08 PM **OA34.5** - IL-13: A New Ally in the Fight for Islet Graft Survival
Kenneth Brayman, USA

5:15 PM Q&A

5:17 PM **OA34.6** - Five Strategies to Use IL-2 Muteins to Expand Foxp3+ Treg Cells and Promote Long-Term Cardiac and Renal Allograft Survival in Naïve and Sensitized Recipients
Wayne Hancock, USA

5:24 PM Q&A

5:26 PM **OA34.7** - Effects of Targeting the Cullin RING E3 Ubiquitin Ligase Using MLN4924 on the Alloimmune Response
Bayan Alsairafi, USA

5:33 PM Q&A

5:35 PM **OA34.8** - Novel Anti-CD94 Treatment Reduces Kidney Ischemia-Reperfusion Injury and Subsequent Acute Lung Injury
Reena Bharti

5:42 PM Q&A

5:44 PM Closing Remarks

OA35 - Immunomodulation

4:30 PM - 5:45 PM
Moscone South – Room 10
Basic Science
Not for CME Credit

Moderator: Angus Thomson, USA

4:30 PM Welcome & Introduction
Angus Thomson, USA

4:32 PM **OA35.1** - A Novel Anti-CD154 Nonantibody Fusion Protein Facilitates Long Term Pig to Primate Kidney Xenograft Survival
Abraham Matar, USA

4:39 PM Q&A

4:41 PM **OA35.2** - Multiple Human Transgenes Prolong Survival of Triple-Carbohydrate Knockout Porcine Kidney Xenografts in Nonhuman Primates
Tatsuo Kawai, USA

4:48 PM Q&A

4:50 PM **OA35.3** - NR4A1 Drives Immunoregulatory Macrophage Development to Protect Renal Allografts by Restraining Tissue-Resident Memory T Cell Activity
Chao Yang, China

4:57 PM Q&A

4:59 PM **OA35.4** - Immunoevasion by Intragraft S emaphorin 3F Following Transplantation
Sayantan Bose, USA

5:06 PM Q&A

5:08 PM **OA35.5** - Targeting HIF-1α and miR-17-92 in CD4+ T Cells to Improve Vascularized Composite Allotransplantation Outcomes
Madonna Anggelia, Taiwan

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:15 PM Q&A

5:17 PM **OA35.6** - Absence of Recipient NKG2D or Allograft Donor Rae-1 Abrogates Acute Antibody-Mediated Rejection of Kidney Allografts in a Novel Mouse Mode
Yuki Maruyama, USA

5:24 PM Q&A

5:26 PM **OA35.7** - Immunoproteasome Inhibitor (KZR-616) Desensitization and Maintenance Therapy in Highly Sensitized Non-Human Primates
Jean Kwun, USA

5:33 PM Q&A

5:35 PM **OA35.8** - Allogeneic Reparative Treg Cell Therapy Augments Local Reparative Macrophages and Promotes Tissue Repair After Lung Injury
Kassandra Baron, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA36 - The Future of Heart Transplant Surveillance?

4:30 PM - 5:45 PM
Moscone South – Room 20
Heart
Not for CME Credit

Moderators: Kiran Khush, USA and Howard Eisen, USA

4:30 PM Welcome & Introduction
Kiran Khush, USA
Howard Eisen, USA

4:32 PM **OA36.1** - Prognostic Value of Donor-Derived Cell-Free DNA in Combination with HLA1 and HLA2 Donor Specific Antibodies After Heart Transplant
Ann Nguyen, USA

4:39 PM Q&A

4:41 PM **OA36.2** - Defining Relationships Among Tests for Heart Transplant Antibody-Mediated Rejection
Katelynn Madill-Thomsen, Canada

4:48 PM Q&A

4:50 PM **OA36.3** - High Level Donor Derived Cell-Free DNA in Asymptomatic Patients After Heart Transplant - Does It Matter?
Andriana Nikolova, USA

4:57 PM Q&A

4:59 PM **OA36.4** - Molecular Classification System for Cardiac Allograft Rejection is Positively Associated with the Pathology Severity of Rejection
Alessia Giarraputo, France

5:06 PM Q&A

5:08 PM **OA36.5** - Leveraging Longitudinal Donor-Derived Cell-Free DNA and Gene Expression Profiling Data for Acute Cellular Rejection Diagnosis After Heart Transplant
Ajay Vaidya, USA

5:15 PM Q&A

5:17 PM **OA36.6** - Association of ImmuKnow with Post-Transplant Coronary Artery Vasculopathy
Stephanie Golob, USA

5:24 PM Q&A

5:26 PM **OA36.7** - Antibody Mediated Rejection in the Contemporary Donor-Derived Cell-Free DNA Era: An Analysis of the Surveillance HeartCare Outcomes Registry
Amit Alam, USA

5:33 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:35 PM **OA36.8** - Impact of Persistently Elevated Simultaneous Gene Expression Profiling and Donor-Derived Cell-Free DNA on Future Clinical Events
Jeffrey Teuteberg, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA37 - Grafts and Germs: Infectious Challenges in Transplant Medicine

4:30 PM - 5:45 PM
Moscone South – Room 153
Infectious Disease
Not for CME Credit

Moderators: Courtney Harris, USA and Tan Ban Hock, Singapore

4:30 PM Welcome & Introduction
Courtney Harris, USA
Tan Ban Hock, Singapore

4:32 PM **OA37.1** - Shifting Trends in Terminal Infections of Post Renal Transplant Recipients: Insights from an Autopsy Study
Nithye Parvathy, India

4:39 PM Q&A

4:41 PM **OA37.2** - Frailty by Chart Review Can Predict Infection in Kidney Transplant Recipients: A Multicenter Study through the AST IDCOP
Joanna Schaenman, USA

4:48 PM Q&A

4:50 PM **OA37.3** - T-Cell Exhaustion Impacts Specific Adaptive Responses After Vaccination in Solid Organ Transplant
Laura Donadeu Casassas, Spain

4:57 PM Q&A

4:59 PM **OA37.4** - Single-Cell RNA Sequencing Reveals the Immune Microenvironment of BK Polyomavirus Nephropathy
Gang Huang, China

5:06 PM Q&A

5:08 PM **OA37.5** - Hepatitis B Vaccine Compliance and Seroresponse Rates Among Solid Organ Transplant Recipients Receiving Recombinant versus Adjuvanted HBV Vaccine
Kapil Saharia, USA

5:15 PM Q&A

5:17 PM **OA37.6** - Influenza Vaccine Effectiveness and Disease Burden in Children and Adolescents with Solid Organ Transplant: 2018-2024
Justin Chen, USA

5:24 PM Q&A

5:26 PM **OA37.7** - Preservation Fluid Cultures in Simultaneous Pancreas and Kidney Transplantation. Twenty Years of Experience
Martin Alejandro Maraschio, Argentina

5:33 PM Q&A

5:35 PM **OA37.8** - Stool Studies in Kidney Transplant Recipients: A Single-Center Retrospective Review of 1,000 Cases
Jazlyn Selvasingh, USA

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA38 - Lifelong Viral Invaders in Transplant

- 4:30 PM - 5:45 PM
- Moscone South – Room 8
- Infectious Disease
- Not for CME Credit

Moderators: Eric Altneu, USA and Ligia Pierrotti, Brazil

4:30 PM Welcome & Introduction
Eric Altneu, USA
Ligia Pierrotti, Brazil

4:32 PM OA38.1 - Clinical Significance of Persistent Low-Level CMV DNAemia in Solid Organ Transplantation
Bailey Conkey, USA

4:39 PM Q&A

4:41 PM OA38.2 - Multicenter Prospective Cohort Study of CMV T Cell Immunity and First Post-Transplant CMV DNAemia in Pediatric Solid Organ Transplant Recipients
Daniel Dulek, USA

4:48 PM Q&A

4:50 PM OA38.3 - Cytomegalovirus Infection After Intestinal/Multivisceral Transplantation: A Single-Center Experience
Mayyadah Alabdely, USA

4:57 PM Q&A

4:59 PM OA38.4 - A Novel gp350/CD89-Targeted Bispecific Antibody Against Epstein-Barr Virus (EBV) Infection and EBV-Associated Hematological Diseases
Yujian Zhang

5:06 PM Q&A

5:08 PM OA38.5 - T Cell Profiling Reveals Functional Immune Defects in Pediatric Transplant Recipients with Chronic Epstein-Barr Virus DNAemia
Edward Vizcarra, USA

5:15 PM Q&A

5:17 PM OA38.6 - Disseminated Varicella-Zoster Virus Infection in Transplant Recipients: A 10-Year Review
Ryosuke Yamamuro, Canada

5:24 PM Q&A

5:26 PM OA38.7 - From Incurable to Successful Transplantation: Long Term Outcomes in HIV+ vs HIV- Liver Transplant Recipients at 1, 3, and 5 Years - A Retrospective Analysis
Avery Koi, USA

5:33 PM Q&A

5:35 PM OA38.8 - Risk of De Novo Hepatitis B Infection in HBsAg- Recipients of HBcAb+/HBsAg- Liver Grafts Who Discontinue Antiviral Prophylaxis
Francis Ibukun, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA39 - Deceased Donor Kidney Procurement, Preservation, and Organ Manipulation

- 4:30 PM - 5:45 PM
- Moscone South – Room 4
- Kidney
- Not for CME Credit

Moderators: Lucrezia Furian, Italy and Justin Steggerda, USA

4:30 PM Welcome & Introduction
Lucrezia Furian, Italy
Justin Steggerda, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:32 PM **OA39.1** - Rescuing Hard-to-Place Kidneys Using a Normothermic Machine Perfusion Service: Results of the OPTIMAL Study
Matthew Holzner, USA

4:39 PM Q&A

4:41 PM **OA39.2** - The Impact of Normothermic Regional Perfusion on the Utilization and Post-Transplant Outcomes for Kidney Transplantation
Yuki Bekki, USA

4:48 PM Q&A

4:50 PM **OA39.3** - Evaluating the Impact of Machine Perfusion on Primary Nonfunction Rates in Deceased Donor Kidneys with Discarded Contralateral Mate
Alexander Cortez, USA

4:57 PM Q&A

4:59 PM **OA39.4** - National Implementation of HMP Increases Local Kidney Utilisation Rate and is Highly Cost-Effectiveness
Laurent Weekers, Belgium

5:06 PM Q&A

5:08 PM **OA39.5** - When Good Kidneys Pump Poorly: Why Some High-Resistance Organs Deserve a Chance
Nicholas Blount, USA

5:15 PM Q&A

5:17 PM **OA39.6** - Effects of Sequential Hypothermic Machine Perfusion After Normothermic Regional Perfusion and Donation After Circulatory Death on Kidney Transplant Outcomes
Sue Fu, USA

5:24 PM Q&A

5:26 PM **OA39.7** - Novel Perfusion Parameters Predict Early and Late Renal Allograft Outcomes
Jennifer Philip, USA

5:33 PM Q&A

5:35PM **OA39.8** - Automated Multi-Sensor Kidney Perfusion Device Enables 5-Day Normothermic Preservation of Human and Porcine Kidneys
Marlene Pühringer, Austria

5:42PM Q&A

5:44 PM Closing Remarks

OA40 - Kidney Immunosuppression Maintenance; Tolerance

4:30 PM - 5:45 PM
Moscone South – Room 24
Kidney
Not for CME Credit

Moderators: Bassam Abu Jawdeh, USA and Sindhu Chandran, USA

4:30 PM Welcome & Introduction
Bassam Abu Jawdeh, USA
Sindhu Chandran, USA

4:32 PM **OA40.1** - Selective Implementation of Belatacept Every Other Month as Standard Care Option with Use of cfDNA Testing
Payaswini Vasanth, USA

4:39 PM Q&A

4:41 PM **OA40.2** - A Donor Derived Cell Free DNA Approach to Immunosuppression Minimization in Elderly Kidney Transplant Recipients
Alex Rogers, USA

4:48 PM Q&A

4:50 PM **OA40.3** - Pretransplant Response to Immunosuppressants Measured with Immunobiogram Predicts First-Year Rejection in Kidney Transplant Recipients
Marta Crespo, Spain

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:57 PM Q&A

4:59 PM **OA40.4** - De Novo Belatacept Maintenance Immunosuppression Protocol as a Strategy to Increase Utilization of Kidney Allografts - 5-Year Experience
Alex Zendel, USA

5:06 PM Q&A

5:08 PM **OA40.5** - HLA-Epitope Mismatches and De Novo Donor Specific Antibodies (dDSA) Development Post-BK Virus Nephropathy
Zahraa Khan, USA

5:15 PM Q&A

5:17 PM **OA40.6** - A Matched Cohort Analysis of Kidney Transplant Recipients Treated with Depleting and Non-Depleting Antibody Induction and Early Corticosteroid Cessation
Elizabeth Hendren, Canada

5:24 PM Q&A

5:26 PM **OA40.7** - Gut Microbiome Meta-Transcriptomics Associated with Mycophenolate Mofetil Enterohepatic Recirculation in Kidney Transplant Recipients
Ajay Israni, USA

5:33 PM Q&A

5:35 PM Closing Remarks

OA41 - Kidney Rejection Pathology

4:30 PM - 5:45 PM
Moscone South – Room 21
Kidney
Not for CME Credit

Moderator: Maziar Riazy, Canada

4:30 PM Welcome & Introduction
Maziar Riazy, Canada

4:32 PM **OA41.1** - Intimal Arteritis ('v') in Kidney Transplant Rejection: Multicenter Clinical and Molecular Evidence Challenging the Banff 2022 Classification
Karolien Wellekens, Belgium

4:39 PM Q&A

4:41 PM **OA41.2** - Biopsy-Based Transcriptomics of Banff 2022 Antibody-Mediated Rejection Categories
Petra Hruba, Czech Republic

4:48 PM Q&A

4:50 PM **OA41.3** - Microvascular Inflammation Alters the Prognosis Associated with T-Cell-Mediated Rejection
Emmett Wong, Singapore

4:57 PM Q&A

4:59 PM **OA41.4** - Molecular Interpretation, Archetype Analysis, and Injury Dimensions Improve Prognostication From Kidney Allograft Biopsies Classified According to Banff 2022
Lukas Weidmann, Switzerland

5:06 PM Q&A

5:08 PM **OA41.5** - Findings and Significance of Early Follow-Up Biopsies After Treatment of Acute Rejection in Kidney Transplant Recipients
Ilkka Helantera, Finland

5:15 PM Q&A

5:17 PM **OA41.6** - Chronic Active TCMR (ca-TCMR) in the Kidney: Definition, Prevalence, Concurrent Acute TCMR and Banff Activity-Chronicity Indices
Parmjeet Randhawa, USA

5:24 PM Q&A

5:26 PM **OA41.7** - Clinical Outcomes Based on Tissue Transcriptomics-Guided Management in Real-World Kidney Transplant Cohort
Sanjiv Anand, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:33 PM Q&A

5:35 PM **OA41.8** - Multimodal and Spatial Profiling of Microvascular Inflammation in Kidney Allografts
Valentin Goutaudier, France

5:42 PM Q&A

5:44 PM Closing Remarks

OA42 - Living Donor Kidney Selection

4:30 PM - 5:45 PM
Moscone South — Room 25
Kidney
Not for CME Credit

Moderators: Sunita Singh, Canada and Christopher Blosser, USA

4:30 PM Welcome & Introduction
Sunita Singh, Canada
Christopher Blosser, USA

4:32 PM **OA42.1** - Comparative Outcomes Analysis of Living Kidney Donors With and Without of Kidney Stones: A Propensity-Matched Study
Badi Rawashdeh, USA

4:39 PM Q&A

4:41 PM **OA42.2** - Exploring Why Potential Living Kidney Donor Candidates Fail to Complete the Donation Process: A Comparison Between Related and Unrelated Donors
Karny Ilan, Israel

4:48 PM Q&A

4:50 PM **OA42.3** - Application of CT Imaging Analysis Technology in Kidney Transplantation
Taiki Ogasa, Japan

4:57 PM Q&A

4:59 PM **OA42.4** - Obese Living Kidney Donors - Weighing the Weight on Donors and Recipients Outcomes
Luke Shen, USA

5:06 PM Q&A

5:08 PM **OA42.5** - Comparative Analysis of Computerised Tomography Volumetry vs. Nuclear Imaging (Dimercaptosuccinic Acid) Scan in Predicting Early Post-Donation Renal Function Using Split Renal Function
Hannah Kek, Singapore

5:15 PM Q&A

5:17 PM **OA42.6** - Donor-Derived Nephritis on Pretransplant Biopsy Does Not Impair Posttransplant Renal Function in Recipients or Donors
Momoko Akasaki, Japan

5:24 PM Q&A

5:26 PM **OA42.7** - The Absence of Sex Related Differences in Pre-Donation eGFR Indicate a Need for Standardization of Living Donor Selection Criteria
Wanda Rojas Gimenez, Canada

5:33 PM Q&A

5:35 PM **OA42.8** - Older Living Kidney Donors ≥ 65 Years Are Infrequently Utilized Despite Excellent Outcomes
Eoghan White, Canada

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA43 - Expanding the Donor Pool

- 4:30 PM - 5:45 PM
- Moscone South – Room 154
- Liver
- Not for CME Credit

Moderators: John Lake, USA and Aleah Brubaker, USA

4:30 PM Welcome & Introduction
John Lake, USA
Aleah Brubaker, USA

4:32 PM OA43.1 - Cost Effectiveness Analysis and Clinical Outcomes of Back-to-Base Normothermic Machine Perfusion with and without FMN: A Multi-Center Risk-Matched Study of 967 Patients
Chase Wehrle, USA

4:39 PM Q&A

4:41 PM OA43.2 - A UNOS Database Outcomes Analysis of DCD Liver Transplantation Using Sequential Normothermic Regional Perfusion and Normothermic Machine Perfusion Versus NRP Alone
Jacquelyn Yu, USA

4:48 PM Q&A

4:50 PM OA43.3 - Impact of Normothermic Machine Perfusion on Liver Transplant Outcomes: A Multi-Institutional Experience from the National Organ Perfusion Registry
Alexander Cortez, USA

4:57 PM Q&A

4:59 PM OA43.4 - Molecular Differences in Injured Cholangiocytes during Cold Static Storage of Livers from Standard and Extended Criteria Donors
Haseeb Zubair, USA

5:06 PM Q&A

5:08 PM OA43.5 - Optimizing Donation After Circulatory Death (DCD) Liver Preservation with Resveratrol during Machine Perfusion
Chunbao Jiao, USA

5:15 PM Q&A

5:17 PM OA43.6 - NRP DCD Liver Grafts Yield Equal Outcomes of DBD Liver Grafts: A Single US Center Experience
Olivia Walker, USA

5:24 PM Q&A

5:26 PM OA43.7 - Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation
David Axelrod, USA

5:33 PM Q&A

5:35 PM OA43.8 - The Impact of a Transplant-Center Based Normothermic Regional Perfusion Program on Liver Transplant Volume and Finances
Anji Wall, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA44 - Liver Malignancies

- 4:30 PM - 5:45 PM
- Moscone South – Room 155
- Liver
- Not for CME Credit

Moderators: Xiaolun Huang, China and Masatoshi Kudo, Japan

4:30 PM Welcome & Introduction
Xialoun Huang, China
Masatoshi Kudo, Japan

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:32 PM **OA44.1** - IL-37 Enhances Immunotherapeutic Potential of Off-the-Shelf Liver NK Cells for Hepatocellular Carcinoma: Overcoming Cryopreservation Challenges
Yuki Imaoka, Japan

4:39 PM Q&A

4:41 PM **OA44.2** - Retinoid Acid Receptor-Related Orphan Receptor Gamma (RORγ): A Potential Target in Transplantation Oncology to Expand Therapeutic Options for Patients with Hepatocellular Carcinoma (HCC)
Sabrina Leo, Canada

4:48 PM Q&A

4:50 PM **OA44.3** - Integrative Multi-Omics Analysis I dentifies Evolving Landscape and Potential Targets for Recurrent HCC After Liver Transplant
Zijie Zhang, France

4:57 PM Q&A

4:59 PM **OA44.4** - Fewer Liver Transplant Recipients with HCC Are Waiting ≥6 Months for Transplant in the USA
Allison Kwong, USA

5:06 PM Q&A

5:08 PM **OA44.5** - Risk Stratification Based on Non-Transplantable Recurrence for Treatment Allocation in Child-Pugh A Patients with Hepatocellular Carcinoma
Jin-Chiao Lee, Taiwan

5:15 PM Q&A

5:17 PM **OA44.6** - Post-Transplant Malignancy Risk in Liver Transplantation Recipients: A Nationwide Matched Cohort Study Comparing Liver Cancer and Non-Cancer Recipients with the General Population
Jiyoung Kim, South Korea

5:24 PM Q&A

5:26 PM **OA44.7** - Enhancing National Liver Review Board (NLRB) Efficiency by Assessing Not Auto-Approved Hepatocellular Carcinoma Medical Urgency Exceptions
Benjamin Schumacher, USA

5:33 PM Q&A

5:35 PM **OA44.8** - Tumor Biology-Driven Recipient Selection Determines Outcomes in Liver Transplantation for Colorectal Liver Metastases
Matthew Byrne, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA45 - Breathing New Life: Improving Outcomes in Lung Transplantation

4:30 PM - 5:45 PM
Moscone South – Room 11
Lung
Not for CME Credit

Moderators: Carli Lehr, USA and Deborah Levine, USA

4:30 PM Welcome & Introduction
Carli Lehr, USA
Deborah Levine, USA

4:32 PM **OA45.1** - Recipient and Donor Factors Associated with BOS/CLAD-Free Graft Survival vs. Graft Survival Alone
Darren Stewart, USA

4:39 PM Q&A

4:41 PM **OA45.2** - Trajectories of FEV1 After Lung Transplantation and Patient Outcomes
Marc Raynaud, France

4:48 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

4:50 PM **OA45.3** - Continuous Distribution of Lungs Decreases Waiting List Mortality without Compromising 6-Month Post-Transplant Outcomes
Samantha Weiss, USA

4:57 PM Q&A

4:59 PM **OA45.4** - Summary of Trends in Pediatric Transplantation under Lung Continuous Distribution
Samantha Weiss, USA

5:06 PM Q&A

5:08 PM **OA45.5** - Every Minute Matters: The Impact of Donor Agonal Time on Recipient Outcomes in DCD Lung Transplantation
Justin Wang, USA

5:15 PM Q&A

5:17 PM **OA45.6** - Donor HLA-Derived Indirect T Cell Epitope and Surface-Accessible Amino Acid Mismatch Loads Predict Lung Allograft Dysfunction
Francisco Alvarez, USA

5:24 PM Q&A

5:26 PM **OA45.7** - Impact of Ex Vivo Lung Perfusion on Post-Transplant Graft Survival: A Retrospective Analysis of UNOS Data
Kiran Thirukonda, USA

5:33 PM Q&A

5:35 PM **OA45.8** - The Worldwide Robotic Lung Transplantation Experience To-Date: Outcomes in the First Three Centers
Dominic Emerson, USA

5:42 PM Closing Remarks

5:43 PM Q&A

OA46 - Education

4:30 PM - 5:45 PM
Moscone South – Room 22
Organ Inclusive
Not for CME Credit

Moderators: Karen Khalil, USA and Medhat Askar, Qatar

4:30 PM Welcome & Introduction
Karen Khalil, USA
Medhat Askar, Qatar

4:32 PM **OA46.1** - Censoring Scientific Dissemination in Transplantation
Jesse Schold, USA

4:39 PM Q&A

4:41 PM **OA46.2** - Advanced Practice Provider Transplant Certification - Results of a Needs Assessment Survey
Gina Jamero, USA

4:48 PM Q&A

4:50 PM **OA46.3** - The Impact of Transplant Metric Visual Icons on Patient Decisions to Select a Transplant Center
Cory Schaffhausen, USA

4:57 PM Q&A

4:59 PM **OA46.4** - Bridging the Gap: A Comprehensive Summer Student Immersion Program in Transplantation
Saad Hussain, USA

5:06 PM Q&A

5:08 PM **OA46.5** - Innovative AI-Driven Transplant Board Review Series: Enhancing Fellow Engagement and Learning in Nephrology Fellowship Training
Kiran Goli, USA

5:15 PM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:17 PM **OA46.6** - Research Exclusive Donation: Revolutionizing Medical Research through Organ Procurement Organizations
Clint Hostetler, USA

5:24 PM Q&A

5:26 PM **OA46.7** - Characteristics Associated with Acceptance of Porcine Xenotransplantation
Jennifer Wainright, USA

5:33 PM Q&A

5:35 PM **OA46.8** - Bridging the Gap: Assessing Knowledge, Preparedness, and Regulatory Perspectives on Genetically Engineered Pig-to-Human Xenotransplants Among Transplant Specialists
Krish Vasudev, USA

5:42 PM Q&A

5:44 PM Closing Remarks

OA47 - Pancreas

4:30 PM - 5:45 PM
Moscone South — Room 23
Pancreas
Not for CME Credit

Moderators: Ty Dunn, USA and Henry Pleass, Australia

4:30 PM Welcome & Introduction
Ty Dunn, USA
Henry Pleass, Australia

4:32 PM **OA47.1** - Outcomes and Predictors of Pancreas Graft Survival in Simultaneous Pancreas-Kidney Transplant Recipients: A Contemporary Analysis of OPTN Database
Farah Abuazzam, USA

4:39 PM Q&A

4:41 PM **OA47.2** - Comparable Outcomes of Pancreas Transplants from Donation After Circulatory Death Compared to Brain Death Donors
Tiffany Lim, USA

4:48 PM Q&A

4:50 PM **OA47.3** - Outcomes of Highly Sensitized Pancreas Transplant Recipients in the Modern Era
Tia Ketsan, USA

4:57 PM Q&A

4:59 PM **OA47.4** - Challenges in Pancreas Transplantation for Obese Recipients with Type II Diabetes
Dianly Centeno, USA

5:06 PM Q&A

5:08 PM **OA47.5** - Pancreas Transplantation in Type 2 Diabetics is Associated with Lower Rates of Graft Rejection and Graft Loss Compared with Type 1 Diabetics
Emma Crichton, USA

5:15 PM Q&A

5:17 PM **OA47.6** - A Multicenter Study of Weight Loss and Side Effects in Pancreas Transplant Recipients Treated with GLP-1 Receptor Agonists
Ali Abbasi, USA

5:24 PM Q&A

5:26 PM **OA47.7** - Positive Malnutrition Risk Factors Pre-Transplant Are Associated with Adverse Outcomes After Simultaneous Kidney and Pancreas and Solitary Pancreas Transplantation
Sandesh Parajuli, USA

5:33 PM Q&A

5:35 PM **OA47.8** - Beta Cell Specific Cell Free DNA and Trypsinogen for the Diagnosis of Rejection in Pancreas Transplantation The EMPAR Study
Argyrios Asderakis, UK

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

5:42 PM Q&A

5:44 PM Closing Remarks

OA48 - Pharmacotherapy and Adherence

4:30 PM - 5:45 PM
Moscone South – Room 9
Pharmacy
Not for CME Credit

Moderators: Lisa Potter, USA and Joelle Nelson, USA

4:30 PM Welcome & Introduction
Lisa Potter, USA
Joelle Nelson, USA

4:32 PM OA48.1 - Improved Tacrolimus XR Dosing and Monitoring Outcomes with a Genotype-Based Dosing Algorithm vs. Weight Based Dosing
Christine Wolesensky, USA

4:39 PM Q&A

4:41 PM OA48.2 - The Characteristics of Early Medication Level Variability in Pediatric Kidney Transplant Recipients
Sarah Kizilbash, USA

4:48 PM Q&A

4:50 PM OA48.3 - Utilizing EHR-Integrated Proportion of Days Covered (PDC) to Monitor Post Kidney Transplant Medication Adherence
Ann Kataria, USA

4:57 PM Q&A

4:59 PM OA48.4 - The SystemCHANGE™ Intervention Improves Medication-Taking Habit: A Secondary Analysis of the MAGIC Studies
Mark Wakefield, USA

5:06 PM Q&A

5:08 PM OA48.5 - Evidence-Based Individualization of Early Steroid Withdrawal and Its Association with Mortality After Kidney Transplantation
Sunjae Bae, USA

5:15 PM Q&A

5:17 PM OA48.6 - More Than Numbers: Predictors of Success in Belatacept Conversion in Kidney Transplant Recipients
Kelsey Coffman, USA

5:24 PM Q&A

5:26 PM OA48.7 - Predicting Unbound Tacrolimus Concentrations during Pregnancy
Nicole Wilson, USA

5:33 PM Q&A

5:35 PM OA48.8 - Telitacicept Treatment for Active Antibody-Mediated Rejection: Case Series Report
Jiqiu Wen, China

5:42 PM Q&A

5:44 PM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS103 - Game Changers in Alloimmune Risk Stratification

7:00 AM - 8:00 AM
Moscone South – Room 21
Basic Science
CME Accredited

Moderators: Elaine F. Reed, USA and Anna Morris, USA

7:00 AM Welcome & Introduction
Elaine F. Reed, USA
Anna Morris, USA

7:00 AM IVS103.1 - Genome-Wide Non-HLA vs HLA Alloimmunity
Rainer Oberbauer, Austria

7:20 AM IVS103.2 - Spatial Phenotyping of Immune Cells in Tolerance Versus Rejection
Fadi Issa, UK

7:40 AM IVS103.3 - The Impact of Innate Allorecognition
Aravind Cherukuri, USA

IVS104 - HIV and Transplantation: A Global Perspective on Milestones Achieved and Milestones Ahead

7:00 AM - 8:00 AM
Moscone South – Room 155
Infectious Disease
CME Accredited

Moderators: Peter Stock, USA and Paolo Grossi, Italy

7:00 AM Welcome & Introduction
Peter Stock, USA
Paolo Grossi, Italy

7:00 AM IVS104.1 - From Breakthroughs to Benchmarks: A Global History of HIV and Transplant
Elmi Muller, South Africa

7:15 AM IVS104.2 - Beyond the Horizon: Pioneering Thoracic and Living Donor Transplants for HIV+ Individuals
Vagish Hemmige, USA

7:30 AM IVS104.3 - Addressing Inequities: Bridging the Gap for Persons Living With HIV
Christine Durand, USA

7:45 AM Q&A

IVS105 - Can I Do That? Preventing Infection

7:00 AM - 8:00 AM
Moscone South – Room 153
Infectious Disease
CME Accredited

Moderator: Blair Weikert, USA

7:00 AM Welcome & Introduction
Blair Weikert, USA

7:00 AM IVS105.1 - Can I Sleep With That? - PrEP for the Transplant Recipient
Priya Kodiyanplakkal, USA

7:15 AM IVS105.2 - Can I Travel There?
Jackrapong Bruminhent, Thailand

7:30 AM IVS105.3 - Can I Do That? Can I Prevent That?
Ingi Lee, USA

7:45 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS106 - Genetic Insights in Improving Kidney Transplant Outcomes – Practical Applications and Ethical Considerations

7:00 AM - 8:00 AM
Moscone South – Room 8
Kidney
CME Accredited

Moderators: Prince Anand, USA and Julliet Emamaullee, USA

7:00 AM Welcome & Introduction
Prince Anand, USA
Julliet Emamaullee, USA

7:00 AM IVS106.1 - Genetic Evaluation of Living Donor Candidates: An International Review
TBC

7:15 AM IVS106.2 - Ethical and Practical Considerations for Genetic Testing in Kidney Transplantation: A Global Dialogue
Ebunoluwa Bamgboye, Nigeria

7:30 AM IVS106.3 - The Future of Genetic Matching Between Kidney Donors and Recipients
Yasar Caliskan, USA

7:45 AM Panel Discussion

IVS107 - A Brave Heart and a Respite Lung - Managing Cardiac and Pulmonary Comorbidities in Non-cardiac Transplantation

7:00 AM - 8:00 AM
Moscone South – Room 4
Organ Inclusive
CME Accredited

Moderator: Jeffrey Edelman, USA

7:00 AM Welcome & Introduction
Jeffrey Edelman, USA

7:00 AM IVS107.1 - "The Spirit Is Willing, but the Heart Is Weak": When Is the Cardiomyopathy Prohibitive for Non-Cardiac Transplantation?
Aasim Afzal, USA

7:15 AM IVS107.2 - "Sustaining Bloodlines": Managing Coronary Artery Disease and Valvular Disease in Patients Undergoing Non-Cardiac Transplantation
Yael Peled-Potashnik

7:30 AM IVS107.3 - "Defeating Enemies": Managing Pulmonary Complications and Pulmonary Hypertension in Patients Undergoing Non-Cardiac Solid Organ Transplantation
Ishna Poojary Hohman, USA

7:45 AM Q&A

IVS108 - HCC and Liver Transplant: Moving Beyond Milan Criteria

7:00 AM - 8:00 AM
Moscone South – Room 12
Liver
CME Accredited

Moderator: Michele Molinari, USA

7:00 AM Welcome & Introduction
Michele Molinari, USA
John Fung, USA

7:00 AM IVS108.1 - Immunotherapy and HCC Management
Masatoshi Kudo, Japan

7:15 AM IVS108.2 - Determining Benefit From LT in HCC and Optimizing Recipient Selection
Neil Mehta, USA

7:30 AM IVS108.3 - Prevention and Management of Post-transplant Recurrent HCC
Reena Salgia, USA

7:45 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

RF09 - Global Pathogens, Local Impact: Fungi and Parasites

7:00 AM - 8:00 AM
Moscone South — Room 154
Infectious Disease
Not for CME Credit

Moderators: Priscilla Rupali, India and Monica Fung, USA

7:00 AM Welcome & Introduction
Priscilla Rupali, India
Monica Fung, USA

7:02 AM RF09.1 - Preventing Invasive Aspergillosis in Lung Transplant Recipients: A Cost-Utility Analysis
Roni Bitterman, Canada

7:07 AM Q&A

7:09 AM RF09.2 - Healthcare Resource Utilization, Total Healthcare Costs and Mortality in Patients with Invasive Aspergillosis and a History of Transplant
Craig Coleman, USA

7:14 AM Q&A

7:16 AM RF09.3 - The Epidemiology of Endemic Fungal infections in Solid Organ Transplant Recipients: A Single-Center Study from 2010 to 2024
Emily Wong, USA

7:21 AM Q&A

7:23 AM RF09.4 - Diagnosing Coccidioidomycosis Among Solid Organ Transplant Recipients in California
Monica Fung, USA

7:28 AM Q&A

7:30 AM RF09.5 - Histoplasmosis in Solid Organ Transplant Recipients: Clinical Presentation, Treatment, and Outcomes
Clayton Hicks, USA

7:35 AM Q&A

7:37 AM RF09.6 - Chagas Disease Reactivation and Outcomes After Solid Organ Transplantation: A Multicenter Study in the U.S.
Cesar Berto Moreano, USA

7:42 AM Q&A

7:44 AM RF09.7 - Pneumocystis jirovecii Pneumonia in Solid Organ Transplantation: PneumoCIST Collaboration
Holenarasipur Vikram, USA

7:49 AM Q&A

7:51 AM Closing Remarks

RF10 - Innovative Techniques in Liver Transplantation

7:00 AM - 8:00 AM
Moscone South — Room 10
Liver
Not for CME Credit

Moderators: Madhukar Patel, USA

7:00 AM Welcome & Introduction
Madhukar Patel, USA

7:02 AM RF10.1 - Indocyanine Green Fluorescence Predicts Biliary Complications in Living Donor Liver Transplantation
Jaewon Lee, South Korea

7:07 AM Q&A

7:09 AM RF10.2 - One Hundred Abdominal Normothermic Regional Perfusion (NRP) DCD Liver Transplants: Zero Ischemic Cholangiopathy
Jean Botha, USA

7:14 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:16 AM **RF10.3** - Splitting the Sandbox: The Use of Abdominal Normothermic Regional Perfusion with Super Rapid Recovery Lung Procurement
Reeder Wells, USA

7:21 AM Q&A

7:23 AM **RF10.4** - Avoid the Liver Graft Recooling at the End of Normothermic Machine Perfusion: First Worldwide Experience and How I Do It
Salvatore Gruttadauria, Italy

7:28 AM Q&A

7:30 AM **RF10.5** - Flip the Liver: Preventing Perfusion Related Liver Graft Injury in Normothermic Machine Preservation
Vijay Subramanian, USA

7:35 AM Q&A

7:37 AM **RF10.7** - Liver Transplant Using the RAPID Technique in a Patient with Colorectal Liver Metastases
Zachary Dietch, USA

7:42 AM Q&A

7:44 AM **RF10.8** - Superior Bioavailability of Tacrolimus in Liver Transplant Recipients Treated with Extended-Release LCP-Tacrolimus (Envarsus) Compared to Prolonged-Release Tacrolimus (Advagraf) After 12 Weeks of Controlled Therapy within a Multicentre, Randomised, Controlled Clinical Trial ("EnGraft")
Ben James, Germany

7:49 AM Q&A

7:51 AM Closing Remarks

RF11 - Liver Allocation and Recipient Selection

7:00 AM - 8:00 AM
Moscone South – Room 11
Liver
Not for CME Credit

Moderators: Amit Mathur, USA and Andrew Butler, UK

7:00 AM Welcome & Introduction
Amit Mathur, USA
Andrew Butler, UK

7:02 AM **RF11.1** - MELD 3.0 - Impact on Sex Disparity One Year After Implementation
Clara Nguyen, USA

7:07 AM Q&A

7:09 AM **RF11.2** - Balancing Spontaneous Recovery and Mortality: Evaluating Model Performance in Patients with ALD Referred for Early Liver Transplantation
Bima Hasjim, USA

7:14 AM Q&A

7:16 AM **RF11.3** - The Sex-Based Survival Disparity Persists in Liver Transplantation: MELD 3.0 Fails to Improve Upon the Disadvantage for Waitlisted Women
Marissa Di Napoli, USA

7:21 AM Q&A

7:23 AM **RF11.4** - Validation of MELD 3.0 Scoring System: A Single-Center Analysis from Germany
Aghnia Putri, Germany

7:28 AM Q&A

7:30 AM **RF11.5** - Comparative Frailty Index Assessment in End-Stage Liver Disease Patients Undergoing Evaluation for Liver Transplant
Anastasia Xynogala, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:35 AM Q&A

7:37 AM **RF11.6** - Long-term Follow-Up in Liver Transplantation and Combined Cardiac Surgery: Validation and Refinement of the LT+CS Risk Score Using Advanced Machine Learning
Laura Batista de Oliveira, USA

7:42 AM Q&A

7:44 AM **RF11.7** - Crossing in the Air in Deceased Donor Liver Transplantation
Daniyar Akizhanov, USA

7:49 AM Q&A

7:51 AM **RF11.8** - A Novel Risk Score Using Flavin Mononucleotide (FMN) for Predicting Graft Loss After Liver Transplantation with Normothermic Machine Perfusion
Sangeeta Satish, USA

7:55 AM Q&A

7:57 AM Closing Remarks

RF12 - All Organs: Precision Medicine, Biomarkers, and Diagnostics

7:00 AM - 8:00 AM
Moscone South – Room 23
Organ Inclusive
Not for CME Credit

Moderators: TBC and TBC

7:00 AM Welcome & Introduction
TBC and TBC

7:02 AM **RF12.1** - Precision Phenotyping Renal Transplant Dysfunction by Spatial Single-Cell Genomics
Swastika Sur, USA

7:07 AM Q&A

7:09 AM **RF12.2** - Epigenetic and Transcriptional Dynamics in Ischemia Reperfusion Injury of Liver Allografts
Haseeb Zubair, USA

7:14 AM Q&A

7:16 AM **RF12.3** - Association of Gene Expression Profile with 10-Year All Cause Graft Loss in a Multicenter Prospective Cohort
Christopher Marsh, USA

7:21 AM Q&A

7:23 AM **RF12.4** - Association of Dual Noninvasive Biomarkers with 10-Year All Cause Graft Loss in a Multicenter Prospective Cohort
James Fleming, USA

7:28 AM Q&A

7:30 AM **RF12.5** - Identification of Anti-A2 Alloreactive Quasi-Public CD8+ T Cell Meta-Clonotypes via Bulk and Paired TCR Sequencing
Fernanda Marconi Roversi, USA

7:35 AM Q&A

7:37 AM **RF12.6** - Impact of Maraviroc on Circulating and Tissue Markers of Kidney Transplant Recipients with HIV
Tara Sigdel, USA

7:42 AM Q&A

7:44 AM **RF12.7** - Epigenomic Changes in DNA Methylation State of cfDNA in Kidney Transplant Recipients with HIV
Minnie Sarwal, USA

7:49 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:51 AM **RF12.8** - Thymo Limbo: Safety and Efficacy of Minimal-Dose Anti-Thymocyte Globulin Induction Therapy in Kidney Transplant Recipients
Kennedy Concannon, USA

7:56 AM Q&A

7:58 AM Closing Remarks

RF13 - Patient and Program Management

7:00 AM - 8:00 AM
Moscone South – Room 20
Organ Inclusive
Not for CME Credit

Moderators: Gina Jamero, USA and Lyndsey Bowman, USA and Lisa Potter, USA

7:00 AM Welcome & Introduction
Gina Jamero, USA
Lyndsey Bowman, USA
Lisa Potter, USA

7:02 AM **RF13.1** - Financial Need Among Solid-Organ Transplant Candidates and Recipients: Evidence from GoFundMe Crowdfunding Campaigns
Amelia Gold, USA

7:07 AM Q&A

7:09 AM **RF13.2** - Extended-Release Tacrolimus Dosing in Obese Kidney Transplant Recipients
Allyssa Webb, USA

7:14 AM Q&A

7:16 AM **RF13.3** - Long-Term Outcomes of GLP-1 Use After Liver and Simultaneous Liver Kidney Transplant
Melissa McGowan, USA

7:21 AM Q&A

7:23 AM **RF13.4** - Validation of Existing Comorbidity Models and Development of a New Transplant-Specific Index
Faith Mendoza, USA

7:28 AM Q&A

7:30 AM **RF13.5** - Post-Transplant Alcohol Use: Biomarker Detection, Treatment, and Outcomes
Sienna Li, USA

7:35 AM Q&A

7:37 AM **RF13.6** - Bridging the Gap in Resource Disparities: Joint Efforts of an Academic Medical Center and a Community Safety Net Hospital to Enhance Transplant Outcomes for Underserved Communities
Elif Kortan, USA

7:42 AM Q&A

7:44 AM **RF13.7** - Transforming Post Transplant Care: Remote Patient Monitoring for Kidney Transplant Recipients and Readmission Outcomes
Leana Yancey, USA

7:49 AM Q&A

7:51 AM **RF13.8** - Dosing of Pegcetacoplan with Plasmapheresis for Treatment of Xenoantibody Mediated Rejection
Karen Khalil, USA

7:56 AM Q&A

7:58 AM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

RF14 - Islet Rapid Fire

7:00 AM - 8:00 AM
Moscone South – Room 9
Pancreas
Not for CME Credit

Moderators: Balamurugan Appakalai, USA and Toby Coates, Australia

7:00 AM Welcome & Introduction
Balamurugan Appakalai, USA
Toby Coates, Australia

7:02 AM RF14.1 - Long-Term Outcomes and Quality of Life Measures After Total Pancreatectomy and Intraportal Islet Autotransplantation in Children with Chronic Pancreatitis
Srinath Chinnakotla, USA

7:07 AM Q&A

7:09 AM RF14.2 - 3D-Bioprinted Bionic Pancreas - ATMP: A Disruptive Innovation in Transplantology
Michal Wszola, Poland

7:14 AM Q&A

7:16 AM RF14.3 - Microporous Annealed Particle (MAP) Gel as a Novel Scaffold for Beta-Cell Replacement Therapy: Enhancing Engraftment and Immunomodulation in a Murine Model
Kenneth Brayman, USA

7:21 AM Q&A

7:23 AM RF14.4 - SR-02, a Pancreatic Islet Replacement Therapy Transplanted to the Omentum
William Rust, USA

7:28 AM Q&A

7:30 AM RF14.5 - CD40L Co-Stimulation Blockade as a Non-Toxic Calcineurin Inhibitor-Free Immunosuppression for Beta Cell Replacement Therapy: Preliminary Results from a Pilot Clinical Study
Nicole Wojcik, USA

7:35 AM Q&A

7:37 AM RF14.6 - The Role of microRNAs as Biomarkers of Pancreas Transplant Rejection; EMPAR Study
Argyrios Asderakis, UK

7:42 AM Q&A

7:44 AM RF14.8 - Experience with Pancreatic Biopsies in SPK Transplantation
Martin Alejandro Maraschio, Argentina

7:49 AM Q&A

7:51 AM Closing Remarks

RF15 - Public Policy

7:00 AM - 8:00 AM
Moscone South – Room 22
Public Policy
Not for CME Credit

Moderators: Jesse Schold, USA and Lloyd Ratner, USA

7:00 AM Welcome & Introduction
Jesse Schold, USA
Lloyd Ratner, USA

7:02 AM RF15.1 - SDI Associated with Access to Kidney Transplant Even After Accounting for Insurance and Cause of End-Stage Kidney Disease
David Schladt, USA

7:07 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

7:09 AM **RF15.2** - Post 5% Rule: International Travel to the USA for Liver Transplant
Hannah Roth, USA

7:14 AM Q&A

7:16 AM **RF15.3** - Annual Variability in Organ Procurement Organization Performance Tiers
Jesse Schold, USA

7:21 AM Q&A

7:23 AM **RF15.4** - Imminent Death Donation: Ethical, Justified, Compassionate and Necessary
Piper Stacey, USA

7:28 AM Q&A

7:30 AM **RF15.5** - Out of Sequence Allocation in Liver Transplants: A Poorly Used Tool to Improve Organ Utilization
Chase Wehrle, USA

7:35 AM Q&A

7:37 AM **RF15.6** - Evidence to Support Accounting for the Donor Pool in OPO Performance Reports
John Roberts, USA

7:42 AM Q&A

7:44 AM **RF15.7** - Waitlist Mortality, Posttransplant Graft Survival, and Time Between Offers for Multiorgan Transplant Candidates in Need of a Kidney
Jonathan Miller, USA

7:49 AM Q&A

7:51 AM Closing Remarks

IVS109 - The Complement System in Transplantation: Broad Consequences and Novel Treatments

8:15 AM - 9:30 AM
Moscone South – Room 9
Basic Science
CME Accredited

Moderators: John Greenland, USA and Zheng Zhang, USA

8:15 AM Welcome & Introduction
John Greenland, USA
Zheng Zhang, USA

8:15 AM **IVS109.1** - Endothelial Activation by Complement
Dan Jane-Wit, USA

8:30 AM **IVS109.2** - Complement as the Apex Regulator of Tissue Inflammation
Ben Afzali, USA

8:45 AM **IVS109.3** - Dysregulated Complement Predisposes to Chronic Rejection via Adaptive Responses
Hrishikesh Kulkarni, USA

9:00 AM **IVS109.4** - Therapeutic Targeting of Complement in Heart and Lung Transplantation
Carl Atkinson, USA

9:15 AM Q&A

IVS110 - Global Perspectives on Donor Pathogen Screening

8:15 AM - 9:30 AM
Moscone South – Room 154
Infectious Disease
CME Accredited

Moderators: Ricardo LaHoz, USA and Paolo Grossi, Italy

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:15 AM Welcome & Introduction
Ricardo LaHoz, USA
Paolo Grossi, Italy

8:15 AM IVS110.1 - Should We Screen for HHV8
Alessandra Mularoni, Italy

8:30 AM IVS110.2 - Optimizing Donor Screening for Tuberculosis
Cybele Lara Abad, Philippines

8:45 AM IVS110.3 - Considering Donors With Hepatitis B
Helen Te, USA

9:00 AM IVS110.4 - Interpreting Donor Risk for Coccidioidomycosis
Hannah Nam, USA

9:15 AM Q&A

IVS111 - Understanding and Communicating Living Kidney Donor Risk

- 8:15 AM - 9:30 AM
- Moscone South — Room 4
- Kidney
- CME Accredited

Moderators: Michelle Josephson, USA and Sunita Singh, Canada

8:15 AM Welcome & Introduction
Michelle Josephson, USA
Sunita Singh, Canada

8:15 AM IVS111.1 - Understanding Different Types of Risk
Hassan Ibrahim, USA

8:30 AM IVS111.2 - What Are the Risks?
Kenneth Newell, USA

8:45 AM IVS111.3 - Communicating Risk - How I Do It
Amanda Leonberg-Yoo, USA

9:00 AM IVS111.4 - Shared Decision Making
Allyson Hart, USA

9:15 AM Q&A

IVS112 - Managing an Increasing and Increasingly Complex Patient Population

- 8:15 AM - 9:30 AM
- Moscone South — Room 23
- Organ Inclusive
- CME Accredited

Moderators: Vineeta Kumar, USA and Gaurav Gupta, USA

8:15 AM Welcome & Introduction
Vineeta Kumar, USA
Gaurav Gupta, USA

8:15 AM IVS112.1 - Expanding the Workforce - Attracting New Trainees to Transplant
Samira Farouk, USA

8:25 AM IVS112.2 - Working More Efficiently: Using Informatics
Christian Larsen, USA

8:35 AM IVS112.3 - Biomarker Driven Follow-Up
John Friedewald, USA

8:45 AM IVS112.4 - Telemedicine
Beatrice Concepcion, USA

8:55 AM IVS112.5 - Advanced Practice Providers
Claudia Praglin, USA

9:05 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

IVS113 - Pancreas Rejection: Diagnosis and Management

8:15 AM - 9:30 AM
Moscone South — Room 11
Pancreas
CME Accredited

Moderators: Matthew Cooper, USA and Silke Niederhaus, USA

8:15 AM Welcome & Introduction
Matthew Cooper, USA
Silke Niederhaus, USA

8:15 AM IVS113.1 - The Role of the Pancreas Biopsy, DSA, and New Biomarkers for Assessment of Pancreas Rejection
Neeraj Singh, USA

8:35 AM IVS113.2 - Management of Early and Late Pancreas Rejection
Tarek Alhamad, USA

8:55 AM IVS113.3 - The Trajectory of Progressive Pancreas Dysfunction: When Should We Consider Retransplantation?
Jonathan Fridell, USA

9:15 AM Q&A

IVS114 - Perfusion Technology to Reduce Non-utilization: Lessons From Europe and Abroad

8:15 AM - 9:30 AM
Moscone South — Room 21
Organ Inclusive
CME Accredited

Moderators: Yanik Bababekov, USA and Ian Currie, UK

8:15 AM Welcome & Introduction
Yanik Bababekov, USA
Ian Currie, UK

8:15 AM IVS114.1 - Using NRP to Expand DCD - Time for the US to Get on Board
Anji Wall, USA

8:30 AM IVS114.2 - The (Hidden) Costs of NRP and Machine Perfusion
Jordan Hoffman, USA

8:45 AM IVS114.3 - A Neuroscientific Appraisal of DCD NRP: Policy, Practice, and Progress
Ajmal Zemmar, USA

9:00 AM IVS114.4 - Pitfalls and Promise: Opportunities to Use Sequential Perfusion Technologies Following NRP
Puck Groen, Netherlands

9:15 AM Q&A

IVS115 - A Constructive Dialogue on Financial Neutrality - Supporting Donation and Protecting Donors

8:15 AM - 9:30 AM
Moscone South — Room 8
Public Policy
CME Accredited

Moderators: Gabriel Danovitch, USA and Steve Chadban, Australia

8:15 AM Welcome & Introduction
Gabriel Danovitch, USA
Steve Chadban, Australia

8:15 AM IVS115.1 - A Health Justice Perspective on Financial Neutrality in Organ Donation
Alexander Capron, USA

8:30 AM IVS115.2 - Financial Neutrality in Organ Donation: Defining the Boundaries
Maria Amalia Matamoros, Costa Rica

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:45 AM **IVS115.3** - Financial Neutrality in an Unequal World: A View from South Asia
Sanjay Nagral, India

9:00 AM **IVS115.4** - AST Task Force on Financial Incentives - Updates and Scope of Work
Nicole Turgeon, USA

9:15 AM Q&A

IVS116 - Virtual Crossmatch: Regulatory Updates, Long-Term Survival, and Allocation Efficiency

8:15 AM - 9:30 AM
Moscone South — Room 153
Basic Science
CME Accredited

Moderators: Peter Nickerson, Canada and Medhat Askar, Qatar

8:15 AM Welcome & Introduction
Peter Nickerson, Canada
Medhat Askar, Qatar

8:15 AM **IVS116.1** - The Virtual Crossmatch: Principles, Applications, Regulatory Updates, Challenges and Best Practices
Robert Bray, USA

8:30 AM **IVS116.2** - Nine Year Outcome Analysis of Over 1,300 Consecutive Kidney Transplants Using Virtual Crossmatch
Rajalingam Raja, USA

8:45 AM **IVS116.3** - How Does Virtual Crossmatch Improve Organ Allocation Efficiency and Geographical Sharing
Caner Süsal, Turkey

9:00 AM Q&A

IVS118 - Donor Care Units: Centralization of Donor Care, Best Practices in ICU and OR Management, Research Opportunities

8:15 AM - 9:30 AM
Moscone South — Room 22
Organ Inclusive
CME Accredited

Moderators: Thomas Leventhal, USA and Axel Rahmel, Germany

8:15 AM Welcome & Introduction
Thomas Leventhal, USA
Axel Rahmel, Germany

8:15 AM **IVS118.1** - How Centralization of Donor Care Can Lead to Increased Utilization and Better Outcomes
Clark Kensinger, USA

8:30 AM **IVS118.2** - Emerging Best Practices for Management of the Brain Dead Donor
Gary Marklin, USA

8:45 AM **IVS118.3** - Creating Uniform Pathways for DCD Management in and out of the OR
Philip Sommer, USA

9:00 AM **IVS118.4** - The Academic Center/OPO Partnership: DCUs and Research Opportunities
Emily Vail, USA

9:15 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

LOA07 - Allocation, Selection, and Outcomes

8:15 AM - 9:30 AM
Moscone South – Room 25
Kidney
Not for CME Credit

Moderators: TBC and TBC

8:15 AM Welcome & Introduction

8:17 AM **LAO7.1** - Impact of a National Wait Time Modification Policy on Racial Inequities in Kidney Transplantation
Martha Pavlakis, USA

8:24 AM Q&A

8: 26 AM **LOA07.2** - Outcomes Analysis of U.S. Transplant Centers Performing High Volumes of Hard to Place Kidneys; 2023-2034 Analysis.
Yasir Qazi, USA

8:33 AM Q&A

8:35 AM **LAO7.3** - Early Impact of a Revised Expedited Kidney Allocation Pathway on Placement Patterns and Sequence Efficiency
Geoffrey Funk, USA

8:42 AM Q&A

8:44 AM **LA07.4** - Early Impact of a Revised Expedited Kidney Allocation Policy on the Utilization of Marginal Organs
Geoffrey Funk, USA

8:51 AM Q&A

8:53 AM **LOA07.5** - No Kidney Left Behind: An Expedited Kidney Allocation Abstract
Geoffrey Funk, USA

9:00 AM Q&A

9:02 AM **LOA07.6** - Innate Allorecognition: SIRPA Locus Mismatches Between the Donor and Recipient are Associated with Kidney Allograft Survival
Aleksandar Senev, USA

9:09 AM Q&A

9:11 AM **LOA07.7** - PIRCHE, DRTC and CTLp Are Directly Correlated with HLA Mismatch and May Be Predictive of Rejection in Kidney Transplant Patients
Shareni Jeyamogan, USA

9:18 AM Q&A

9:20 AM **LOA07.8** - Assessing Post-Transplant Outcomes in Marginal Kidney Transplants at the Center Level
Amirhossein Moosavi, USA

9:27 AM Q&A

9:29 AM Closing Remarks

OA49 - Basic Approaches on Organ Optimization

8:15 AM - 9:30 AM
Moscone South – Room 10
Basic Science
Not for CME Credit

Moderators: Jason Wertheim, USA and Anji Wall, USA

8:15 AM Welcome & Introduction
Jason Wertheim, USA
Anji Wall, USA

8:17 AM **OA49.1** - Post-Translational Modifications to DAMPs Generated during Ischemia-Reperfusion Injury Drives Differential Allosensitization and Outcomes in Liver Transplant Recipients
Rebecca Sosa, USA

8:24 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

8:26 AM **OA49.2** - Mechanically Perfused P-Selectin Binding Peptide Extracellular Vesicles Alleviate Ischemia-Reperfusion Injury in Donation After Circulatory Death Liver Transplantation
Yongqiang Ma, China

8:33 AM Q&A

8:35 AM **OA49.3** - Ischemia-Reperfusion Injury Drives Cytokine Dysregulation, Early Monocyte Activation, and Poor Outcomes in Liver Transplantation
Adil Bhat, USA

8:42 AM Q&A

8:44 AM **OA49.4** - Partial Frozen Enables Long-Term Preservation of the Kidney
McLean Taggart, USA

8:51 AM Q&A

8:53 AM **OA49.5** - CCL5-Engineered Exosomes Alleviate Hepatic Ischemia-Reperfusion Injury in Donation After Circulatory Death by Targeting C1QC⁺ Macrophages via the CCR5/TGF-β Signaling Axis
Yongqiang Ma, China

9:00 AM Q&A

9:02 AM **OA49.6** - A Novel Rodent Model of In Situ Abdominal Normothermic Regional Perfusion: Assessing Liver Injury in Marginal Steatotic Livers After Donation from Circulatory Death
Omar Alomar, USA

9:09 AM Q&A

9:11 AM **OA49.7** - First Successful Preclinical Transplantations Following 72 Hours Subzero Pig Kidney Preservation with Nature-Inspired Cryoprotectants
Byoung Chol Oh, USA

9:18 AM Q&A

9:20 AM Closing Remarks

OA50 - Kidney Chronic Rejection

8:15 AM - 9:30 AM
Moscone South — Room 155
Kidney
Not for CME Credit

Moderator: Sita Gourishankar, Canada

8:15 AM Welcome & Introduction
Sita Gourishankar, Canada

8:17 AM **OA50.1** - High-Affinity NK Cell IgG Receptors and De Novo DSA Are Linked to Poor Kidney Transplant Outcomes
Stalinraja Maruthamuthu, USA

8:24 AM Q&A

8:26 AM **OA50.2** - HLA-DQ: The Dominant Driver of De Novo Donor-Specific Antibody-Mediated Graft Failure in Pediatric Kidney Transplantation
Daniel Turudic, Croatia

8:33 AM Q&A

8:35 AM **OA50.3** - First-Line Treatment in Patients with Chronic-Active Antibody-Mediated Rejection Confers Similar Kidney Graft Survival and Post-Transplant Glomerulopathy as Patients Without Chronicity
Luis Camacho-Murilo, Mexico

8:42 AM Q&A

8:44 AM **OA50.4** - Defining the Hierarchy of Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection
Katelynn Madill-Thomsen, Canada

8:51 AM Q&A

8:53 AM **OA50.5** - Intra- and Extraglomerular Transcripts in Chronic Antibody Mediated Rejection Reveal Distinct Immune Responses
Ivy Rosales, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

9:00 AM Q&A

9:02 AM **OA50.6** - Single-Cell Spatial Transcriptomics Reveal Intraglomerular Cell Activation and Ligand-Receptor Relationships in Chronic, Active Antibody Mediated Rejection
Alessia Giarraputo, USA

9:09 AM Q&A

9:11 AM **OA50.7** - Comparison of a Gene Expression Profiling Panel with Combined Histopathology and Microarrays to Classify Kidney Allograft Rejection
Esteban Arroyave, USA

9:18 AM Q&A

9:20 AM **OA50.8** - Anti-CD38 Monoclonal Antibody Daratumumab for the Treatment of Chronic Active-Antibody Mediated Kidney Allograft Rejection
Wai Choong Lye, Singapore

9:27 AM Q&A

9:29 AM Closing Remarks

OA51 - Deceased Donor Management

8:15 AM - 9:30 AM
Moscone South – Room 20
Organ Inclusive
Not for CME Credit

Moderators: Rohit Gaurav, UK and Daniel Borja-Cacho, USA

8:15 AM Welcome & Introduction
Rohit Gaurav, UK
Daniel Borja-Cacho, USA

8:17 AM **OA51.1** - Two Years of Centralizing Donation After Cardiopulmonary Death
Geoffrey Funk, USA

8:24 AM Q&A

8:26 AM **OA51.2** - Establishing Donor Care Units for Donation After Circulatory Death Donors: An Exploratory Analysis Using Geospatial Epidemiology Framework
Vishnu Potluri, USA

8:33 AM Q&A

8:35 AM **OA51.3** - Overdose Deaths Are Decreasing, but Donor Numbers Continue Increasing
Jesse Howell, USA

8:42 AM Q&A

8:44 AM **OA51.4** - Comparison of Back-to-Base and Upfront Normothermic Machine Perfusion in Liver Transplantation: A Retrospective Cohort Study
Jacob Hallesy, USA

8:51 AM Q&A

8:53 AM **OA51.5** - A Collaborative "Donor to Base" Abdominal Normothermic Regional Perfusion Program Leads to Superior Organ Utilization and Recipient Allograft Outcomes
Casey Ward, USA

9:00 AM Q&A

9:02 AM **OA51.6** - A Novel Donor Risk Index for Normothermic Machine Perfused Liver Allografts
Justin Hu, USA

9:09 AM Q&A

9:11 AM **OA51.7** - Cradle Compression during Normothermic Machine Perfusion in Liver Transplantation: Incidence and Impact on Postoperative Outcomes
Junpei Tarashi, USA

9:18 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

9:20 AM **OA51.8** - Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation
David Reich, USA

9:27 AM Q&A

9:29 AM Closing Remarks

OA52 - Evolving Challenges in Transplant Oncology

8:15 AM - 9:30 AM
Moscone South – Room 12
Organ Inclusive
Not for CME Credit

Moderator: Ala Ali, Iraq

8:15 AM Welcome & Introduction
Ala Ali, Iraq

8:17 AM **OA52.1** - De Novo Cancer Incidence After Solid Organ Transplantation in England: The EpCOT Study
Charlotte Stephens, UK

8:24 AM Q&A

8:26 AM **OA52.2** - Epidemiologic Contributions to Changing Cancer Incidence Among Solid Organ Transplant Recipients (SOTRs) in the USA
Qianlai Luo, USA

8:33 AM Q&A

8:35 AM **OA52.3** - Donor-Transmitted Cancer in Organ Donation and Solid Organ Transplantation in Germany from 2016-2024
Ana Paula Barreiros, Germany

8:42 AM Q&A

8:44 AM **OA52.4** - Lung Transplantation in Men with High-Risk Prostate Cancer without a Mandatory Cancer-Free Period
Dylan Isaacson, USA

8:51 AM Q&A

8:53 AM **OA52.5** - The Effect of CD300a on the Survival of Epstein-Barr Virus (+) B Cell Lymphomas in Post-Transplant Lymphoproliferative Disorder
Chimere Ezeiruaku, USA

9:00 AM Q&A

9:02 AM **OA52.6** - Machine Learning Models for Predicting Post-Transplant Lymphoproliferative Disease Risk: Insights from a Large-Scale Retrospective Cohort Study
Seyed M. Hosseini-Moghaddam, Canada

9:09 AM Q&A

9:11 AM **OA52.7** - Normothermic Machine Perfusion Allows for Use of Higher Donor Risk Index Livers in Patients with Hepatocellular Carcinoma
Kimberly Feeney, USA

9:18 AM Q&A

9:20 AM Closing Remarks

LOA08 - Past Meets Future: Redefining the Limits of Transplantation

10:00 AM - 11:15 AM
Moscone South – Room 4
Organ Inclusive
Not for CME Credit

Moderators: Stefan Schneeberger, Austria and Maryam Valapour, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:00 AM Welcome & Introduction
Stefan Schneeberger, Austria
Maryam Valapour, USA

10:02 AM **LOA08.1** - Normothermic Machine Perfusion in Pediatric Liver Transplantation: A National and Institutional Retrospective Analysis
Nihal Aykun, USA

10:09 AM Q&A

10:11 AM **LOA08.2** - Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: A Multicenter Study
Francisco Hernández Oliveros, Spain

10:18 AM Q&A

10:20 AM **LOA08.3** - Evaluation of a SUNTRAC-Based Skin Cancer Surveillance Program in Solid Organ Transplant Recipients
David Lee, USA

10:27 AM Q&A

10:29 AM **LOA08.4** - Outcomes of Solid Organ Transplant Recipients with Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis
Nida Saleem, Australia

10:36 AM Q&A

10:38 AM **LOA08.5** - Double Lung Transplantation in Patients with Advanced Bilateral Lung-Limited Non-Small Cell Lung Carcinoma
Ankit Bharat, USA

10:45 AM Q&A

10:47 AM **LOA08.6** - Effectiveness of Belumosudil for Chronic Lung Allograft Dysfunction after Lung Transplantation
Chunrong Ju, China

10:54 AM Q&A

10:56 AM **LOA08.7** - SPP1 Mediated Short-Term Epithelial-Mesenchymal Transition in Rapid Kidney Growth in Extreme Weight-Mismatched Renal Transplantation
Tianhui Pan, China

11:03 AM Q&A

11:05 AM **LOA08.8** - Donor-Derived Cell-Free DNA-Guided Prednisone Weaning and Reduced Endomyocardial Biopsy Surveillance Following Heart Transplantation
Daryl Nnani, USA

11:12 AM Q&A

11:14 AM Closing Remarks

LOA09 - Immunosuppression and Immune Monitoring

10:00 AM - 11:15 AM
Moscone South – Room 25
Kidney
Not for CME Credit

Moderators: Gilles Blancho, France and Klemens Budde, Germany

10:00 AM Welcome & Introduction
Gilles Blancho, France
Klemens Budde, Germany

10:02 AM **LOA09.1** - Desensitization with CD38 Monoclonal Antibody and CTLA4-Ig Enables Transplantation in Highly Sensitized Kidney Candidates with CPRA ≥99.9%
Raja Rajalingam, USA

10:09 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:11 AM **LOA09.2** - C5aR1 Inhibition Ameliorates DGF in a DCD Porcine Kidney Auto-Transplantation Model
Nader Abraham, USA

10:18 AM Q&A

10:20 AM **LOA09.3** - Mechanism Study of Tacrolimus Inhibiting FXR Mediated Toxicity of Renal Tubular Epithelial Cells
Zhao Feng Liu, China

10:27 AM Q&A

10:29 AM **LOA09.4** - Liquid-Biopsy Risk Assessment Versus Invasive Surveillance in Kidney Transplant: a Randomized Controlled Trial
Romain Brousse, France

10:36 AM Q&A

10:38AM **LOA09.5** - First Year Pre-transplant Immunobiogram (IMBG) Predictability of de novo Rejection or Infection after 3 months in Biotraim Study
Marta Crespo, Spain

10:45 AM Q&A

10:47 AM **LOA09.6** - Combining percentage and concentration of dd-cfDNA in Kidney Transplantation is highly sensitive and specific for rejections. Results from five clinical cohort
Klemens Budde, Germany

10:54 AM Q&A

10:56 AM **LOA09.7** - Analytical and Clinical Validation of TransplantTrace cfDNA Test
Tasha Kalista, USA

11:03 AM Q&A

11:05 AM **LOA09.8** - Donor-derived cell-free DNA (dd-cfDNA) trends in adult kidney transplant recipients with cytomegalovirus (CMV) viremia
Katerina Hysi, USA

11:12 AM Q&A

11:14 AM Closing Remarks

OA53 - Advancing Organ Tolerance: Mechanisms, Strategies, and Clinical Frontiers

10:00 AM - 11:15 AM
Moscone South – Room 10
Basic Science
Not for CME Credit

Moderators: Xunrong Luo, USA and Rainer Oberbauer, Austria

10:00 AM Welcome & Introduction
Xunrong Luo, USA
Rainer Oberbauer, Austria

10:02 AM **OA53.1** - Myeloid-Hepatic Crosstalk by Human Antigen R (HuR) Regulation of CEACAM1 Improves Ischemia Tolerance in Liver Transplantation
Kenneth Dery, USA

10:09 AM Q&A

10:11 AM **OA53.2** - Repeated Dosing of Apoptotic Donor B Cell Infusions for Tolerance in a Non-Human Primate Model of Allogeneic Kidney Transplantation
Matthew Tunbridge, USA

10:18 AM Q&A

10:20 AM **OA53.3** - Targeting the Genomic Stability of Activated Alloreactive T Cells in the Induction of Transplant Tolerance
Xiang Xiao, USA

10:27 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:29 AM **OA53.4** - Donor and Host Type DC Subsets in Mixed Chimeras Differentially Regulate the Development of Host-Type Peripheral Treg Cells to Promote Immune Tolerance
Yaxun Huang, China

10:36 AM Q&A

10:38 AM **OA53.5** - Targeted Modulation of the Fas Death Pathway Induces Tolerance to Cardiac Allograft in Mice
Haval Shirwan, USA

10:45 AM Q&A

10:47 AM **OA53.6** - Oral Tributyrate Promotes Treg-Mediated Immune Modulation and Prolongs Allograft Survival in Murine Transplant Models
Daniel Marconi Mendes, USA

10:54 AM Q&A

10:56 AM **OA53.7** - Single Center Phase 2 and 3 Experience with Tolerance Induction in Living Donor Renal Transplant Recipients
Joseph Leventhal, USA

11:03 AM Q&A

11:05 AM **OA53.8** - Evidence for Human Thymopoiesis in a Porcine Thymus Graft and T Cell Tolerance to the Source Pig in a Living Human Recipient of a Porcine Thymokidney Xenotransplant
Farshid Fathi, USA

11:12 AM Q&A

11:14 AM Closing Remarks

OA54 - What's New in Chronic Organ Rejection

10:00 AM - 11:15 AM
Moscone South – Room 12
Basic Science
Not for CME Credit

Moderators: Luis Hidalgo, USA and Emmanuel Zorn, USA

10:00 AM Welcome & Introduction
Luis Hidalgo, USA
Emmanuel Zorn, USA

10:02 AM **OA54.1** - Conditional Deletion of the BET Family Protein BRD4 in Macrophages Inhibits M2 Cells and Prevents Chronic Rejection
Xiaojun Su, USA

10:09 AM Q&A

10:11 AM **OA54.2** - Multiome Sequencing of Chronic Ductopenic Rejection Reveals Roles for Th2 Immunity and Activated Fibroblasts in Cholangiocyte Injury
Anna Peters, USA

10:18 AM Q&A

10:20 AM **OA54.3** - Blocking NKG2A/CD94 Interaction with Qa-1-Peptide Complex Prolongs Survival of Heart Allografts
Soltan Al Chaar, USA

10:27 AM Q&A

10:29 AM **OA54.4** - Elovl6-Mediated Fatty Acid Elongation Enhances Memory-Like NK Cell Formation
Zijie Xu, China

10:36 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:38 AM **OA54.5** - Suppressive Effects of Anti-Mouse and Human C4d Chimeric Antigen Receptor Regulatory T Cells on Antibody-Mediated Rejection
Hwan Lee, South Korea

10:45 AM Q&A

10:47 AM **OA54.6** - CD8-Driven Cleavage of MerTK Rewires Macrophage Metabolism to Accelerate Cardiac Allograft Vasculopathy
Connor Lantz, USA

10:54 AM Q&A

10:56 AM **OA54.7** - Preclinical Study for Evaluating the Impact of Cholangiocyte-Coated Silicone Stent on Porcine Model for Bile Leakage
Sung-hae Park, South Korea

11:03 AM Q&A

11:05 AM **OA54.8** - Spatialomic Analysis of Kidney Biopsies Identifies Differential Abundance of Transcripts and Cell Types by Glomerular and Non-Glomerular Regions Associated with Kidney Allograft Loss
Casey Dorr, USA

11:12 AM Q&A

11:14 AM Closing Remarks

OA55 - Infectious Risks: Bacterial Threats in Transplant Patients

10:00 AM - 11:15 AM
Moscone South — Room 9
Infectious Disease
Not for CME Credit

Moderators: Elena Beam, USA and Cedric Spak, USA

10:00 AM Welcome & Introduction
Elena Beam, USA
Cedric Spak, USA

10:02 AM **OA55.1** - Management and Outcomes of Lung Transplant Recipients with Post-Transplant Mycobacterium abscessus Complex Infection
Brennan Collis, USA

10:09 AM Q&A

10:11 AM **OA55.2** - Incidence and Clinical Impact of Carbapenem-Resistant Enterobacterales Infections in Solid Organ Transplant Recipients
Andrea Cona, Italy

10:18 AM Q&A

10:20 AM **OA55.3** - Isoniazid Prophylaxis in High-Risk Kidney Transplant Recipients: Discontinuation Rates and Active Tuberculosis Incidence
Anselaine Silva, Brazil

10:27 AM Q&A

10:29 AM **OA55.4** - Effectiveness of Universal Isoniazid Prophylaxis in Kidney Transplant Recipients in Tuberculosis-Endemic Regions: A Multicenter Pooled Analysis
Jackrapong Bruminhent, Thailand

10:36 AM Q&A

10:38 AM **OA55.5** - Zoonotic Infections in Solid Organ Transplant Recipients at a Single Center
Deepali Boothankad Sharath, USA

10:45 AM Q&A

10:47 AM **OA55.6** - Sepsis-Associated Acute Kidney Injury in Kidney Transplant Recipients: Risk Factors and the Impact on Graft Function
José Souto, Brazil

10:54 AM Q&A

10:56 AM **OA55.7** - Infectious Complications After ERCP in Liver Transplant Recipients: Impact of MDRO and Antibiotic Use
Jehanzaeb Khan, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

11:03 AM Q&A

11:05 AM **OA55.8** - Sulfonamide Antibiotic Allergy in Solid Organ Transplant: Defining the Impact and Identifying Opportunities for De-Labeling
Jennifer Hu, USA

11:12 AM Q&A

11:14 AM Closing Remarks

OA56 - Artificial Intelligence for Clinical Decision Making: Kidney

10:00 AM - 11:15 AM
Moscone South — Room 22
Kidney
Not for CME Credit

Moderators: Varvara Kirchner, USA and Lisiane Pruinelli, USA

10:00 AM Welcome & Introduction
Varvara Kirchner, USA
Lisiane Pruinelli, USA

10:02 AM **OA56.1** - Bias in Kidney Transplant Risk Prediction: Fairness of the Kidney Donor Risk Index and Estimated Post-Transplant Survival Score
Christie Rampersad, Canada

10:09 AM Q&A

10:11 AM **OA56.2** - Developing and Validating K-CRS, a Novel Medical Urgency Score for Adult Kidney Transplant Candidates
Nour Asfour, USA

10:18 AM Q&A

10:20 AM **OA56.3** - A Data-Driven Approach to Predict Waiting Times in Kidney Transplantation Using Machine Learning
Gustavo Fernandes Ferreira, Brazil

10:27 AM Q&A

10:29 AM **OA56.4** - Enhanced Prediction of Recipient Renal Function Using Donor Kidney Volume and Pre-Transplant Characteristics via Machine Learning
Jayeon Ahn, South Korea

10:36 AM Q&A

10:38 AM **OA56.5** - Assessing Public Dialogue About Financial Concerns Related to Living Kidney Donation of Reddit Posts Using Artificial Intelligence and Qualitative Analysis
Amy Waterman, USA

10:45 AM Q&A

10:47 AM **OA56.6** - Novel Artificial Intelligence-Based Measures of Inflammation Associate with Graft Loss
Mateo Velasquez Mejia, USA

10:54 AM Q&A

10:56 AM **OA56.7** - Evaluating an Open-Weight LLM for Information Extraction from Deceased Donor Renal Worksheets
Morgan Stuart, USA

11:03 AM Q&A

11:05 AM **OA56.8** - Transparency in Kidney Transplant Recipient Selection Criteria: A Nationwide Analysis Using AI
Belen Rivera, USA

11:12 AM Q&A

11:14 AM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA57 - Deceased Donor Kidney Access to Waitlist and Outcomes

10:00 AM - 11:15 AM
Moscone South — Room 154
Kidney
Not for CME Credit

Moderators: Shaheed Merani, USA and Istvan Mucsi, Canada

10:00 AM Welcome & Introduction
Shaheed Merani, USA
Istvan Mucsi, Canada

10:02 AM OA57.1 - Outcomes of High CPRA, Bypassed or Refused Offer Candidates: The Missed Chance Might Be the Last
Bonnie Lonze, USA

10:09 AM Q&A

10:11 AM OA57.2 - HLA Matchability and Access to Kidney Transplantation: Disparities in Eurotransplant
Hans de Ferrante, Netherlands

10:18 AM Q&A

10:20 AM OA57.3 - Access to HLA-DR Mismatched (MM) Deceased Donor Kidney Transplantation (DDKT) by HLA-DR Haplotype
Deena Brosi, USA

10:27 AM Q&A

10:29 AM OA57.4 - Tale of Two Transplants: A Kidney Pair Analysis on the Impact of Social Determinants of Health
Bima Hasjim, USA

10:36 AM Q&A

10:38 AM OA57.5 - Improvement in Cognition After Kidney Transplantation is Associated with Improvement in White Matter Integrity
Jacob Hiss, USA

10:45 AM Q&A

10:47 AM OA57.6 - Barriers in Access to Transplant in the Setting of a New Transplant Program
Gloria Chen, USA

10:54 AM Q&A

10:56 AM OA57.7 - Hispanic Kidney Transplant Recipients Are Significantly More Likely to Be Lost to Follow-Up Than Non-Hispanic Whites
Sixto Giusti, USA

11:03 AM Q&A

11:05 AM OA57.8 - How Patient Navigators Can Improve Patient Journeys for Aboriginal and Torres Strait Islander People with Kidney Disease: The COMPASS Project
Kelli Owen, Australia

11:12 AM Q&A

11:14 AM Closing Remarks

OA58 - Kidney, Psychosocial, Equity, and Access

10:00 AM - 11:15 AM
Moscone South — Room 23
Kidney
Not for CME Credit

Moderators: Vivek Kute, India and Ming Hwei Yek, USA

10:00 AM Welcome & Introduction
Vivek Kute, India
Ming Hwei Yek, USA

10:02 AM OA58.1 - Examining the Patient Experience of a Novel African American Transplant Access Program: A Qualitative Study
Joy Obayemi, USA

10:09 AM Q&A

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:11 AM **OA58.2** - Impact of a Race-Neutral eGFR Policy on Black Kidney Transplant Candidates
Martha Pavlakis, USA

10:18 AM Q&A

10:20 AM **OA58.3** - Association of Race and Ethnicity with Marginal Kidney Allocation: A Nationwide Study
Belen Rivera, USA

10:27 AM Q&A

10:29 AM **OA58.4** - Access Inhibited by Intersecting Marginalization (AIIM) in Kidney Transplantation
David Leeser, USA

10:36 AM Q&A

10:38 AM **OA58.5** - Sociocultural Factors, Racial Disparities, and Kidney Transplant Outcomes in the Kidney Transplant Fast Track (KTFT) Program
Miriam Velez-Bermudez, USA

10:45 AM Q&A

10:47 AM **OA58.6** - Impact of the Wait Time Modification Policy on Kidney Transplant Access
Martha Pavlakis, USA

10:54 AM Q&A

10:56 AM **OA58.7** - Are We There Yet? Determinants of Links Between Dialysis Units and Local Transplant Programs
Jillian Caldwell, USA

11:03 AM Q&A

11:05 AM Closing Remarks

OA59 - Kidney: Hot Topics 2

10:00 AM - 11:15 AM
Moscone South – Room 21
Kidney
Not for CME Credit

Moderators: Oren Shaked, USA and TBC

10:00 AM Welcome & Introduction
Oren Shaked, USA
TBC

10:02 AM **OA59.1** - Unveiling Shared Genetic Risks of Type 2 and Post-Transplant Diabetes Mellitus in East Asians through Polygenic Risk Scores
Seokwoo Park, South Korea

10:09 AM Q&A

10:11 AM **OA59.2** - Mosaic Loss of Y Chromosome in Proximal Tubular Cells is Associated with Recovery from DGF Post DCD Kidney Transplantation: A New Single Nucleus RNA-Seq Signature of Organ Quality
Giuseppe Orlando, USA

10:18 AM Q&A

10:20 AM **OA59.3** - Cost-Effective Diagnostic Testing Models Using Four Kidney Rejection Biomarkers
Akhil Singla, USA

10:27 AM Q&A

10:29 AM **OA59.4** - Renal Transplant Recipients with Elevated Donor-Derived Cell-Free DNA (dd-cfDNA) Are at Increased Risk of Graft Loss
Daniel Brennan, USA

10:36 AM Q&A

10:38 AM **OA59.5** - Individual and Center-Level Variation of eGFR Wait Time Modification for Black Kidney Transplant Candidates in the USA
Jesse Schold, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:45 AM Q&A

10:47 AM **OA59.6** - Efficacy of Bariatric Surgery (BSx) versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) After Kidney Transplantation
Joseph Kahwaji, USA

10:54 AM Q&A

10:56 AM **OA59.7** - Kidney Donor Failure Index: A Proposal for a New Way to Present Kidney Donor Risk Based on Kidney Donor Risk Index
Jonathan Miller, USA

11:03 AM Q&A

11:05 AM **OA59.8** - The Role of Genetic Testing on Kidney Transplant Evaluation and Outcomes
Yasar Caliskan, USA

11:12 AM Q&A

11:14 AM Closing Remarks

OA60 - Kidney: Novel Immunosuppressant Strategies

10:00 AM - 11:15 AM
Moscone South – Room 155
Kidney
Not for CME Credit

Moderators: Minnie Sarwal, USA and Gustavo Ferreira, Brazil

10:00 AM Welcome & Introduction
Minnie Sarwal, USA
Gustavo Ferreira, Brazil

10:02 AM **OA60.1** - STEADFAST Study Update: A Phase 1/2 Clinical Trial of Regulatory T Cells Expressing a Chimeric Antigen Receptor Directed Towards HLA-A2 in Renal Transplantation
Paul Harden, UK

10:09 AM Q&A

10:11 AM **OA60.2** - Every 2-Month Belatacept Maintenance Therapy in Kidney Transplant Recipients: 5-Year Follow-Up of a Randomized, Noninferiority Trial
Idelberto Badell, USA

10:18 AM Q&A

10:20 AM **OA60.3** - Clinical Validation of a Novel Rapid Test for Point-of-Care Tacrolimus Monitoring in Kidney Transplant Recipients
Trong Nguyen, USA

10:27 AM Q&A

10:29 AM **OA60.4** - Late Abatacept Conversion in Kidney Transplant Recipients Receiving Belatacept: A Prospective, Randomized Controlled Noninferiority Trial
Idelberto Badell, USA

10:36 AM Q&A

10:38 AM **OA60.5** - Daratumumab (Anti-CD38) Desensitization in HLA Sensitized Patients: Long-Term Follow-Up
Ashley Vo, USA

10:45 AM Q&A

10:47 AM **OA60.6** - Mechanistic Insights Underlying Persistent Beneficial Impact on Kidney Function of CCR5 Blockade Following Treatment Discontinuation
Ali Abbasi, USA

10:54 AM Q&A

10:56 AM **OA60.7** - Histological Reversal of Refractory ABMR with Daratumumab in Kidney Transplant Patients
Oriol Bestard, Spain

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

11:03 AM Q&A

11:05 AM **OA60.8** - Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1B Study
John Gill, Canada

11:12 AM Q&A

11:14 AM Closing Remarks

OA61 - Living Donor Kidney Outcomes

10:00 AM - 11:15 AM
Moscone South – Room 20
Kidney
Not for CME Credit

Moderators: Shaifali Sandal, Canada and Amanda Leonberg-Yoo, USA

10:00 AM Welcome & Introduction
Shaifali Sandal, Canada
Amanda Leonberg-Yoo, USA

10:02 AM **OA61.1** - Living Kidney Donor's Residential Neighborhood: Driver or Barrier of Post-Transplant Follow-Up
Yiting Li, USA

10:09 AM Q&A

10:11 AM **OA61.2** - Living Kidney Donors Fathering a Post Transplant Pregnancy: No Impact on Graft Survival or Pregnancy Outcomes
Michael Moritz, USA

10:18 AM Q&A

10:20 AM **OA61.3** - Long-Term Risks in Obese Living Kidney Donors: A Systematic Review and Meta-Analysis
Fawaz Al Ammary, USA

10:27 AM Q&A

10:29 AM **OA61.4** - Postdonation Outcomes for Living Kidney Donors by Relationship to Recipient
Daniel Waller, USA

10:36 AM Q&A

10:38 AM **OA61.5** - Twice is Just as Nice: Favorable Donor Outcomes in Living Donor Liver Transplantation After Previous Kidney Donation
Binuri Hapuarachchy, USA

10:45 AM Q&A

10:47 AM **OA61.6** - Prospective Eplet Matching in Unsensitized Recipients of Living Donor Kidneys is Associated with a Lower Incidence of De Novo DSA
Raja Kandaswamy, USA

10:54 AM Q&A

10:56 AM **OA61.7** - Impact of APOL1 Risk Variants on Post-Donation Kidney Function in Living Kidney Donors
Daniel Del Castillo Rix, USA

11:03 AM Q&A

11:05 AM **OA61.8** - The Impact of Living Kidney Donor Status on the Donor-Recipient Relationship
Zoe Gonzales, USA

11:12 AM Q&A

11:14 AM Closing Remarks

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

OA62 - Liver and Kidney Transplantation

10:00 AM - 11:15 AM
Moscone South – Room 8
Liver
Not for CME Credit

Moderator: Nicholas Lim, USA and Marcelo Cantarovich, Canada

10:00 AM Welcome & Introduction
Nicholas Lim, USA
Marcelo Cantarovich, Canada

10:02 AM OA62.1 - Holes in the Safety Net: Examining Equity in Access to Kidney Transplantation for Liver Recipients under the Safety Net Policy
Maggie Jones-Carr, USA

10:09 AM Q&A

10:11 AM OA62.2 - The Impact of Normothermic Machine Perfusion in Liver Transplantation on Early Postoperative Renal Outcomes in Simultaneous Liver-Kidney Transplantation: A Propensity Score-Matched Analysis
Muhammad Ahmad Nadeem, USA

10:18 AM Q&A

10:20 AM OA62.3 - Inferior Waitlist Outcomes Among Patients Listed for Simultaneous Liver-Kidney Transplantation
John Montgomery, USA

10:27 AM Q&A

10:29 AM OA62.4 - The Role of Machine Perfusion in Expanding Donor Utilization for Simultaneous Liver and Kidney Transplantation
Rikako Oki, USA

10:36 AM Q&A

10:38 AM OA62.5 - Randomized Clinical Trial of SARS-CoV-2 Peri-Vaccination Immunosuppressive Reduction in Kidney and Liver Transplant Recipients
William Werbel, USA

10:45 AM Q&A

10:47 AM OA62.6 - Variation in Donation After Circulatory Death Donor Organ Yield Across Organ Procurement Organizations
Wei San Loh, USA

10:54 AM Q&A

10:56 AM OA62.7 - DCD Simultaneous Liver-Kidney (SLK) Transplants in the Landscape of Expanded SLK Required Sharing
Sarah Booker, USA

11:03 AM Q&A

11:05 AM OA62.8 - Exploring Disease-Specific Waitlist Dynamics in Simultaneous Liver-Kidney Transplantation
Rikako Oki, USA

11:12 AM Q&A

11:14 AM Closing Remarks

OA63 - Non-Organ Specific: Disparities in Outcome and Access to Healthcare

10:00 AM - 11:15 AM
Moscone South – Room 11
Organ Inclusive
Not for CME Credit

Moderators: Rudolf Garcia-Gallont, Guatemala and Allison Kwong, USA

10:00 AM Welcome & Introduction
Rudolf Garcia-Gallont, Guatemala
Allison Kwong, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:02 AM **OA63.1** - A Contemporary Analysis of ESRD Risk After Non-Renal Solid Organ Transplantation
Deirdre Sawinski, USA

10:09 AM Q&A

10:11 AM **OA63.2** - Long-Term Conditional Graft Survival in Liver and Kidney Transplants: Does Race Matter Differently?
Ingrid Rocha, USA

10:18 AM Q&A

10:20 AM **OA63.3** - A Novel Measure of Spatial Accessibility to Transplant Services Predicts Population-Based Access to Liver Transplant
Katherine Ross-Driscoll, USA

10:27 AM Q&A

10:29 AM **OA63.4** - Advancing Health Equity: Public-Private Partnerships for Organ Donation and Transplantation in North-East India's Underserved Regions
Sunil Shroff, India

10:36 AM Q&A

10:38 AM **OA63.5** - Pregnancy Complications Following Solid Organ Transplant Varies by Organ Type: A Multicenter Database Analysis
Deepika Devuni, USA

10:45 AM Q&A

10:47 AM **OA63.6** - Evolving Trends in Organ Donation and Transplantation Rates Across Muslim Majority Countries in the Last Decade
Fatima Malik, UK

10:54 AM Q&A

10:56 AM **OA63.7** - Cervical Dysplasia and Malignancy in Women After Solid Organ Transplant
Ami Patel, USA

11:03 AM Q&A

11:05 AM **OA63.8** - Impact of a Dedicated DM Clinic on Glycemic Control in Post-Solid Organ Transplant Patients, Lung, Liver and Kidney: A Retrospective Longitudinal Study
Lama Amer, Saudi Arabia

11:12 AM Q&A

11:14 AM Closing Remarks

OA64 - US Public Policy

10:00 AM - 11:15 AM
Moscone South – Room 153
Public Policy
Not for CME Credit

Moderators: Lloyd Ratner, USA and TBC

10:00 AM Welcome & Introduction
Lloyd Ratner, USA
TBC

10:02 AM **OA64.1** - Exploring a New Framework for US Heart Allocation: Development of an Evidence-Based Medical Urgency Score for Adult Heart Transplant Candidates
Grace Lyden, USA

10:09 AM Q&A

10:11 AM **OA64.2** - National IOTA Policy Will Fail to Classify Center Performance Appropriately Based on Unadjusted Models
Jesse Schold, USA

10:18 AM Q&A

10:20 AM **OA64.3** - Evaluating the Impact of Data Source on Organ Procurement Organization Performance Metrics
Jesse Schold, USA

LEGEND
IVS Invited Symposia
KN Keynote
LOA Late-Breaking Oral Abstracts
OA Oral Abstracts
P Posters
PL Plenary Abstracts
RF Rapid Fire Oral Abstracts

10:27 AM Q&A

10:29 AM **OA64.4** - Developing a Tiered Survival After Listing Metric to Communicate Comparative Information About Patient Experience at Transplant Centers in the USA
Ajay Israni, USA

10:36 AM Q&A

10:38 AM **OA64.5** - Match-Run Analysis for Designing and Evaluating Allocation Policies
Nicholas Wood, USA

10:45 AM Q&A

10:47 AM **OA64.6** - Clearing the Air: The Environmental and Financial Cost of Solid Organ Transplant in the US
Gabriel Schnickel, USA

10:54 AM Q&A

10:56 AM **OA64.7** - Government Investment in OPTN Infrastructure Has Been a Bargain
Samantha Klitenic, USA

11:03 AM Q&A

11:05 AM **OA64.8** - Anticipating Hurdles to Benefitting from Advanced Biopreservation of Human Organs
Alexander Capron, USA

11:12 AM Q&A

11:14 AM Closing Remarks

PL04 - Closing Plenary: Reflection, Revelations, and the Road Ahead

11:30 AM - 12:30 PM
Moscone South – San Francisco Ballroom
Not for CME Credit

Moderators: Tim Pruett, USA and Marcelo Cantarovich, Canada

11:30 AM Welcome & Introduction
Tim Pruett, USA
Marcelo Cantarovich, Canada

11:30 AM Panelists
Yanik Bababekov, USA
Dempsey Hughes, USA
Ala Ali, Iraq

Poster Numbering Format Guide

What Do the Numbers Mean?

To help you find posters easily, each one is labeled with a unique number using the following format:

P1.07.11

P1 – Day of Presentation

P1 = August 3 P2 = August 4 P3 = August 5

07 – Topic Number

See full topic list below:

Topic Number	Program Topic
01	Administrative
02	APP
03	Basic Science
04	Heart
05	Infectious Disease
06	Intestine
07	Kidney
08	Liver
09	Lung
10	Organ Inclusive
11	Pancreas
12	Pharmacy
13	Psychosocial & Ethics
14	Public Policy
15	VCA

11 – Poster Sequence Number

Posters are ordered left to right, with the smallest number on the far left

Example

P2.04.03

August 4
Heart Topic
3rd Poster in the Heart Topic Section

Poster Presentation Times for Each Topic

Number	Topic	Sunday, August 3 3:30 PM - 4:30 PM	Monday, August 4 3:30 PM - 4:30 PM	Tuesday, August 5 3:30 PM - 4:30 PM
1	Administration	✗	✗	✓
2	APP	✗	✗	✓
3	Basic Science	✓	✓	✓
4	Heart	✓	✓	✓
5	Infectious Disease	✓	✓	✓
6	Intestine	✗	✗	✓
7	Kidney	✓	✓	✓
8	Liver	✓	✓	✗
9	Lung	✓	✓	✓
10	Organ Inclusive	✓	✗	✓
11	Pancreas	✗	✗	✓
12	Pharmacy	✗	✓	✗
13	Psychosocial & Ethics	✓	✗	✗
14	Public Policy	✓	✗	✓
15	VCA	✓	✗	✗

Poster Listing

Sunday, August 3 3:30 PM - 4:30 PM

P1.03
Topic: Basic Science

P1.03.1 An Immortalized Renal Proximal Tubule Epithelial Cellular Model Overexpressing Organic Anion Transporters 1 & 3 for Characterizing the Cellular Uptake and Intrinsic Clearance Interactions Involving Mycophenolic Acid
Tony Kiang, Canada

P1.03.2 Effects of Music on Mycophenolic Acid Metabolism in Sprague Dawley Rats
Tony Kiang, Canada

P1.03.3 SGLT2i Treatment Modulates Tacrolimus-Mediated Nephrotoxicity
Sharon DB de Morais, USA

P1.03.6 TP53 Mutations Dysregulate Genes Involved in Lipid Metabolism in Hepatocellular Carcinoma: Implications for Reduced Survival
Ali Rajabi Abhari, USA

P1.03.8 Kidney Allograft Podocyte Epithelial-to-Mesenchymal Transition Detected by Single-Cell RNA Sequencing of Urinary Cells
Thangamani Muthukumar, USA

P1.03.9 Hepatic Human Antigen R (HuR) Regulation of CEACAM1 3'UTR Enhances Immune Surveillance to Improve Ischemia Tolerance in Liver Transplantation
Kenneth Dery, USA

P1.03.10 The Effect of Autophagy on the Development of Senescence in Biopsies from Kidney Transplant Patients
Yohana Vanesa Fernandez, Argentina

P1.03.11 HDAC-6 Inhibition Provides Protection Against Acetaminophen-Induced Liver Injury
Matthew Levine, USA

P1.03.12 Normothermic Machine Perfusion of Human Liver as a Platform to Study Delivery of Gene Therapy
Shekhar Kubal, USA

P1.03.14 Breakthroughs in 3D Printing, Functional Human Islets in an Alginate-dECM Bioink
Giuseppe Orlando, USA

P1.03.15 Adenosine, a Key Regulator of Human Pancreatic Islet Insulin Content and a Shield Against Hypoxia Injury
Giuseppe Orlando, USA

P1.03.16 Novel Antigen Specific HLA-E Restricted CD8 Regulatory T Cell Therapy Promotes Superior Allograft Survival Compared to CD4 Regulatory T Cells and CAR-T Regulator Cells
Soltan Al Chaar, USA

P1.03.17 Study Design of the First-in-Human Clinical Trial of a 10 Gene-Edited Xenokidney
Andrew Cameron, USA

P1.03.18 A Novel Cold Preservation Fluid for Static Cold Storage of Procured Organs
Danielle Kinsey, USA

P1.03.19 Transforming Organ Transplantation through Ex Situ Lipid Nanoparticle-Mediated Gene Editing
Leonie van Leeuwen, USA

P1.03.20 Pretransplant Rifaximin Treatment Improves Liver Transplant Outcomes through Gut Microbiota and Metabolite Modification
Hidenobu Kojima, Japan

P1.03.21 Subcutaneous Administration of a CD28 Co-Stimulation Blocker Demonstrates Efficacy in an NHP Model of Kidney Allotransplantation
Daniel Schuster, USA

P1.03.22 Synthetic Interferon Exhibits Broad, Potent Antiviral Activity with the Potential for an Improved Safety Profile
Wade Blair, USA

P1.03.23 Examining the Potential Therapeutic Effects of Extracellular Vesicles in Explanted Kidneys Using Precision-Cut Kidney Slices (PCKS) as an Ex Vivo Model
Bingda Li, USA

P1.03.24 STAT3 Inhibition Mitigates Fibrosis Development in AKI-to-CKD by Regulating Macrophage-Fibroblasts Crosstalk
Kyu Hong Kim, Korea

P1.03.25 Targeting RORg: A Novel Approach to Transplant Rejection and Cancer Therapy
Jean Tchervenkov, Canada

P1.03.26 Pro-Regenerative Effects of an MKK4 Inhibitor Drug in a Porcine Model of Steatohepatitis
Silvana Wilken, USA

Poster Listing

P1.03.27 Anti-CD154 Promotes Long-Term Liver Transplant Survival in Nonhuman Primates
Michael Dryden, USA

P1.03.28 Preventing Allograft Rejection After Heart Transplantation Using Circular RNA ZMIZ1-Engineered Dendritic Cells
Kevin Vytlingam, Canada

P1.03.29 Inhibition of Innate Immune Allorecognition Using Nanobiologics Effectively Reverses Ongoing Allograft Rejection
Megan Stasik, USA

P1.03.30 Targeting Porcine Liver Endothelium with Lipid Nanoparticles to Improve Xenograft Survival
Jing Liu, USA

P1.03.31 IL-10+CD19+CD5hiCD1dhi Regulatory B Cells Facilitate to Lung Allograft Acceptance
Zhongcheng Mei, USA

P1.03.32 Defining Optimal Cryoprotectant Agent Conditions for Cryopreservation of Regulatory T Cells for Tolerogenic Cell Therapy in Transplant Recipients
Sarjana Alam, Canada

P1.03.33 Defensive Tolerance Drives the Reprogramming and Dysfunction of Infiltrating Pathogenic B Cells Resulting in the Promotion of Tolerance
Koki Hayashi, USA

P1.03.34 Selective Enrichment and Functional Preservation of Treg Cells during IL-2 Mutein-Mediated Expansion and Contraction
Jean Kwun, USA

P1.03.35 The Low-Intensity Conditioning Regimen with Fludarabine Achieved Mixed Chimerism and Minimization of Immunosuppression without Cytokine Release Syndrome
Tatsuo Kawai, USA

P1.03.39 Macrophage-Derived C1q Induces Exhaustion of Graft-Infiltrating CD8+ T Cells and Promotes Renal Allograft Tolerance in Murine Models
Jifu Ge, China

P1.03.41 Using Donor-Specific CAR Regulatory T-Cells to Promote Heart Allograft Tolerance in NHPs
Jane O, USA

P1.03.42 The Dual Nature of Acute Rejection in Human Kidney Allografts
Zahraa Khan, USA

P1.03.43 Human CD4+CD25+CD127lo Treg Have Enhanced Expression of IL-12Rb1 Upon Activation with Alloantigen and rIL-2
Nirupama Verma, Australia

P1.03.44 T Regulatory Cell Phenotypes in Renal Transplant Patients with Long Surviving Graft: Increased Th2-Like Treg and Reduced Th1- and Th17-Like Treg
Bruce M. Hall, Australia

P1.03.46 Expression of T Regulatory Cell Effector Molecules, CD39, HLA-DR and PD-1 in Renal Transplant Patients with Long Surviving Graft, Not Different to Healthy Volunteers
Bruce M. Hall, Australia

P1.03.47 Deciphering Thymic Tolerance in Vascularized Bone Marrow Transplantation: The Role of B Cells
Cheng-Hung Lin, Taiwan

P1.03.48 Neuropilin 2 Expression Pattern on Murine CD4+ T Cell Subsets
Johannes Wedel, USA

P1.03.49 Characterizing the Relationship Between T Cell of Operational Tolerance (TOT) Cells and Regulatory T Cells (Tregs) in Pediatric Solid Organ Transplantation
Wenming Zhang, USA

P1.03.50 Changes in Immune Cell Markers: A Cross-Sectional Analysis of the Elderly Wait-Listed and Kidney Transplant Recipients
Lavanya Kodali, USA

P1.03.51 Differential Transcriptomic Profiles of A2.CAR-Tregs in Recipients with Rejecting versus Accepting Allogeneic Heart Allografts
Jong Cheol Jeong, USA

P1.03.54 Prediction Power of CIITA RNA Editing in Kidney Transplantation Outcomes
Daniel Marconi Mendes, USA

P1.03.56 Spatial Proteomic Profiling of Recurrent FSGS Using Next Generation MICS Technology
Giuseppe Castellano, Italy

Poster Listing

P1.03.57 Metabolic Dysregulation-Driven Expansion of Centrilobular Hepatocytes via Proinflammatory and Fibrotic Pathways
Ali Rajabi Abhari, USA

P1.03.58 Integration of scRNAseq Analyses of Kidney and Liver Allograft Rejection Enables Identification of Common and Unique Characteristics
John Caldwell, USA

P1.03.59 Integrative CyTOF and Olink Analysis of Pediatric Transplant Recipients Identifies an NK Cell Subset Associated with Graft Rejection
Wenming Zhang, USA

P1.03.61 HLA-I Antibody Promotes Endothelial-to-Mesenchymal Transition in Primary Human Endothelial Cells
Masaaki Hirata, USA

P1.03.63 Rejuvenating Aged Liver Regenerative Capacity in Age-Mismatched Transplantation: A Target That Reshapes Hepatocyte Plasticity
Chenhao Jiang, China

P1.03.65 Endothelial Cell Expression of TCR Ligands is Necessary for Optimal Trans-Endothelial Migration of Primed CD8 T Cells into Allografts
Austin Schenk, USA

P1.03.66 Heterogeneity in Activation and Immunomodulatory Responses in Heart, Kidney and Lung Endothelial Cells
Suchita Jadhav, USA

P1.03.67 Thermal Rejection Assessment: New Strategies for Early Detection
Eline Herman, USA

P1.03.68 Age and Liver Transplantation: A Key Factor in Clinical Outcomes?
Gabriel Eduardo Gondolesi, USA

P1.03.69 CD43 1B11+ CD8+ T Cells Undergo Progressive Differentiation from Potent Effectors into Memory
Scott Krummey, USA

P1.03.70 Dual TCR T Cells in the Acute Rejection Heterotopic Transplant Model
Michael Lee, USA

P1.03.71 Mapping Class I Allele Specific Alloreactive CD8 T Cell
Fernanda Marconi Roversi, USA

P1.03.72 Marchf1 Ablation in Dendritic Cells Reduces Alloimmunity and Promotes Long-Term Graft Survival
Karina Lima, USA

P1.03.73 Transcriptional Reprogramming of ILC2s Drives MHCII Pathway Upregulation and Immune Modulation in Allograft Microenvironment
Jifu Ge, China

P1.03.74 Interleukin-27 Regulates B and T Cell Responses in Transplantation and Shapes Donor-Specific Alloantibody Production
José Valenzuela, USA

P1.03.75 Stepwise Models Identify Risk of Kidney Allograft Failure Associated with HLA Amino Acid Mismatches Among Adult FSGS Recipients
Keith McCullough, USA

P1.03.76 Donor-Specific Hypo-Responsiveness Occurs in Kidney Transplant Recipients During the First Year Post-Transplantation
Keisuke Maeda, Japan

P1.03.77 Unconventional Pairing: Evidence for Functional HLA-DRα:DQβ Cross-Heterodimers in Antigen Presentation
Connor Lantz, USA

P1.03.78 Insights into Heterologous Immunity: ELISpot Analysis of Diverse Mouse Stimulator-Responder Strain Combinations
Jacob Ingber, USA

P1.03.79 Expression of CD40 on Monocytes and Lymphocytes in Kidney Transplant Patients
Eduardo Chuluyan, Argentina

P1.03.80 Mutein IL-2 Attenuates Antigen-Mediated Rejection in Murine Kidney Transplant Model
Yoshikazu Ganchiku, USA

P1.03.81 TNFRSF13B Polymorphisms Impact Antibody Quality Determining Allograft Immunopathogenesis
Marilia Cascalho, USA

P1.03.82 Marchf1 Deficiency Attenuates Antibody-Mediated Rejection by Modulating B Cell Responses
Minxue Liao, USA

P1.03.85 Age and Sex Are Critical in Driving Humoral Alloimmune Response
Friederike Martin, USA

P1.03.86 Identification of Neuropilin 2 on a B Cell Subset with a Regulatory Phenotype
Nicolas Sailliet, USA

P1.03.89 Cellular Basis of Anti-HLA Antibody Rebound and Rejection in Kidney Transplant Patients Desensitized with Imlifidase
Laura Donadeu Casassas, Spain

P1.03.90 Human Long-Lived Plasma Cells Acquire Resistance to Proteasome Inhibitor-Based Desensitization Treatment by Upregulating Autophagy
Ashley Burg, USA

P1.03.92 A Novel Strategy for Glycocalyx-Recovery in Lungs After Warm Ischemic Injury during Ex Vivo Lung Perfusion Improves Graft Quality in Rats
Kentaro Noda, USA

P1.03.94 A Three-Dimensional Bioartificial Platform to Study the Immune Response in Kidney Transplant Patients
Kevin Matamoros Alcivar, USA

P1.03.95 Genome-Wide CRISPR Screening Identifies FNDC7 and CYP3A7 as Novel Therapeutic Targets for Reducing Liver Fat Accumulation
Murat Dogan, USA

P1.03.96 Rapid Hepatic Defatting for Transplant by Knocking Down tPA Using Lipid Nanoparticles
Katherine Badior, USA

P1.03.98 Study of Siplizumab Induction: Effect of an Anti-CD2 mAb on T-Cell Subsets in Kidney Transplant Recipients
Jesse Scott, USA

P1.04
Topic: Heart

P1.03.1 An Immortalized Renal Proximal Tubule Epithelial Cellular Model Overexpressing Organic Anion Transporters 1 & 3 for Characterizing the Cellular Uptake and Intrinsic Clearance Interactions Involving Mycophenolic Acid
Tony Kiang, Canada

P1.04.1 HLA-Antibody Class and Its Association with Clinical Outcomes in Sensitized Patients Awaiting Heart Transplantation
Yosef Manla, USA

P1.04.2 Should Steroid Free Heart Transplant Patients with Renal Insufficiency Be Candidates for CNI-Free Renal Sparing Protocols?
David Chang, USA

P1.04.3 Single Center Clinical Outcomes Following Implementation of New Safety Net Policies for Kidney After Heart Allocation
James Zhang, USA

P1.04.4 Kidney Function during the First Year After Heart Transplantation in Recipients on Tacrolimus-Based Immunosuppression: A Retrospective Analysis of the CTOT-11 Trial
Lilian Lipovetsky, USA

P1.04.5 Elevated Donor Derived Cell Free DNA in Heart Transplants After 5 Years: An Early Warning or False Alarm?
Juka Kim, USA

P1.04.6 Daratumumab for Desensitization or Antibody-Mediated Rejection in Heart and Kidney Transplantation
Taylor Sprague, USA

P1.04.7 Donor-Derived Cell-Free DNA and Heart Transplant Outcomes with Different Combinations of HLA1 and HLA2 Donor Specific Antibodies
Amit Alam, USA

P1.04.8 Is There Benefit of ATG Induction for Patients with Mild Kidney Dysfunction Undergoing Heart Transplantation?
Mason Lee, USA

P1.04.9 The Clinical Impact of Early vs Late De Novo DSA After Heart Transplantation: Does Timing of Detection Matter?
Avani Kanungo, USA

Poster Listing

P1.04.10 Off-Label Use of Belatacept for Renal Sparing in Heart Transplant
Konstantinos Sideris, USA

P1.04.11 Quantifying HLA Expression on Heart Allografts Using Imaging Mass Cytometry
Vincent Lam, USA

P1.04.12 Outcomes Associated with De Novo DSA Development in Heart Transplant Recipients with High-Risk HLA-DQ Heterodimer Mismatch
Melina Valdo Giugni, USA

P1.04.13 The Clinical Outcome of Antibody Mediated Rejection 1H in the First Year After Transplant and Its Subsequent Meaning
Peter Deckerman, USA

P1.04.14 High MELD-XI Can Predict Worse Kidney Graft Outcomes in Simultaneous Heart Kidney Transplantation
Kenji Okumura, USA

P1.04.15 Implications of Updated eGFR on Simultaneous Heart-Kidney Transplant Eligibility and Clinical Outcomes
Colin Stomberski, USA

P1.04.16 The Impact of Pre-Formed vs De Novo Donor-Specific Antibodies on Heart Transplant Outcomes
Shira Okhovat, USA

P1.04.17 BEWARE: Renal-Sparing Protocol After Heart Transplantation May Result in Significant Morbidities
Angela Velleca, USA

P1.04.19 The Molecular Microscope Machine Learning Classifiers Under-Diagnose TCMR and Over-Diagnose ABMR Compared to the International Society of Heart Transplantation (ISHLT) Criteria
Parmjeet Randhawa, USA

P1.04.20 Effect of Induction Choice on Renal Function in Heart Transplantation
Kaitlyn Legg, USA

P1.04.21 Variables Associated with HLA A, B, and DR Mismatch in Heart Transplantation
Melina De Oliveira Valdo Giugni, USA

P1.04.22 Impact of Donor and Recipient Characteristics on Post-Transplant ImmuKnow and AlloMap Following Heart Transplantation
Paramvir Singh, USA

P1.04.23 Molecular Diagnostic Classification of Heart Allograft Rejection: A Calibrated and Validated System
Alessia Giarraputo, France

P1.04.24 Avoiding Unnecessary Biopsies with Stable ImmuKnow Following Heart Transplantation
Mohamed Moussa, USA

P1.04.25 Divergent Early Immune Trajectories in Dual-Organ Heart Transplantation: Insights from ImmuKnow Monitoring
Mittal Rana, USA

P1.04.26 Rejection without Graft Injury? Biopsy-Negative Rejection in the Modern Era of dd-cfDNA and MMDx
Amarat Kongsompong, USA

P1.05
Topic: Infectious Disease

P1.05.1 Renal Transplant Outcomes with Dual-Infected HCV and HBV Viremic Donor Kidneys; the Hines VA Experience
Annie Przybylski, USA

P1.05.2 Impact of Active Hepatitis C Virus Infection on Post-Liver Transplantation Outcomes in the Direct-Acting Antiviral Era
Yash Shah, USA

P1.05.3 Secondary Syphilis Presenting as Fulminant Hepatic Failure, a Case Report and Literature Review
Ignacio Gondolesi, Argentina

P1.05.4 The Role of Screening and Prophylaxis for Vancomycin-Resistant Enterococcus Prior to Liver Transplant
Lea Matsuoka, USA

P1.05.5 Global Survey of Tuberculosis Infection Screening and Management Practices in Liver Transplantation
Samantha Jacobs, USA

P1.05.6 Nontuberculous Mycobacteria Disease in Solid Organ Transplant Recipients and the General Population
Seyed M. Hosseini-Moghaddam, Canada

Poster Listing

P1.05.7 Mycobacterium Bovis Infection Following Intravesical BCG Administration in Solid Organ Transplant Recipients
Holenarasipur Vikram, USA

P1.05.8 Outcomes of Early vs. Late Clostridioides difficile Infection in Solid Organ Transplant Recipients
Stanley Otiwu, USA

P1.05.9 Evaluation of Bedaquiline in Treatment of Nontuberculous Mycobacterial Infections in Transplant Patients
Julie England, USA

P1.05.10 Early Onset Bacteremia in Deceased Donor Kidney Transplant Recipients at a Large Volume Transplant Center: Characteristics and Risk Factors
Lana Hasan, USA

P1.05.11 Incidence Rate of Catheter-Related Bloodstream Infection (CRBSI) Post Solid Organ Transplant: A Single Center Experience
Kassem Safa, USA

P1.05.12 The Impact of Exercise Habits on Clinical Infections After Kidney Transplantation
Hiroki Kurata, Japan

P1.05.13 Omadacycline for the Treatment of Non-Tuberculous Mycobacterial Infection in Solid Organ Transplant Recipients
Stella Radosta, USA

P1.05.14 A Persistent Threat: The Burden of Pseudomonas aeruginosa Left Ventricular Assist Device Infections
Pedro Diaz Jr., USA

P1.05.15 Prevalence of Latent Tuberculosis Infection Among End-Stage Kidney Disease in a High Tuberculosis Burden Country
Yingyos Avihingsanon, Thailand

P1.05.16 Timing and Distribution of Blood Stream Infections in Solid Organ Transplant Recipients: A Retrospective Cohort Study
German Contreras, USA

P1.05.17 The Clinical Burden of Pseudomonas aeruginosa Urinary Tract Infections in Kidney Transplant Recipients
Shilpa Gopinath, USA

P1.05.18 Losing an Effective Tool in the Fight Against Clostridioides difficile: Bezlotoxumab Improves Outcomes in Transplant Recipients
Moosa Malik, USA

P1.05.19 Gram Negative Antibiotic Resistance in the Deceased Donor Setting
Anthony Montedonico, USA

P1.05.20 One-Year Infection Outcomes in Simultaneous Pancreas-Kidney vs. Kidney Transplantation: A Multi-Center Study
Benjamin Wick, USA

P1.05.22 Mycobacterium Tuberculosis Infection in Kidney Transplant: Outcomes
Ada Chavez, Guatemala

P1.05.23 Plasma Metagenomic Sequencing to Diagnose Infections Among Solid Organ Transplant Recipients
Natasha Spottiswoode, USA

P1.05.25 Infectious Outcomes in Kidney Transplant Recipients After Ureteral Stent Removal
Anne Przybylski, USA

P1.05.26 A Deadly Intruder: The Impact of Pseudomonas aeruginosa Infections on Left Ventricular Assist Device Outcomes
Pedro Diaz Jr., USA

P1.05.27 Clostridioides difficile Infection Management Optimization in Solid Organ Transplant Recipients
Hannah Reynolds, USA

P1.05.28 Outcomes of Vancomycin-Resistant Enterococcus Infections in Liver Transplant Recipients
Jessica Ferguson Toll, USA

P1.05.29 Microbial Cell-Free DNA Sequencing Diagnostics: A Critical Tool for Advancing Xenotransplantation Safety and Infection Monitoring
Sivan Bercovici, USA

P1.05.30 Indeterminate Coccidioidomycosis Stat Serology Results in the Deceased Donor Population
Sara Dionne, USA

P1.05.31 Donor-Derived Mucormycosis in a Liver Transplant Recipient Diagnosed by Microbial Cell Free DNA: A Case Report
Kelly Daus, USA

P1.05.32 Impact of Induction Therapy on Infectious Complications in Simultaneous Liver-Kidney Transplant Recipients
Abigail Servais, USA

P1.05.33 Metamycoplasma hominis: An Underrecognized Donor Derived Infection
Melissa Colaluca, USA

P1.05.34 Identifying Infectious Disease Challenges to Organ Donation: Insights from Donate Life Clinicians
Shanti Narayanasamy, Australia

P1.05.35 Donor and Recipient Microbiological Profiles in Lung Transplant
Kevin He, USA

P1.05.36 Pre-Transplant Infections and Post-Transplant Outcomes: A Prospective Cohort Study of Liver Transplant Recipients
Stephanie Perrodin, Switzerland

P1.05.37 Non-Tuberculous Mycobacteria Colonization and Infection Post Lung Transplantation: Risk Factors and Outcomes
Christopher Lopez, USA

P1.05.39 Effect of Donor Blood Stream Infections on Post Liver Transplant Infections and Outcomes
Vijay Subramanian, USA

P1.05.40 Non-Tuberculous Mycobacterium Colonization: A Contraindication for Lung Transplantation?
Christopher Lopez, USA

P1.05.41 Contamination of Preservation Solution in Renal Transplantation and Infection Transmitted to the Recipient
Maria Pia Glorioso, Argentina

P1.05.42 Glycemic Control in Thoracic Recipients of Hepatitis C Nucleic Acid Testing-Positive (HCV NAT+) Donor Organs
Shana Katz, USA

P1.05.43 Clinical Utility of the BioFire Pneumonia Panel in the Diagnosis and Treatment of Pneumonia Among Solid Organ Transplant Patients
Ryan Chapman, USA

P1.05.44 Donor-Derived Infections and Hyperammonemia Syndrome: Diagnosis in Two Non-Lung Transplant Recipients via Next Generation Sequencing
Christopher Lopez, USA

P1.05.45 Ureterovesical Anastomotic Techniques in Kidney Transplantation: A Comparative Study of Urologic Complications—Intravesical Politano-Leadbetter versus Extravesical Lich-Gregoir
Javier Sanchez Maldonado, Mexico

P1.07
Topic: Kidney

P1.07.1 Standard Kidney Biopsy Results and Impacts on Organ Use
Thomas Dolan, USA

P1.07.2 The Deceased Transplant Recipients Organs: A Solution to Organ Shortage
Dai Nghiem, USA

P1.07.3 Long Term Graft Survival and Rejection Rate of Zero-Human Leukocyte-Leukocyte-Antigen-Mismatched Deceased Donor Kidney Transplant Recipients: A Retrospective Multicentric Cohort Study
Jun Young Lee, Korea

P1.07.4 HLA DR Mismatching is of Limited Utility and is Biased Against Minority Candidates in the Current Kidney Allocation System
Douglas Keith, USA

P1.07.5 Dialysis Exposure Prior to Transplant Based on Dialysis Status at Listing. Should Preemptively Listed Kidney Transplant Candidates Receive Waiting Time Points Prior to Dialysis?
Douglas Keith, USA

P1.07.6 Improving Access to Minorities with A2 to B Kidney Transplantation: A Systematic Review and Meta-Analysis
Patricia Viana, Brazil

Poster Listing

P1.07.7 The Impact of Backdating Waiting Time to Start of Dialysis on Ultimate Outcome of Adult Kidney-Alone Candidates on the Waiting List: Altering the Balance of Competing Risks
Douglas Keith, USA

P1.07.8 Modeling the Effects of DonorNet Attachment Availability on Organ Offer Decision
Marcus Thoreson, USA

P1.07.9 How Are Donor Kidneys Distributed in the Kidney Allocation System: Analysis of Donor Distribution Based on Priority Groups and KDPI Lanes
Douglas Keith, USA

P1.07.10 AI-Enabled Approach to Understand the Impact of Deceased Donor Characteristics on Kidney Disposition
Lirim Ashiku, USA

P1.07.11 A 20-Year Single Center Experience with Zero HLA-Mismatch Deceased Donor Kidney Transplants: Time for Policy Change
Arianna Cabrales, USA

P1.07.12 Urinary Biomarkers and Warm Ischemia in Circulatory Death Donors
Chirag Parikh, USA

P1.07.13 Understanding the Relationship Between Donor Diabetes Insipidus, Kidney Donor Profile Index (KDPI), and Recipient Kidney Function
Lucia Calthorpe, USA

P1.07.14 Trends and Outcomes in Kidney Re-Transplantation: A Two Decades Longitudinal Analysis
Reza Saidi, USA

P1.07.15 Dual Kidney Transplantation from Extended Marginal Donors in the USA: An Analysis of SRTR and Literature Review
Reza Saidi, USA

P1.07.16 The Impact of Non-Protocolized Language in Donor Narratives on Kidney Acceptance: A Machine Learning-Aided Analysis
Ritah Chumdermpadetsuk, USA

P1.07.17 Insights from Refusal Patterns for Deceased Donor Kidney Offers
Grace Guan, USA

P1.07.18 Dynamic Predictions for Assessing Hard-to-Place Deceased Donor Kidneys>
Grace Guan, USA

P1.07.19 Risk Stratification of Chronic Kidney Allograft Failure in Donor-Recipient (D-R) Pairs
Agnieszka Swiatecka-Urban, USA

P1.07.21 Expanding the Donor Pool without Compromising Outcomes: A Single Center Experience with Out-of-Sequence Kidney Allocation
Hafiz Umair Siddiqui, USA

P1.07.22 Chartering Kidneys for Transplant - Economic Impact and Recipient Outcomes
James Stathakios, USA

P1.07.23 Is It Time to Remove HLA Mismatching from the Kidney Allocation System? Analysis of Duration of Dialysis and HLA Mismatching on Patient and Graft Outcomes in the USA
Douglas Keith, USA

P1.07.24 Avoiding Closed Referrals for Stability and Family Decline through Efficient Rapid and Expedited Organ Processes While Maximizing Organs Transplanted
Sherry Quire, USA

P1.07.26 Successful Kidney Transplantation without Prospective Crossmatch in Recipients at Low Immunological Risk: A Retrospective Cohort Study
Simon Pans, Belgium

P1.07.27 Association of Neighborhood Socioeconomic Status and Access to Deceased Donor Kidney Transplantation Among US Transplant Candidates
Olivia Christensen, USA

P1.07.28 Transplant of Serologic A1 but Genotype A2 Kidneys to ABO O and B Recipients is Feasible and Safe
Nassir Thalji, USA

P1.07.30 Optimizing Kidney Allograft Survival Years: Underutilization of Pediatric Donors
Nicholas Herrera, USA

P1.07.31 Availability of HLA-Matched Donors for Every Transplant Candidate in a 250-Nautical Mile Concentric Circle Allocation System
Dulat Bekbolsynov, USA

Poster Listing

P1.07.32 Switching from Anti-A1 to Anti-A2 Titers for ABO Incompatible Kidney Transplant: Is It Worth the Lift?
Sanjiv Anand, USA

P1.07.33 Integrating Surgeon Expertise and AI: The Transplant Surgeon Fuzzy Associative Memory Model for Enhanced Kidney Transplant Decision-Making
Rachel Dzieran, USA

P1.07.34 Influence of an Expedited Algorithm for Placement of Kidney Allografts with a Kidney Donor Profile Index (KDPI) >50%
Luke Shen, USA

P1.07.35 Contemporary Logistical and Clinical Drivers of Kidney Non-Use: From the Allocation Journey Perspective
Carlos Martinez, USA

P1.07.36 Understanding the Impact of Risk Tolerance in Open-Offer Kidney Acceptance
Yili Wang, USA

P1.07.37 Military Share Deceased Donor Initiated Chains
Michael Rees, USA

P1.07.38 Applying the 6-Month Offer Filters Refresh Retrospectively
Carlos Martinez, USA

P1.07.39 Timing of Biopsies during Deceased Donor Kidney Allocation
Carlos Martinez, USA

P1.07.40 Optimizing Kidney Utilization in the Era of Increasing Donor Complexity: Impact of a Targeted OPO QAPI Initiative
Woodlhey Ambroise, USA

P1.07.41 High Rates of Functioning Grafts at Death in Elderly Kidney Transplant Recipients: Implications for Resource Allocation in the Setting of Organ Shortage
Hannah Gilligan, USA

P1.07.42 Clinical Utility of KDPI Models After Race and HCV Removal: A Decision Curve Analysis
William Parker, USA

P1.07.43 Stratification of Risk for DSA Positive/Flow Cytometry Crossmatch Negative Deceased Donor Kidney Transplantation: A Single-Centre UK Experience
Fatima Malik, UK

P1.07.44 Enhancing Kidney Biopsy Accuracy and Organ Placement with On-Site and Telepathology Reads
Woodlhey Ambroise, USA

P1.07.45 Balancing Risks and Benefits: Outcomes of Simultaneous Pancreas-Kidney vs. Kidney-Only Transplantation
Pooja Budhiraja, USA

P1.07.46 Evaluating Potential Gender Bias in Kidney Discard Prediction Leveraging the Deceased Donor Allocation Model
Cihan Dagli, USA

P1.07.47 Kidney Transplant Allograft Outcomes in Incarcerated End Stage Renal Disease Patients
Rungwasee Rattanavich, USA

P1.07.48 Assessment of Potential Bias in Kidney Transplant Acceptance Decision Using the Deceased Donor-Recipient Attributes Matching AI Model
Cihan Dagli, USA

P1.07.49 Profound Temporal Changes in Deceased Kidney Donors over the Last 25 Years in the USA: The Necessity of Doing More with Less Quality
Douglas Keith, USA

P1.07.50 The Impact of Donation After Circulatory Death (DCD) Donation on Kidney Allograft Survival is Influenced by Donor Race: An UNOS Registry Analysis
Afolarin Otunla, UK

P1.07.51 Enhancing Organ Allocation Efficiency: A Pilot Study Evaluating Artificial Intelligence-Assisted Assessment of Donor Kidney Pathology
Jeffrey Campsen, USA

P1.07.52 Machine Perfusion Improves Outcomes of Kidneys with Long Cold Ischemic Time in Combined Heart-Kidney Transplantation
Justin Steggerda, USA

P1.07.53 Kidney Transplantation from Hepatitis C Viremic Donors and the Impact of Donor Liver Fibrosis - A Case Series
Sana Shaikh, USA

P1.07.54 Outcomes of High KDPI Kidneys in DCD vs. DBD Transplants: A Single-Center Analysis
Isabella Faria, USA

Poster Listing

P1.07.55 Can Donors After Cardiac Death Eliminate the Deficit Between Listings and Kidney Transplants? An Analysis of DCD Donations Based on OPOs in USA
Douglas Keith, USA

P1.07.56 How Many Potential Candidates Are There for Clinical Kidney Xenotransplantation in Japan?
Naoya Iwahara, Japan

P1.07.57 Racial and Ethnic Make-Up of Donors After Cardiac Death: Is More Public Education Needed?
Douglas Keith, USA

P1.07.58 Transplantation of Hepatitis B Surface Antigen Positive or Viremic Kidneys: A Systematic Review and Meta-Analysis
Yvonne EL Kassis, USA

P1.07.59 Experience with 117 Donation After Circulatory Death Expanded Criteria Donor Kidney Transplants: Does the Presence of Delayed Graft Function Make a Difference?
Christopher Webb, USA

P1.07.60 What Can We Learn from Analyzing Paired Mate Kidneys Transplanted Sequentially at the Same Center?
Arianna Cabrales, USA

P1.07.61 The Correlation of Total and Functional Warm Ischemic Time of Donation After Circulatory Death Donors with Transplant Kidney Graft Survival
Olivia Ong, USA

P1.07.62 Missed Opportunities in Kidney Transplantation: Time to Rethink Acceptance Practices
Zoe Lu, USA

P1.07.63 Expanding Transplant Opportunities: Rethinking the Role of Offer Biopsy in Kidney Selection
Zoe Lu, USA

P1.07.64 Toward Better Organ Utilization: Identifying Missed Opportunities in Kidney Transplantation
Zoe Lu, USA

P1.07.65 Expanding the Donor Pool; Utilization of Kidneys from Donors with Lupus Nephritis - Case Report and Review of Literature
Yasir Qazi, USA

P1.07.66 How Much Does Willingness to Accept High Kidney Donor Profile Index Kidneys Differ Across Transplant Centers?
Jonathan Miller, USA

P1.07.67 Abdominal Normothermic Regional Perfusion Kidney Transplant Early Outcomes Are Comparable to Brain Dead Donor Kidneys Despite Higher Kidney Donor Risk Index
Motaz Selim, USA

P1.07.68 Optimizing Donor Kidney Utilization: Integrating Histopathology and Clinical Factors to Enhance Transplant Outcomes
Yu Cui, China

P1.07.69 Short-Term Kidney Graft Outcomes from Medically Complex Donors: A Single Center Analysis
Raga Dilip, USA

P1.07.70 Love the One You're With? Outcomes of Kidney Transplant Recipients with Persistent Creatinine Above 2.5mg/dL
Jennifer Motter, USA

P1.07.71 Impact of the Deceased Donor's Risk Profile on Recipient and Kidney Survival: A Single-Centre Study
Alberto D'Annunzio, Italy

P1.07.72 Profiles of Non-Used Kidneys and Their Expected Potential Survival
Samantha Weiss, USA

P1.07.73 Short-Term Kidney Graft Outcomes from Donors with Liver Cirrhosis with Stratification by MELD Score
Raga Dilip, USA

P1.07.74 Trends in Discarded Kidneys from Hepatitis C Viremic Donors in the USA, 2020-2023
Tarek Alhamad, USA

P1.07.75 Are Procurement Biopsies Enough? Evaluating Concordance with Time-Zero Reperfusion Biopsies
Tatsuma Yanagimoto, USA

P1.07.76 Scope of Organ Donation from Neonates and Infants: A Review of Five-Year Mortality in a Neonatal Intensive Care Unit (NICU) at the Women and Children Hospital, Corniche, Abu Dhabi, UAE
Salwa Alremeithi, United Arab Emirates

Poster Listing

P1.07.77 Outcomes of High Kidney Donor Profile Index Hepatitis C Nucleic Acid Testing Positive Kidneys Are Equivalent to Matched Hepatitis C Nucleic Acid Testing Negative Kidneys
Shengliang He, USA

P1.07.78 From Discard to Transplant: Are Grafts with Stage 3 Acute Kidney Injury Viable?
Maria Pia Glorioso, Argentina

P1.07.79 Survival Benefit of Deceased Donor Kidney Transplantation Versus Ongoing Dialysis in Transplant-Eligible Kidney Disease Patients Aged 70 Years or Older: A Target Trial Emulation Study
Napat Leeaphorn, USA

P1.07.80 Outcomes After Kidney Transplantation from Cyanide-Poisoned Donors
Cheol Woong Jung, South Korea

P1.07.81 Outcomes of Kidney Grafts from Older Donors with AKI That Were Declined - A Single Center Analysis
Raga Dilip, USA

P1.07.82 Evaluating Machine Perfusion (Pump) in Deceased Donor Kidneys: A Study of Transplanted and Discarded Kidneys from the Same Donor
Samy Riad, USA

P1.07.83 The Prognostic Role and Limitations of Donor Kidney Remuzzi Score in Adult Kidney Transplant Recipients
Yuchen Wang, China

P1.07.84 Scope of Deceased Kidney Donation from Children: A Review of One-Year Mortality in the Pediatric Intensive Care Unit at Sheikh Khalifa Medical City, Abu Dhabi, UAE
Jessica Sim, USA

P1.07.85 Comparison of the Predictive Power of Delayed Graft Function According to Korea Network for Organ Sharing Expanded Donor Criteria and United Network for Organ Sharing Criteria in Kidney Transplantation
Seung Hwan Song, South Korea

P1.07.87 Correlation Between Kidney Donor Profile Index (KDPI) and Post-Transplant Graft Survival Rate
Rabar Mudhher, USA

P1.07.88 Operative Donor Warm Ischemia Time is Associated with Inferior Graft Survival After Circulatory Death Kidney Transplantation
Yuki Bekki, USA

P1.07.89 One-Year Outcome of HMP(O2)-Perfused Kidneys After the Implementation of a National Machine Perfusion Service
Laurent Weekers, Belgium

P1.07.90 Donor Factors Predicting Allograft Loss and Function in Deceased-Donor Kidney Transplant Recipients
Anu Murthy, USA

P1.07.91 Patient Survival After Kidney Transplantation: Impact Frailty Evaluation with SPPB (Short Physical Performance Battery) and Grip Strength in Patients over 65 Years
Denise Simao, Brazil

P1.07.92 Pumping Resistance vs. Donor Factors: What Truly Determines Renal Allograft Success?
Mason Henrich, USA

P1.07.93 Donor Type and Renal Function: Critical Determinants of Physical Quality of Life After Kidney Transplantation
Peter Gullickson, USA

P1.07.94 Evolving Practices in Deceased Donor Kidney Procurement Biopsies: Trends, Clinical Correlations, and Organ Utilization in a Cohort Study
Krista Lentine, USA

P1.07.95 Beyond KDPI: The Role of Biopsy in Kidney Graft Selection
Jimena Alaniz, USA

P1.07.96 Evaluating the Impact of Extended Ischemia Time in Biopsied High KDPI Kidney Grafts
Jimena Alaniz, USA

P1.07.98 Outcomes of Robotic-Assisted Radical Prostatectomy (RARP) for Localized Prostate Cancer in Men with Chronic Kidney Disease Stages 4 or 5
Dylan Isaacson, USA

P1.07.99 Safety and Outcomes of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in Kidney Transplant Recipients
Dylan Isaacson, USA

Poster Listing

Sunday, August 3 3:30 PM - 4:30 PM

P1.07.100 Protocol Biopsies in Delayed Graft Function Kidney Transplants from Brain-Dead Donors
Amanda Ahlmark, Finland

P1.07.101 Superior Efficacy of Belatacept with mTOR Inhibitor vs Mycophenolate Mofetil: A Retrospective Study
Run Banlengchit, USA

P1.07.102 Association of Subclinical Kidney Transplant Rejection with 10-Year All Cause Graft Loss in a Multicenter Prospective Cohort
James Fleming, USA

P1.07.103 Protocol Biopsy Results Among Kidney Transplant Recipients on Belatacept with Everolimus vs Mycophenolate Mofetil
Run Banlengchit, USA

P1.07.104 Effect of LAG-3 Gene Polymorphism on Graft Rejection of Renal Transplantation
Yu Cui, China

P1.07.105 Co-Stimulatory Blockade Prevents Intragraft Accrual of Class-Switched, Activated B Cells and Th17 T Cells and Promotes Accrual of Tregs
John Caldwell, USA

P1.07.106 Safety of Late Steroid Withdrawal Post Kidney-Transplant
Vinay Nair, USA

P1.07.107 One-Year Kidney Function Outcomes in Kidney Transplant Recipients from Deceased Donors with COVID-19
Tarek Alhamad, USA

P1.07.108 Findings in Early Protocol Biopsies during Slow or Delayed Graft Function in Kidney Transplants from Donors After Circulatory Death
Ilkka Helantera, Finland

P1.07.112 Intimal Arteritis without Significant Tubulointerstitial Inflammation in Kidney Transplant Rejection
Michelle Keyser, USA

P1.07.114 Sulfamethoxazole-Trimethoprim-Associated Granulomatous Acute Interstitial Nephritis Causing Delayed Graft Function: A Case Report
Fangning Gu, USA

P1.07.115 False Elevation of Tacrolimus in Pediatric Kidney Transplantation
Emma Hills, USA

P1.07.116 Prevalence and Risk Factors of Frailty and Sarcopenia in Long-Term Kidney Transplant Survivors
Young Jin Yoo, South Korea

P1.07.117 Comparison of Post-Renal Transplant Ischemia Based on Pre-Transplant Revascularization
Khang Nguyen, USA

P1.07.118 Improving Value Delivery and Transplant Access by Incorporating Weight Loss Clinic in Transplant Clinical Workflow: A Pilot Study
Zubair Saeed Zafar, USA

P1.07.119 Practices in the Management of Kidney Transplant Candidates and Recipients with Obesity: A Survey of U.S. Transplant Programs
Kenneth Woodside, USA

P1.07.120 Novel Link Between Peri-Renal Fat Distribution and New Onset Diabetes After Kidney Transplant
William Butak, USA

P1.07.121 Do Pre-Transplant Labs and Medical History Predict New Onset Diabetes After Kidney Transplant?
Jacob Matthews, USA

P1.07.123 Largest, Five-Year Outcomes of Glucagon-Like Peptide-1 Receptor Agonists in Kidney Transplant Recipients a Retrospective Single-Center Study
Priyamvada Singh, USA

P1.07.124 Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real World Experience from a Single Center Study
Mary Ann Lim, USA

P1.07.125 Impact of Glucagon-Like Peptide-1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients
Stephanie Martin, USA

P1.07.126 Pulse Pressure: A More Relevant Risk Factor for Graft Outcomes in Deceased Donor Kidney Transplantation Than Living Donor Transplantation
Sun Duk Hwang, South Korea

P1.07.127 A Novel Multidisciplinary Approach for Longitudinal Cardiovascular Care of Patients with Kidney Disease
Mallika Gupta, USA

Poster Listing

P1.07.129 Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Proteinuria in Kidney Transplant Recipients
Stephanie Martin, USA

P1.07.130 Association of Antiplatelets with Cardiovascular Adverse Outcomes and Mortality in Kidney Transplant Recipients
Gavin Christy, USA

P1.07.131 Outcomes of Management of Transplant Renal Transplant Artery Pseudoaneurysm
Yazin Marie, UK

P1.07.132 Comparison of Warfarin and Direct Oral Anticoagulants in Kidney Transplant Recipients: Safety and Efficacy Outcomes
Sun Young Park, South Korea

P1.07.133 Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) for Weight Loss in Solid Organ Transplant (SOT): A Matched Control Study
Joseph Kahwaji, USA

P1.07.134 Prescribing Patterns and Impact of Glucagon-Like Peptide-1 Receptor Agonists Among Kidney Transplant Population in British Columbia, Canada
Hyunwoong Harry Chae, Canada

P1.07.135 Weight Gain After Kidney Transplantation: Incidence, Risk Factors, and Impact on Outcomes
Nihal Sadagah, Saudi Arabia

P1.07.137 Comparative Analysis of Six-Minute Walk Functional Performance and Traditional Pre-Operative Cardiac Testing in Kidney Transplant Candidates
Dhiren Kumar, USA

P1.07.138 Incidental Common Iliac Artery Pseudoaneurysm in a Deceased Donor Kidney Transplant Recipient
Raga Dilip, USA

P1.07.139 Patterns of Use of Antidiabetic Medications in Kidney Transplant Recipients
Sindhura Bobba, USA

P1.07.140 Post-Transplant Oxalate Burden and Renal Injury: Insights from Molecular and Histologic Analysis
Ambreen Azhar, USA

P1.07.141 Antithrombotic Agent Use at Time of Renal Transplant is Associated with Increased Blood Transfusions and Wound Infections
Derek Owen, USA

P1.07.142 Glucagon-Like Peptide-1 Receptor Analogs for Weight Loss in Advanced Chronic Kidney Disease Patients Waiting for a Kidney Transplant - A Nephrologist-Driven Approach
Priyamvada Singh, USA

P1.07.143 A Longitudinal, Retrospective, Descriptive Study of Post-Transplant Diabetes Mellitus in Adult Kidney Transplant Recipients: The MoPTDM Study
Mark Wakefield, USA

P1.07.144 The Influence of Hyperglycemia on the Immune Microenvironment of Mouse Allogeneic Kidney Grafts
Jifu Ge, China

P1.07.145 Association of Statins with Adverse Outcomes Following Kidney Transplantation
Andres Mata, USA

P1.07.146 Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Kidney Transplant Recipients with Chronic Kidney Disease with or without Diabetes
Goran Flajc, USA

P1.07.147 Predictors of High Post-Void Residual in Kidney Transplant Recipients: The Role of Diabetes Mellitus
Jiro Kimura, USA

P1.07.148 Risk Factors for Infections in Long-Term Surveillance of Kidney Transplant Patients: Insights from the KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)
Jung-Hwa Ryu, South Korea

P1.07.149 Combined Use of Empagliflozin and Liraglutide Protects Against Tacrolimus-Induced Pancreatic and Kidney Injury through Suppression of Oxidative Stress
Bioh Kim, South Korea

P1.07.151 Survival and Clinical Benefits of Kidney Transplantation in the Elderly with Kidney Failure
Jeeyoung Kim, South Korea

P1.07.152 Physician-Reported Impact of Kidney Transplantation on Patient Employment and Caregiving Needs: Results from a Real-World Survey
Lobat Hashemi, USA

P1.07.153 Segmental Bioelectrical Impedance Analysis Derived Measures of Body Composition Are Associated with Physical Frailty in Kidney Transplant Candidates
Danielle Kirkman, USA

Poster Listing

P1.07.154 Identifying High-Risk BMI Ranges Associated with Poor Kidney Transplant Outcomes in Veterans: A Retrospective Analysis
Lucy Hoard, USA

P1.07.156 Association of Pre-Transplant Echocardiographic Findings with Post-Transplant Kidney Allograft Outcomes and Cardiovascular Events
Anjana Murali, USA

P1.07.157 Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2is) in Kidney Transplant Recipients
Kristin Kreitler, USA

P1.07.158 Tirzepatide Safely Improves Obesity and Glycemic Control in Diabetic Kidney Transplant Recipients
Masayoshi Miura, Japan

P1.07.160 Cardiovascular Risks and Cognitive Recovery After Kidney Transplant
Nidhi Ghildayal, USA

P1.07.161 Hemoglobin A1c Target in Kidney Transplant Recipients with Type 2 Diabetes Mellitus
Sindhura Bobba, USA

P1.07.162 Association of Left Atrial Strain with Major Adverse Cardiovascular Events Following Kidney Transplantation
Ava DeLonais-Parker, USA

P1.07.163 Comparison of Outcomes Between Patients with Positive versus Negative Stress Echocardiography Before Renal Transplantation
Spencer Hobbs, USA

P1.07.165 Association of Pulmonary Hypertension with Major Adverse Cardiovascular Events Following Kidney Transplantation
Yanqing Lyu, USA

P1.07.166 Sex Differences in Combined Obesity and Diabetes Mellitus Risk Amongst Kidney Transplant Recipients
Roxaneh Zaminpeyma, Canada

P1.07.167 Immunosuppression and Cancer on Renal Transplant Recipients. New Drugs Impact on Evolution?
Maria del Carmen Rial, Argentina

P1.07.168 Bariatric Surgery vs. GLP-1 Receptor Agonists: Mortality Risk and Access to Kidney Transplantation
Babak Orandi, USA

P1.07.169 Starting an ACE Inhibitor or Angiotensin Receptor Blocker within Three-Months of Kidney Transplantation: Who Receives It and How Do They Fare?
Joseph Kim, Canada

P1.07.170 Association of Cytomegalovirus and New-Onset Diabetes After Kidney Transplantation
Sunil Karhadkar, USA

P1.07.171 Comparison of Outcomes Between Kidney Transplantation with Immunological High-Risk Living Donor versus Deceased Donor Transplantation
Natavudh Townamchai, Thailand

P1.07.172 Desensitization with Plasma Exchange, High-Dose IVIG, and Rituximab in XM-Positive Kidney Transplantation: ABO-Compatible vs. Incompatible Cases
Yoichi Kakuta, Japan

P1.07.173 Comparing Persistent vs. Resolved Donor-Specific Anti-HLA Antibodies and Their Impact on Antibody-Mediated Rejection and Transplant Outcomes: A 10-Year Tertiary Care Center Experience in Thailand
Natavudh Townamchai, Thailand

P1.07.174 Achieving Successful Kidney Transplantation in Highly Sensitized Patients through Tailored, Time-Indefinite Desensitization under Immune Surveillance
Kentaro Ide, Japan

P1.07.175 Current Status of ABO Incompatible Kidney Transplantation in Japan Based on Statistical Data of Renal Transplantation in Japan
Yuki Nakagawa, Japan

P1.07.176 Appropriate Risk Classification and Single-Dose Rituximab Can Help Prevent Antibody-Associated Rejection in ABO-Compatible Kidney Transplants
Miruzato Fukuda, Japan

P1.07.178 Dynamics of Preformed Donor-Specific Antibody in Thai Kidney Transplant Recipients
Nuttasith Larpparisuth, Thailand

P1.07.179 Impact of IVIG Desensitization in Kidney Transplant Recipients with Angiotensin II Type 1 Receptor Antibodies
Matthew Gillespie, USA

P1.07.180 Long-Term Outcomes of Cross-Match Positive Living Kidney Transplantation: A Retrospective Study
Daigo Okada, Japan

Poster Listing

P1.07.182 Daratumumab and Belatacept Dual Targeting Impacts on B-Cell Immunity in Highly Sensitized Patients
Laura Donadeu Casassas, Spain

P1.07.184 Pre-Transplant Tocilizumab Based Desensitization and Post-Kidney Transplant Outcomes
Irfan Moinuddin, USA

P1.07.185 Kidney Transplant in Sensitized Recipients: Graft Survival Based on Desensitization and DSA Type
Daniela Acosta, Uruguay

P1.07.186 Is Rituximab Useful or Harmful in Blood Group Incompatible (ABOi) Renal Transplantation?
Rolf Weimer, Germany

P1.07.187 Delayed CNI Induction in Donation After Circulation Death Kidney Transplantation Promotes Early Dialysis Withdrawal
Toyoshi Seito, Japan

P1.07.188 Induction-Free Belatacept-Based Immunosuppression in Kidney Transplantation - Early Outcomes
Payaswini Vasanth, USA

P1.07.189 Early versus Delayed Tacrolimus Administration: Implications for Kidney Transplant Outcomes with Thymoglobulin Induction
Woo Yeong Park, South Korea

P1.07.190 Differential Intra-Operative Peripheral Blood Gene Expression Dynamics in Delayed Graft Function during Kidney Transplantation: Revisiting S1P Receptor Signaling
Michael Kueht, USA

P1.07.191 Final Results of the Protection of Renal Function After Conversion of Fast IR-Tac Metabolizers to Envarsus Study (The Protect RENvarusus Study)
Gerold Thölking, Germany

P1.07.193 Early Substitution of Subcutaneous Abatacept for Belatacept to Minimize CNI Exposure After Kidney Transplantation
Idelberto Badell, USA

P1.07.194 Successful Positive Flow Crossmatch Kidney Transplantation with 2-Dose Eculizumab and Belatacept Based Desensitization
Kentaro Yoshikawa, USA

P1.07.195 Evolution of Belatacept Protocols for HLA Zero Mismatch Living Donor Kidney Transplantation: A 13-Yr Experience
Payaswini Vasanth, USA

P1.07.196 CT-Assisted Visceral Fat Area Measurement Outperforms BMI as a Predictor of Wound Complications in a Predominantly Hispanic and American Indian Post-Renal Transplant Population
Kelsea Carrier, USA

P1.07.197 Real-Time Intraoperative Evaluation of Ureteral Blood-Flow Using Indocyanine Green
Heisuke Iijima, Japan

P1.07.198 Deep Learning Model for Predicting Delayed Graft Function Using Pre-Implantation Kidney Images: Interim Results from the DeepGraft Project
Silvana Daher Costa, Brazil

P1.07.199 Kidney Transplantation Using Third-Party Vessel Conduits: Vascular and Allograft Outcomes
Wei Kelly Wu, USA

P1.07.200 Robot Assisted and Open Kidney Transplant Outcomes Are Comparable in Recipients with BMI Greater Than 35
Dylan Isaacson, USA

P1.07.201 Robotic Kidney Transplantation with Multiple Arteries: Safety and Efficacy in a Multicenter US Cohort
Katsunori Miyake, USA

P1.07.202 Innovative Surgical Synergy: Feasibility of Simultaneous Single-Port Donor Nephrectomy and Kidney Transplantation
Hafiz Umair Siddiqui, USA

P1.07.203 Anesthetic Challenges in Single-Port versus Multi-Port Robotic Kidney Transplant
Hafiz Umair Siddiqui, USA

P1.07.204 Robotic Assisted Deceased Donor Kidney Transplantation Improves 30-Day Readmission Rates and Post-Operative Analgesic Requirements Compared to Open Approach
Kassandra Zaila Ardines, USA

P1.07.205 Incidence and Predictive Factors of Incisional Hernia After Robotic Living Donor Nephrectomy: A 7-Year Retrospective Cohort Analysis
Michael McCabe, USA

Poster Listing

Sunday, August 3 3:30 PM - 4:30 PM

P1.07.206 Precision Cooling in Robotic Kidney Transplantation: A Benchtop Model for Intraoperative Organ Protection
Keith Hansen, USA

P1.07.209 Importance of Data Granularity in Using eGFR Slope as a Surrogate for DCGF
Vikas Sridhar, Canada

P1.07.210 Obesity as a Predictor After Kidney Transplantation Outcomes in South Korea: A Propensity Score Weighted Analysis
Hye Jin Chong, South Korea

P1.07.211 Impact of HLA Mismatch on the Incidence of BK Viremia After Kidney Transplantation
Srilekha Sridhara, USA

P1.07.212 Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide 1 Agonist in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis
Rucháma Verhoeff, USA

P1.07.213 Impact of Fractures on Death, Graft Loss and Acute Decompensated Heart Failure After Kidney Transplantation
Yuki Shimamoto, Japan

P1.07.214 Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Rate of Decline in the Estimated Glomerular Filtration Rate of Kidney Transplant Patients with Recurrent or De Novo Glomerulonephritis
Hyukyong Kwon, South Korea

P1.07.215 Impact of Immunosuppression Withdrawal on Dialysis Survival Among Failed Kidney Transplant Recipients
Deirdre Sawinski, USA

P1.07.216 Robotic Repair for Ureteral Stricture Following Kidney Transplantation: A Minimally Invasive, Safe, and Effective Alternative
Hafiz Umair Siddiqui, USA

P1.07.217 Early Urinary Tract Infections in Kidney Transplant Recipients: Risk Factors and Graft Outcomes from a 13-Year Cohort Study
Patarasaya Roekrat, Thailand

P1.07.219 Do Social Determinants of Health Contribute to Inactivation of Adult Kidney Candidates?
Grace Lyden, USA

P1.07.220 HCV Positive Kidneys: Time to Change Our Mental Model
Goni Katz-Greenberg, USA

P1.07.221 Impact of UNOS Race-Neutral eGFR Policy Changes on Racial Disparities in Kidney Transplantation
Karen Pineda-Solis, USA

P1.07.223 Ethnic Disparities in Cytomegalovirus Infection Among Zero-A-B-DR Mismatched Kidney Transplant Recipients
Kellie Cho, USA

P1.07.225 HTRACK; The Hines Transplant Risk Assessment Calculator for Kidney Recipients, a Comprehensive Tool to Determine Post-Transplant Outcomes
Annie Przybylski, USA

P1.07.226 Primary Care Shortage Areas and Access to Kidney Transplantation- A National Registry Study
Gayathri Menon, USA

P1.07.227 Variations in Access to Living Donor Kidney Transplantation - Insights from the Parent Transplant Centre Model in Australia and New Zealand
Lachlan McMichael, Australia

P1.07.228 Language Barriers and Infectious Post-Transplant Outcomes: A Propensity-Matched Analysis of Spanish-Speaking Kidney Transplant Recipients
Benjamin Wick, USA

P1.07.229 Predicting Adult Kidney Transplant Wait Times: A Novel Risk-Based Model for Early Patient Stratification in the USA
Michael Allison, USA

P1.07.230 Examining the Impact of Out-of-Sequence Kidney Allocation on Racial Disparities and Non-Use Rates: A Retrospective Analysis of Pre- and Post-Policy Changes
Mike Fruscione, USA

P1.07.231 Disparities in Post-Transplant Follow-Up: A Study of Risk Factors in Renal Transplant Recipients
Sunil Karhadkar, USA

P1.07.232 Use and Utility of Early Allosure Testing
Brian Shaw, USA

P1.07.233 Operational Checks for Real-Time Urinary Biomarker Measurements for Deceased Donor Kidney Quality Assessment
Chirag Parikh, USA

Poster Listing

P1.07.234 Proteomic Changes Associated with Histological Progression in Diabetic Kidney Disease at 5 Years Post-Transplantation
Andrew Bentall, USA

P1.07.235 Two-Stage Diagnostic Models for Kidney Rejection with Economic Framework
Akhil Singla, USA

P1.07.236 Association of Donor-Derived Cell-Free DNA with 10-Year All Cause Graft Loss in a Multicenter Prospective Cohort
Raymond Heilman, USA

P1.07.237 Using Urine Chemokines as a Personalised Serial Monitoring Tool for Kidney Rejection
Akhil Singla, USA

P1.07.238 Donor-Derived Cell-Free DNA Post-Kidney Transplant Rejection
Lauren Schumacher, USA

P1.07.239 Influence of Baseline Donor and Recipient Clinical Characteristics on Donor-Derived Cell-Free DNA (dd-cfDNA) Levels in Stable Kidney Transplant Patients
David Taber, USA

P1.07.240 Donor-Derived Cell-Free DNA (dd-cfDNA) Trajectory Identifies Subclinical Rejection in Kidney Transplant Recipients (KTR)
Sandesh Parajuli, USA

P1.07.241 Early Elevations in Donor-Derived Cell-Free DNA Are Associated with Increased Risk of Future Rejection and Graft Dysfunction After Kidney Transplant
Sandesh Parajuli, USA

P1.07.242 Correlation of Activity and Chronicity Indices Derived from Banff Lesion Scores with Injury Dimension, Rejection Classifier, and Rejection Archetype Scores from Biopsy-Based Transcript Diagnostics
Thomas Schachtner, Switzerland

P1.07.243 Analytical Validation of myOLARIS-KTdx, a Non-Invasive Urine Assay for Detecting and Differentiating Graft Injury in Kidney Transplant Recipients
Elizabeth O'Day, USA

P1.07.245 Demonstration of First-Order Associations Between Urinary Cell Three-Gene Scores and Banff Acute Lesion Scores in Kidney Allograft Biopsies
Darshana Dadhania, USA

P1.07.246 Association of AlloView (AV) with Histopathologic Severity and Graft Outcomes in Kidney Transplant Recipients (KTR)
Sapna Shah, USA

P1.07.247 Increased Treg in Kidney Transplant Recipients with Erythrocytosis
Carolina Bigatti, USA

P1.07.248 Performance of Donor-Derived Cell-Free DNA Testing for Rejection Detection in Japanese Kidney Transplants: Insights from a Multicenter Study
Toshihito Hirai, Japan

P1.07.249 Rise and Fall of Donor-Derived Cell-Free DNA Following Treatment of Antibody-Mediated Rejection in Asian Kidney Transplant Recipients
Pei Xuan Ang, Singapore

P1.07.250 The Immune Landscape of Inflammation in Interstitial Fibrosis and Tubular Atrophy (i-IFTA) - An Imaging Mass Cytometry Based Study
Mariam Alexander, USA

P1.07.252 Machine Learning Models Using Routine Laboratory Parameters for Predicting BK Virus Infection and Allograft Rejection in Kidney Transplant Recipients
Ahram Han, South Korea

P1.07.253 Utility of Rejection Biomarker Tutivia in Managing Kidney Transplant Recipients at Risk of BK Nephropathy
Mohammed Javeed Ansari, USA

P1.07.254 Health Care Utilization in Elderly Deceased Donor Kidney Transplant Recipients: Does Kidney Donor Profile Index matter
Rachana Punukollu, USA

P1.07.255 Donor Transmitted Adenocarcinoma in a Kidney Transplant Recipient
Nerses Petrosyan, USA

P1.07.256 Temporal, AI-Driven, Risk and Prediction Analysis of the Impact of Early Acute Rejection on Patient and Graft Outcomes in a Unique Cohort of >20,000 Renal Allograft Recipients
Brenda Ametepe, USA

P1.07.257 Results of Kidney Transplant Biopsies and Characteristics of Their Treatment
Dildora Komilova, Uzbekistan

P1.07.258 The Experience of One Center: The First Direct Results of the Introduction Into Practice the Method of Preparing Patients With High Immunological Risk Before Kidney Transplantation in the Preoperative Period
Dildora Komilova, Uzbekistan

P1.07.259 Individualized Analgesic Management In complex pain Kidney-Transplant Recipients: Safety And Efficacy Of A Multidisciplinary, Stepped Protocol
Beatriz Rodriguez-Cubillo, Spain

P1.07.260 Early Advance Care Planning And Specialist Palliative Care Reduce End-Of-Life Suffering In Kidney-Transplant Recipients
Beatriz Rodriguez-Cubillo, Spain

P1.07.261 Incidence of CMV Infection & BK Viremia Post-Belatacept Conversion: Single Center Retrospective Study
Elizabeth Cho, USA

P1.07.262 Effect of BMI on Pregnancy Outcomes in Kidney Transplant Recipients.
Sajid Ansari, USA

P1.07.263 Association of Donor-Derived Cell-Free DNA and PBMC Gene Expression Profile With Graft Function in Early Post Kidney-Transplant Phase
Abdolreza Haririan, USA

P1.07.264 Characterization of Genes Associated With Tolerance in Peripheral Blood of Kidney Transplant Patients With Immunological Rejection Events, Measured Using RT-PCR Microarray of 96 Genes
Marco Carmona-Escamilla, Mexico

P1.07.265 Immunosuppression Minimization in Kidney Transplant Recipients with Transplant Excellence Based on the TruGraf Test
V Ram Peddi, USA

P1.07.266 Effect of Kidney Transplantation on Serum Total Prostate Specific Antigen Levels
Uzodimma Onwuasoanya, Nigeria

P1.08
Topic: Liver

P1.08.1 Duct-to-Duct versus Hepaticojejunostomy for Biliary Reconstruction Following Liver Transplantation for Primary Sclerosing Cholangitis: Updated Systematic Review and Meta-Analysis
Victor Perim, USA

P1.08.2 Early Allograft Dysfunction After Liver Transplantation: Analysis of the Clinical Outcome and the Risk Factors
Sukwon Suh, South Korea

P1.08.4 Extracorporeal Membrane Oxygenation in the Post-Liver Transplantation Setting
Spencer Goble, USA

P1.08.5 Liver Retransplantation Outcomes in the Era of Machine Perfusion
Siddharth Desai, USA

P1.08.6 Management of Patients with Vascular Reconstruction during Liver Transplantation
Yara Dababneh, USA

P1.08.7 Safety of Endoscopic Retrograde Cholangiopancreatography (ERCP) in Liver Transplant Patients: A Population-Based Propensity-Matched Study
Mohammed Abusuliman, USA

P1.08.8 Combined Liver Transplant and Sleeve Gastrectomy Surgical and Nutritional Outcomes
Suhani Patel, USA

P1.08.9 Temporal Changes in BMI and Outcomes in Liver Transplantation
Suhani Patel, USA

P1.08.10 Association Between Intraoperative Cryoprecipitate Transfused and Postoperative Deep Vein Thrombosis in Patients Undergoing Orthotopic Liver Transplantation
Marissa Kuo, USA

P1.08.12 Early Fibrosis Regression with Resmetirom in a Liver Transplant Recipient with De Novo MASH
Mary Chandran, USA

P1.08.13 Evolution of Practice and Outcomes in Repeat Liver Transplantation in the Normothermic Perfusion Era
Ingrid Woelfel, USA

Poster Listing

P1.08.14 Association Between Klebsiella pneumoniae and the Recurrence of Primary Sclerosing Cholangitis (PSC) After Liver Transplantation
Jun Ichikawa, Japan

P1.08.15 Similar Rates of Rejection and Excellent Graft Survival in Patients with Preexisting Inflammatory Bowel Disease Who Undergo Solid Organ Transplant
Jacquelin Blomker, USA

P1.08.16 The Role of High Dose Continuous Renal Replacement Therapy in Acute Liver Failure Following High Grade Liver Trauma
Mehraban Kavoussi, USA

P1.08.17 Successful Liver Transplantation and Long-Term Survival in Patients with Perioperative Heparin-Induced Thrombocytopenia and Thromboembolic Complications
Daiki Soma, USA

P1.08.18 The Outcomes of Deceased Donor Liver Transplantation Using Re-Use Graft in Korea
Kyung Chul Yoon, South Korea

P1.08.19 GPX3 Regulates Liver Regeneration by Preserving Mitochondrial Quality Control
Haoming Zhou, China

P1.08.20 Reducing Post Procedure Infections Using Single-Use Duodenoscopes in Liver Transplant Recipients with Biliary Complications: A Large Single Center Experience
Colin Ly, USA

P1.08.21 Impact of Glucagon Like Peptide-1 (GLP-1) Analogue Medications on Liver Transplant Risk Factors
Muhammad Saad Faisal, USA

P1.08.22 Leukocyte Recovery in Liver Transplant Recipients After Letermovir Conversion
Alex Rogers, USA

P1.08.23 Primary Non-Function After Liver Transplant in the U.S.: Characteristics and Impact of Center Level Volume
Sarah Huber, USA

P1.08.24 Complications After Liver Transplantation in Low Medical Acuity Patients: Impact on Long-Term Outcomes
Shekhar Kubal, USA

P1.08.25 Female Sex is a Predictor for Early Readmissions Following Liver Transplant
Sonali Kaluri, USA

P1.08.26 Strategies for Success in Endoscopic Retrograde Cholangiopancreatography (ERCP) Intervention in Liver Transplant Patients with Biliary Complications and Altered Intestinal Anatomy
Muhammad Saad Faisal, USA

P1.08.27 Grafted but Forgotten: Examining Risk Factors for Patients Lost to Follow Up After Liver Transplantation
Sunil Karhadkar, USA

P1.08.28 Current Status of CMV Prophylaxis Strategies, Viremia, Infection and Antiviral Side Effects, in Liver Transplant Recipients: Time for New Strategies? A Single-Center Retrospective Study
Winnie Shivega, USA

P1.08.29 Robotic Donor Hepatectomy: Early Single-Center Experience and Outcomes on the First 18 Consecutive Cases
Nishtha Singh, USA

P1.08.30 Sarcopenia and Long-Term Outcome in Adults and Children Undergoing Split Liver Transplantation
Xin Sui, China

P1.08.31 Onset of Post-Transplant Lymphoproliferative Disorder Subtypes in Liver Transplantation: UNOS-STAR Database Analysis
Charles Withington, USA

P1.08.32 Differential Effects and Risks of Donor Obesity in Living Liver Transplantation
Sunil Karhadkar, USA

P1.08.33 Characterization and Risk Factors for Readmission and Emergency Department Presentations in Dual Liver-Lung Transplantation Patients
Abdulmalik Saleem, USA

P1.08.34 Karnofsky Performance Status Predicts Worse Patient and Graft Survival After Re-Liver Transplantation
Avesh Thuluvath, USA

P1.08.35 Outcomes and Risk Factors for Post-Operative Rejection and Transaminitis Following Dual Liver-Lung Transplantation: A Retrospective Cohort Study
Abdulmalik Saleem, USA

Poster Listing

P1.08.36 An Overview of Arterial Complications Following Liver Transplantation in Adults from a Single Institution
Srinivas Chava, UK

P1.08.37 The Current System for Simultaneous Liver-Kidney Transplant with the Safety Net System Has Not Curtailed the Growth in Kidney Usage by Liver Transplants Recipients
Douglas Keith, USA

P1.08.38 Impact of Donation After Circulatory Death Simultaneous Liver-Kidney Transplantation in Hepatitis C: Outcomes, Trends and Impact of Direct-Acting Anti-Viral Therapy
Jesse Schold, USA

P1.08.40 Kidney After Liver Transplantation (KALT) in the Post-Safety Net Era
Simon Park, USA

P1.08.41 Integration of Clinical Characteristics with Molecular Signatures to Accurately Identify Cause of Acute Kidney Injury in Liver Transplant Recipients
Anjana Murali, USA

P1.08.42 Outcomes of Simultaneous Liver and Kidney Transplant vs. Liver Transplant Alone: Insights from a Midwest Transplant Center
Mohammed Abusuliman, USA

P1.08.43 Clinical Application of Angiotensin II for Hemodynamic Stabilization in an Anephric Pediatric Liver Transplant Recipient
Megan Crawford, USA

P1.08.44 Prospective Assessment of Acute Kidney Injury in Liver Transplant Recipients: Incidence, Risk Factors, and Outcomes in the Early Postoperative Period
Lama Amer, Saudi Arabia

P1.08.45 Indocyanine Green Fluorescence Imaging in Liver Transplantation: A Systematic Review of Its Diagnostic and Prognostic Value
Roshan Afshan, USA

P1.08.46 Investigating and Predicting Renal Function Outcomes in Liver-Alone Transplant Recipients with Preoperative Renal Impairment: A Single-Center Study
Binuri Hapuarachchy, USA

P1.08.47 Pre-Transplant Steroid Therapy is Associated with Adverse Renal Outcomes in Patients Transplanted for First-Time Episode of Alcohol Associated Hepatitis
Deepika Devuni, USA

P1.08.48 The Effect of Normothermic Machine Perfusion on Renal Outcomes Following Liver Transplantation: A Propensity Score - Matched Analysis
Muhammad Ahmad Nadeem, USA

P1.08.49 Renal Recovery and Long-Term Outcomes in Hepatorenal Syndrome and Chronic Kidney Disease After Liver Transplantation
Tiffany Wong, Hong Kong

P1.08.50 Extension of Liver Graft Preservation Times Using Normothermic Machine Perfusion in Simultaneous Liver-Kidney Transplantation May Indirectly Lead to Increase in Ureteral Complication Rates
William Archie, USA

P1.08.51 Advanced Perfusion Techniques Reduce AKI Risk in DCD Liver Transplantation
Hani Wadei, USA

P1.08.52 Safety of Dapagliflozin in Non-Renal Solid Organ Transplantation with Chronic Kidney Disease
Elmar Jaeckel, Canada

P1.08.53 The Feasibility of Simultaneous Liver-Kidney Transplantation Using Donors After Cardiac Death: A Comparative Analysis
Hiromichi Sato, USA

P1.08.55 Effect of Steroids in Cirrhotic Patients with Shock Awaiting Transplant: A Single Center Retrospective Study
Vineeth Sudhindran, USA

P1.08.56 Terminal Hospitalizations in Liver Transplant Recipients: Reducing Costs and High-Intensity Care through Palliative Care
Stephanie Rodriguez, USA

P1.08.57 Social Drivers of Health and Cognition in Cirrhosis: A Scoping Review
Samadhi Wijethunga, USA

P1.08.58 Association of Mean Arterial Pressure (MAP) with Mortality in Patients with Liver Cirrhosis Awaiting Transplantation
Yara Dababneh, USA

Poster Listing

P1.08.59 Liver Outcomes After Isolated Heart Transplant in Patients with Fontan Procedure at Two Tertiary Centers
Chaowapong Jarasvaraparn, USA

P1.08.60 Entecavir Monotherapy for Chronic Hepatitis B After Liver Transplantation: A 17-Year Follow-Up Study
Tiffany Wong, Hong Kong

P1.08.61 Factors Associated with Adverse Cardiovascular Event Following Liver Transplantation: A Single Center Experience
John Pueringer, USA

P1.08.62 Liver Transplantation Rates in Patients with Hepatorenal Syndrome-Acute Kidney Injury Treated with Terlipressin: Effect of Selecting an Appropriate Patient Population
Hugo Vargas, USA

P1.08.63 Liver Explant Findings in Alcoholic Liver Disease: Comparing Early and Standard Transplantation
Pallavi Menon, USA

P1.08.64 Mortality and Risk Prediction in Patients Waitlisted for MASH Related Cirrhosis
Saurav Panda, USA

P1.08.65 Pre-Liver Transplant Trans-Papillary Gallbladder Drainage in Cirrhosis: Comparing Intra and Postoperative Outcomes
Ahmed El-Sadek, USA

P1.08.66 Hospitalization Patterns and In-Hospital Resource Utilization in Liver Cirrhosis and Association with Socioeconomic Deprivation
Paola Barrios Martinez, USA

P1.08.67 Safety of Robotic Cholecystectomy in Cirrhotic Patients
Brennan Smith, USA

P1.08.68 A Novel Prognostic Model to Predict 1-Year Post-Transplant Mortality for Acute-on-Chronic Hepatitis B Liver Failure: A Nationwide, Multicenter, Cohort Study
Zhiyong Guo, China

P1.08.69 CD38 Promotes Regulatory T Cells Survival by Activating the Calcium/Ras/GGT1 Pathway to Reduce ROS and Induce Post-Transplant Immune Tolerance
Yunjie Lu, China

P1.08.70 Interferon-Signaling and Differential Immune Cell Activation Characterize Subclinical Liver Transplant Rejection versus Allograft Quiescence
Yannis Hadjiyannis, USA

P1.08.71 Analytical Validation of a Serum miRNA RT-qPCR Assay for Monitoring Allograft Liver Rejection
Yipeng Wang, USA

P1.08.72 Management of Graft versus Host Disease Involving the Bone Marrow: Interventions and Outcomes
Razan Aburumman, USA

P1.08.73 Pregnancy Outcomes and Tacrolimus Pharmacokinetics in Liver Transplant Recipients
Yasunori Shirakawa, Japan

P1.08.74 A Novel Mechanistic Mathematical Model of Liver Transplant Immune Dynamics Predicts Important Drivers of Patient Outcome
Julia Bruner, USA

P1.08.75 DNase I to Limit the Proinflammatory Role of Donor-Derived Cell-Free DNA in Liver Transplant Ischemia and Reperfusion
Mike Schnepppfister, USA

P1.08.76 Donor-Derived Cell-Free DNA is an Accurate Marker for Detecting Acute Rejection and Injury in Liver Transplant Recipients
Sander Florman, USA

P1.08.77 Revolutionizing Post Liver Transplant Management Care: Molecular Diagnostics for Precision Immunosuppression
Kyle Schneider, USA

P1.08.78 Elevated Levels of Circulating Oxidized Mitochondrial DNA Contribute to the Development of Ischemia Reperfusion Injury Following Liver Transplantation
Shabir Bhat, USA

P1.08.79 Efficacy and Safety of Intravenous Immunoglobulin in ABO-Incompatible Adult Living Donor Liver Transplantation: A Phase 2 Clinical Trial
Sanggyun Suh, South Korea

P1.08.81 Impact of Preemptive Mycophenolate Dose Reduction on Leukopenia in Liver Transplant Recipients
Jennifer Hagopian, USA

Poster Listing

P1.08.82 Normothermic Machine Perfusion of DCD Liver Grafts is Associated with Increased 90-Day Acute Cellular Rejection Rates and Continues in a Time Dependent Manner
William Archie, USA

P1.08.83 Tacrolimus Monotherapy After Early Antimetabolite Withdrawal and Complete Steroid Avoidance Following Liver Transplantation
Adam Bodzin, USA

P1.08.84 Impact of Ideal Body Weight-Based rATG Induction Dosing on Rejection and Infection Rates in Liver Transplant Recipients
Uerica Wang, USA

P1.08.85 Decreased Rate of Rejections Post Liver Transplant in Patients on a Glucagon-Like Peptide 1 (GLP-1) Analogue
Muhammad Saad Faisal, USA

P1.08.86 Management in the Era Before Biomarkers: Long-Term Outcomes and Immunosuppression Strategies Following Liver Transplantation
Abdulmalik Saleem, USA

P1.08.87 Range of Donor-Derived Cell Free DNA in Liver Transplant Recipients: An Updated and Expanded Analysis in a Single Center
Kyle Schneider, USA

P1.08.88 Rejection Rates After Liver Transplant (LT) Are Not Higher with Hormonal Contraception Use
Elle Oberweis-Manion, USA

P1.08.89 Orthopedic Surgery in Liver Transplant Recipients: Does Surgical Urgency Influence Post Operative Morbidity
Abdulmalik Saleem, USA

P1.08.90 Molecular Signatures of Chronic Antibody-Mediated Rejection in Human Liver Transplants
Elmar Jaeckel, Canada

P1.08.91 Liver Transplantation in Recipients with a Positive Crossmatch: Desensitize or DO NOT Desensitize? - Middle East Case Series Experience
Luis Campos-de-la-Borbolla, United Arab Emirates

P1.08.92 Trends in Psychosocial Burden and Its Impact on Listing in Liver Transplant Selection
Audrey Bankes, USA

P1.08.93 Days Alive out of the Hospital: Measuring Quality of Life and Utilization After Liver Transplantation
Ethan Louie, USA

P1.08.96 Should Frailty Stratification Be Considered as a Pre-Transplant Evaluation Tool to Optimize Liver Transplant Recipients?
Rajat Nog, USA

P1.08.97 Liver Transplant Outcomes and Complications for Metabolic- Dysfunction Associated Alcohol Related Liver Disease (MetALD)
Avi Toiv, USA

P1.08.98 Listed or Left Behind: The Impact of Social Support on Liver Transplant Access
Avi Toiv, USA

P1.08.100 Equivalent Operative and Peri-Operative Outcomes with Increased Liver Transplantation for Severely and Morbidly Obese Patients: A Single-Center Study
Winnie Shivega, USA

P1.08.101 Associations of Frailty, Sarcopenia, and Malnutrition with Mortality in Liver Transplant Candidates: A Real-World Assessment
Rohan Karanth, USA

P1.08.102 De Novo Malignancy After Liver Transplantation: The Impact of Health Risk Behaviors
Jin-Chiao Lee, Taiwan

P1.08.103 Outcomes for Liver Candidates on the OPTN Waiting List by Social Determinants of Health
Dzhuliyana Handarova, USA

P1.08.104 Diverging Three-Year Survival Trends in ALD and MASH Liver Transplant Recipients Following the COVID-19 Pandemic
Maria Machicao, USA

P1.08.105 Predictors of Clinical Improvement in Liver Transplant Waitlist Candidates with Alcohol-Associated Liver Disease
Ramsey Albahra, USA

P1.08.106 Characteristics of Individuals Aged Seventy Years or Greater Evaluated for Liver Transplantation, a Single Center Analysis
Bridgette McNally, USA

P1.08.107 Can Current Preservation Techniques Expand Utilization of Liver Grafts Donated After Circulatory Death for Re-Transplant?
David Krist, USA

P1.08.108 Short-Term Sobriety Does Not Impact Cardiovascular Outcomes After Liver Transplantation for Alcohol-Associated Liver Disease-A Multicenter Study
Giovanni Roldan, USA

P1.08.109 Center Variation and Disparities in Expedited Evaluation for Liver Transplant Candidates - A Multicenter Competing Risk Analysis
Mignote Yilma, USA

P1.08.110 Impact of Alcohol Abstinence Duration and SIPAT Score on Liver Transplant Outcomes: A Predictive Analysis
Raphael Meier, USA

P1.08.111 Prevalence of Malnutrition and Micronutrient Deficiencies in End Stage Liver Disease Patients Undergoing Transplant Evaluation
Caprice Pierre, USA

P1.08.112 Risk Factors for Seven-Day Graft Loss Following Adult Liver Transplantation: A UNOS-Based Analysis
Melanie Vugelman, USA

P1.09
Topic: Lung

P1.09.1 Extracorporeal Photopheresis in Chronic Lung Allograft Dysfunction: A Therapeutic Perspective from a Single-Center Experience
Alonso Marquez, USA

P1.09.2 Ruxolitinib for Chronic Lung Allograft Dysfunction
Katelyn Rudzik, USA

P1.09.3 Outcomes and Evolving Trends in Combined Lung-Abdominal Transplantation: Insights from the UNOS Database
John Treffalls, USA

P1.09.4 Impact of Donor Radiographic Pneumonia on Lung Transplant Recipient Outcomes
Kevin He, USA

P1.09.5 Reintubation After Lung Transplant Surgery is Independently Associated with Worse Outcomes: An Analysis of UNOS Database
Natasha Banga, USA

P1.09.6 DPP-4 Inhibitor Utilization Post-Lung Transplant
Brittany Huynh, USA

P1.09.7 Belatacept with Calcineurin Inhibitor Elimination in Lung Transplant Recipients with Calcineurin Inhibitor Renal Toxicities
Krysta Walter, USA

P1.09.8 Pretransplant and Perioperative Risk Factors for Baseline Lung Allograft Dysfunction
Bradley White, USA

P1.09.9 Outcomes in Lung Transplant Recipients ≥75 Years Compared with Those 65-74 Years: A Retrospective Analysis of UNOS Database
Remzi Bag, USA

P1.09.10 Clinical Utility of Methicillin-Resistant Staphylococcus aureus Nasal PCRs in Lung Transplant Recipients
Samantha Curnow, USA

P1.09.11 Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA) in Lung Transplant
Helen Sweiss, USA

P1.09.12 Relationship Between Donor-Derived Cell-Free DNA and Reflux in Post-Lung Transplant Patients
Renata Ponsirenas, USA

P1.09.13 Novel Insights into Extreme Molecular Injury After Lung Transplantation: Investigating the Risk Factors and Outcomes
Alonso Marquez, USA

P1.09.14 Frailty in Lung Transplant Candidates Predicts Post-Transplant Outcomes: A Multicenter Study
Joanna Schaenman, USA

P1.09.15 Inhaled Tobramycin for Pseudomonas Eradication Post-Lung Transplantation
Jennifer Ferrante, USA

P1.09.17 Diabetes, Donor-Derived Cell Free DNA, and Extreme Molecular Injury: A New Paradigm in Lung Transplantation
Alonso Marquez, USA

Poster Listing

P1.09.18 Impact of Chronic Pseudomonas Infection on Donor-Derived Cell-Free DNA Levels in Lung Transplant Recipients
Camilo Avendano Capriles, USA

P1.09.20 Characteristics and Outcomes for Lung Transplant Recipients with Connective Tissue Disease: A Single Center Experience
Rachel Powers, USA

P1.09.21 Post-Transplant Atrial Fibrillation Clinical Impact and Associated Complications in Lung Transplant Recipients
Alonso Marquez, USA

P1.09.22 Dysregulation of Fibroblast Inflammatory and Fibrotic Pathways in Pediatric Lung Transplant Recipients with Acute Cellular Rejection
Grace Bieghler, USA

P1.09.23 Electron Microscopy as a Reliable Diagnostic Tool for Lung Allograft Antibody-Mediated Rejection
Jose Torrealba, USA

P1.09.25 Relative Change in Donor-Derived Cell-Free DNA for the Diagnosis of Lung Allograft Injury or Infection in Bilateral and Single Lung Recipients
S. Samuel Weigt, USA

P1.09.26 Double Lung Transplantation in Patients with Recent History of Malignancy
Liam Il-Young Chung, USA

P1.09.27 [Trial in Progress] DREAM Study: Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers
Liam Il-Young Chung, USA

P1.10
Topic: Organ Inclusive

P1.10.1 Incidence and Pattern of Post-Transplant Malignant, Premalignant and Clonal Disorders in Iraqi Kidney Transplant Recipients
Ala Ali, Iraq

P1.10.2 Cancer Risk Among US Solid Organ Transplant Recipients, 2009-2019
Qianlai Luo, USA

P1.10.3 Cancer Incidence and Associated Risk Factors in Patients Undergoing Renal Transplantation in a Colombian Population: A Historical Analytical Cohort
Rodolfo Eduardo Torres Serrano, Colombia

P1.10.4 Characterizing Native Renal Lesions in Kidney Transplant Candidates - Comparing Contrast-Enhanced Ultrasound versus Computed Tomography
Megan McCaughey, USA

P1.10.5 Cancer-Related Mortality After Solid Organ Transplantation in England: The EpCOT Study
Charlotte Stephens, UK

P1.10.6 Epidemiology of Cancer After Solid Organ Transplant (EpCOT): Dataset Overview
Charlotte Stephens, UK

P1.10.7 Perinephric Myxoid Pseudotumor of Fat in Kidney Transplant Recipients Evaluated for Repeat Transplantation: A Single Center Experience
Srilekha Sridhara, USA

P1.10.8 Shifting Cancer Incidence Rates Amongst Kidney Transplant Recipients: A Single Center Experience from 2000 to 2021
Nicolas Vendeville, Canada

P1.13
Topic: Psychosocial & Ethics

P1.13.1 Provider Moral Distress Related to Early Liver Transplantation for Alcohol Related Liver Disease
Julia Lopez, USA

P1.13.2 Finding Meaning in Life Among Patients Experiencing Transitions Associated with Liver Transplantation
Dinah Hernandez, USA

P1.13.3 Easy-to-Use Urine Assay for The Direct Measurement of MMF Medication Adherence in Kidney Transplant Recipients
Elizabeth O'Day, USA

P1.13.4 The Potential Benefit of Deferrals in Liver Transplant Selection: Which Patients' Liver Disease Will Improve?
Lindsay Beaman, USA

Poster Listing

P1.13.5 How to Ethically Engage Living Donors in Transplant Oncology
Matthew Byrne, USA

P1.13.7 Exploration of Treatment Burden Associated with Live Donor Renal Transplantation: A Longitudinal Qualitative Study
Catrin Jones, UK

P1.13.8 Assessment of Alcohol Recidivism in Post Liver Transplant Patients Using Phosphatidyl Ethanol Testing - A TriNetX Cross Institutional Study
Stephan Weinland, USA

P1.13.9 Psychological Risk is Independent of Readmission Risk Post Liver Transplant in Alcohol Use Disorder Patients
Christine Machado Denis, USA

P1.13.10 Longitudinal Associations Between Social Circumstances, Psychological Symptoms, and Cognition in Liver Transplant: A Preliminary Study
Dami Ko, USA

P1.13.11 Feasibility and Acceptability of a Group-Based Alcohol Relapse Prevention Program for Liver Transplant Recipients
Sophia Hurr, USA

P1.13.12 Symptoms of Posttraumatic Distress in Patients on Ventricular Assist Device Support: Something to Worry About?
Christiane Kugler, Germany

P1.13.13 The Relationship of Pre-Kidney Transplant Cognitive Function and Post-Kidney Transplant Medical and Biological Outcomes
Wasim Dar, USA

P1.13.14 Sentiment Analysis and Reason Classification of Medical Social Worker Notes to Better Understand Patient Attitudes towards Liver Transplantation in Singapore
Chanda Ho, Singapore

P1.13.15 Characterization of the Transplant Social Worker Workforce
Colleen Satarino, USA

P1.13.16 Functional Impairment and Sleep Quality in Long-Term Recipients of Organ Transplantation
Stacy Al-Saleh, USA

P1.13.17 Feasibility and Acceptability of a Post-Transplant Alcohol Relapse Prevention Group for Patients with Alcohol-Related Liver Disease
Ming Hwei Yek, USA

P1.13.18 Transplant Social Worker Evaluation and Interventions: The Missing Voice in the Social Support Debate
Gloria Chen, USA

P1.13.19 Health-Related Quality of Life in Kidney Transplant Patients: A Pilot Study of PROMIS9 Surveys
Krista Lentine, USA

P1.13.20 The Associations Between Perceived Helplessness, Self-Efficacy, Depression, & Anxiety Among Liver Transplant Patients
Sarah Brill, USA

P1.13.21 Symptom Burden and Patient-Reported Outcomes in Brazilian Kidney Transplant Recipients
Juliana Giannoni Ferreira, Brazil

P1.13.22 Baseline Cognitive Functioning in Advanced Heart Failure Patients Evaluated for Heart Transplant: Preliminary Data from the Transplant Neuropsychology Clinic
Jenessa Price, USA

P1.13.23 Models to Predict Immunosuppression Non-Adherence in Kidney Transplant Recipients
Harry Morford, USA

P1.13.24 Evaluating the Impact of Relative Neighborhood Resource Disparity at Time of Evaluation as a Predictor of One-Year Liver Transplant Outcomes
Kashif Osmani, USA

P1.13.25 Evaluating Differences in Neighborhood Resource Deprivation in Liver Transplantation: Insights from Single versus Multiple Etiologies of Liver Failure
Kashif Osmani, USA

P1.13.26 The Utility of Serial Neuropsychological Assessment Post-Liver Transplant: A Case Study
Jenessa Price, USA

P1.13.27 Ten Years of Kidney Transplantation in Ethiopia: Results of a Capacity Assessment Toolkit Pilot
Alan Zambeli-Ljepovic, USA

P1.13.28 A Cost-Effective Strategy for Kidney Transplant Histocompatibility Testing in Resource-Limited Settings
Ali Abbasi, USA

P1.13.29 Projecting Cost Savings of Increased High-Risk Kidney Utilization in the USA
Angela Gifford, USA

P1.13.30 Understanding Financial Hardship for Liver Transplant Recipients: A National Evaluation of Pre-Transplant Costs and Insurance Instability
Jacob Guorgui, USA

P1.13.31 Donor Family Perspective on the Deceased Organ Donation Experience
Tessa Flower, USA

P1.13.32 Voluntariness in First-in-Human Pig Kidney Xenotransplant Clinical Trials
Elisa Gordon, USA

P1.13.34 Does Spirituality or Religious Affiliation Improve Chances of Listing in Liver Transplant?
Frank Lee, USA

P1.13.37 Assessing the Importance of Tracking Patients' Progress through the Transplant Evaluation Process for Developing an Equity Dashboard to Address Social Drivers of Health: Patient and Provider Perspectives
Marianna Frazee, USA

P1.13.38 Navigating Privacy in Facial Transplantation: Ethical Considerations and Institutional Strategies
Laura Kimberly, USA

P1.13.39 An Ethical Approach to Anti-Obesity Interventions in Living Organ Donor Candidates
Laura Kimberly, USA

P1.13.40 Comparison of Metabolic Outcomes of a Belatacept-Based Immunosuppression Regimen in Hispanic versus Non-Hispanic Kidney Transplant Recipients
Dana Pierce, USA

P1.13.41 Sexual Orientation and Gender Identity Data Collection in Solid Organ Transplant Programs in the USA
Phillip Chen, USA

P1.13.42 Why Would Kidney Disease Patients' Family Members Be Willing to Donate a Kidney? Results from the Families of Renal Patients Survey
Jonathan Daw, USA

P1.13.43 Transplanting Change: The Slow Progress of Gender Equity in Editorial Leadership
Christie Rampersad, Canada

P1.13.44 Early Insights on Calculated Panel Reactive Antibody Variability Among Multi-Listed Kidney Transplant Candidates A Cohort Analysis
Amber Paulus, USA

P1.13.45 Evaluation of Differences in Resource Disparity and Transplant Outcomes Between an Academic Medical Center and Community Safety Net Hospital
Elif Kortan, USA

P1.13.46 Community Resource Disparity as a Predictor of Renal Transplant Outcomes: A Collaboration Between Community and Academic Medical Centers
Elif Kortan, USA

P1.13.47 Predictors of Time on Dialysis Before Referral to Evaluation for Renal Transplant: A Comparison of Community Hospital and Academic Medical Center
Elif Kortan, USA

P1.13.48 Disagreements in AI Adoption for Organ Procurement Organizations: Source of Efficiency or Inequity?
Amaneh Babaee, USA

P1.14
Topic: Public Policy

P1.14.1 Evaluation of Clinical and Laboratory Characteristics of Kidneys Transplanted and Offered for Transplantation in the Capital of Brazil
Thiago Carvalho, Brazil

P1.14.2 Regional Variation in Reimbursement and Hospital Internal Costs for Kidney Transplant Admissions in the U.S. Medicare Population
Dicken S. C. Ko, USA

P1.14.3 The Landscape of Kidney Transplant Admissions in the U.S. Medicare Population
Dicken S. C. Ko, USA

P1.14.4 Variation in Clinical Characteristics of Kidney Transplant Admissions in the U.S. Medicare Population by All-Payer Hospital Transplant Volume
Dicken S. C. Ko, USA

P1.14.6 Trends and Recipient Outcomes in Multiorgan Transplantation in the USA 2013-2023
Mason Lai, USA

P1.14.7 Impacts of the Post-Transplant Graft Survival Performance Metric on Trends in One-Year Post-Transplant All-Cause Graft Failure Rates
Erin Schnellinger, USA

P1.14.8 Perceptions of the Patient and Family Volunteer Workforce in the Organ Procurement and Transplantation Network
Jennifer Lau, USA

P1.14.9 Regional Differences in Changes in Travel under the Acuity Circles Policy
Allison Marsh, USA

P1.14.10 Long-Term Outcomes of Pre-Existing DSA in Highly Sensitized Kidney Transplant Recipients
Darnell Mompoint-Williams, USA

P1.14.11 Socioeconomic Deprivation is Associated with Fewer Organs Transplanted per Donor: A Binomial Generalized Estimating Equation Analysis
David Leeser, USA

P1.14.12 Center-Level Analysis of Donation After Circulatory Death Kidney and Liver Transplantation: Utilization Patterns and Influential Utilization Factors
Amirhossein Moosavi, USA

P1.14.13 Evaluating the Impact of Exclusion Criteria on Organ Procurement Organization Performance Metrics
Ana Rocio Lopez Moscoso, USA

P1.14.14 Anticipatory Governance for the Next Frontier in Organ Preservation
Erik Finger, USA

P1.14.15 Insurance and Cause of End-Stage Liver Disease Attenuate Association of SDI on Time to Liver Transplant
David Schladt, USA

P1.15
Topic: VCA

P1.15.1 IL-17A-Producing T Cells and Classical Monocytes Are Associated with a Rapid Alloimmune Response Following Vascularized Composite Allotransplantation in Mice
Sheri Krams, USA

P1.15.2 Characterizing Donor- and Recipient-Derived Macrophages in Vascularized Composite Allotransplantation Rejection
Hui-Yun Cheng, Taiwan

P1.15.3 Long Term Immunosuppression Free Survival of a Face Allotransplant via Donor Hematopoietic Chimerism in Non Human Primates
Haïzam Oubari, USA

P1.15.4 Induction Immunosuppression with Combination B and T Cell Depletion Results in Greater Than 1 Year Initial Rejection Free Interval in VCA Transplantation
Bruce Gelb, USA

P1.15.5 Topical Tacrolimus for Treatment of Acute Rejection in Vascularized Composite Allotransplantation - A Systematic Review
Bruce Gelb, USA

P1.15.7 A Multi-Omics Approach to Unravel VCA Immune Rejection Mechanisms
Ren-Wen Huang, Taiwan

P1.15.8 Multimodal Imaging of Acute and Chronic Rejection in Vascularized Composite Allotransplantation
Jelena Janjic, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.03
Topic: Basic Science

P2.03.1 Novel Resolution Pathways in Liver Ischemia and Reperfusion Injury
Yuan Zhai, USA

P2.03.2 Dual C3 Blockade Promotes Effective Allograft Accommodation in Sensitized Nonhuman Primate Recipients, yet Escalating DSA Trigger Late Complement-Independent Rejection
Jean Kwun, USA

P2.03.3 Recipient TLR9 is Required for Endogenous Donor-Reactive Memory CD8 T Cell Proliferation and Effector Function to Mediate High Risk Allograft Rejection
Hidetoshi Tsuda, USA

P2.03.4 Wnt3a-AIF1 Axis Augments Inflammation in Kidney Transplant Rejection
Irma Husain, USA

P2.03.5 Innate Allorecognition at the Maternal-Fetal Interface Optimizes Reproductive Success
Riwa Kanj, USA

P2.03.7 Deciphering HLA-DQ Allo-Immunogenicity in Transplantation by Systematic Empirical and In-Silico Analysis
Grace Matias, USA

P2.03.8 Potential Different Reactivities of Intra-Graft and Serum Donor-Specific Antibodies in Liver and Kidney Transplantation
Tsukasa Nakamura, USA

P2.03.9 Indirect T Cell Epitope Mismatch Loads Are Correlated with Increased Levels of Panel-Reactive HLA Antibodies After Kidney Transplantation
Matthias Niemann, Germany

P2.03.10 De Novo Donor Specific Antibodies to HLA-DR Associated with Cardiac Allograft Vasculopathy
Xiaohai (Sam) Zhang, USA

P2.03.11 Immunopeptidome Analysis Demonstrates the Complexity of HLA-DQ: Implications for T Cell Allo-Recognition
Anat Tambur, USA

P2.03.12 Quantitative Evaluation of DSA by Serial Titration Associates with Severity of Acute Rejection in Kidney Transplant Recipients
Clarkson Crane, USA

P2.03.13 Extracting Quality from Quantity: Hierarchical Clustering of HLA-DQ Molecules by Physio-Chemical Metrics Predicts Immunogenicity in a Large Multicenter Cohort
Dennis van den Broek, Netherlands

P2.03.14 Detection of Immunogenic T Cell Epitopes (Peptides) Involved in De Novo DSA Production Using Machine Learning Methods
Takaaki Kobayashi, Japan

P2.03.15 HLA Molecular Mismatch and Risk of Adverse Kidney Transplant Outcomes - A Systematic Review
Chethan Puttarajappa, USA

P2.03.16 Functional Relevance of Anti-HLA Antibodies in Unsensitized Individuals: Benign or Pathologic?
Franz Fenninger, Canada

P2.03.17 Unmasking the ABO Antibody Ingredient List in IVIg Preparations
Francis Leier, Canada

P2.03.18 HLA-DRB1 Serotype Incompatibility is Associated with Kidney Graft Acute Rejection
Renato de Marco, Brazil

P2.03.19 MHC Class II Matching Does Not Predict Survival in Organ and Bone Marrow Transplantation in Non-Human Primates
Casey Winter, USA

P2.03.20 HLA-Specific B Memory (Bmem) Cell Frequencies in Highly Sensitized Kidney Transplant (Tx) Candidates
Shengli Song, USA

P2.03.21 Intact Donor Derived Extracellular Vesicles Detectable with Full-Spectrum Nanoscale Cytometry in Setting of High, Low, and Negative Circulating Donor Specific Antibody
Samuel Grinberg, USA

P2.03.22 Delayed-Graft Function and Fate of Transplant Survival Assessment: The Promotor Region of Cytokine Genes
D. Olga McDaniel, USA

P2.03.23 ATGAM versus Thymoglobulin in Kidney Transplant Tolerance Induction in Non-Human Primates
Avery Wilson, USA

P2.03.24 Exploring Serum Protein Signatures of Tolerance versus Rejection After Combined Kidney and Bone-Marrow Transplantation in a Non-Human Primate Model
Ryo Otsuka, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.03.25 Progressive Hyperglycemia in Tolerant Miniature Swine Recipients of Composite Islet-Kidney Grafts is Not Due to Islet Loss but Rather to Increased Insulin Demand with Growth
Ishit Chauhan, USA

P2.03.27 Cryopreservation of Nonhuman Primate Skin for Transplantation
Meghan Hu, USA

P2.03.28 Flow-Based Assessment of COVID-19 Vaccine-Induced Protective Immunity Using a SARS-CoV Spike Protein Reporter Cell Panel in a Nonhuman Primate Model
Shengli Song, USA

P2.03.29 Induction of Mixed Chimerism for Renal Allograft Tolerance Using Bcl-2 Inhibition and Nanoparticle Encapsulated Rapamycin without Genotoxic Treatments
Andre Souffrant, USA

P2.03.30 mTOR Inhibitor Nanoimmunotherapy Prolongs Heart and Lung Allograft Survival in Non-Human Primates
Jane O, USA

P2.03.31 Spleen SORT-LNP with mTOR Inhibitor Rapamycin Target Myeloid Cells to Promote Renal Allograft Acceptance in Mice
Chao Yang, China

P2.03.32 Minimal Impact of Anti-BAFF mAb on B Cell Depletion, Repopulation, DSA Production, and Graft Survival in Highly Sensitized NHP Recipients
Jean Kwun, USA

P2.03.33 Successful Tolerance Induction with Delayed Donor Bone Marrow Transplantation in Orthotopic Liver Transplantation Using a Non-Human Primate Model
Katsuhiro Tomofuji, USA

P2.03.34 Allogeneic Islets Engineered to Transiently Display Thrombomodulin and CD47 Proteins on Their Surface Achieve Long-Term Survival in a Preclinical Model
Esma Yolcu, USA

P2.03.35 Mycophenolate Mofetil Therapy and Dosing Impacts Post-Transplant Peripheral Blood T Cell Phenotypes and Key Immune Signaling Pathways
Harry Pickering, USA

P2.03.36 A Novel Rhesus Chimeric Anti-FcgRIII (CD16) Antibody in Non-Human Primates
Matthew Tunbridge, USA

P2.03.38 Transcriptional Profiling of Nonhuman Primate CD34+ Regulatory Monocytes That Effectively Suppress Alloimmune Responses
Neal Iwakoshi, USA

P2.03.40 Blockade of Selectins and Integrins in Gene-Edited Pig Lungs Perfused with Human Blood
Sho Takemoto, USA

P2.03.41 Treg-Mediated Donor-Specific Hyporesponsiveness in a Pig-to-Baboon Thymokidney Xenotransplant Model
M. Esad Gunes, USA

P2.03.42 SLA-6, -7 and -8 as Potential Xenoantigens: A Structural Study
Ana Flavia Santarine Laureano, USA

P2.03.43 Novel Recombinant Endopeptidase, IceMG, Cleaving Both IgM and IgG in a Sensitized Nonhuman Primate Model for Xenotransplantation
Jean Kwun, USA

P2.03.44 Xenogeneic Interaction of Human Red Blood Cells and Mesenchymal Stem Cells with 10-Gene-Edited Pig Endothelium Preserves Endothelial Barrier Function
Raphael Meier, USA

P2.03.46 Nanoparticle-Based Rapamycin Delivery to Porcine Endothelial Cells Modulate Human Xeno-Reactive T Cell Immune Responses
Shu Li, USA

P2.03.47 Modulation of NK Cell-Mediated Immune Responses by HLA-E-Expressing Genetically Modified Porcine Endothelial Cells
Jonathan Schulz, USA

P2.03.48 Porcine Xenograft Thymokidney Function in a Living Human Recipient with a Left Ventricular Assist Device
Jacqueline Kim, USA

P2.03.49 Porcine Endothelial Xenoantigens Induce Xeno-Reactive Th17 and Th1/Th17 CD4 Cell-Mediated Immune Responses
Shu Li, USA

P2.03.50 Sequential Ultrasound and Contrast-Enhanced Ultrasound Imaging in the First Two Human Kidney Xenotransplant Recipients
Sylvain Bodard, USA

Poster Listing

P2.03.51 Rapid High-Resolution Swine Leukocyte Antigen (SLA) Typing for Enhanced Xenocompatibility Assessment
Sam Ho, USA

P2.03.52 Xenotransplant Rejection with Membranous Nephropathy Features in Allosensitized Nonhuman Primate Kidney Transplant Models
Matthew Tunbridge, USA

P2.03.53 Impact of Sialoadhesin Blockade, GPIb Inhibition, and Genetic Modifications on Human Neutrophil Rolling over Porcine Endothelium under Microvascular Flow Conditions
Sho Takemoto, USA

P2.03.54 Retention of Native Kidney with Ligated Ureter Preserves Renin-Angiotensin System Function After Pig Kidney Xenotransplantation
Kohei Kinoshita, USA

P2.03.55 Neutrophil PAD4 and Platelet Activation in Xeno-Islet Transplantation: Their Roles and Remediation
Mingqing Song, USA

P2.03.56 Is Proteinuria the Final Hurdle to Successful Pig Kidney Xenotransplantation?
Kohei Kinoshita, USA

P2.03.57 Xenogeneic Profiling of Human Plasma Protein Abundance Following Pig Hepatocyte Exposure during Bioartificial Liver Treatments
Angeles Baquerizo, USA

P2.03.58 C-Reactive Protein as a Biomarker of Inflammation in Kidney and Heart Xenotransplantation in Non-Human Primates
Tjasa Zaletel, USA

P2.03.59 Longitudinal Analysis of Immune Responses in Porcine Kidney Transplant Recipients
Shreyas Joshi, USA

P2.03.60 Endothelial Injury and Fibrogenesis Drives Post-Transplant Response After Pig-to-Human Heart Xenotransplantation
Amol Shetty, USA

P2.03.61 Assessing Compatibility for Xenotransplantation: Human Serum with Gene Edited Porcine Cells
Kristen Getchell, USA

P2.03.63 Recovery of Rat Hearts After Cold Storage with Acid Sensing Ion Channel Inhibitor Hi1a Varies by Sex
Sanjay Dutta, Australia

P2.03.66 Heterogenicity of Liver Monocytes/Macrophages in Response to Ischemia Reperfusion Injury
Yuan Zhai, USA

P2.03.68 147 as a Novel Therapeutic Agent to Ameliorate Liver Ischemia-Reperfusion Injury via Protective Effects on Hepatocytes and Macrophages
Siyuan Yao, USA

P2.03.69 MiR-423-5p is a Novel Predictor of Fibrosis and Microvascular Rarefaction in Renal Allografts
Francis Migneault, Canada

P2.03.70 Dietary Fiber-Derived Short-Chain Fatty Acid (SCFA) Treatment After Acute Injury Protected Against Kidney Ischemia Reperfusion Injury (IRI)
Huiling Wu, Australia

P2.03.71 MiR-423-5p Regulates Microvascular Homeostasis and Renal Function After Ischemia-Reperfusion Injury
Francis Migneault, Canada

P2.03.73 Cell Death in Mouse Kidneys during Cold Ischemia Shows Sexual Dimorphism and Can Be Delayed by a Bax Inhibitor
Samuel Liburd Jr, USA

P2.03.75 Extended Subzero Organ Preservation with Novel Bio-Inspired Cryoprotectants: In Vivo Assessment in a Mouse Heart Transplantation Model
Siavash Khaki, USA

P2.03.76 Extended Subzero Preservation of Vascularized Composite Allografts Using a Novel Bio-Inspired Cryoprotectant: Evaluating Functional Recovery through an Orthotopic Forelimb Transplantation Model
Narges Lamsehchi, USA

P2.03.79 Evaluation of the Utility of Novel Self-Assembled Redox Nanoparticles in Organ Transplantation
Kazuhiro Takahashi, Japan

P2.03.80 Biochemical Markers in Steatotic Liver Preservation: A Comparative Analysis of Conventional and Next-Generation Solutions
Arnau Rosello, Spain

P2.03.83 Biopsy-Based Assessment of Transplantability in Rat Livers Using Resonance Raman Spectroscopy
Rohil Jain, USA

P2.03.84 Assessing Hemopure Based Oxygenated Flushing in Liver Transplantation: A Bioenergetic Molecular Analysis Approach
Anil Kharga, USA

P2.03.89 LIMS1 Genotype Modulates Kidney Response to Ischemia-Reperfusion Injury
Yasar Caliskan, USA

P2.03.91 Assessment of Liver Graft Viability through Fluorescence-Based Cellular Function Monitoring
Nijkem Asong Fontem, France

P2.03.92 Secretory Leukocyte Protease Inhibitor (SLPI) Regulates the Intensity of Kidney Ischemia Reperfusion Injury
Kevin Matamoros Alcivar, USA

P2.03.93 Ischemia Minimization Shows Protective Effect on Both GalTKO and 10GE Porcine Hearts in and Ex Vivo Working Heart Model
Sho Takemoto, USA

P2.03.94 Unveiling the Molecular Signatures of Macrophages in AKI-to-CKD
Kyu Hong Kim, South Korea

P2.03.95 Computational Analysis of Full Transcriptome Molecular Characterization of Experimental Cold Ischemic Kidney Injury
Hamid Rabb, USA

P2.03.96 Subzero Preservation Minimizes Histopathological Damage in Primary Kidney Cells Relative to Static Cold Storage
Heyyoung Kim, USA

P2.03.97 Renal Ischemia Reperfusion Injury Severity Differentiation Using Hyperpolarized Imaging
Alexander Zavriyev, USA

P2.03.98 Hypoxia Inducible Factor 2α (HIF2- α) Regulates Serine/Arginine-Rich Splicing Factor 5 (SRp55) to Induce RNA Splicing in Liver Ischemia-Reperfusion Injury in Mice and Humans
Kenneth Dery, USA

P2.03.100 Differing Functions of Estrogen Receptors alpha and beta on Tolerance of Renal IRI in Females
Matthew Levine, USA

P2.03.102 Transketolase Activation Improves Fatty Liver Ischemia Reperfusion Injury by Inhibiting Ferroptosis via Ncoa4 Downregulation
Maogen Chen, China

P2.03.103 Attenuation of Mitochondrial Damage via TRIM14-Mediated Mitophagy in Ischemia-Free Liver Transplantation
Zhiyong Guo, China

P2.03.104 Evaluating Intestinal Absorption During Ex-Situ Normothermic Perfusion of Porcine Multivisceral Grafts
Leonie van Leeuwen, USA

P2.04
Topic: Heart

P2.04.2 Does Glucose Control in Diabetic Heart Transplant Recipients Lead to Less Infectious Complications
David Chang, USA

P2.04.3 The Need for Overlap of Mycophenolate Transitioned to Sirolimus Therapy After Heart Transplantation: What Are the Pharmacokinetics vs Patient Experience?
Lawrence Czer, USA

P2.04.4 The Efficacy of Biodegradable Polymer Everolimus-Eluting Stents in Patients with Cardiac Allograft Vasculopathy
Masaki Tsuji, USA

P2.04.5 Outcomes of Heart Transplantation in Recipients with HIV
Tao Liang, USA

P2.04.6 IL-33 Enhances Group 2 Innate Lymphoid Cell-Driven Immunoregulation and Prolongs Allograft Survival in Murine Heart Transplantation
Weikang Pan, USA

P2.04.7 Comparison of Mycophenolate Dosing Strategies in Pediatric Heart Transplant
Dawn Nguyen, USA

P2.04.8 Heart Transplant in Cardiac Amyloidosis vs Other Restrictive Cardiomyopathies
Laura Wubker Diaz, USA

P2.04.9 Does Dosing of ATG Induction Impact Clinical Outcome After Heart Transplantation?
Peter Deckerman, USA

P2.04.10 Chronic Troponin Leak in Asymptomatic Patients After Heart Transplantation: What Does It Mean?
Avani Kanungo, USA

P2.04.11 Heart Transplant in Cardiac Amyloidosis vs Dilated Cardiomyopathy
Laura Wubker Diaz, USA

P2.04.12 Variation in Heart Transplant Allocation Across the USA
Luckmini Liyanage, USA

P2.04.13 Does Early CAV in the First 2-Years After Heart Transplantation Truly Make a Difference for Eventual Redo Transplant Outcomes?
Avani Kanungo, USA

P2.04.14 Can Sensitized Patient After Heart Transplant Be Safely Weaned off Prednisone?
Andriana Nikolova, USA

P2.04.15 Risk Factors for Severe Sternal Wound Infections After Heart Transplantation
Peter Deckerman, USA

P2.04.16 Outcomes of Patients Denied First Listing by Exception Request
Stephanie Golob, USA

P2.04.17 Protection of Transplanted Heart Function by Regulation of Na/K ATPase Activity
Leonardo da Costa, USA

P2.04.18 Understanding the Transplant Community's Priorities in Heart Allocation
Kelsi Lindblad, USA

P2.04.19 Quantitative Association Between Donor Smoking and Risk of Coronary Allograft Vasculopathy
Mason Lee, USA

P2.04.20 Restrictive Physiology Due to Microvascular Disease After Heart Transplant: When is It Time to Consider Retransplant?
Gina Jamero, USA

P2.04.21 Outcome of Tricuspid Valve Intervention After Heart Transplantation
Monet Welton, USA

P2.04.22 A Novel Web-Based Model to Predict Graft Survival After Heart Transplant: Clinical Utility and Limitations
Kiran Khush, USA

P2.04.23 What is the Timing of CMV and EBV Infection in Pediatric Heart Transplantation: A Comprehensive Institutional Review
Andrew Potter, USA

P2.04.24 Evaluation of Low-Dose vs High-Dose Cytomegalovirus Immune Globulin on Viremia in High-Risk CMV Mismatch Heart Transplant Recipients
Jose Lazo, USA

P2.04.25 The Modified Schwartz Equation Overestimates GFR Relative to Cystatin-C in Children Hospitalized with Heart Failure
Mohit Kalia, USA

P2.05
Topic: Infectious Disease

P2.05.1 Pre-Transplant Anti-Cytomegalovirus Immunoglobulin G Titers as Predictor of Cytomegalovirus Infection in Seropositive Filipino Kidney Transplant Recipients: A Retrospective Cohort Study
Vienne Pinlac, Philippines

P2.05.2 A Qualitative Study of Cytomegalovirus Awareness and Experience in Kidney Transplant Recipients
Afolarin Otunla, UK

P2.05.3 Assessment of a Cytomegalovirus Drug Resistant Testing Stewardship Initiative: A Pre- and Post-Intervention Analysis
Thomas Rust, USA

P2.05.4 Post-Prophylaxis CMV DNAemia in CMV Seronegative Heart, Kidney and Liver Recipients with Seropositive Donors (D+R-): A Comparison Across Organ Groups
Madeleine Heldman, USA

P2.05.5 Tolerability and Clinical Efficacy of Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis After Solid Organ Transplantation
Jennifer Chow, USA

P2.05.6 Impact of Absolute Lymphocyte Count-Guided Surveillance on Early Detection of Cytomegalovirus After Prophylaxis in High-Risk Kidney Transplant Recipients
Carlos Portales Castillo, USA

P2.05.7 Real World Maribavir Use in Solid Organ Transplant Patients in a Single Academic Center
Alia Boland, USA

Poster Listing

P2.05.8 Low-Dose Rituximab as Induction Therapy Does Not Increase the Risk of Cytomegalovirus Infection Following Kidney Transplantation
Tatsuya Hoshi, Japan

P2.05.9 Healthcare Provider (HCP) Preferences for Treatment of Post-Transplant Cytomegalovirus Infection (CMVi)
David Taber, USA

P2.05.10 Outcomes with Belatacept Conversion in CMV High-Risk Kidney Transplant Recipients
Kelsey Coffman, USA

P2.05.11 Real-World Use of Maribavir vs. Valganciclovir in Solid Organ Transplant (SOT) Patients with or without Refractory Cytomegalovirus Disease
Mirna Eshaya, USA

P2.05.12 Epidemiology of Recurrent Cytomegalovirus Infection in Solid Organ Transplant Recipients
Maria Vega Brizneda, USA

P2.05.13 Impact of Viremia Clearance on Outcomes in Transplant Recipients with Refractory Cytomegalovirus or Intolerance to Anti-Cytomegalovirus Agents
Paolo Grossi, Italy

P2.05.14 Predicting Cytomegalovirus Treatment Efficacy in Liver Transplant Patients Using the MELD Score
Yin Lai, Taiwan

P2.05.15 Evaluation of Cytomegalovirus "Blips" in Cardiothoracic Transplant Recipients
Brian Lindner, USA

P2.05.16 Lymphocytic Redemption: Letermovir Conversion for Primary CMV Prophylaxis in Thoracic versus Abdominal Transplant
Allison Yun, USA

P2.05.17 In-Depth T-Cell Phenotyping and Its Association with Relapse in Transplant Recipients with Human Cytomegalovirus (CMV) DNAemia
Victor Ferreira, Canada

P2.05.18 De Novo Letermovir for Cytomegalovirus Prophylaxis in High Risk Liver Transplant Recipients
Hanna Kleiboeker, USA

P2.05.19 Pre-Emptive CMV Monitoring in Intermediate-Risk Kidney Transplant Recipients on Belatacept
Mariam Ali, USA

P2.05.20 Real-World Use of Letermovir and Maribavir in Solid Organ Transplant: A Dual-Centre Study
Man Ting Xu, Canada

P2.05.21 Assessing Infection Risks with Belatacept in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analytic
Ibrahim Tawhari, Saudi Arabia

P2.05.22 Prevention Strategies Based on Risk of CMV Infection in Pediatric Kidney Transplants
Jose Souto, Brazil

P2.05.23 Cytomegalovirus Retinitis in Kidney Transplant Recipients
Maria del Carmen Rial, Argentina

P2.05.24 A Retrospective, Observational Analysis of Real-World Maribavir Treatment Patterns for Post-Transplant Refractory Cytomegalovirus Infection (CMVi) in the US
Daniele Gelone, USA

P2.05.25 A Historical Controlled, Single Center Open Label Pilot Study Comparing the Effectiveness and Tolerability of De Novo Initiation of Letermovir versus Valganciclovir for Cytomegalovirus Prophylaxis in African American Kidney Transplant Recipients
Idris Yakubu, USA

P2.05.26 Navigating the First Six Months: Prophylaxis Gaps and Cytomegalovirus DNAemia, Insights from Early Post-Transplant Analysis: A Single-Center Analysis
Naga Sumanth Reddy Gopireddy, USA

P2.05.27 Efficacy and Safety Comparison of Letermovir versus Valganciclovir for Use in Cytomegalovirus Prophylaxis in Adult Kidney Transplant Recipients
Lynley Heinrich, USA

P2.05.28 A Single-Center Review of Resistant CMV Infection in Solid Organ Transplant Recipients
Sean Tyler, USA

P2.05.30 Impact of Cytomegalovirus Mismatch Serostatus on Kidney Transplant Outcomes: A Single Center Retrospective Cohort Study
Vishnu Potluri, USA

P2.05.31 The Impact of Induction Therapy on CMV DNAemia in Kidney Transplantation: A Single Center Analysis
Sahil Grover, USA

Poster Listing

P2.05.32 The Impact of CMV-Seropositive Donor Status on Post-Transplant Outcomes in CMV-Seronegative Kidney Transplant Recipient: A US National Registry Study
Sara Belga, Canada

P2.05.33 Association of Risk Factors with Fasting Blood Glucose in Recipients with De Novo Hepatitis C Viremia of Donor Origin: Quantile Regression Analysis
Alfonso Santos, USA

P2.05.34 Infectious Disease Providers' Perspectives on the Benefits and Risks of Living Organ Donation for People with HIV in the USA
Karen Vanterpool, USA

P2.05.35 Barriers and Needs in Counseling Individuals with HIV Regarding HIV D+/R+ Living Organ Donation: Perspectives from Infectious Disease Providers in the USA
Karen Vanterpool, USA

P2.05.37 Evaluation of Ultra-Short Course Hepatitis B Immune Globulin (HBIG) in Combination with Antiviral Agents for Hepatitis B Recurrence Prevention in Liver Transplant Recipients
Uerica Wang, USA

P2.05.38 Hepatitis B Vaccination for Liver Transplant Recipients in the USA
Jeong Han, USA

P2.05.39 Utilization and Surveillance of HCV Ab+/NAT- Donors in Hepatitis C Naïve Solid Organ Transplant Recipients
Courtney Harris, USA

P2.05.40 Is Hepatitis B Immunity Failing Post-Transplant? Time to Rethink Re-Vaccination
Hena Brucia, USA

P2.05.41 APOL1 Status of HIV-Positive Kidney Transplant Recipients and Its Impact on Survival: A Single-Centre UK Experience
Fatima Malik, UK

P2.05.42 Spatiotemporal Molecular Characteristics of the Development of BK Polyomavirus-Associated Tumors
Yuchen Wang, USA

P2.05.43 Arboviral Infection in Solid Organ Transplant Recipients in Southern Thailand: A Case Series
Sorawit Chittrakarn, Thailand

P2.05.44 Outcomes of Sapovirus Infection in Kidney Transplant Recipients
Alan Koff, USA

P2.05.45 Underutilization of Vaccine Strategies to Optimize Protection Against Influenza in Solid Organ Transplant Recipients
Kapil Saharia, USA

P2.05.46 Home Infusion Short Course Remdesivir for Solid Organ Transplant Patients with COVID-19
Grace DeMarco, USA

P2.05.47 Characterizing the Urinary Microbiome in Renal Transplant Patients with Significant BK Polyomavirus (BKPyV) Reactivation
Rajat Nog, USA

P2.05.48 Seasonal Coronavirus Infection in Hospitalized Solid Organ Transplant Recipients: International Multicenter Study
Raul Rodriguez, USA

P2.05.49 Safety of Alternative Influenza Vaccination Strategies in Adult Solid Organ Transplant Recipients
Haya Hayek, USA

P2.05.50 Repeat Plasma and Urine Donor-Derived Cell-Free DNA Monitoring for Assessing BK Polyomavirus Nephropathy Outcomes
Gang Huang, China

P2.05.51 A Hydrogel-Based Point-of-Care Testing Method for Rapid Quantitative Detection of Urinary Polyomavirus DNA in Kidney Transplant Recipients
Chen Dai, China

P2.05.52 Safety and Immunogenicity of an Adjuvanted Monovalent COVID-19 Vaccine in Kidney Transplant Recipients with Low SARS-CoV-2 Antibody
William Werbel, USA

P2.05.53 Humoral Immunity Against Highly Pathogenic Avian Influenza is Low in Transplant Recipients and Minimally Augmented by Seasonal Vaccination
Moreno Rodrigues, USA

P2.05.54 XBB.1.5 Monovalent COVID-19 Vaccination Improves JN.1 Neutralization in Solid Organ Transplant Recipients
Woudase Gallo, USA

Poster Listing

P2.05.55 Variant Updated Novavax COVID-19 Vaccination is a Safe Alternative to mRNA Vaccines in Transplant Recipients
Xori Green, USA

P2.05.56 Efficacy and Safety of Conversion from Mycophenolate Mofetil to Mizoribine in Kidney Transplant Recipients with BK Polyomavirus Nephropathy
Gang Huang, China

P2.05.57 Impact of BK Viremia Management on Progression to Nephropathy: A Single-Center Retrospective Review
McKenna Person, USA

P2.05.58 Spatially Resolved Transcriptomic Profiling Reveals Immune-Stromal Dysregulation in BK Polymavirus-Associated Nephropathy
Gang Huang, China

P2.05.59 Post-Pyloric Enteral Immunoglobulin for Chronic Norovirus in Solid Organ Transplant Recipients
Fahad Buskandar, USA

P2.05.60 Low IgG Titer Against SARS-CoV-2 Puts Significant Risk on Kidney Transplant Recipients in the Post-Pandemic Era
Masayoshi Miura, Japan

P2.05.61 Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients with Prior Omicron Infection - Limited Neutralization but Robust CD4+ T-Cell Activity
Victor Ferreira, Canada

P2.05.62 Kinetics of Donor Derived Cell-Free DNA (dd-cfDNA) in BK Virus Infection: A Potential Diagnostic Biomarker
Anissa Vachachira, USA

P2.05.63 Beyond Neutralization: Transplant Recipients Display Deficient Antibody-Dependent Cellular Phagocytosis (ADCP) Responses Following SARS-CoV-2 Vaccination
Victor Ferreira, Canada

P2.05.64 Infectious Disease Complication in Kidney Transplant Recipients with Belatacept: Systematic Review and Meta-Analysis
Brian Yousif, USA

P2.05.65 Cross-Reactive Serologic Responses Arise after Early Post-Transplant Influenza Immunization
Anoma Nellore, USA

P2.05.66 Equivalent RSV Specific IgG and IgA Increases After Vaccination in Transplant Recipients
Andrew Karaba, USA

P2.05.67 Immunological Response and Clinical Efficacy of SARS-CoV-2 Vaccination in Kidney Transplant Patients
Roman Safranek, Czech Republic

P2.05.68 Off-Target Effects of Mycophenolic Acid on BK Polyomavirus Replication in Human Primary Renal Proximal Tubular Epithelial Cells
Caroline Hillenbrand, Switzerland

P2.05.69 Incidence of BK Viremia Among Kidney Allograft Recipients in Qatar
Mohammad Al Awad, Qatar

P2.05.70 Impact of COVID-19 Infection and Vaccination on Long-Term Graft Function in Kidney Transplant Recipients
Guilherme Ferreira, Brazil

P2.05.71 Long-Term Safety of Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients
Xori Green, USA

P2.05.72 Parainfluenza Infection in Solid Organ Transplant Recipients - A Review of Clinical Presentation, Treatment, and Outcomes
Melissa Kerkelis, USA

P2.05.73 SARS-CoV-2 Infection Incidence in Solid Organ Transplant Recipients during XBB and JN.1 Sublineage Waves
Woudase Gallo, USA

P2.05.74 Big Data: Human Metapneumovirus is Implicated in Acute Rejection in Solid Organ Transplant Patients
Eric Altneu, USA

P2.05.75 Efficacy and Safety of Pemivibart Monoclonal Antibody Prophylaxis in Immunocompromised Transplant Patients: A Retrospective Cohort Study
Christine Atallah, USA

P2.05.76 West Nile Virus in Kidney Transplant Recipients: Insights from a Colorado Retrospective Case Series
Shannon Lyons, USA

P2.05.77 Management of Persistent Asymptomatic EBV Viremia with Rituximab in Four Adult Kidney Transplant Patients: A Single-Center Experience
Nouman Akbar, USA

P2.05.78 CD8+ T Cell Immunity and Exhaustion in Asymptomatic EBV+ Pediatric Heart Transplant Patients That Carry Chronic EBV Loads
Camila Both, USA

P2.05.79 The Role of NKG2A+ NK Cells in the Control of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disorders
Cecilia Ledezma-Soto, USA

P2.05.80 Variability in the Reported Prevalence of EBV-Seronegative Status Among US Kidney Transplant Recipients
Vishnu Potluri, USA

P2.05.81 Time-Varying Risk of Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients by Donor/Recipient Epstein-Barr Virus Serostatus
Christie Rampersad, Canada

P2.05.82 Time-Varying Risk of Post-Transplant Lymphoproliferative Disorder in Pancreas Transplant Recipients by Donor-Recipient Epstein-Barr Virus Serostatus
Christie Rampersad, Canada

P2.05.83 Successful Use of Belatacept in Patients Who Received HCV NAT(+) Kidneys and Receiving DAAs
Sarthak Virmani, USA

P2.05.84 Longitudinal Assessment of BK Polyoma Virus Specific Immune Responses After Kidney Transplantation
Ambreen Azhar, USA

P2.05.85 Clinical, Histopathological Characteristics and Long-Term Follow-Up of BK Polyomavirus Nephropathy After Renal Transplantation
Anjali Gupta, India

P2.05.86 Conversion of Tacrolimus to Cyclosporine or Low-Dose Belatacept for Refractory BK Virus Kidney Transplant Nephropathy
Irfan Moinuddin, USA

P2.05.87 A Multiclass Machine Learning (ML) Model With EBV-Specific T-Cells Predicts EBV Viremia and EBV-Induced Post-Transplant Lymphoproliferative Disease (PTLD) After Liver or Intestine Transplantation
Udeme Ekong, USA

P2.07
Topic: Kidney

P2.07.1 Impact of Out-of-Sequence Kidney Transplantation on Access and Equity for Marginalized Populations: Effect of KAS-250 Allocation Policy
Christopher Webb, USA

P2.07.2 5-Year Outcome of TELE Kidney Transplantation Clinic in a Tertiary Center in Thailand
Salin Wattanatorn, Thailand

P2.07.3 Digital Community Engagement Among Transplant Recipients, Donors, and Care Partners: A Four-Year Analysis
Karin Hehenberger, USA

P2.07.4 Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life in Kidney Transplant Recipients
Courtney Hurt, USA

P2.07.5 De Novo Anxiety and Depression in KT Recipients: A Large, National Cohort Study Using Electronic Health Records
Kelly Terlizzi, USA

P2.07.7 Depression Symptom Severity is Associated with Social Participation Among Kidney Transplant Recipients
Nolan Marblestone, Canada

P2.07.8 The Longest-Living Human with a Xenograft: A Qualitative Case Study
Macey Levan, USA

P2.07.9 Measures of Cognitive Function in Patients Awaiting and Undergoing Kidney Transplant
Kristy Engel, USA

P2.07.10 Air Pollution Contributes to Cognitive Impairment and Dementia Among Older, Minoritized Kidney Transplant Candidates
Jingyao Hong, USA

P2.07.11 Stanford Integrated Psychosocial Assessment for Transplant as a Predictor for Kidney Transplant Rejection
George Grant, USA

P2.07.12 Perceived Support Among Unpaid Caregivers Along the Kidney Transplant Trajectory
Rhiannon Reed, USA

Poster Listing

P2.07.13 Perspectives and Experiences of Women with a Kidney Transplant on Access to Healthcare - An International Qualitative Study
Nicole Scholes-Robertson, Australia

P2.07.14 Sources of Information in Pre Renal Transplantation
Ruben Omar Schiavelli, Argentina

P2.07.15 Dermatologic Conditions in Inner-City Kidney Transplant Recipients (KTRs): High Prevalence, Effects on Quality of Life (QoL) and Use of Home Remedies
Gabriel Cruz, USA

P2.07.16 Depression and Frailty in Kidney Transplant Candidates
Christine Liu, USA

P2.07.17 Change in Allograft Function of Pediatric Kidney Transplant Recipients from Childhood to Adolescence
Sandesh Parajuli, USA

P2.07.18 Caregiver Confirmation in an Era of Reduced In-Person Interactions and Its Effects on Patient Outcomes Post Kidney Transplant
Christina Delvalle, USA

P2.07.19 Depressive Symptom Improvement After KT for Some but Not All Recipients
Nan-Su Huang, USA

P2.07.20 It Matters Who is in Your Inner Circle: Exploring the Association Between Social Capital and Kidney Transplant Outcomes
Joy Obayemi, USA

P2.07.21 Changes in Living Kidney Donors' Expected and Received Donation Benefits and the Influence of Donor-Related Adverse Events
Angela Gifford, USA

P2.07.22 What's PACT Got to Do with It? Association of Psychosocial Assessment with Post-Transplant Outcomes
Goni Katz-Greenberg, USA

P2.07.23 The Lived Experiences of Patients Seeking Renal Autotransplant: A Qualitative Study
Carrie Thiessen, USA

P2.07.24 Pattern of Menstrual Cycle After Kidney Transplantation in Reproductive Women
Muhammad Tassaduq Khan, Pakistan

P2.07.25 Frailty and Its Association with PROMIS Physical Function T-Scores in Patients on Kidney Replacement Therapy
Istvan Mucsi, Canada

P2.07.28 Sleep Disturbances in a Population of Inner-City Kidney Transplant Recipients (KTRs) Are Common and Affect Quality of Life (QoL)
Rose Cytryn, USA

P2.07.29 The Importance of Virtual Peer-to Peer Support Groups for Organ Transplant Patients in Their Journey Towards Physical and Psychosocial Well-Being
Karin Hehenberger, USA

P2.07.30 Tired but Trying to Transition- Understanding the Cognitive and Psychosocial Challenges in AYA Kidney Transplant Recipients
Allyson Friederich, USA

P2.07.31 Psychosocial Factors Associated with Cognitive Functioning in Patients Who Are Being Considered or Listed for Kidney Transplant
Megan Ramthun, USA

P2.07.32 Quality of Life and Caregiver Burden Trajectories Among Caregivers of Kidney Transplant Recipients
Chethan Puttarajappa, USA

P2.07.33 Attitudes Towards Kidney Xenotransplantation: What Does the Recent Literature Say?
Karim Soliman, Canada

P2.07.34 Alterations in Stem-Like Memory T Cell After Kidney Transplantation: A Potential Mechanism of Impaired T Cell Homeostasis
Mark Stegall, USA

P2.07.35 Measuring the Recipient Response to Induction Immunosuppression, Multi-Omic Prototyping of the Circulating Pre-Reperfusion Milieu
Michael Kueht, USA

P2.07.36 Induction Immunosuppression with Basiliximab: Investigating the Infection-Rejection Dynamic in SLK Recipients
Avery Koi, USA

P2.07.37 The Coefficient of Variation of Tacrolimus QD at 1 Year Posttransplant is Associated with Mid-Long Term Kidney Graft Function
Eri Sekido, Japan

Poster Listing

P2.07.38 Outpatient Basiliximab Induction in Low-Immunologic Risk Kidney Transplant Recipients Provides Significant Pharmacoeconomic Advantages without Impacting Clinical Outcomes
Matthew Gillespie, USA

P2.07.39 Outcome of Induction with Very Low Dose Anti Thymocyte Globulin in Renal Transplantation in Pakistan
Khawar Sultan, Pakistan

P2.07.40 The Effect of Immunosuppressant Dose Variability on Diversity of Gut Microbiome in Kidney Transplant Recipients
Mehdi Nayebpour, USA

P2.07.41 Strategic Minimization of Immunosuppression Maintains Low Rejection Rates and Reduces Infection
Athena Brooks, USA

P2.07.42 Cardiovascular Outcomes in Kidney Transplant Recipients Based on Induction Agent - A Single Center Experience
Brenda Astorga, USA

P2.07.43 Empasiprubart in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function: A Phase 2 Trial in Progress
Stanley Jordan, USA

P2.07.44 Real-World Outcomes of Reduced Tacrolimus with Everolimus versus Standard Tacrolimus with Mycophenolate Mofetil in Kidney Transplant Recipients: A Retrospective Observational Study
Junji Uchida, Japan

P2.07.45 Longitudinal Analysis of q2m Belatacept Maintenance: Infection Trends in Low Immunologic Risk Kidney Transplant Recipients
Johanna Christensen, USA

P2.07.46 Quantitative Measurement of Tacrolimus-Induced Tremor in Renal Transplant Recipients: A Prospective Feasibility Study
Annudesh Liyanage, Canada

P2.07.47 Clinical Evaluation of the Importance of IgG Levels in Kidney Transplant Recipients
Yasushi Mochizuki, Japan

P2.07.48 Leveling Up Immunosuppression: A 4-Drug Approach with Belatacept
Dayoung Moon, USA

P2.07.49 Treg Therapy to Minimize Immunosuppression (IS) in Living Donor Kidney Transplant (LDKTx)
Joseph Leventhal, USA

P2.07.50 Clinical and Histopathological Outcomes of Kidney Transplant Recipients Converted to Belatacept-Based Immunosuppression
Juan Pablo Huidobro Espinosa, USA

P2.07.51 Addition of Belatacept to Tacrolimus-Mycophenolate-Prednisone (Quadruple Immunosuppression) in Kidney Transplant Recipients with Donor Specific Antibodies and/or Antibody Mediated Rejection
Anne Przybylski, USA

P2.07.52 GFR Stabilizes and Donor Specific Antibody Levels Fall After Adding Belatacept to a Low Dose Tacrolimus/Mycophenolate/Prednisone Regimen in Nonadherent Pediatric and Adolescent Kidney Transplant Recipients
Niloufar Nikfarjam, USA

P2.07.53 Cost Effectiveness Evaluation of Tolerance Induction
Nahel Elias, USA

P2.07.54 Benefit of Belatacept Conversion with Early Poor Graft Function: Is It Ever Futile?
Paige Dunton, USA

P2.07.55 Targeted Therapy for De Novo IgA Nephropathy in a Kidney Transplant Recipient: A Case Report and Emerging Therapeutic Strategies
Monika Koirala, USA

P2.07.56 The Promise and Perils That Novelty Bestows: A Case of Pulmonary Mucor in a Patient Treated with Tegoprubart
Krishna Brucia, USA

P2.07.57 Use of Donor Derived Cell-Free DNA (dd-cfDNA) to Facilitate Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression
Courtney Kelley, USA

P2.07.58 Which Bela is Best? Evaluating Outcomes Among Various Belatacept Dosing Strategies in Kidney Transplant Recipients
Corey Burrelli, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.07.59 Tacrolimus Toxicity in Kidney Transplant Recipient After Wedge Liver Resection: A Case Report
Nuanjanthip Naiyarakseree, Thailand

P2.07.60 Sensitized and Unsensitized Kidney Transplant Recipients on a Belatacept-Based Regimen Demonstrate Comparable Allograft Outcomes
Dana Pierce, USA

P2.07.63 Outcomes of Belatacept with Low-Dose Tacrolimus in Kidney Transplant
Keaton Tauer, USA

P2.07.65 Comparison of Immunosuppression Regimens on Outcomes of High KDPI Allograft Recipients
Dana Pierce, USA

P2.07.67 Long-Term Risk of Infectious Disease on Living Kidney Donor: A Nationwide Population Cohort Study
Chih-Yang Hsu, Taiwan

P2.07.68 Cancer Screening Examination is Essential After Living Donor Kidney Transplantation
Takahisa Hiramitsu, Japan

P2.07.69 Partnering with a Community Advisory Board to Improve Research on Living Kidney Donation
Katya Kaplow, USA

P2.07.70 DMSA-Based Pre-Donation Differential Renal Function Does Not Significantly Impact the New Baseline Glomerular Filtration Rate: A Retrospective Five-Year Cohort Study of 125 Kidney Donors
Hannah Kek, Singapore

P2.07.72 Outcomes of Preformed Anti-HLA Donor-Specific Antibodies Positive Kidney Transplantation at a Single Center in Japan: Successful Long-Term Graft Survival
Yoshihiro Itabashi, Japan

P2.07.74 Incidence of Postoperative Cytomegalovirus and BK Polyoma Virus Infections and Graft Loss in ABO Incompatible Renal Transplant Recipients: A Multicenter Retrospective Study
Hirotake Kodama, Japan

P2.07.75 Recipient BMI is Not a Predictor of Outcomes in Sequential Sensitized Renal Transplants: Results from the STEP Study (Sequential Transplant Predictor Study)
Hemant Sharma, UK

P2.07.76 Long term outcomes of Right Renal Vein Lengthening using gonadal vein after Laparoscopic Right Donor Nephrectomies in Living Donor Transplantation
Sarbpreet Singh, India

P2.07.77 Laparoscopic Left Donor Nephrectomy: Experience of 564 Cases
Omprakash Prajapati, India

P2.07.78 Graft Outcomes in Living Donor Kidney Transplants from Marginal Donors: A Multicenter Retrospective Study
Hirotake Kodama, Japan

P2.07.79 Evaluation of Immune Status of Renal Transplant Recipients with Functioning Graft over 20 Years
Umamaheswara Rao Ch, India

P2.07.80 Public Knowledge of Kidney Disease and Perceptions of Living Kidney Donors
Shreya Madan, USA

P2.07.81 Improving Living Kidney Donor Solicitation: A Systematic Review and Meta-Analysis of Interventions
Melanie Wyld, Australia

P2.07.83 The Impact of Family Size on Sibling Living Donor Transplant in the USA
Douglas Keith, USA

P2.07.84 Post-Operative Outcomes After Robot-Assisted Laparoscopic Donor Nephrectomy vs Laparoscopic Hand-Assisted Donor Nephrectomy
Sue Fu, USA

P2.07.85 Influence of Body Mass Index on the Perioperative Period of Living Donor Kidney Transplantation
Masahiro Todaka, Japan

P2.07.86 Risk Factors for One Year Post-Nephrectomy Decline in Renal Function in Living Kidney Donors: Analysis Stratified by GFR Reduction Percentiles
Alfonso Santos, USA

P2.07.87 The Value and the Impact of a Living Donor Kidney Transplant Program from the Different Stakeholders Perspectives
Ignacio Revuelta, Spain

P2.07.88 Prospective Living Kidney Donors' Motivations to Donate by Relation to Intended Recipient
Katya Kaplow, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.07.89 Development and Validation of Virtual Crossmatch Algorithm in Living Donor Kidney Transplantation
Naoya Iwahara, Japan

P2.07.90 Misconceptions Regarding Living Kidney Donation Among Adolescents and Young Adults with Chronic Kidney Disease
Alexandra Bicki, USA

P2.07.91 The First Comprehensive Study on Living Donor Kidney Transplantation in Azerbaijan
Rashad Sholan, Azerbaijan

P2.07.92 Role of Broad Gene Panel for Kidney Disease in Kidney Transplant Donor Selection: A Case Study
Vasanthi Balaraman, USA

P2.07.93 Prognostic Value of Early eGFR Improvement After Living-Donor Kidney Transplantation
Yuichi Machida, Japan

P2.07.94 Evolution of Renal Ultrasound Parameters from Pre-Donation to Post-Transplantation in Living Kidney Donor Recipients in British Columbia, Canada
Hyunwoong Harry Chae, Canada

P2.07.95 Is Vascular Reconstruction Before Transplanting a Right-Sided Living Donor Kidney a No Brainer?
Laura Niño Torres, USA

P2.07.96 Donor Detours: Understanding the Barriers to Living Kidney Donation
Alexandra Kastelz, USA

P2.07.98 Surgical Complications and Risk Factors in 2,095 Cases of Pure Retroperitoneoscopic Living Donor Nephrectomy: A 20-Year Experience
Yasuo Ito, Japan

P2.07.99 Comparative Outcomes of Single-Port Robotic versus Open Surgical Approaches in Living Donor Kidney Transplantation
Hafiz Umair Siddiqui, USA

P2.07.100 Access to Transplantation Among Prior Organ Donors
Suhani Patel, USA

P2.07.101 IDEA: Development of the First Decisional Support Tool for Black American Potential Living Kidney Donors Contemplating APOL1 Genetic Testing
Heather Gardiner, USA

P2.07.102 Infectious Complications After Robotic Guided vs Open Living Donor Kidney Transplantation
Yoichiro Natori, USA

P2.07.103 Initial Experience with Single-Port Robotic Donor Nephrectomy Using the da Vinci SP System: A Case Series Evaluating Safety, Feasibility, and Early Outcomes
Francheska Nieves-Rivera, USA

P2.07.104 Living-Donor Kidney Transplant in Hereditary Angioedema: A Multidisciplinary Approach
Ezequiel Varela, Argentina

P2.07.106 Case Study: Impact of Creatine Supplementation on Kidney Function Tests in an Active Living Kidney Donor
Kelley Hitchman, USA

P2.07.107 The Outcomes of Kidney Transplants Between Elderly Spouses Are Well Tolerated
Yuki Miyauchi, Japan

P2.07.109 Follow-Up Matters: Variations in Living Kidney Donor Follow-Up by Citizenship Status
Gayathri Menon, USA

P2.07.110 Outcomes of Kidney Transplantation with Sacrifice of a Small Upper Pole Artery
Takatora Sawada, Japan

P2.07.111 Telemedicine for Living Kidney Donation: Provider Focus Groups Qualitative Study
Fawaz Al Ammary, USA

P2.07.112 Living Donor Awareness and Support: An Experiential Strategy to Combat Organ Trafficking in Resource-Limited Countries
Obi Ekwenna, USA

P2.07.113 Robotic-Assisted Living Donor Nephrectomy versus Laparoscopic Living Donor Nephrectomy: A Propensity Score Matched Analysis
Haaris Kadri, USA

P2.07.115 Rapid Reduction of Mycophenolate Mofetil for Treating Cytomegalovirus Infection in Renal Transplant Patients
Allen Chen, Taiwan

P2.07.116 Recovery of Living Kidney Donations by Race After the COVID-19 Pandemic
Deena Brosi, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.07.117 Racial and Socioeconomic Disparities in Live Donor Kidney Transplant Access
Amit Tevar, USA

P2.07.118 Evaluation of Pregnancy in Kidney Transplant Recipient: A Nationwide Study
Essa Abuhelaiqa, Qatar

P2.07.119 Does Volume Matter? Trends and Outcomes in Right-Sided Living Donor Nephrectomy
Syed Omair Nadeem, USA

P2.07.120 Use of a Telehealth Based Patient and Family Support Group to Increase Patient Comfort with Pursuing Living Donor Outreach
Wanda Rojas, Canada

P2.07.121 Antibody Reduction Between Double-Filtration Plasmapheresis and Immunoadsorption in ABO-Incompatible Kidney Transplantation: The Largest Cohort in Thailand
Chalida Rattanapinyopong, Thailand

P2.07.122 Dual Kidney Transplantation: How to Do It
Dai Nghiem, USA

P2.07.123 Analysis of Predictive Analytics' "Time to Next Offer" Predictive Accuracy
Morgan Stuart, USA

P2.07.127 Frequency of Acute Kidney Injury in Renal Transplant Recipients during the First Month After Transplant: A Single Centre Study in a Resource Limited Setting
Adil Manzoor, Pakistan

P2.07.130 Single Surgeon Transition from Open to Robotic-Assisted Kidney Transplantation: Trends, Learning Curve, and Comparative Outcomes
Hafiz Umair Siddiqui, USA

P2.07.131 Incidence and Causes of Surgical Reintervention Following Living Kidney Transplantation: Insights From 534 Consecutive Cases
Nao Nakajima, Japan

P2.07.132 Let s Get Them United: In Block Reconstruction for Dual Graft Kidney Transplantation
Francisco Osella, Argentina

P2.07.133 Microvascular Anastomosis for Accessory Renal Arteries in Living Donor Kidney Transplantation. A Retrospective Study of Feasibility and Long-Term Outcomes
Darren Gordon, USA

P2.07.134 Pretransplant Inguinal Hernia Repair May Be a Risk Factor for Surgical and Urological Complications in Kidney Transplantation
Ronen Ghinea, Israel

P2.07.135 Ex-Vivo Ureteroscopy to Help Transplant a Kidney with Significant Stone Burden: A Case Report
Kunal Yadav, USA

P2.07.136 Horseshoe Kidney Transplantation: A Single Institution Case Series
Hassan Abbas, USA

P2.07.137 Programmatic Development of a Minimally Invasive Renal Transplant Program at a Single High-Volume Center: A 6-Year Retrospective Review
Michael McCabe, USA

P2.07.138 Impact of Aortoiliac Calcifications on Kidney Transplant Survival: A Latin American Cohort Study
Juan Yglesias Rosales, Costa Rica

P2.07.139 Evaluation of Transplant Ureter Perfusion Using Indocyanine Green Fluorescence Imaging: A Single-Center Experience
Keita Okubo, Japan

P2.07.140 Utilization of Primary Transplant Renal Vessels for Secondary Living Donor Kidney Transplantation: A Feasible Alternative for Patients with Vascular Challenges
Keita Okubo, Japan

P2.07.141 Overcoming Artery Size Mismatch Before End-to-End Arterial Anastomosis during Living Kidney Transplantation: Plication Technique
Kiyoshi Setoguchi, Japan

P2.07.144 Feasibility of Skin Flap as a Tool for Remote Site Monitoring of Allograft Rejection in Deceased Donor Kidney Transplant
Sarbpreet Singh, India

P2.07.145 Usability Testing of a Novel Intraoperative Cooling System for Kidney Transplantation: A Qualitative Analysis
Keith Hansen, USA

Poster Listing

P2.07.146 Impact of Donor Creatinine, Urine Output and Ischemia Time on Transient Increase in Systolic Blood Pressure Immediately Following Kidney Reperfusion
Michal Macech, Poland

P2.07.150 A Continuous Flow Cooling Sleeve (Cool Sleeve) for Kidney Transplantation to Minimize Warm Ischemia Time and Its Consequences - A Pilot Study in a Porcine Model
Francisco Reyna-Sepulveda, Mexico

P2.07.151 Renal Transplant with Complex Vascular Anatomy: A Single Center Experience
Omprakash Prajapati, India

P2.07.152 The Miami Transplant Institute Kidney Transplant Technique
Armando Salim Munoz Abraham, USA

P2.07.153 A Systematic Review of the Utility of Contrast Enhanced Ultrasonography in the Assessment of Renal Allograft Function
Rajith Amaratunga, Australia

P2.07.154 Is Delayed Graft Function in Renal Transplantation Surgeon Driven
Rohan Bhattacharjya, Australia

P2.07.155 Acceptability of Elderly Donors in Living Kidney Transplantation: Long-Term Outcomes from Donors Aged 70 Years or Older
Yoichi Kakuta, Japan

P2.07.156 Comparison of Different eGFR Formulas to Measured Glomerular Filtration Rate Using Inulin Clearance in Living Kidney Donors
Yoichi Kakuta, Japan

P2.07.157 Impact of Age Difference Between Donor and Recipient in Renal Transplantation
Jiyoon Choi, South Korea

P2.07.158 Development and Evaluation of a Culturally Targeted Counseling Training Program on APOL1 and Living Donation
Elisa Gordon, USA

P2.07.159 Assessing the Predictive Ability of the Living Kidney Donor Profile Index for Graft Survival
Neetika Garg, USA

P2.07.161 Superior Efficiency of High-Volume Specific Immunoadsorption Than Plasma Exchange in ABOi LDKT with Medium or High Isoagglutinin Titters
Ignacio Revuelta, Spain

P2.07.162 Facilitating Living Kidney Donation: A Retrospective Evaluation of Weight Loss Interventions to Support Kidney Donation
Roslyn Mannon, USA

P2.07.163 Perspectives of Transplant Professionals on Gender Differences in Living Kidney Donation: A Semi-Structured Interview Study
Eswari Vilayur, Australia

P2.07.164 Assessing the Impact of Social Deprivation on Living Donor Candidates' Approval to Donate: Analysis of the U.S. SRTR Living Donor Collective
Amy Waterman, USA

P2.07.165 Experiences Regarding Use of Genetic Testing in Living Donor Candidate Evaluation: A Survey of US Transplant Center Staff
Krista Lentine, USA

P2.07.166 Barriers to Living Donation in Young Adults: Insights from Kidney and Liver Donor Evaluations
Weslyn Bunn, USA

P2.07.167 Assessment of Potential Kidney Donors for Future Risk of Diabetes Using Validated Indices Derived from Oral Glucose Tolerance Test
Katafan Achkar, USA

P2.07.168 The Effect of Social Determinants of Health versus Medical and Surgical Guidelines on Disparities in Living Kidney Donation in Minority Populations
Wasim Dar, USA

P2.07.169 The Right Dilemma: Exploring Surgeon Comfort with Right Living Donor Nephrectomy
Syed Omair Nadeem, USA

P2.07.170 Daratumumab (Anti-CD38) for Treatment of Antibody-Mediated Rejection of Renal Allografts
Ashley Vo, USA

P2.07.171 BK Virus Nephropathy (BKVN) and Antibody-Mediated Rejection (AMR): Impact on 1-Year Graft and Patient Survival in Kidney Transplant Recipients
Ruchi Naik, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.07.172 ABO Incompatible Kidney Transplantation: The Best and the Worst Incompatibilities
Lama Amer, Saudi Arabia

P2.07.173 Two Cases of Hyperacute Rejection After AB0 Incompatible Kidney Transplantation: What Lurks Behind the Titre?
Kerstin Huebel, Switzerland

P2.07.174 The Outcomes of Mixed Rejection by Biopsy-Based Transcriptomics
Eva Girmanova, Czech Republic

P2.07.175 Potential of Simultaneous Monitoring of IgG and IgM Titers in Improving ABO-Incompatible Kidney Transplant Outcomes for Blood Type O Recipients
Hyeeun Kwon, South Korea

P2.07.176 Validation of an Automated Diagnosis System for Kidney Transplant Pathology: A Comparison with Pathologists' Diagnoses
Jun Matsushita, Japan

P2.07.178 Rol of Microvascular Injury (MVI) in Kidney Transplant Recipient
Luis Roberto Leon, Argentina

P2.07.180 Clinical Outcomes and Potential Causes of Antibody-Mediated Rejection without Donor-Specific Antibody in Kidney Transplant Patients
Kyu Hyun Han, South Korea

P2.07.182 Plasma Cell-Rich Acute Rejection (PCAR) in Kidney Transplantation: Should It Be Considered a Subtype of Antibody-Mediated Rejection?
Lama Amer, Saudi Arabia

P2.07.183 Pre-Emptive Bortezomib Prevents Antibody-Mediated Rejection and Preserves Renal Function in Sensitised Renal Transplant Recipients
Anantharaman Vathsala, Singapore

P2.07.184 Acute Kidney Allograft Dysfunction is Associated with Increased Number of Non-HLA Antibodies in Absence of Donor Specific HLA Antibodies
Tambi Jarmi, USA

P2.07.185 Long Term Outcomes of Early Active Antibody Mediated Rejection Treated with Eculizumab
Jose Arriola-Montenegro, USA

P2.07.186 Improved Survival of Kidney Graft After Repetitive Treatment in Patients with Antibody Mediated Rejection and Persistent Microvascular Inflammation with Active Histologic Surveillance
Erick Zuñiga Gonzalez, Mexico

P2.07.187 HLA-A/B/C and HLA-DRB1/DQB1 Mismatching Among Kidney Transplant Recipients with Post-Transplant Immune-Mediated Graft Outcomes: A Retrospective Study from a Mexican Tertiary-Care Center
Angel Ortiz Bello, Mexico

P2.07.191 Optimization of Immunosuppressive Therapy by Epitope Matching
Yuki Hasegawa, Japan

P2.07.192 Out-of-Sequence Deceased Donor Kidney Allocation is Not Associated with De Novo Donor Specific Antibodies or Antibody Mediated Rejection
Dylan Isaacson, USA

P2.07.194 Daratumumab Monotherapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Efficacy, NK Cell Dynamics, and Long-Term Outcomes
Yu Cui, China

P2.07.195 The Impact of Tocilizumab and Clazakizumab on Molecular Rejection and Injury Scores in Chronic-Active Antibody-Mediated Rejection in Kidney Transplantation: A Case Series
Kai Castrezana Lopez, Switzerland

P2.07.196 Trial Design of the Phase 2 Study SHAMROCK Evaluating the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Kidney Transplant Recipients with Antibody-Mediated Rejection
Stanley Jordan, USA

P2.07.197 Outcome of Renal Transplant in the Elderly: A Single Center Study in a Resource Limited Country
Adil Manzoor, Pakistan

P2.07.198 Calling All DSA Positive Allows Existing Banff Guidelines to Diagnose Many More Cases of Histologic ABMR Currently Missed Only Because They Are DSA-Negative
Katelynn Madill-Thomsen, Canada

P2.07.199 Dynamics of Antibodies in Patients with Pre Transplant and De Novo DSAs
Taba Kheradmand, USA

P2.07.200 TRANSCEND: A Phase 3 Trial of the Anti-CD38 Antibody Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection
Georg A. Bohmig, Austria

P2.07.201 Differences in Histologic Progression of Microvascular Inflammation on Surveillance Biopsy Among De Novo DSA, Preexisting DSA, and Negative DSA Kidney Transplant Recipients
Suryanarayanan Balakrishnan, USA

P2.07.202 Conversion from Tacrolimus to Full Dose Cyclosporin Controls BK Virus Infection without DSA Formation
Moussa Jabbour, USA

P2.07.203 Safety and Efficacy of Anti-CD38 Therapy (Isatuximab) for Antibody Mediated Rejection in Kidney Transplantation
Anshul Bhalla, USA

P2.07.204 Pre-Health Students Can Extend the Kidney Transplant Navigator Workforce to Help Patients Search for Living Donors
Jeff Belkora, USA

P2.07.205 Single Antigen Bead ABO Assay Enables Successful ABO-A2-Incompatible Kidney Transplantation
Cathi Murphey, USA

P2.07.206 1,000 Robotic Operations: Establishing Standards for the Safe Integration of Robotic Innovation in Transplant Surgery
Amen Kiani, USA

P2.07.207 Hypothermic Machine Perfusion for Renal Preservation in Low-Income Regions
Marco Arizmendi, Mexico

P2.07.208 Preliminary Results of the Use of Renal Perfusion Machines in Argentina
Liliana Bisigniano, Argentina

P2.07.209 Not All Antibodies are Created Equal: gG Glycosylation and Severity of Antibody-Mediated Rejection in Kidney Transplantation
Johan Noble, France

P2.08
Topic: Liver

P2.08.3 Risk Stratification of Hepatocellular Carcinoma Patients Undergoing Living Donor Liver Transplantation Using JAPAN Criteria: Proposal for a Novel Predictive Model
Yuki Imaoka, Japan

P2.08.4 Augmented Donor Liver-Derived NK Cell Therapy for HCC and Bacteremia Prevention Post-Liver Transplantation
Masahiro Ohira, Japan

P2.08.5 Evaluating the Efficacy of Locoregional Therapy in Achieving Complete Pathological Response in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation
Ola Shaltout, USA

P2.08.6 Outcomes of Living Donor Liver Transplants for Hepatocellular Carcinoma in the Modern Era
Binuri Hapuarachchy, USA

P2.08.7 Culturing Whole Human Liver with Cancer for Disease Modeling and Drug Screening
Qiang Zhao, China

P2.08.8 The Impact of Machine Perfusion on Liver Transplantation for Hepatocellular Carcinoma
Luckshi Rajendran, USA

P2.08.9 Re-Emergence of Early Liver Transplant Access for Hepatocellular Carcinoma in the Era of Normothermic Machine Perfusion: Time to Re-Define Allocation Policy?
Toshihiro Nakayama, USA

P2.08.10 Disparities in Referral for Liver Transplant Evaluation in Individuals with Hepatocellular Carcinoma: The California Liver Network
Monica Tincopa, USA

P2.08.12 Access to Referral, Evaluation, and Listing for Liver Transplantation in Patients with HCC: A National Analysis of Granular EHR Data
Conor Donnelly, USA

P2.08.13 Impact of Combination Therapy on Downstaging Hepatocellular Carcinoma for Transplant Eligibility: Tumor Recurrence and Survival Outcomes
Ali Khurram, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.08.14 Long-Term Survival Outcomes of Liver Transplantation, Liver Resection, Ablative Therapy Among Patients with Early Solitary Primary Hepatocellular Carcinoma: A Population-Based Longitudinal Study
Babawale Oluborode, USA

P2.08.15 Survival Outcomes of Liver Transplantation in Hepatocellular Carcinoma Patients with Isolated Lymph Node Metastasis
Nattawut Keeratibharat, Thailand

P2.08.16 Defining Stage Specific Molecular Pathways and Immunoprofile of HCC Using RNA Sequencing and Immune Deconvolution for Personalized Therapies
Joshua Badshah, USA

P2.08.18 Predictive Value of Oncoguard in Patients with Cirrhosis & Hepatocellular Carcinoma with Indeterminate Lesions
Ryan Parkinson, USA

P2.08.20 Burden-Dependent Outcomes of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Retrospective Analysis
Samar Semaan, USA

P2.08.22 Margins Matter, but Survival Stands: Role of Margin Status in Outcomes After Curative-Intent Resection for Perihilar Cholangiocarcinoma
Ion Profirii, USA

P2.08.23 Everolimus Does Not Alter Non-Hepatic Malignancy Following Liver Transplant
Mohammed Abusuliman, USA

P2.08.24 Relevance of Pre-Operatively Elevated CA 19-9 in Patients Undergoing Liver Transplantation?
Yasmeen Dhindsa, USA

P2.08.25 Single Center, Long Term Outcomes of Liver Transplant for Primary Liver & Biliary Cancers
Samar Semaan, USA

P2.08.26 Ischemia-Free Liver Transplantation Improves Long-Term Outcomes in a 5-Year Follow-Up Study
Zhiyong Guo, China

P2.08.27 Large Liver Could Be at Risk for Liver Graft Failure during Normothermic Machine Perfusion
Jeffrey Orlowski, USA

P2.08.32 VA-ECMO in Liver Transplantation - A Single-Center Series
Dilan Bhakta, USA

P2.08.33 Evaluating the Impact of Normothermic Machine Perfusion on Liver Transplant Outcomes and Surgical Team Wellbeing
Samuel Wolfe, USA

P2.08.34 The Utility of the Endoscopic Device "Vasoview Hemopro 2" for Harvesting the Great Saphenous Vein in Vascular Reconstruction during Living-Donor Liver Transplantation
Yoshitaka Saegusa, Japan

P2.08.35 The Long Term Outcome of Renoportal Anastomosis on Liver Transplantation
Kazuki Sasaki, Japan

P2.08.38 Integrating 4D Portal Flow MRI and Computational Fluid Dynamics for Enhanced Liver Transplantation Decision Making
Catherine Anosova, Russian Federation

P2.08.40 Hepatic Vein Reconstruction under Total Clamping of Inferior Vena Cava During Liver Transplantation
Katsunori Sakamoto, Japan

P2.08.41 Ischemia-Free Liver Transplantation Protects Coagulation Function via HNF4α-Coagulation Factors Axis: A Post Hoc Analysis from IFLT-DBD Randomized Controlled Trial
Yuqi Dong, China

P2.08.42 Long-Term Experience with Hepatic Artery Anastomosis in Living Donor Liver Transplantation Using Surgical Loupes: A Reliable and Reproducible Technique
Shih-Chao Hsu, Taiwan

P2.08.43 Comparative Outcomes of Liver Transplantation with Complex Vascular Techniques versus Multivisceral Transplantation in Extensive Porto-Mesenteric Vein Thrombosis: A Systematic Review
Carlos Garcia Ochoa, Canada

P2.08.44 Advancing Hepatic Artery Aneurysm Treatment: A Comparative Study of Open and Endovascular Techniques
Vishal Rajesh, USA

P2.08.45 Improved Perioperative and Biliary Outcomes with Normothermic Machine Perfusion in Donation After Circulatory Death Liver Transplantation: A Single Center's Experience
Maggie Jones-Carr, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.08.46 The Impact of Temporary Portocaval Shunt in Intraoperative and Postoperative Outcomes in Liver Transplantation: A Systematic Review and Meta-Analysis
Isabella Faria, USA

P2.08.47 Initial Experience with Normothermic Machine Liver Perfusion for Combined Liver and Thoracic Transplantation
Joe Habbouche, USA

P2.08.48 Indications, Selection Criteria, and Outcomes of Combined Heart-Liver Transplant: A Systematic Review and Meta-Analysis
Laura Batista de Oliveira, USA

P2.08.49 Normothermic Machine Perfusion Reduces Post-Reperfusion Syndrome and Improves Perioperative Outcomes in Liver Transplantation
Ahmed Hussein, USA

P2.08.50 Graft Preservation in Simultaneous Liver Transplantation and Cardiac Surgery: The Role of Normothermic Machine Perfusion
Sasha Xu, USA

P2.08.51 Early Experience of Histotripsy in a Multidisciplinary Liver Cancer Program
Nishtha Singh, USA

P2.08.52 Bile Duct Reconstruction in Liver Transplantation for PSC: Bile Duct Grading System and Long Term Outcomes for Roux-en-Y and Duct-to-Duct Anastomoses
Richard Mangus, USA

P2.08.53 Graft Inflow Modulation in Orthotopic Liver Transplantation - Use of Intraoperative Flow Probe to Guide Partial Splenic Artery Banding: A Case Report
Winnie Shivega, USA

P2.08.54 Combined Heart-Liver Transplantation in a Patient with Situs Inversus Totalis: The Role of Normothermic Machine Perfusion
Joe Habbouche, USA

P2.08.55 Does Duct-to-Duct Anastomosis Using an Eversion Technique Reduce Biliary Complications in Living Donor Liver Transplantation: A Prospective Analysis
Sabin Subedi, USA

P2.08.56 Basiliximab Reduces Acute Rejection in a Corticosteroid Free Regimen in Living Donor Liver Transplant Recipients
David Quan, USA

P2.08.57 Automated 3D Modeling for Hepatic Venous Territory Mapping in Living Donor Liver Transplantation
Jinsoo Rhu, South Korea

P2.08.58 120 Pediatric Liver Transplants: Donor Outcomes from a Single Center Argentina
Francisco Orozco, Argentina

P2.08.59 Living Donor Liver Transplantation for Colorectal Cancer with Liver Metastases: The Experiences in a High-Volume Asian LDLT and Colorectal Center
Shih-Chao Hsu, Taiwan

P2.08.60 Donor-Recipient Age Matching May Improve Survival After Living Donor Liver Transplantation in Recipients Aged ≥65 Years
Masahiro Tomita, Japan

P2.08.61 Update on Elucidating the Impact of Recipient and Donor Abdominal Aortic Calcification on Living Donor Liver Transplantation
Ichiya Chogahara, Japan

P2.08.62 Liver Transplantation for Acute Liver Failure: Auxiliary or Non-Auxiliary Transplantation
Li-Ying Sun, China

P2.08.63 Managing Bile Duct and Vascular Variations in Robotic - Assisted Living Donor Right Hepatectomy - A Single-Center U.S. Experience
Smita Pancholia, USA

P2.08.64 Bridging the Organ Shortage Gap: Improved Survival in Living Donor Liver Transplantation over Two Decades
Reza Saidi, USA

P2.08.65 Optimizing Outcomes in Robotic Living Donor Right Hepatectomy: A Single-Center Experience in the U.S.
Smita Pancholia, USA

P2.08.66 Navigating Living Donor Anatomical Variations in a New LDLT Program
Sorabh Kapoor, USA

P2.08.67 Intraoperative and Postoperative Analgesic Strategies in Live Donor Hepatectomy: A National Survey
Peyton Crest, USA

P2.08.69 Three Decades of Living Liver Donor Outcomes: Evolving Patterns in Risk and Recovery
Morgan Kelly, USA

Poster Listing

P2.08.70 Reconstruction of Middle Hepatic Vein Tributaries in Living Donor Liver Transplantation with Right Lobe Graft
Hidenobu Kojima, Japan

P2.08.71 Prediction of Grade B/C According to New Criteria for Small-for-Size Syndrome After Adult Living Donor Liver Transplantation with Simultaneous Splenectomy
Kyohei Yugawa, Japan

P2.08.72 Improved Short-Term Outcomes of Robotic Hepatectomy in High BMI Living Liver Donors
Lauren Leung, USA

P2.08.74 Living Donor Liver Transplant: 24-Year Single-Center Analysis of Donor Quality of Life
Piper Stacey, USA

P2.08.75 Anatomical Variations of the Biliary Tract in Living Donor Robotic Hepatectomies
Andrew Park, USA

P2.08.76 Living Donor Hepatectomy Outcomes over Two Eras
Binuri Hapuarachchy, USA

P2.08.77 PINK1/Parkin Signaling Regulates Mitochondrial ATP and Succinate Production of Hepatocytes through Modulating ER-Mitochondria Calcium Transfer to Promote Liver Regeneration
Haoming Zhou, China

P2.08.78 Outcomes After Adult Living-Donor Liver Transplantation in Patients with Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
Patricia Viana, Brazil

P2.08.79 Impact of Donor Warm Ischemic Time and Surgical Experience on Recipient Biliary Stricture in Pure Laparoscopic Donor Right Hepatectomy
Gayoung Kim, South Korea

P2.08.80 Predicting 90-Day Graft Loss Following Living Donor Liver Transplantation: Right and Left Lobe Grafts Require Distinct Risk Prediction Models
Piper Stacey, USA

P2.08.81 Factors Influencing Liver Regeneration After Living Donor Hepatectomy: A Retrospective Study in a Small-Volume Center
Minjae Kim, South Korea

P2.08.82 Outcomes After Emergent ABO-Incompatible Living Donor Liver Transplantation
Sung Hyo An, South Korea

P2.08.83 Expanding the Donor Pool for Pediatric Liver Transplantation with Living Donor Left Side Technical Variant Grafts
Maria Minetto, Argentina

P2.08.84 Graft Hemodynamics Evaluation in Living Donor Liver Transplantation in the Era of Transplant Oncology
Yutaka Endo, USA

P2.08.85 The Use of Distal Gastroduodenal Arterial Inflow as a Strategy for Living Donor Liver Transplantation - A Single Center American Experience
Hyunyoung Kim, USA

P2.08.86 The Use of Portal Vein Anatomic Variants in Living Donor Liver Transplant - A Single Center American Experience
Jillian Woodworth, USA

P2.08.87 Recovery of Living Liver Donors Older Than 50
Hojung Park, USA

P2.08.88 You Want a Piece of Me? Evaluating Living Liver Donor Pain Management Outcomes After Donation
Adina Poparad-Stezar, USA

P2.08.89 The Impact of Social Deprivation and Distressed Communities on Access to Living Donor Liver Transplantation
Amit Tevar, USA

P2.08.90 Outcomes in LDLT Donors and Recipients with Heterozygous α-1 Antitrypsin Mutant Donors
Surmai Shukla, USA

P2.08.92 Temporal and Regional Trends in Adult Living Liver Donation
Sunil Karhadkar, USA

P2.08.93 Long-Term Patient Survival After Liver Transplantation by Donor Type
Fawaz Al Ammary, USA

P2.08.94 Drug Overdose Donor Transplants: Comparable Success Rates Before and During COVID-19 Pandemic
Riah Lee, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.08.96 Normothermic Machine Perfusion Improves Graft Survival After Circulatory Death Liver Transplantation in Primary Sclerosing Cholangitis
Sienna Li, USA

P2.08.97 The Relationship Between Neurologic Exam Documentation and Organ Acceptance
Ritah Chumdermpadetsuk, USA

P2.08.98 Kaposi Sarcoma Herpesvirus Risk and Disease in Donors and Liver Transplant Recipients with HIV
Moreno Rodrigues, USA

P2.08.99 Utilization of and Outcomes Following Donation After Circulatory Death (DCD) Liver Transplantation for Recipients with High Model for End-Stage Liver Disease (MELD) Score in the USA
Jesse Schold, USA

P2.08.100 Mission Impossible: Maximizing Deceased Liver Allograft Utilization Does Not Solve the Organ Shortage
Shubham Akshat, USA

P2.08.101 Impact of Implementing Routine Normothermic Machine Perfusion in Liver Transplantation: A Single-Center Retrospective Study
Yuzuru Sambommatsu, USA

P2.08.102 The Predictive Value of Neurologic Exam Parameters for Donor Warm Ischemia Time
Ritah Chumdermpadetsuk, USA

P2.08.103 Assessment of Intravascular Volume Status Using Spectral Power of Central Venous Pressure Corresponding to Heart Rate Frequency in Living Donors Undergoing Laparoscopic Hepatectomy
Jonghae Kim, South Korea

P2.08.104 Geographic Variation in Utilization of Deceased Donor Livers in the USA in the Era of Normothermic Machine Perfusion
Maggie Jones-Carr, USA

P2.08.105 Reducing Financial Barriers to Living Liver Donation through the National Living Donor Assistance Center: A Qualitative Study of Transplant Centers with High Living Liver Volume
Rebecca Mandell, USA

P2.08.106 Listing for Blood Type A2 Donors and Associated Waitlist Outcomes Among Blood Type O Liver Transplantation Candidates in the USA
Toshihiro Nakayama, USA

P2.08.107 Red Light, Green Light: A Delayed Call-In Protocol for Liver Transplant Recipients
Ralph Quillin III, USA

P2.08.108 Cost Analysis of Machine Perfusion in DCD Liver Transplantation: Balancing Expenses and Post-Transplant Outcomes
Shunji Nagai, USA

P2.08.109 Utilization of Liver Grafts from Donation After Circulatory Death Donors on Extracorporeal Membrane Oxygenation Support Using Normothermic Regional Perfusion
Olivia Walker, USA

P2.08.110 The Impact of Normothermic Oxygenated Machine Perfusion in Donation After Brain Death Compared with Donation After Circulatory Death: A Systematic Review and Meta-Analysis
Isabella Faria, USA

P2.08.111 A Simplified Risk Assessment Tool to Predict Post Deceased Donor Liver Transplantation Outcomes in Taiwan
Hao-Chien Hung, Taiwan

P2.08.113 Survival Benefit of Accepting Livers from Donation After Cardiac Death Donors Older Than or Equal to 60 Years in the USA
Toshihiro Nakayama, USA

P2.08.114 Steatotic Liver Grafts Can Be Safely Utilized in Algorithmically Selected Patients with Excellent Outcomes
Parth Agrawal, USA

P2.08.117 Development and Evaluation of a New Liver Donor Risk Index
Sunil Kurian, USA

P2.08.118 Expanding Viability Criteria for Extended Criteria Grafts in Liver Transplantation Using Normothermic Machine Perfusion: To Transplant or to Discard?
Vinona Muralidaran, USA

P2.08.119 Outcomes of Hypothermic Oxygenated Perfusion versus Static Cold Storage in Transplantation of Extended Criteria Liver Grafts: A Systematic Review and Meta-Analysis
Valberto Sanha, USA

Poster Listing

Monday, August 4 3:30 PM - 4:30 PM

P2.08.121 Reducing Costs and Post Liver Transplant Complications Associated with Donation After Circulatory Death Grafts Using Normothermic Machine Perfusion
Vijay Subramanian, USA

P2.08.122 Variation in 10-Year Mortality After Living Liver Donation: Informing the Need for Non-Donor Controls
Uchenna Agbim, USA

P2.08.123 Marginal No More: Machine Perfusion Improves Liver Transplant Utilization and Outcomes from DCD and Elderly Donors
Steven Wisel, USA

P2.08.124 Center-Level Variation and Factors Associated with Receiving a Perfused vs. Non-Perfused DCD Liver
Tanveen Ishaque, USA

P2.08.125 Combining NIR Spectroscopy and Fluorescence for Liver Steatosis Assessment
Nijkem Asong Fontem, France

P2.08.126 Real-World Experience with Extended Criteria-Donation After Circulatory Death Livers Perfused with Normothermic Machine Perfusion
Simon Chu, USA

P2.08.127 Patients Who Received DCD Grafts Preserved with Normothermic Machine Perfusion Had Better 90-Day Outcomes Than Those Who Received DBD Grafts Preserved with Ischemic Cold Storage
William Archie, USA

P2.08.128 The Impact of Normothermic Regional Perfusion on the Utilization and Post-Transplant Outcomes for Liver Transplant
Yutaka Endo, USA

P2.08.129 Do Livers from Deceased Donors without Kidney Recovery Have Inferior Outcome?
Motohisa Tsuruta, USA

P2.08.130 The Upper Time Limit of Normothermic Machine Preservation of Liver Grafts from Donation After Circulatory Death is Yet to be Defined
William Archie, USA

P2.08.131 Significant Improvement in Waitlist Drop-Off Rate and 1 Year Intention-to-Treat Survival Rate in Liver Transplant over the Past 5 Years
Rei Matsumoto, USA

P2.08.132 Increased Yield and Observed to Expected Organ Utilization with DCD-NRP Recovery and Liver NMP: A Single OPO Study
Gregory Martens, USA

P2.08.133 Expanding the Donor Pool for Combined Heart-Liver Transplantation Using Ex-Situ Machine Perfusion
Nicolas Muñoz, USA

P2.08.134 Liver Transplantation Outcomes from Donation After Circulatory Death Recovered by Thoracoabdominal versus Abdominal Normothermic Regional Perfusion
Jacquelyn Yu, USA

P2.08.135 A UNOS Database Outcomes Analysis of DCD Liver Transplantation Using Normothermic Regional Perfusion versus Normothermic Machine Perfusion
Jacquelyn Yu, USA

P2.08.136 Transitioning to Aggressive Organ Acceptance: A Small Center's Approach for Liver Transplant
Brianna Ruch, USA

P2.08.137 Pumping Equity: NMP May Reduce Geographic Disparities in Access to Liver Transplant
Deena Brosi, USA

P2.08.138 DCD Liver Transplantation from Donors Aged 70 Years and Over: A Single Center's Experience
Stephanie Ohara, USA

P2.08.139 Insights from Aborted Donor Hepatectomies to Expand the Living Donor Pool: A Systematic Review of Global Trends
Sunil Karhadkar, USA

P2.08.140 Donor Liver Macrosteatosis and Its Impact on Post-Transplant Outcomes: A Registry-Based Study
Omar Alattar, USA

P2.08.141 Deciphering DCD Liver Preservation: A Network Meta-Analysis of NRP, NMP (Back-to-Base & On-Site), and SCS - Unveiling the Superior Methodology
Victor Perim, USA

P2.08.142 DCD Liver Transplantation: Expanding Beyond Large Centers
Brianna Ruch, USA

P2.08.143 Improving Early Liver Allograft Survival by Using LDRI and MELD to Optimize Normothermic Machine Perfusion
Sunil Karhadkar, USA

Poster Listing

P2.08.144 Successful Clinical Outcomes Using Hepatitis B Surface Antibody-Guided HBIG and Tenofovir Therapy in Pediatric Liver Transplant Patients: A Case Series
Tebyan Rabbani, USA

P2.08.145 Post-Donation Outcomes for Sequential Liver and Kidney Donors Versus Single Donor Matched Controls
Swaytha Ganesh, USA

P2.08.146 Billiary Reconstruction With Y-Shaped Stent During Living Donor Liver Transplantation
Luka Jashi, Georgia

P2.08.147 Impact of Hypothermic Oxygenated Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: Stratified Analysis Based on Donor Age
Marco Maria Pascale, Italy

P2.08.148 Evaluation of the Effect of Thrombectomy Through Umbilical Vein for Portal Vein Thrombosis After Liver Transplantation
Jinzhen Cai, China

P2.08.149 Single Center Experience in Complex Liver Transplantation
Jinzhen Cai, China

P2.08.150 Single Center Experience of ABO-Incompatible Adult-to-Adult Living Donor Liver Transplantation: A Case Report
Hong Seok Han, South Korea

P2.09
Topic: Lung

P2.09.1 Donor ECMO Support in DCD Lung Transplantation: Expanding Organ Volume without Compromising Outcomes
Justin Wang, USA

P2.09.2 Predictors and Outcomes Among Patients with Need of Extracorporeal Membrane Oxygenation Support Early After Lung Transplantation
Amit Banga, USA

P2.09.3 Management of Post-Operative Pain in Lung Transplant Recipients
Ashley Feist, USA

P2.09.4 Accept...or Wait? Consequences of Declining Lungs at Risk of Disease Transmission
Alexandra Rizaldi, USA

P2.09.5 Optimizing CMV Management in Lung Transplantation: A Modified Delphi Method to Address Complex Challenges
Camille Kotton, USA

P2.09.6 Mitochondrial Transplantation During Ex Vivo Lung Perfusion to Mitigate Gastric Aspiration and Ischemia Reperfusion Injury and Mitigate Primary Graft Dysfunction in a Porcine Lung Transplant Model
Sandra Lindstedt, Sweden

P2.09.8 Surgeon and Center-Level Heterogeneity in the Choice of Single vs. Bilateral Lung Transplantation
Darren Stewart, USA

P2.12
Topic: Pharmacy

P2.12.2 CYP3A5 Genomics-Guided Tacrolimus Dosing in the Setting of Azole Antifungals in Lung Transplantation
Christine Pham, USA

P2.12.3 Comparison of Area under the Curve versus Trough Monitoring of Vancomycin in Recent Kidney Transplant Recipients
Keaton Tauer, USA

P2.12.4 Evaluation of Tacrolimus Therapeutic Drug Monitoring in Lung Transplant Recipients After Voriconazole Discontinuation in the Outpatient Setting
Sara Farghaly, USA

P2.12.5 Evaluating ChatGPT-o-3-Mini High for Detecting Tacrolimus Drug-Drug Interactions: Accuracy, Limitations, and Clinical Implications
Oscar Garcia Valencia, USA

P2.12.6 Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5-Guided versus Standard Weight-Based Dosing in a Multi-Ethnic Cohort of Kidney Transplant Recipients in Singapore
Rou Wei Lim, Singapore

P2.12.7 Exploring T Cell RNA-seq-Derived Insights into Tacrolimus Pharmacokinetics in Kidney Transplant Cases
Kinji Furuya, Japan

Poster Listing

P2.12.8 Influence of Extended-Release Tacrolimus Metabolism Rate on BKV Infection in Renal Transplant Recipients
Lyndsey Bowman, USA

P2.12.9 Personalizing Tacrolimus Regimen for Pediatric Heart Transplant Recipients: Powered by GatorPGx
Salma Anis, USA

P2.12.10 Safety of Apixaban Compared to Warfarin in Liver Transplantation
Suhail Shaikh, USA

P2.12.11 Characterizing Immunosuppressive Regimes at Induction Associated with Colorectal Cancer Recurrence and Survival Rates
Angela Gifford, USA

P2.12.12 Impact of Immunosuppressive Drug Levels on Microvascular Inflammation in Kidney Transplant Recipients without DSA and C4d Deposition
Yoichi Kakuta, Japan

P2.12.13 Perioperative Management in Patients Taking Apixaban Prior to Kidney Transplant
Anne Przybylski, USA

P2.12.14 Effects of a Pharmacist-Led Collaborative Practice Agreement on Vitamin D Outcomes Post-Adult Liver Transplantation
Mary Leick, USA

P2.12.15 Characterization of Morbidity Associated with Alemtuzumab Administration for Allograft Dysfunction in Lung Transplant Recipients
Amanda Driver, Canada

P2.12.16 Analysis of Weight-Based Dosing of Tacrolimus in Liver Transplantation
Danielle Brandman, USA

P2.12.17 Canadian Transplant Pharmacists' Knowledge and Perspectives on Chimeric Antigen Receptor T Cell Therapy
Rob Wright, Canada

P2.12.18 Immunosuppressant Level Fluctuations as a Potential Surrogate Marker of Adherence
Emina Halimanovic, USA

P2.12.19 Off-Label Letermovir Use in Solid Organ Transplant Recipients at a Large Academic Medical Center
Mariam Ali, USA

P2.12.20 Assessment of De Novo Extended-Release Tacrolimus Weight-Based Dosing Compared to Immediate-Release Tacrolimus in Kidney Transplant Recipients Leads to Improved Outcomes
Jacqueline Quenzer, USA

P2.12.21 Implementation of a Standardized Immunosuppression Protocol in an Established Kidney Transplant Program Produces Improved Results
Jacqueline Quenzer, USA

P2.12.22 Evaluation of GLP-1 Receptor Agonists Use in Post-Kidney Transplant Recipients with Type 2 Diabetes Mellitus
Ngoc-Yen Pham, USA

P2.12.23 Sparsentan, a Novel Dual Endothelin Angiotensin Receptor Antagonists (DEARAs) for Post Transplant Proteinuria - A Single Center Outcomes Analysis
Yasir Qazi, USA

P2.12.24 Efficacy and Safety of De Novo Extended-Release Tacrolimus Weight-Based Dosing in Obese vs. Non-Obese Kidney Transplant Recipients
Jacqueline Quenzer, USA

P2.12.25 Single Institution Experience Using Intraoperative Human Fibrinogen Concentrate Fibryga in Orthotopic Liver Transplantation - A Case Series
Jazmyn Ayers, USA

P2.12.26 Elevated Tacrolimus Concentration in Graft Tissue Relative to Whole Blood is Associated with Severe Arteriolar Hyalinosis Following Kidney Transplantation
Sho Nishida, Japan

P2.12.27 Targeted-Release Budesonide for Early Recurrent IgA Nephropathy in a Kidney Transplant Recipient: A Case Report
Laura Chargualaf, USA

P2.12.28 Organizational Targeting of Burnout Reduction Among Transplant Pharmacists: An Actionable Response
Stacy Bernard, USA

P2.12.29 Characterization of Beta Lactam Allergy and Outcomes Associated with Perioperative Antibiotic Choice in Kidney Transplant Recipients
Johanna Papanikolla, USA

P2.12.31 Breastfeeding After Transplantation: 25 Year Review (1999-2024)
Dorothy Kliniewski, USA

Poster Listing

P2.12.33 Impact of Transplant Pharmacist Driven Continuous Glucose Monitoring Post-Kidney Transplant
Jeffrey Mikolay, USA

P2.12.34 Rejection Outcomes in Simultaneous Liver-Kidney Transplant versus Liver Transplant Alone in Recipients with Chronic Kidney Disease
Paige Stratton, USA

P2.12.35 Efficacy and Safety of High versus Moderate Dose Mycophenolate in Adult Liver Transplant Recipients
Laura Chargualaf, USA

P2.12.36 Changes in Renal Function After Switching to Extended-Release Tacrolimus in Heart Transplant Recipients
Nicholas Olivieri, USA

P2.12.37 Characterization of Infectious Timeline in Positive-Crossmatch and ABO-Incompatible Kidney Transplant Recipients
Brendan Steiner, USA

P2.12.39 Comparison of Direct-Acting Oral Anticoagulation versus Warfarin Following Kidney Transplantation in a Predominantly Obese Population
Dana Pierce, USA

P2.12.40 Transverse Myelitis: A Rare Adverse Effect of Calcineurin Inhibitors
Jay Pandav, USA

P2.12.42 Efficacy of Midodrine Use Post-Kidney Transplantation for Tapering off Vasopressors
Dana Pierce, USA

P2.12.43 Immunosuppression Minimization in Stable Heart Transplant Recipients with Dual Non-Invasive Testing
Rachel Rikard, USA

P2.12.44 Effectiveness of Antithymocyte Globulin Dosed on Ideal Body Weight in Kidney Transplant Recipients with and without Obesity
Jamie Benken, USA

P2.12.45 Evaluation of Early Conversion to Belatacept in Renal Transplant Recipients with Poor Renal Function
Leanna Borges, USA

P2.12.46 Less is More? Low-Dose Valganciclovir in Pancreas Transplantation
Taylor Pasley, USA

P2.12.47 Recurrent IgA Nephropathy in a Kidney Transplant Recipient Treated with Sparsentan
Zara Ijaz, USA

P2.12.48 Sparsentan for Halting Renal Disease Progression in Transplant Recipients with Recurrent IgA Nephropathy
Benjamin Saul, USA

P2.12.49 Assessing the Impact of Pharmacy Medication Adherence Assessments during Kidney Transplant Evaluation on Post-Transplant Tacrolimus Time in Therapeutic Range
Vishnu Potluri, USA

P2.12.50 Efficacy and Tolerability of Tocilizumab for Treatment of Antibody Mediated Rejection in Heart Transplant Recipients
Daryl Nnani, USA

P2.12.51 User-Centered Design of an At-Home Test for Immunosuppressant Drugs
Christopher Blosser, USA

P2.12.52 Post-Operative Anti-Thymocyte Globulin: When to Give It and Does Timing Matters
Syed Omair Nadeem, USA

P2.12.53 Pharmacokinetics of AIC468 in Healthy Volunteers from a First-in-Human Phase 1 Clinical Trial: A Novel Antisense Oligonucleotide Targeting BK Virus Transcripts
Susanne Bonsmann, Germany

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.01
Topic: Administrative

P3.01.1 Implications for Changes in US Federal Death Record Databases for Estimation of Mortality After Delisting
Maria Masotti, USA

P3.01.2 The Correlation of Time Spent Discussing Patients in Liver Transplant Selection Committee on Listing Outcomes
Frank Lee, USA

P3.01.3 A Novel Approach to Enhancing Organ Transplantation Efficacy through OPO-Transplant Center Partnerships
Jennifer Grant, USA

P3.01.4 Successful International Adoption of an Interoperable and Secure Digital Organ Management Platform
Aditi Srinivasan, USA

P3.01.5 Increase Referrals, Donors, and Transplants via Interoperability
Christian Rivas, USA

P3.01.6 Histoplasmosis Screening Prior to Heart Transplant: A Quality Improvement Analysis from a High-Prevalence Institution
Landon Withrow, USA

P3.01.7 Automating Organ Offer Evaluation: Streamlining Transplant Decision-Making in a Closed API System
Tyler Dann, USA

P3.01.8 Financial Implications of Robotic Living Donor Nephrectomy
Michael McCabe, USA

P3.01.9 Toward Zero Waitlist Mortality: A Mixed-Methods Review of Loss of Life While Awaiting Pediatric Liver Transplant
Joshua Gossett, USA

P3.01.10 Transplant without Borders: Expansion of International Transplant Centers
Giselle Guerra, Brazil

P3.01.12 Hayat Software: An Integrated Approach in UAE
Jaclyn Aikler, United Arab Emirates

P3.02
Topic: APP

P3.02.1 Empowering Sustainability during Kidney Transplants Using a Patient Safety Framework
Maria Lee, USA

P3.02.2 Evaluation of the Frailty Assessment Program in a Kidney Transplant Center
Michael Hulburt, USA

P3.02.3 Complex Patient Committee - A Quality Improvement Forum to Enhance the Care of Complex Kidney Transplant Recipients
Srilekha Sridhara, USA

P3.02.4 Easing the Transition to Rehabilitation for Lung Transplant Recipients: Interdisciplinary, Cross-Setting Quality Improvement and Knowledge Translation
Nikki Marks, Canada

P3.02.5 Modified Deceased Donor Delayed Graft Function (DGF) Biopsy Protocol from 1 Week to 2 Weeks Reduces Biopsy Rate without Compromising Kidney Allograft Outcome
Payaswini Vasanth, USA

P3.02.6 Factors Influencing Enrollment in Transplantation Clinical Studies
Tina Sledge, USA

P3.02.7 Implementation of an Opioid Sparing Pain Management Protocol Following Kidney Transplantation
Hailey Kessler Hourigan, USA

P3.02.9 Enhancing Kidney Transplant Patient Knowledge to Improve Medication Adherence, Quality Improvement Project
Tashra Thomas, USA

P3.02.11 Advanced Practice Provider Hybrid Role: A Novel Approach to Patient Care in Liver Transplant
Janine Hyden, USA

P3.02.12 The Effect of the VIP-FIT Virtual Physical Training Program in Older Kidney Transplant Candidates: A Prospective Interventional Pilot Study
Anna Pomahac, USA

P3.02.13 Discontinuation of Complement Inhibitors After the Resolution of Thrombotic Microangiopathy Post-Kidney Transplant
Thangamani Muthukumar, USA

P3.02.14 Participation Drop Outs in a Telemedicine Aftercare in Kidney Transplant Recipients
Klemens Budde, Germany

P3.02.15 Efficacy of Antibody-Drug Conjugates as a Potential Treatment for Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis of Clinical Trials
Muhammad Ali Khan, USA

P3.02.16 Weight Loss Clinic for Kidney Transplant Candidates and Recipients
Gianna Mladenova, USA

P3.02.17 Burnout, Compassion Fatigue and Other Emotional Experiences Among Transplant Coordinators in Singapore
Anastasia Lim, Singapore

P3.02.18 A Virtual Continuing Education Program for Multidisciplinary Transplant Professionals
Denise Lo, USA

P3.03
Topic: Basic Science

P3.03.1 RELIEF, a Phase 2, Multicenter Clinical Trial to Achieve Donor Hematopoietic Chimerism and Immunosuppression-Free Tolerance After Living Donor Kidney Transplantation
Ephraim Fuchs, USA

P3.03.2 A Modified Tolerance Induction Regimen Incorporating Total Lymphoid Irradiation, Anti-Thymocyte Globulin, and Low-Dose Total Body Irradiation Achieves Sustained Mixed Chimerism and Immunosuppression Withdrawal or Minimization to Mycophenolate Mofetil in Haplotype-Matched Kidney Transplant Recipients
Stephan Busque, USA

P3.03.3 Non-HLA and Cell Surface Antigen Epitope Mismatch Load as Potential Regulator of Xenotransplant Rejection
Nilesh Chitnis, USA

P3.03.4 Pig Kidney Xenograft Size after Pig-to-Human Transplantation - 10 GE vs GGTA1 KO
Tal Eitan, USA

P3.03.6 Hypothermic Oxygenated Machine Perfusion of Liver Grafts Using HTK (Custodiol©) is an Alternative to Standard Use of UW Machine Perfusion in a Single Solution Strategy
Thomas Soliman, Austria

P3.03.7 Observations from the First Series of Human Intestine Graft Normothermic Machine Preservation
Nader Abraham, USA

P3.03.8 Impact of BMP-7 Mimetic (TBD 184) for Graft Recovery from Warm Ischemia Using Normothermic Machine Perfusion
Anil Kharga, USA

P3.03.9 Identifying Molecular Signatures in Donation After Circulatory Death Liver Grafts Undergoing In-Situ Normothermic Regional Perfusion
Luke Cybulski, USA

P3.03.10 Hypothermic Oxygenated Machine Perfusion Inhibits the Cellular Senescence in the Liver Graft in a Swine Model
Kazushige Migita, Japan

P3.03.11 Normothermic Machine Perfusion of Porcine Small Intestines from Donation After Cardiac Death
Yuqi Dong, China

P3.03.12 Long Term Enhanced Subnormothermic Machine Perfusion of Discarded Human and Porcine Kidney Grafts
Madeeha Hassan, USA

P3.03.13 First Series of Successful Subzero Kidney Transports Aboard a Commercial Transatlantic Flight
Anne Heberle, Austria

P3.03.14 Glucose Utilization in Normothermic Machine Perfusion: Evaluating Its Role as a Liver Viability Criterion
Avery Fortier, USA

P3.03.15 Cryopreservation of Pig Kidneys Using a Novel Cryoprotectant Cocktail: A Viability Assessment
Bat-Erdene Namsrai, USA

P3.03.16 Liver Perfusion Defects Following Normothermic Machine Perfusion - Not Really a Cradle Effect
Vijay Subramanian, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.03.18 Give It Some Time - The Six Hour Threshold to Determine Usability of Livers Following Normothermic Machine Perfusion
Vijay Subramanian, USA

P3.03.19 Hypothermic Oxygenated Perfusion (HOPE) Machine Perfusion Using the Organ Angel Device of Donor Hearts in a Porcine Model
Toby Coates, Australia

P3.03.20 BMP-7 Mimetic (TBD 184) as a Prophylactic Agent Against Warm Ischemia in Perfused Rat Liver Grafts
Anil Kharga, USA

P3.03.21 Cost-Effective and Highly Flexible Perfusion Machine
David Machacek, Switzerland

P3.03.22 Ischaemia-Free Liver Transplantation Protects the Liver Against Twice Ischemia-Reperfusion Injury in Comparison to Normothermic Machine Perfusion
Zhiyong Guo, China

P3.03.23 Rapamycin during Normothermic Machine Perfusion: Exploring Response in a Rodent Model
Christopher Taveras, USA

P3.03.24 Impact of Heart OCS Perfusate on Neutrophil Behavior in a Microfluidic System under Shear Stress
Sho Takemoto, USA

P3.03.25 Rapamycin during Normothermic Machine Perfusion Associated with Improved Function of Human Livers
Alissa Cutrone, USA

P3.03.26 Mitochondrial Injury and Function Comparing Hypothermic and Normothermic Machine Perfusion of Human Livers
Omer Faruk Karakaya, USA

P3.03.27 Burgeoning Role of NMP in Liver Transplantation in the US: A Single-Center Experience
Kimberly Feeney, USA

P3.03.28 A Pressure-Regulating Bypass Loop and a Magnetic Compression Bag: Circuit Innovations to Facilitate Prolonged Normothermic Ex Vivo Kidney Perfusion
Natalie Meyer, USA

P3.03.29 Hypothermic Perfusion with the Adsorptive Cartridge Persorb Limits Ischemia-Reperfusion Injury of Pig Kidneys by Sustaining Mitochondrial Function and Inhibiting Senescence of Tubular Epithelial Cells
Vincenzo Cantaluppi, Italy

P3.03.30 Kidney in a Bag: A Low-Cost Strategy for Establishing Proficiency in Normothermic Ex Vivo Organ Perfusion
Heiko Yang, USA

P3.03.31 Impact of Hepatic Steatosis on Immune Profile of Perfused Livers
Joshua Badshah, USA

P3.03.32 Temperature Matters: Normothermic versus Hypothermic Machine Perfusion in a DCD Rat Model for Uterus Transplantation
Keyue Sun, USA

P3.03.33 Automated Hypothermic Machine Perfusion for Donor Kidney Preservation
Jake Miles, USA

P3.03.34 Expanding the Limits: The Role of Hypothermic Oxygenated Perfusion (HOPE) in a Rodent Model of DCD Uterus Transplantation
Keyue Sun, USA

P3.03.36 Plasma Metabolomics: A Non-Invasive Approach for Detecting Acute Cellular Rejection in Heart Transplant Recipients
Rachel Holstein, USA

P3.03.38 Benchmarking In Vivo Metabolomics of DCD NRP and DBD Human Livers
Yanik Bababekov, USA

P3.03.39 Inhibition of Transglutaminase 2 as Putative Therapeutics Target Inhibits Kidney Fibrosis Inducing End-Stage Renal Failure
Hong-Beom Park, South Korea

P3.03.40 STAT3β Isoform Specific Aptamer-Based Targeted Therapy for End-Stage Kidney Diseases
Hong-Beom Park, South Korea

P3.03.41 Impacts of High Mobility Group Box Protein 1 Gene Polymorphisms on Morbidity and Mortality After Living Donor Liver Transplantation
Yuka Tanaka, Japan

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.03.42 GeneGraftDB: A Developing Database of Analyzed scRNAseq Data Pertaining to Transplantation Immunology
Khodor Abou-Daya, USA

P3.03.43 Kidney Protective Effect of Anti-Leukotriene in Hypertensive Nephropathy
Hong-Beom Park, South Korea

P3.03.44 RSV Vaccination Increases CD4 T-Cell Response, but Not CD8, in Solid Organ Transplant Recipients
Andrew Karaba, USA

P3.03.45 Modeling Live Donor Nephrectomy in Mice Reveals a Role for Immune Cells in GFR Adaptation
Hamid Rabb, USA

P3.03.47 Elevated Kidney-Derived uEVs Signal Acute Rejection Post-Transplantation
Carla C. Baan, Netherlands

P3.03.48 Novel miRNA Profiling to Predict Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplant Recipients
Mary Sauceda, USA

P3.03.49 Comparison of Gene Expression in Persufflated vs Static Cold Storage Preservation in Isolated Porcine Kidneys
Lindsey Butts, USA

P3.03.50 Monitoring the Response to Treatment of Kidney Allograft Rejection with Donor-Derived Cell-Free DNA
Suphamai Bunnapradist, USA

P3.03.51 Elucidating Molecular Mechanisms of Hepatocellular Recovery during NMP to Improve Liver Viability Assessment for Transplantation
Greta Cywinska, USA

P3.03.52 Gram Negative A. muciniphila Improves Acute Liver Damage in Mouse and Human Recipients
Kenneth Dery, USA

P3.03.53 Longitudinal Analysis of Persistent Immune Dysfunction as a Predictor of Outcomes in Liver Transplant Recipients
Shakhzoda Alimdjanova, USA

P3.03.54 Post Liver Transplant Morbidity and Mortality Associated with Severe Pre-Liver Transplant Immune Dysfunction
Nedine Abdelhamid, USA

P3.03.55 A Two-Threshold Algorithm Using Donor-Derived Cell-Free DNA Fraction and Quantity to Detect Acute Rejection After 21 Days Post Heart Transplantation
Paul Kim, USA

P3.03.56 Monitoring Changes in Donor-Derived Cell-Free DNA Levels in Treated Lung Allograft Rejection: Pilot Data
Katherine Vandervest, USA

P3.03.57 Cell-Free DNA Does Not Discriminate Acute Rejection from Infection After Lung Transplant: Pilot Study
David Ross, USA

P3.03.58 'Baseline Lung Allograft Dysfunction' is Associated with Different Cell-Free DNA Dynamics After Lung Transplantation
Katherine Vandervest, USA

P3.03.59 Donor-Derived Cell-Free DNA is Not Associated with White Blood Cell Count in Heart Transplant Recipients
Eileen Hsich, USA

P3.03.60 Trajectory of dd-cfDNA Levels in Patients Undergoing Repeat Kidney Transplantation
Navchetan Kaur, USA

P3.03.61 Differential Expression of miRNA in Heart Transplant Patients with Severe Rejection
Rajat Nog, USA

P3.03.62 Transcriptomic Profiling of Infiltrating T Cells and NK Cells in Human Cardiac Allograft Vasculopathy
Hang Nguyen, USA

P3.03.64 Difference of Molecules and Transcripts in Chronic Antibody-Mediated Rejection Mice Models
Taro Banno, USA

P3.03.65 Impaired Complement Activation Drives Chronic Lung Allograft Dysfunction After Lung Transplantation
Hrishikesh Kulkarni, USA

P3.03.66 Donor KIM-1 Drives Premature Allograft Failure
Lakshman Gunaratnam, Canada

P3.03.68 Differential Gene Expression in Endothelial Cells Highlights HLA-F as a Marker for ABMR
Toshihito Hirai, Japan

P3.03.70 T Cell-Mediated Rejection Produces Unique Patterns of Molecular Injury: An Underestimated Menace
Philip Halloran, Canada

Poster Listing

P3.03.71 Simultaneous Pharmacological Inhibition of ROCK2 and HDAC6 Impairs Macrophage Motility and Induces Early Apoptosis through the mTOR/Akt Signaling Pathway
Marta Halasa, USA

P3.03.72 The RNA-Binding Protein Regnase-1 Modulates Life and Death of T Cells and Transplant Survival
Xiaojun Su, USA

P3.03.74 IL-15/mTOR Signaling Controls Development of CD57+PD1- CD4 Cells In Vitro and In Vivo
Shu Li, USA

P3.03.75 Endothelial Cell Tissue Identity Shapes Unique Responses to Inflammation and HLA-DQ Expression
Joey Lockhart, USA

P3.03.76 Chronic Inflammation Reshapes HLA Class II Regulation in Endothelial Cells, Revealing Delayed and Immunogenic HLA-DQ Expression
Connor Lantz, USA

P3.03.79 Post-Thymectomy Cytokine and Regulatory Gene Expression Changes Precede Development of Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients
Andrew Potter, USA

P3.03.80 Estrogen Drives Sex Differences in Dendritic Cell-Mediated Alloimmune Responses via Estrogen Receptor alpha
Sarah Tsou, USA

P3.03.81 Depletion of Senescent Cells and Targeting the Senescence Associated Secretory Phenotype (SASP) Effectively Treats Chronic Rejection
Yao Xiao, USA

P3.03.82 Biological Sex-Specific Alloimmunity is Driven by Estrogen Receptor-α (ERα)-Mediated Modulation of 4-1BB
Yao Xiao, USA

P3.03.83 Persisting Inflammatory and Fibrotic Gene Signatures Linking Acute Cellular Rejection to Chronic Lung Allograft Dysfunction
Andrew Potter, USA

P3.03.84 Inhibition of Late Autoantibody Production Attenuates Development of Chronic Antibody-Mediated Rejection of Kidney Allografts in Mice
Taro Banno, USA

P3.03.85 Inflammatory Gene Expression Profile of Bronchoalveolar Lavage CD8+CD57+ CD69+ T Cells Suggests a Functional Role in the Pathogenesis of Lung Allograft Dysfunction
Sajad Moshkelgosha, Canada

P3.03.86 Autoreactive B Cells in the Kidney Chronic Graft Rejection
Jong Cheol Jeong, USA

P3.03.88 Alloreactive TCF-1+ T Cells Sustain Localized Effector Responses to Mediate Kidney Allograft Rejection
Faruk Sacirbegovic, USA

P3.03.89 Development of a Novel Imaging Mass Cytometry Panel to Distinguish Antibody-Mediated and T Cell-Mediated Rejection in Human Kidney Allografts
Amy Tsai, USA

P3.03.90 A Rich-Club Network Approach to Identifying Key Proteins in Cirrhosis Progression
Paola Barrios, USA

P3.04
Topic: Heart

P3.04.1 Race, Costs and Transplant: An Analysis of Differences in Hospital Expenditures Between Races in Heart Transplant Patients Across the USA
Aleena Abbasi, USA

P3.04.2 Gender-Based Differences in Long-Term Complications Post-Cardiac Transplant: A TriNetX Database Analysis
Nandini Nair, USA

P3.04.3 Comparison of Long-Term Survival of Amyloidosis Patients Undergoing Mechanical Circulatory Support versus Cardiac Transplantation: A TriNetX Database Analysis
Nandini Nair, USA

P3.04.4 Impact of Pre-Transplant Durable Mechanical Circulatory Support on Clinical Outcomes of Sensitized Heart-Kidney Transplant Recipients
Mason Lee, USA

P3.04.5 Is Pulmonary Aspergillosis in Heart Transplant Patients Fatal? Early Detection with Screening Says Maybe Not!
Geetha Bhat, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.04.6 New Donor Strategies and Their Association with One-Year Heart Transplant Survival
Bruno Stehlik, USA

P3.04.7 Evaluation of Uterine Blood Flow in a Pregnant Woman with Cardiogenic Shock under ECMO Support: A Case Report
Luis Carlos Perez Illidge, Argentina

P3.04.8 Household Material Hardship and Psychological Distress in Caregivers of Pediatric Heart Transplant Candidates and Recipients
Leanne Duhaney, USA

P3.04.9 Access to Transplantation: Global Survey on Knowledge and Comfort in Accepting Donors for Thoracic Transplantation
Marcelo Cantarovich, Canada

P3.04.10 Bridging the Gap: A Retrospective Analysis of In-House and Transferred ECMO Patients at a Quaternary Care Center
Bennett Yang, USA

P3.04.12 Safety and Efficacy of SGLT2i and GLP-1RA for Weight Loss in Heart Transplant Patients
Andriana Nikolova, USA

P3.04.13 Impact of Temporary Mechanical Support on Long-Term Post-Transplant Outcomes in the Current Era
Colin Stomberski, USA

P3.04.14 Decrease in Number of Heart Candidates with Pump Thrombosis Qualifying Criteria
Alina Martinez, USA

P3.04.15 Self-Selected Transition Goals: A Tool for Adolescent Heart Transplant Recipients in Preparation for Transition to Adult Care
Anne Dipchand, Canada

P3.04.16 Physical versus Chart-Based Frailty Assessment of Heart Transplant Candidates to Predict Clinical Outcomes
Yoon Lee, USA

P3.04.17 LVAD Patients Undergoing Heart Transplantation Administered ATG: What Are the Complications?
Peter Deckerman, USA

P3.04.18 The Use of Much Older Donor Hearts in Younger Recipients (Up to 28 Years Difference): Acceptable Outcomes?
Avani Kanungo, USA

P3.04.19 Does Preservation Strategy Modify Sex-Specific Risk of Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis
Amy Fiedler, USA

P3.04.20 Impella 5.5 in Women with Cardiogenic Shock and Small LV Cavities: Insights into Safety, Efficacy and Renal Recovery
Aarti Desai, USA

P3.04.21 The Effect of USA Citizenship Status on Heart Transplant Outcomes
Noah Weingarten, USA

P3.04.22 Sex-Based Differences in Characteristics and Outcomes of Left Ventricular Assist Device Recipients
Pedro Diaz Jr., USA

P3.04.23 Sex Differences in Risk for Severe Primary Graft Dysfunction After Heart Transplantation: A GUARDIAN-Heart Analysis
Amy Fiedler, USA

P3.04.24 Quantification of Xenograft Perfusion Following Combined Ventricular Assist Device and Thymokidney Transplantation
Imad Aljabban, USA

P3.04.25 Status of Heart Transplant Race Equity in a Single Institution
Madison House, USA

P3.05
Topic: Infectious Disease

P3.05.2 Genitourinary Aspergillosis in Solid Organ Transplant Recipients
Srilekha Sridhara, USA

P3.05.3 Incidence and Outcomes of Candidemia in Solid Organ Transplant Recipients in Ontario- A Population-Based Cohort Study
Roni Bitterman, Canada

P3.05.4 Retrospective Evaluation of Dapsone Induced Anemia in Kidney, Kidney/Pancreas, and Liver Solid Organ Transplant Recipients
Johanna Papanikolla, USA

P3.05.5 High Histoplasmosis Incidence in Kidney Transplant Recipients. 10 Year's Experience in an Endemic Region of Argentina
Judith Gaite, Argentina

P3.05.6 Rising Cases of Baker's Yeast: Saccharomyces cerevisiae as an Emerging Pathogen in Solid Organ Transplant
Joseph Berger, USA

P3.05.7 Invasive Fungal Infection After Solid Organ Transplant in Children and Young Adults
Mario Landa, USA

P3.05.8 Targeted Antifungal Prophylaxis in Living Donor Liver Transplant Recipients: A Risk-Based Approach
Abdulaziz Alsubaie, Canada

P3.05.9 Candida auris in Liver Transplant Recipients: Clinical Impact and Management Challenges
Garrett Wortham, USA

P3.05.10 Investigating Increase of Very Early Cryptococcal Infections in Liver Transplant Recipients
Rachel Sigler, USA

P3.05.12 When the Stars Align: ID-Led and Allergy-Supported Beta-Lactam Allergy De-Labeling in Solid Organ Transplant Patients
Jennifer Hu, USA

P3.05.13 Development and Validation of a Novel Multiplexed Real-Time qPCR Panel for the Detection and Quantification of Trypanosoma cruzi in Whole Blood Specimens
Evan Sander, USA

P3.05.14 Cryptococcosis in Kidney Transplant Recipients: Early vs. Late Onset Immunologic Profiles
Hyunah Yoon, USA

P3.06
Topic: Intestine

P3.06.2 Three-Way T Cell Chimerism and Alloreactivity Using Single Cell Profiling in a Patient Receiving a Second Intestinal Transplant
Jianing Fu, USA

P3.06.3 Intestinal Autotransplantation for Locally Advanced Tumors Invading the Superior Mesenteric Artery: A Single Arm Meta Analysis
Patricia Viana, Brazil

P3.06.4 Outcomes of Intestinal Biopsies Which Are Indeterminate for Rejection Following Intestine Transplant
Allison Malick, USA

P3.06.5 Trending Microbiome Dysbiosis over Time as an Early Assessment of Intestinal Transplant Rejection Risk
Julie Hong, USA

P3.06.6 The Effects of Demographic Factors Upon Intestinal Transplant Outcomes
Avi Toiv, USA

P3.06.7 Adult Type of Megacystis-Microcolon-Hypoperistalsis-Syndrome (MMIHS) Patient Undergoing Intestinal Transplantation: Clinical Significance and Challenges of Whole Genome Sequencing
Shih-Chao Hsu, Taiwan

P3.06.8 The Role of PET/CT in Diagnosing Acute Rejection in Small Bowel Transplantation: Potential and Challenges of Non-Invasive Methods
Shih-Chao Hsu, Taiwan

P3.06.9 Non-Vascularized Rectus Fascia Transplantation as an Emerging Technique in Surgical Practice: A Single-Center Case Series
Ewout Muylle, Belgium

P3.06.10 Recipient γδ T Cells Contribute to Graft Rejection After Human Intestinal Transplantation
Bing Chen, USA

P3.06.11 Two-Stage Approach to Intestinal and Multi Visceral Transplantation: Analysis of Pre-Transplant Predictors and Post-Transplant Outcomes
Carolyn Smullin, USA

P3.06.12 Utilization of Paragonix LIVERguard® Donor Organ Transport System for Static Hypothermic Preservation of a Multivisceral Allograft
Carolyn Smullin, USA

P3.06.13 Outcomes Following Graft Enterectomy After Intestinal and Multivisceral Transplantation: A Multicenter Analysis
Avi Toiv, USA

Poster Listing

P3.06.14 Sublingual Tacrolimus Intrapatient Variability in Intestinal Transplant Recipients
Benito Valdepenas, USA

P3.06.15 Intestinal Transplantation for Short Bowel Syndrome from Gun Shot Wounds: A Case Series
Renieh Nabaty, USA

P3.06.16 Glucagon-Like Peptide-2 Therapy Outcomes Following Intestinal and Multivisceral Transplantation: A Multicenter Experience
Avi Toiv, USA

P3.06.17 Recovery Technique of En Bloc Multivisceral Abdominal Grafts for Normothermic Perfusion in a Swine Model
Kimberly Feeney, USA

P3.06.18 Exploring the Impact of Sociodemographic Factors on Intestinal Transplant Outcomes
Jimena Alaniz, USA

P3.06.19 Infectious Morbidity and Mortality in Small Intestine Transplantation: A Decade of Experience
Abdulmalik Saleem, USA

P3.07
Topic: Kidney

P3.07.2 Optimizing KDPI or HLA Mismatches to Improve Survival for Pediatric Kidney Transplantation
Saritha Ranabothu, USA

P3.07.4 Kidney Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Treated with Long-Term Lumasiran
Michael Somers, USA

P3.07.5 Both Low Eplet Mismatch and Low Indirect T-Cell Recognition Scores Are Strong Prognosticators of Reduced Alloimmune Rejection in Pediatric Kidney Transplants
Yang Li, USA

P3.07.6 Increased Incidence of EBV DNAemia Among Pediatric Kidney Transplant Recipients in the COVID Era
Isa Ashoor, USA

P3.07.7 A Successful Pediatric Kidney Transplant in a Highly Sensitized Recipient with Compassionate Use of Imlifidase: A Case Study with One Year Follow Up
Julie Houp, USA

P3.07.8 Single Dose Basiliximab in a Pediatric Kidney Transplant Recipient: A Case Report
Elisabeth Kincaide, USA

P3.07.9 Single vs. En Bloc Kidney Transplantation from Donors ≤5 Years of Age in the USA: An Analysis of the Scientific Registry of Transplant Recipients (SRTR) from 1987 to 2023
Reza Saidi, USA

P3.07.10 BKV-Specific T-Cell Responses Correlate with Reduced Viral Load and Enhanced Humoral Immunity in Pediatric Kidney Transplant Recipients
Bongha Shin, USA

P3.07.11 Association Between Donor Derived Cell Free DNA, Donor Specific Antibody, and Rejection in Pediatric Kidney Transplant Recipients
Lyndsay Harshman, USA

P3.07.12 Pediatric to Adult Transition: Analysis of a Standardized Assessment Protocol for Kidney Transplant Patients
Jonathan Garrison, USA

P3.07.13 Impact of Vesicoureteral Reflux Post Pediatric Kidney Transplant: A Pediatric Nephrology Research Consortium Study
Namrata Jain, USA

P3.07.14 Donor-Derived Cell-Free DNA is Higher in Small Pediatric Transplant Recipients Receiving Kidneys from Obese Donors
Julia Steinke, USA

P3.07.15 Hyponatremia After Pediatric Kidney Transplant Surgery: Is Type of Intravenous Fluid a Risk Factor?
Ishaan Aravindaksha, USA

P3.07.16 Long Term Outcomes of Sirolimus Based Immunosuppression Among Haplotyped-Matched Pediatric Living Donor Kidney Transplant Recipients
Adrian Banerji, USA

P3.07.17 The Use of Deceased Donor Kidneys Prioritized for Pediatric Candidates and the Implications of the Refit KDPI Policy
Elizabeth Sonnenberg, USA

P3.07.18 Successful Use of Daratumumab (Anti-CD38) for the Treatment of Pediatric Post-Transplant Proteinuric Diseases: A Case Series
Dechu Puliyanda, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.21 Prevalence and Associations of Nephrocalcinosis in Pediatric Kidney Transplant Recipients
Yaritzy Astudillo, USA

P3.07.22 Alemtuzumab Induction via Intravenous vs. Subcutaneous Administration in Pediatric Kidney Transplantation
Helen Pizzo, USA

P3.07.23 Kidney Allograft Rejection and Survival in Combined (CLKT) and Sequential Liver Kidney Transplants (SLKT) in Children
Michelle Keyser, USA

P3.07.24 Obesity Definition by Percentage of Body Fat Compared to Body Mass Index in a Kidney Transplant Transition Clinic
Allyson Friederich, USA

P3.07.25 Relationship Between AASI, Hypertension, and Left Ventricular Hypertrophy in Pediatric Kidney Transplant Patients
Samantha Krieger, USA

P3.07.26 Comparative Analysis Between Pediatric and Adult Kidney Transplant Recipients: A Multicentric Retrospective Study
Carolina Bigatti, USA

P3.07.27 Iliocaval Anomaly with Resulting Congestive Nephropathy: A Rare Etiology of Allograft Dysfunction Following Kidney Transplantation
Shengliang He, USA

P3.07.28 Low Incidence of Rejection and De Novo Donor-Specific Antibody Formation Following COVID-19 Vaccination or Infection Among Pediatric Kidney Transplant Recipients
Helen Pizzo, USA

P3.07.29 Induction Immunosuppression in Pediatric Kidney Retransplants: A SRTR Data Analysis
Juhi Kumar, USA

P3.07.30 Study the Outcomes of Split Pediatrics Kidney Transplant in Adult Recipients: Single Centered Retrospective Cohort Study
Shivakumar S P, India

P3.07.31 Impact of the COVID 19 Medicaid Continuous Enrollment Provision on Pediatric Transplant Outcomes
Vanessa Niba, USA

P3.07.32 Robotic Kidney Transplantation in Children
Pranjal Modi, India

P3.07.33 Evaluating the Long-Term Safety and Viability of Steroid Minimization Protocols in Pediatric Kidney Transplantation
Sunil Karhadkar, USA

P3.07.34 Reevaluating the Necessity of Steroid Immunosuppression in Black Pediatric Kidney Transplantation Patients: A Race-Stratified Study
Sunil Karhadkar, USA

P3.07.35 Evaluating the Safety of Recombinant Growth Hormone Therapy Post-Kidney Transplant in Pediatric Recipients
Ian Jaffe, USA

P3.07.36 Consideration of Donor Type and Induction Agent on 10-Year Graft Survival in Steroid-Free Pediatric Kidney Transplantation
Sunil Karhadkar, USA

P3.07.37 Belatacept: A New Ring in Pediatric Kidney Transplant Immunosuppression
Krishna Daiya, USA

P3.07.38 HLA-DRB3/4/5 Mismatches and De Novo Donor-Specific Antibody Formation in Pediatric Kidney Transplantation
Vaka Sigurjonsdottir, USA

P3.07.39 Surgical Challenges in Pediatric Renal Transplant: A Single Center Experience
Omprakash Prajapati, India

P3.07.43 Associations of Pretransplant Patient-Reported Outcomes Measurement Information System Physical Function Score with Early Kidney Transplant Outcomes
Divya Raghavan, USA

P3.07.44 The Effect of Direct Acting Antiviral Agents on Outcomes in Renal Transplant Recipients with Hepatitis C Virus Infection
Tung Yu, Taiwan

P3.07.45 A Case of Mantle Cell Lymphoma Infiltrating the Kidney Allograft
Julia Liang, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.46 Recurrence of Oxalate Nephropathy After Roux en Y Gastric Bypass in a Live Donor Kidney Transplant
Elizabeth Cho, USA

P3.07.47 The Impact of a New National Defined Complexity Criteria for the Accreditation of Complex Transplant Centers in the Long-Term Follow-Up
Ignacio Revuelta, Spain

P3.07.48 Parvovirus-Induced Anemia and Nephropathy in a Kidney Transplant Patient: A Case Report
Thunyatorn Wuttiputhanun, Thailand

P3.07.49 GLP-1 and Glucagon Receptor Dual Agonism Ameliorates Kidney Allograft Fibrosis by Improving Lipid Metabolism
Guodong Chen, China

P3.07.50 Protective Effects of Prednisolone on Cyclosporine Induced Nephropathy in a Mouse Model
Kazuhiro Ujihashi, Japan

P3.07.51 Rare Case of Donor-Derived Membranous Nephropathy Post Deceased Donor Kidney Transplant
Elizabeth Cho, USA

P3.07.52 Comparative Analysis of Cancer Risk Between Kidney Transplant Recipients and End-Stage Kidney Disease Patients: A Nationwide Matched Cohort Study
Eunjeong Kang, South Korea

P3.07.53 Post-Transplant Massive Ascites Due to Non-Cirrhotic Portal Hypertension with a Conservative Path to Resolution- A Case Report
Kiran Goli, USA

P3.07.54 Simultaneous Unilateral Native Nephrectomy with Kidney Transplantation Prolongs Patient and Graft Survival in Recipients with ESRD Due to ADPKD
Hajime Sasaki, Japan

P3.07.55 Renal Cell Carcinoma Incidence and Mortality Among Kidney Transplant Recipients: An Analysis of OPTN Data
Farah Abuazzam, USA

P3.07.57 Patient Perspectives on Peritoneal Dialysis and Re-Transplant Following Kidney Allograft Failure
Warren McKinney, USA

P3.07.58 Impact of Corticosteroids and Other Immunosuppression on Dialysis After Kidney Graft Loss
John Larkin, USA

P3.07.59 Post-Transplant Gout is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients
Brad Marder, USA

P3.07.60 Delayed Graft Function in Kidney Transplantation for Patients Aged 65 and Older: A 20-Year Single-Center Experience
Sungwon Jung, South Korea

P3.07.61 Evaluation of Risk Factors and Clinical Outcomes of Acute Respiratory Failure from Post Renal Transplant Recipients: A Five-Year Data of a Single Center
Muhammad Tassaduq Khan, Pakistan

P3.07.62 Third Generation Beta-Blocker and Tacrolimus Effects on Renal Function, and Vasodilator Nitric Oxide Levels of Kidney Transplant Recipients: A Secondary Stratified Analysis
Alfonso Santos, USA

P3.07.63 Incidence and Clinical Relevance of Acute Kidney Injury (AKI) in Hospitalized Renal Transplant Recipients: Correlation with Delayed Graft Function (DGF) and with Acceleration of Graft Failure
Vincenzo Cantaluppi, Italy

P3.07.64 Prognostic Impact of Changes in High-Density Lipoprotein Cholesterol After Kidney Transplantation: A Nationwide Prospective Cohort Study
Jang-Hee Cho, South Korea

P3.07.65 Post-Kidney Transplant Hyperparathyroidism in Colombia: Five-Year Prevalence and Associated Factors
Elkin Jose Mendoza Olmos, Colombia

P3.07.66 Predicting Delayed Graft Function After Kidney Transplantation: A New Look at an Old Problem
Joseph Kim, Canada

P3.07.67 Sustained Virologic Response and Kidney Transplant Outcomes After a Short-Course of a Direct-Acting Antiviral and Ezetimibe in Recipients of Kidneys from HCV-Infected Deceased Donors
Joseph Kim, Canada

P3.07.68 Navigating BK Virus Management in HIV-Positive Kidney Transplant Recipients: Challenges and Considerations
Sunil Karhadkar, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.71 Outcomes, Clinical and Histopathology Characteristics of Recurrent Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits
Jesty Tom, India

P3.07.72 Outcome of Kidney Transplant Patients Following Treatment with Checkpoint Inhibitors: A Case Series
Ahmed Abdelkader, USA

P3.07.73 A Novel Machine Learning Algorithm Discovers Mismatched HLA Class I Amino Acid Positions That Confer Incremental Kidney Graft Failure Risk Independent of HLA Class II
Malek Kamoun, USA

P3.07.74 Mortality and Kidney Allograft Failure Risk Factors in Thai Kidney Transplant Recipients: A Competing Risk Analysis
Pitchamon Inkong, Thailand

P3.07.75 Molecular T Cell-Mediated Rejection Signals Emerge with Higher Degrees of Tubulitis in Chronic-Active T Cell-Mediated Rejection but Not with Isolated Tubulitis
Lukas Weidmann, Switzerland

P3.07.76 Inter-Center Variability of Biopsy-Based Transcript Diagnostics: Comparison of Banff Lesions with Molecular Scores
Lukas Weidmann, Switzerland

P3.07.77 Role of GCC2 in T Cell Mediated Allograft Rejection in Mice
EM Tanvir, USA

P3.07.80 Dialysis After Kidney Graft Loss: Demographic Trends and Survival Outcomes
John Larkin, USA

P3.07.81 Enhancing Outcomes for Compatible Living Donor Pairs through Kidney Paired Exchange
David Pinelli, USA

P3.07.82 Expanding Kidney Transplantation Opportunities via Global Organ Exchange within Incompatible Pairs
John Friedewald, USA

P3.07.83 Developing City Based Paired Kidney Exchange Program - A Ray of Hope for Sensitized Patients; 10 Years' Outcome Data
Feroz Aziz, India

P3.07.84 US National Registry Continues to Undercount Kidney Paired Donation
Alvin Thomas, USA

P3.07.85 Evolution of the Kidney Paired Exchange (KPE) Program at a Large Volume Transplant Center
Akansha Agrawal, USA

P3.07.86 Fairness without Discrimination: Individual Fairness in Kidney Exchanges
Calvin Nau, USA

P3.07.87 The Use of Imlifidase Desensitisation in the Australian and New Zealand Paired Kidney Exchange Program
Peter Hughes, Australia

P3.07.88 Safety and Effectiveness of Subcutaneous Daratumumab in Plasma Exchange Dependent and Rituximab Resistant Focal Segmental Glomerulosclerosis After Kidney Transplant
Rohan Mehta, USA

P3.07.89 Kidney Transplant for Patients with Proliferative Glomerulonephritis with Monoclonal Immune Deposits
Victor Prado, USA

P3.07.90 AST-KPCOP Survey on Clinical Practice Patterns in Kidney Transplants for Plasma Cell Dyscrasia
Samhita Boppana, USA

P3.07.91 Daratumumab for Treatment of Recurrent FSGS and PGNMID in Kidney Transplant
Jun Shoji, USA

P3.07.92 Genetic Thrombophilia Profile of Kidney Transplant Recipients with Pre- or Post-Transplant Thromboembolic Events
Bogdan Sorohan, Romania

P3.07.93 Successful Transplant Outcome in a Patient with Renal aHUS Manifesting as Hypertension
Nissreen Elfadawy, USA

P3.07.94 Incidence and Outcome of Recurrent IgA Nephropathy in Post Renal Transplant Patients in South Asian Population: A Single Center Study
Adil Manzoor, Pakistan

P3.07.95 Genetic Testing Among Kidney Transplant Candidates
Asim Rizvi, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.97 Recurrent C3 Glomerulonephritis (C3GN) in Kidney Transplant Recipients: A Case Highlighting the Role of Iptacopan
Kamil Sardarli, USA

P3.07.98 The Best Approach to Prevent Recurrence of High-Risk Primary Membranous Nephropathy (PMN)
Fadee Abualrub, USA

P3.07.101 Successful Transplant of a Kidney Graft with Membranous Nephropathy
Mike Fruscione, USA

P3.07.102 Recurrent C3 Glomerulonephropathy in a Kidney Transplant Recipient Treated with Iptacopan
Jessica Lowe, USA

P3.07.103 Single Center Experience with Rituximab and Daratumumab as Rescue Therapy for Post-Transplant FSGS Recurrence, Short-Term Follow-Up
Fareeha Mubin, USA

P3.07.104 Daratumumab in Combination with Rituximab for the Treatment of Focal Segmental Glomerulosclerosis Post-Kidney Transplant
Pranjal Jain, USA

P3.07.105 Complete Remission of Post-Renal Transplant Refractory Focal Segmental Glomerulosclerosis with Rituximab Combined with Adrenocorticotropic Hormone
Jiqiu Wen, China

P3.07.106 What Lies Beneath: Light Chain Restricted Membranous Nephropathy After Kidney Transplantation
Diala Khirfan, USA

P3.07.107 Re-Transplantation Outcomes in Patients with Recurrent IgA Nephropathy
Pooja Lokkur, India

P3.07.108 Digital First-Person Patient Storytelling to Encourage Living Donor Kidney Transplant
LaShara Davis, USA

P3.07.109 Transplant Outreach Program: A Comparison of Kidney Transplant Outcomes Between the Main Campus and Outreach Clinics
Muhammad Yaqub, USA

P3.07.110 Access to Kidney Transplantation via Main Campus versus Outreach Clinics
Muhammad Yaqub, USA

P3.07.111 Kidney Transplantation from Presumed Undocumented Donors in the USA
Krishna Daiya, USA

P3.07.112 Analysis of the Geographic Distribution of Adult Kidney Transplant Programs in the USA: Where Are Programs Needed?
Douglas Keith, USA

P3.07.113 Frailty in Kidney Transplant Candidates: The Role of Social Determinants
Ilana Mittleman, USA

P3.07.114 Digital Enrollment and Survey Response of Diverse Kidney Transplant Seekers in a Remote Trial (KidneyTIME): An Observational Study
Rhys Mendel, USA

P3.07.115 Multi-Session Transplant Education Program to Improve Dialysis Social Worker Knowledge and Confidence in Referring and Supporting Dialysis Patients through Transplant Listing
Talia Giordano, USA

P3.07.116 Association of Race and Ethnicity with Live Donor Kidney Transplantation in the USA from 2015 to 2022
Jasmine Akhtar, USA

P3.07.117 Temporal Trends in the Influence of Socioeconomic Factors on Kidney Transplant Outcomes
Saleh Al-Juburi, USA

P3.07.118 Trends in Bariatric Surgery and Kidney Transplantation Status Among Patients with Advanced Chronic Kidney Disease: A 12-Year Retrospective Review
Rikako Oki, USA

P3.07.119 State-Level Structural Sexism and Access to the Kidney Transplant Waitlist in the USA
Annika Gompers, USA

P3.07.120 Ethnic Disparities in CKD Risk Factors: Community Screening Insights
Abdelrhman Refaey, USA

P3.07.121 Geographic Variation in Sex Disparities in Access to the Living Kidney Donor Transplant: A National US Cohort Study 2015-2021
Jessica Harding, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.122 Predicting Waiting Times for Deceased Donor Kidney Transplantation in Brazil: A Machine Learning Approach Using Cox Regression and XGBoost Models
Gustavo Fernandes Ferreira, Brazil

P3.07.123 Renal Transplant Outcomes in Elderly Recipients: Age Alone Should Not Be a Barrier
Zoe Lu, USA

P3.07.124 Enhancing Kidney Transplant Evaluation: Barriers and Facilitators to Conducting the Access to Kidney Transplant in Minority Populations (AKT-MP) Trial
Shoshana Adler Jaffe, USA

P3.07.125 Using Interviews of Lay Caregivers to Identify Modifications to a Single Website for Kidney Transplant Access
Niaya Jackson, USA

P3.07.126 Telemedicine Services for Rural and Non-Rural Kidney Transplant Patients in the USA
Fawaz Al Ammary, USA

P3.07.127 Outcomes After Preemptive Waitlisting for Kidney Transplantation in the USA
Simeon Adeyemo, USA

P3.07.128 Factors Affecting the Prospective Integration of an Equity Dashboard into Transplant Practice
Elisa Gordon, USA

P3.07.130 An Interactive Virtual Transplant Nephrologist to Engage and Educate Patients About Kidney Transplantation
Peter Reese, USA

P3.07.131 Patient-Perceived Barriers in Communication Affecting Kidney Transplantation in the Hispanic Population
Aditi Gupta, USA

P3.07.132 Location of Dialysis Centers Impacts Kidney Transplant Referral Success: A Retrospective Review
Eden Gallegos, USA

P3.07.133 Expanding Access to Kidney Transplantation: Impact of a Community-Based Outreach Clinic and Equity Initiative
Abraham Cohen-Bucay, USA

P3.07.134 Equity in Kidney Allocation: Examining Demographics in Out-of-Sequence Kidney Acceptance
Christina Delvalle, USA

P3.07.135 Examination of Kidney Transplantation Short-Term Rehospitalizations in California, Florida, and New York State Inpatient Databases 2017-2020
Tanjala Purnell, USA

P3.07.136 From Exclusion to Inclusion: Bariatric Surgery as a Pathway to Kidney Transplant and Patients' Willingness to Participate
Alexandra Kastelz, USA

P3.07.138 Clinical Significance of Sarcopenic Obesity in Kidney Transplant Recipients
Jae Berm Park, South Korea

P3.07.139 Improving Transplant Access and Equity through LatinX Transplant Clinic
Sanjiv Anand, USA

P3.07.141 Access to Waitlisting and Kidney Transplantation for Patients with Incident Kidney Failure in Australia and the UK - A Binational Comparative Analysis
Lachlan McMichael, Australia

P3.07.142 Digital Health Disparities in Public Interest in Kidney Transplantation Across the USA
Benjamin Bizer, USA

P3.07.143 The Impact of Female Sex and Intersectional Disadvantage on Access to Deceased Kidney Transplantation in Australia: A 17-Year National Cohort Study
Tennille Vitagliano, Australia

P3.07.144 Kidney Transplant Recipient Perspectives and Priorities for Goal-Setting Programs: A Workshop Report
Chandana Guha, Australia

P3.07.145 Development and Application of the Kidney Access Disparity Index (KADI) to Evaluate Socioeconomic Inequities in Kidney Transplant Waitlisting
David Leeser, USA

P3.07.146 Frail Kidney Transplant Candidates Are Responsive to Prehabilitation
Danielle Kirkman, USA

P3.07.147 Impact of Educational Attainment on Graft and Patient Survival in Kidney Transplant Recipients in the USA
Oscar Garcia Valencia, USA

P3.07.148 Gut Microbiome Diversity and Insurance Type of Kidney Transplant Recipients
Mehdi Nayebpour, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.151 Establishing a Kidney Transplant Program in Resource Restricted Setting in Sri Lanka through Commitment and Collaboration (2022-2024: JAFFNA - SRI LANKA) Trio of IMHO - Committed Transplant Surgeon from US - Needy Population in SL
B.U.E.W.Duraiswamy R Thangarajah, Sri Lanka

P3.07.153 Expanding Access to Kidney Transplant Evaluations: The Role of Pre-Transplant Satellite Clinics
Taylor Nguyen, USA

P3.07.154 Exploring the Challenges of the Kidney Transplant Evaluation Process from the Perspective of Black Patients: A Qualitative Study
Joy Obayemi, USA

P3.07.155 Prevalence of Genetic Kidney Disease in African American Patients: A Review from an Urban Transplant Center
Fadee Abualrub, USA

P3.07.156 Race-Neutral GFR Kidney Allocation Policy: Too Early to Tell
Arianna Cabrales, USA

P3.07.157 Exploring Barriers to Chronic Kidney Disease Awareness and Prevention Actions in At-Risk Black Patients
Thomas Potter, USA

P3.07.158 Barriers to Living Donor Kidney Transplantation in Black Patients with Kidney Disease
Rohini Prashar, USA

P3.07.159 Utilization of the USA Renal Data System for Transplant-Related Research
Vagish Hemmige, USA

P3.07.160 A Southern State Transplant Center Experience Examining Impact of Waittime Modification After the Introduction of Race Neutral GFR Equations
James Littlejohn, USA

P3.07.161 The Hidden Impact of Race-Based eGFR Calculation in Access to Kidney Transplantation
Michael Wallace, USA

P3.07.162 Geographic Variability in Access to Investigations Required for Kidney Transplant Assessments in a Large Catchment Area
Jiwon Hwang, Canada

P3.07.164 Non-Contact Impedance Measurement to Assess Kidney Degradation in Real-Time
Jarno Tanskanen, Finland

P3.07.165 Utility of Torque Teno Virus Assay in Kidney Transplant Recipients on Everolimus-Based Immunosuppression
Madhuri Ramakrishnan, USA

P3.07.166 Risk Factors Associated with Donor-Derived Cell-Free DNA Levels in Kidney Transplant Recipients with De Novo Hepatitis C Viremia of Donor Origin
Alfonso Santos, USA

P3.07.167 Urinary HSP90 Concentration May Be Associated with Renal Tubular Damage in Kidney Allografts
Kimihito Tachikawa, Japan

P3.07.168 Urinary mRNA Biomarkers for the Non-Invasive Diagnosis of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients
Yu Ho Lee, South Korea

P3.07.169 Diagnostic Performance of Gene Expression and dd-cfDNA in Liver-Kidney Transplant Recipients
Ziad Zaky, USA

P3.07.170 Elevated Zinc Transporter 8 Autoantibodies in Type 1 Diabetes Patients Awaiting Kidney and Pancreas Transplants: A Potential Biomarker for Disease Monitoring
Bongha Shin, USA

P3.07.171 Cell-Free DNA in Decision-Making for Kidney Transplant Immunosuppression: Utilization in Malignancy, Infection, or Pre-Conception Planning
Amer Belal, USA

P3.07.172 Utilization of Microbial Cell-Free DNA (Karius Testing) for Early Infection Detection in Kidney Transplant Recipients: A Single Center Experience
Yasir Qazi, USA

P3.07.173 Negative Impact of Antibiotics on Fecal Short Chain Fatty Acid Levels: Implications for Gut Health in Kidney Transplant Recipients
Friederike Selbach, USA

P3.07.176 Deciphering the Mechanistic Basis for Sex-Based Differences in Kidney Transplant Outcomes
Thalia Salinas, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.177 Unsupervised Machine Learning with Dynamic Time Warping Helps Understand Longitudinal dd-cfDNA Trajectories in Kidney Transplant Patients
Ziad Zaky, USA

P3.07.179 Trends in Molecular Diagnostics for Low Eplet Mismatch Kidney Recipients Managed with Reduced Immunosuppression
Nicole Ali, USA

P3.07.180 Effect of Tacrolimus Metabolism on Outcomes in Kidney Transplantation: A Retrospective Multicentre Study Using a Clinical Data Warehouse
Sangwan Kim, South Korea

P3.07.182 Does Glycosuria Due to SGLT2 Inhibitors Interfere with Proteinuria Measurement?
Elizabeth Oguntuwase, USA

P3.07.183 Longitudinal Donor-Derived Cell-Free DNA Kinetics in Recipients of "Hard-to-Place" Kidneys
Yasir Qazi, USA

P3.07.184 Impact of Metabolic Variability of Tacrolimus on Post-Transplant Clinical Outcomes in Kidney Transplant Recipients
Woo Yeong Park, South Korea

P3.07.185 Relative Changes in Donor-Derived Cell-Free DNA as a Marker of Allograft Rejection in a Kidney Transplant Recipient with Metastatic Cancer Undergoing Immunotherapy
Nan Katsurayama, Japan

P3.07.186 Real-Time Bioelectronic Monitoring of Temperature and Strain to Detect Acute Rejection in a Kidney Transplant Model
Elisa Gessaroli, USA

P3.07.187 YAP (Yes Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) as Novel Biomarkers of Kidney Transplant Dysfunction: Our Preliminary Study
Dharshini Suresh, USA

P3.07.188 Dual-Energy CT Bone Erosion Findings Before and After Pegloticase Treatment in Kidney Transplant Patients with Uncontrolled Gout: PROTECT Trial
Brad Marder, USA

P3.07.189 Donor-Derived Cell-Free DNA Analysis in a Kidney Transplant Recipient with Malignancy-Associated Loss of Heterozygosity and Concomitant Antibody-Mediated Rejection
Yasir Qazi, USA

P3.07.190 AlloView in the Prediction of Kidney Allograft Rejection
Varsha Swamy, USA

P3.07.191 Achieving and Maintaining Target Immunosuppression Levels by Combined Pharmacogenetic and Torque Teno Viral Load Testing
Anna Chikova, USA

P3.07.192 Recovery from Lymphopenia After Renal Transplantation is Associated with Improved Allograft Function
Kevin Eappen, USA

P3.07.193 Correlation of Donor-Derived Cell Free DNA Results with For-Cause Kidney Allograft Biopsies: A Single-Center Retrospective Review
Elizabeth Cho, USA

P3.07.194 Clinical Utility of the Donor-Derived Cell-Free DNA Fraction in Monitoring Kidney Transplant Recipients at Least Two Decades Post-Transplantation: A Single-Center Experience
Yasir Qazi, USA

P3.07.196 Use of TUTIVIA in the Early Post-Transplant Period for Distinction of Rejection from Quiescence Among Kidney Transplant Recipients - A Single Center Experience
Vasil Peev, USA

P3.07.197 Urinary Chemokines for the Non-Invasive Detection of Kidney Allograft Rejection
Valentin Goutaudier, France

P3.07.198 Quantitative Urine Proteomics Analysis Reveals Differences Between Kidney Transplant Rejection and Normal Pathology
Stephanie Kuo, Australia

P3.07.199 TCF7L2 rs7903146 is Associated with Increased Risk of New-Onset Diabetes After Transplant: A Meta-Analysis of Literature
Muhammad Tassaduq Khan, Pakistan

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.07.200 Tissue miRNA Profiles as Biomarkers for Kidney Transplant Rejection and BK Nephropathy
Neva Bezeljak, Slovenia

P3.07.201 Real-World Application of dd-cfDNA in Screening for Rejection and Post-Treatment Monitoring in Asian Kidney Transplant Patients
Pei Xuan Ang, Singapore

P3.07.202 Understanding the Drivers of Donor-Induced Thrombotic Microangiopathy in Kidney Transplant Recipients: A Case Series Analysis
Mike Fruscione, USA

P3.07.203 Biopsy-based Transcriptomics Support Rejection Monitoring through Repeated Kidney Allograft Biopsies
Lukas Weidmann, Switzerland

P3.07.204 Clinical Utility of Local Assessment of Donor Derived Cell-Free DNA in Kidney Transplant Recipients Undergoing Indication Biopsy
Renato de Marco, Brazil

P3.07.205 Correlation of Antibody-Mediated Rejection Grades by mRNA Transcripts with Histology After Kidney Transplantation: A Single Center Experience
Rebecca Tong, USA

P3.07.207 Sequential Measurement of Donor Derived cfDNA and Correlation with Patient Outcomes Post Kidney Transplant
Laurine Bow, USA

P3.07.208 Bone Mineral Disease in Kidney Transplant Patients
James Roe, USA

P3.07.210 Serial Donor-Derived Cell-Free DNA (dd-cfDNA) Surveillance Following Immunosuppression Modification in Kidney Transplant Recipients with BK Polyomavirus Viremia
Nicole Ali, USA

P3.07.211 Transient Elevations in Donor-Derived Cell-Free DNA Following Intravenous Immunoglobulin Administration in Kidney Transplant Recipients
Nicole Ali, USA

P3.07.212 sCD14 as a Novel Biomarker for AKI in Deceased Kidney Donors
Stephanie Almeida, USA

P3.07.213 Donor Organ-Induced Thrombotic Microangiopathy in Kidney Transplant Recipients: A Novel Process or Better Understanding of an Old Problem?
Mike Fruscione, USA

P3.07.214 The Value of Routine Monitoring of LDH (Lactate Dehydrogenase) Early Post Kidney Transplant
Samuel Sultan, USA

P3.07.215 The Role of Gene Expression Profile in Predicting Acute Rejection
Zahraa Hajjiri, USA

P3.07.216 Comparison of Gene Expression Profiling with Histopathology and Molecular Pathology in Detection of Acute Rejection in Kidney Transplant Recipients
Rupinder Sodhi, USA

P3.07.217 Leveraging Topological Data Analysis and Machine Learning to Predict Kidney Transplant Rejection
Khodor Abou-Daya, USA

P3.07.218 Tutivia Biomarker Testing Provides Accurate Results for Medical Management in Severely Obese Kidney Transplant Patients
Zahraa Hajjiri, USA

P3.07.219 Can Pretransplant Donor Cystatin-C Identify High-Risk Kidneys? Insights into Grafts with Primary Non-Function and Long-Term Transplant Outcomes
Ioannis Michelakis, UK

P3.07.220 Fgl2 is an Immunomodulatory Molecule That is Upregulated in Tolerant Kidney Graft Recipients
Jenna Lancey, USA

P3.07.221 Pediatric kidney donor risk factors for graft loss in deceased-donor pediatric kidney transplant recipients
Qiang Zhang, China

P3.07.222 Donor Derived Cell Free DNA in Predicting BK Polyomavirus-Associated Nephropathy
Elizabeth Cho, USA

P3.07.223 Role of clonal hematopoiesis in Renal Transplantation Outcomes
Surbhi Shah, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.08
Topic: Liver

P3.08.1 Clinical Outcomes with Positive Crossmatch or Preformed DSA in Simultaneous Kidney and Liver Transplant Recipients
Kamil Sardarli, USA

P3.08.2 Graft and Immunologic Outcomes with HLA-Incompatible Simultaneous Liver-Kidney Transplantation
Reiad Najjar, USA

P3.08.3 Liver Transplantation and Decompensation in Patients with Cirrhosis Secondary to Metabolic Associated Steatotic Liver Disease After Bariatric Surgery
Ami Patel, USA

P3.08.4 Positive Crossmatch with Persistent Donor Specific Antibodies Increases Risk of Rejection in Liver Transplantation: A Retrospective Single-Center Analysis
Megan Henderson, USA

P3.08.5 Post Transplant Biliary Complications in Acute on Chronic Liver Failure - A Single Center Study
Rachel Davis Bouvette, USA

P3.08.6 Disparities in Liver Transplant Recipients Between 2014 and 2024 Using Organ Procurement and Transplantation Network Data
Razan Aburumman, USA

P3.08.7 Post-Transplant Outcome of Acute on Chronic Liver Failure - A Single Center Comparison Study
Rachel Davis Bouvette, USA

P3.08.8 Liver Transplantation for Hepatocellular Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors Therapy: Efficacy and Safety
Grazia Conte, Italy

P3.08.9 Assessing Liver Transplant Outcomes in Severely Obese Patients: The Influence of Performance Status
Alejandro Cracco, USA

P3.08.10 Non-Medical Declines for Waitlisting: A Frequent and Overlooked Barrier to Accessing Liver Transplantation
Shayana Seneviratne, USA

P3.08.11 SALT-M Score as a Predictor of Post-Liver Transplant Mortality - Is the Jury Still Out?
Prakash Chauhan, USA

P3.08.12 Cardiac Evaluation and Management of Liver Transplant Recipients with Myocardial Iron Overload
Marilyn Ndukwe, USA

P3.08.13 Risk Factors Affecting Functional Status in Liver Transplant Recipients over the Age of 70 Years
Konstantinos Ouranos, USA

P3.08.14 Outcomes from Referral to Transplant for Patients with MASLD: A California Liver Network Study
Tiffany Lim, USA

P3.08.15 Muscle Density, Not Size: A Key Predictor of Frailty in Liver Transplant Candidates
Peter Gullickson, USA

P3.08.16 Liver Transplant Recipients with Limited Sobriety Have Similar Rates of Alcohol Relapse Compared with Traditional Criteria
Nikolai Harroun, USA

P3.08.18 The Real World: A Single-Center Experience Launching DCD Liver Transplant Utilization
Brianna Ruch, USA

P3.08.19 Effect of Hereditary Clotting Deficiencies on Liver Transplant Outcomes
Alejanro Chiodo Ortiz, USA

P3.08.20 Correlation Between BMI and Long-Term Outcomes in Liver Transplant Recipient
Dean Abdehou, USA

P3.08.21 Ten-Year Prognostic Significance of AFP and PIVKA-II in HCC Following Living Donor Liver Transplantation
Kwang-Woong Lee, South Korea

P3.08.22 Complementary Organ Recovery Techniques and Devices to Maximize Liver Utilization
Bruce Nicely, USA

P3.08.23 Outcome of Liver Transplantation on Waiting List in the Face of a New Prioritization System in the Argentinian Allocation Model
Cecilia Broeders, Argentina

P3.08.24 MELD 3.0 Thresholds: Improving Selection Criteria for Patients with ALD Referred for Early Liver Transplantation
Bima Hasjim, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.08.26 Higher Risk of Deceased Donor Liver Transplantation Recipients with a Donor-Recipient Height Difference ≥30cm: UNOS Database Study
Jinsoo Rhu, USA

P3.08.27 Survival Benefit of Liver Transplantation in the Modern Era Across All MELD Categories
Previn Ganesan, USA

P3.08.28 Assessing the Safety of Living Donor Liver Transplantation in Low MELD Patients: Risk Factors for Early Graft Loss
Yuki Nakayama, Japan

P3.08.29 Sex Disparities in Liver Transplant Vary Across Centers and Persist After MELD 3.0 Implementation
Katherine Ross-Driscoll, USA

P3.08.30 Assessing Socioeconomic Disparities in Pediatric and Adult Deceased Donor Liver Transplant Rates Before and After the Acuity Circle Policy Implementation
Sana Murtaza, USA

P3.08.31 Intestinal Insufficiency Increases Risk of Death and Prolonged Hospitalization in Pediatric Liver Recipients
N. Thao Galvan, USA

P3.08.32 Unpacking the Increase in Access to Liver Transplantation for Pediatric Registrants
Conor Donnelly, USA

P3.08.33 Donor-Derived Cell-Free DNA Levels in Pediatric Liver Transplant Recipients Undergoing For-Cause and Surveillance Biopsies
Andres Rivera, USA

P3.08.34 The Utilization and Accuracy of FibroScan in Pediatric Liver Transplant at a Single Tertiary Center
Chaowapong Jarasvaraparn, USA

P3.08.35 Ultrasound of the Rectus Femoris Muscle and Association with Pediatric Liver Failure - Preliminary One-Year Pilot Outcomes Data
Christopher Chu, USA

P3.08.36 Non-Immunologic Allograft Injury Predisposes to Acute Cellular Rejection (ACR) in the First Year After Liver Transplantation (LT) in Children
Rakesh Sindhi, USA

P3.08.38 Geographic Disparities in Pediatric Liver Transplantation
Vikram Raghu, USA

P3.08.39 Antibody-Mediated Rejection in Pediatric Liver Transplantation: A Single Center Experience
Tanya Su, USA

P3.08.40 A 10-Year Analysis of the UNOS Registry: Insights into Strategies to Prevent Death on the Pediatric Waitlist Using Liver Preservation Technologies
Leonie van Leeuwen, USA

P3.08.41 Epitope Mismatch Successfully Identifies Pediatric Liver Transplant Recipients at Risk for Late T Cell Mediated Rejection
Deepika Reddy, USA

P3.08.42 Tailored Steroid Protocol Use Improves Bile Drainage and Native Liver Survival After Kasai Portoenterostomy
Jaimie Nathan, USA

P3.08.44 Impact of Decreasing Median PELD at Transplant on Children
Dzhuliyana Handarova, USA

P3.08.45 What is the Environmental Impact of Pediatric Liver Transplantation?
Emilie Landry, Canada

P3.08.46 Optimizing Liver Utilization for Adult and Pediatric Transplantation with Deceased Donor Partial Grafts Undergoing Normothermic Machine Perfusion: Proposed Standardization of Logistic Options
William Archie, USA

P3.08.47 Liver Transplantation for Maple Syrup Urine Disease: Outcomes Analysis of 245 Liver Transplant Recipients from the United Network for Organ Sharing Registry
William Archie, USA

P3.08.48 Evaluating the Role of Multi-Center Listing in Access and Outcomes in Pediatric Liver Transplantation
Sunil Karhadkar, USA

P3.08.49 Effect of Sex, Race and Donor Type on Liver Transplant Outcomes in Biliary Atresia
Alejanro Chiodo Ortiz, USA

P3.08.50 ABO Non-Identical Liver Transplantation Disadvantages Pediatric Waitlist Candidates with Blood Group O
Tess Coker, USA

P3.08.51 A Confounder Debiasing Method for RCT-Like Comparability Enables Machine Learning-Based Personalization of Living Donor Liver Transplantation Survival Benefit
Bima Hasjim, USA

P3.08.52 The AI Agent in the Room: Informing Objective Decision Making at the Transplant Selection Committee
Bima Hasjim, USA

P3.08.53 Association Between Hard-to-Place Indicators and Survival Among Liver Transplant Recipients from 2018-2023
Matthew Caputo, USA

P3.08.54 De Novo Anxiety and Depression in LT Recipients: A Large, National Cohort Study Using Electronic Health Records
Kelly Terlizzi, USA

P3.08.55 The Impact of Race and Socioeconomical Status on the Conditional Graft and Patient Survival After 5-Year in Liver Transplantation
Atsushi Nishimagi, USA

P3.08.56 Computer Vision Assessment of Liver Steatosis at Time of Donation
Colin Wilson, UK

P3.08.57 Comparative Analysis of Liver Transplantation Outcomes in USA and South Korea: The UNOS and KOTRY Registry Analyses
Jiyoung Kim, South Korea

P3.08.58 Machine Learning-Based Cytokine Profiling for Predicting Early Allograft Dysfunction in Transplant Patients
Sunil Kurian, USA

P3.08.59 Development of a Dynamic Model for Urgency of Liver Transplantation in Hepatocellular Carcinoma
Allison Kwong, USA

P3.08.60 Assessment of the Performance of Large Language Models for Detecting the Presence of Rejection and Its Severity in Post-Transplant Liver Biopsies
Ashley Spann, USA

P3.08.61 Surgical Video Auto-Segmentation by a Commercially Available Platform is Not Inferior to Manually Edited Operative Recordings When Utilized for Expert Review and Training
William Archie, USA

P3.08.62 Prospective Tumor Molecular Profiling After Liver Transplantation
Samar Semaan, USA

P3.08.63 Evaluating the Impact of Neighborhood-Level Environmental Burden Score on Patient Outcomes in Liver Transplant Recipients
Samar Semaan, USA

P3.08.64 Leveraging AI for Answering Most Frequently Asked Questions (FAQs) in Organ Transplantation
Nishtha Singh, USA

P3.08.65 Identifying Risk Profiles Among Patients with Liver Transplantation Using Machine Learning: A Clustering Analysis
Adaluz Escalona, Colombia

P3.08.67 New Frontiers in Predicting Post-Transplant Hepatocarcinoma Recurrence Powered by Artificial Intelligence
Adaluz Escalona, Colombia

P3.09
Topic: Lung

P3.09.1 Early Trends in Access to Lung Transplant by Candidate Biology After the ABO Score Modification
Grace Lyden, USA

P3.09.2 Early Use of Crushed Posaconazole via Enteral Tube Did Not Reduce Time to Goal Trough Concentration Post-Lung Transplant
Max Weder, USA

P3.09.3 Examining US Center-Level Variation in Lung Transplant Waitlist Updates
Maryam Valapour, USA

P3.09.4 Open Offer Donor Lungs Are Non-Inferior to Standard Waitlist Donors
Marianna Frazee, USA

P3.09.6 Impact of the Affordable Care Act Medicaid Expansion on Racial Disparities in Lung Transplant Access
Rachel Holstein, USA

P3.09.7 Pulmonary Hypertension and Lung Transplantation Waitlist Outcomes for Hypersensitivity Pneumonitis
Alonso Marquez, USA

P3.09.8 Geographic Variability in Lung Transplant Access Across Three Policy Eras
Tanveen Ishaque, USA

P3.09.9 Examining the Effects of Increased Prioritization for Blood Type O Candidates in U.S. Lung Transplantation
Maryam Valapour, USA

P3.09.10 Likelihood of Lung Transplantation Before and After the Implementation of Lung Continuous Distribution
Tatenda Mupfudze, USA

P3.09.11 The Impact of Continuous Distribution on Lung Candidate Survival from Listing, to Transplant, to Post-Transplant Survival
Samantha Weiss, USA

P3.09.12 Shifting Boundaries: The Effect of the Composite Allocation Score (CAS) on Lung Transplantation and Waitlist Outcomes
Ekta Upadhyay, USA

P3.09.13 Impact of Lung Transplant Allocation Policy on Patients with Idiopathic Pulmonary Fibrosis
Thomas Egan, USA

P3.09.14 The Impact of Lung Continuous Distribution on Geographically Isolated Transplant Centers
Samantha Weiss, USA

P3.09.15 Evaluating the Geographic Barriers to Lung Transplant for Smoking-Associated Diseases Across the USA
Alexandra Rizaldi, USA

P3.09.16 The Challenge of Donor Lung Selection for Single Lung Transplantation in Older Candidate Recipients
Richa Asija, USA

P3.09.17 Fungal Foes: A Decade of Antifungal Practices in Pediatric Lung Transplant
Sruti Nadimpalli, USA

P3.10
Topic: Organ Inclusive

P3.10.1 Donor Age is Associated with Intravascular Release of HSP90 in Kidney Grafts
Toshiaki Tanaka, Japan

P3.10.2 Controlled Hypothermic Preservation of Donor Livers with Back-to-Base Normothermic Machine Perfusion Facilitates Expansion of the Donor Pool
Vijay Subramanian, USA

P3.10.3 Organ Procurement Organization Utilization of Portable Hypothermic Oxygenated Machine Perfusion in Liver Transplantation: The First US Experience
Ralph Quillin, USA

P3.10.4 Transcriptional and Cytokine Profiling for Feasibility, Viability, and Damage Assessment in Preclinical Ex-Vivo Normothermic Perfusion (EVNP) of Discarded Kidneys
Michael Goldstein, USA

P3.10.6 Determinants of Early Allograft Dysfunction in Liver Transplantation Using Normothermic Machine Perfusion
Brendan Flynn, USA

P3.10.7 Bench Testing of a New Australian Device for Hypothermic Oxygenated Perfusion (HOPE) of Donated Hearts and Kidneys
Toby Coates, Australia

P3.10.8 Reanimation of Porcine Kidneys Perfused by a New Australian Device for Hypothermic Oxygenated Perfusion (HOPE) of Donated Kidneys
Toby Coates, Australia

P3.10.9 The Predictive Value of Kidney Resistive Index for Delayed Graft Function in Kidney Transplantation: Results of the BEST-Fluids Trial Imaging Sub-Study
Michael Collins, Australia

P3.10.10 Innovation in Organ Transplantation through Wireless Real-Time Temperature Monitoring
Ignacio Gondolesi, Argentina

P3.10.11 Restoration of Coagulative Dynamics as Remedy for Pelvic Bleedings in a Kidney Normothermic Machine Perfusion Model
Marlene Pühringer, Austria

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.10.12 Real-World Indications for Normothermic Machine Perfusion Use and Their Relationship to Transplant Demographics: A National Organ Perfusion Registry Study
Sarah Sheskey, USA

P3.10.13 The Current Landscape of In Situ and Ex-Situ Machine Perfusion Utilization for Liver Grafts from Non-Cardiac Donation After Circulatory Death Donors
Anji Wall, USA

P3.10.14 Hypothermic Oxygenated Perfusion vs. Static Cold Storage in Liver Transplantation: A Systematic Review and Meta-Analysis of Post-Transplant Outcomes
Ahmed Uosef, USA

P3.10.15 Hypothermic Liver Perfusion: A Retrospective Analysis of Its Implementation and Procedural Impact
Marc Bohils, Spain

P3.10.16 Proteomic Analysis of Perfusate from Normothermic Machine Perfusion of Human Livers Suggests Markers Associated with Organ Recovery
Tara Sigdel, USA

P3.10.17 Machine Perfusion of Kidney Allografts during Simultaneous Liver and Kidney Transplantation Improves Kidney Outcomes
Justin Steggerda, USA

P3.10.18 Reframing Warm Ischemia: Defining "Out-of-Ice" Time by Temperature, Not Elapsed Minutes
Keith Hansen, USA

P3.10.19 Development of Cryopreservation Protocol for Long-Term Storage of Transplant Organs
Isla Weber, USA

P3.10.20 Lactate Trends in A-NRP and TA-NRP: A Single Center Analysis
Kelly Cederquist, USA

P3.10.21 The Unmet Need for Solid Organ Transplantation in the U.S. Pacific Islands: A Summary of Current Data & Challenges
Dylan Bush, USA

P3.10.22 Understanding Disparities in Progression from Living Donor Candidate Evaluation to Approval: Analysis of the US SRTR Living Donor Collective
Krista Lentine, USA

P3.10.23 The Association Between Neighborhood Socioeconomic Status and Post-Transplant Cancer Outcomes Among Kidney Transplant Recipients in the USA
Nathan Pan, USA

P3.10.24 Segregation: A Driver of Racial Disparities in Air Pollution-Associated Post-Kidney Transplant Mortality
Yiting Li, USA

P3.10.25 Navigating Motherhood After Kidney Transplant: Pregnancy Rates
Chenxi Gao, USA

P3.10.26 Impact of an Organ Recovery Center on Organ Utilization from Hospitals in Distressed vs Prosperous Communities
Victoria Filardi, USA

P3.10.27 A Feasibility Assessment of the Comprehensive Obesity Management Pre-Kidney Transplant (COMP-KT) Program: Process Evaluation
Johanna Christensen, USA

P3.10.28 Expansion of Multiorgan Transplantation in People with HIV
Zeba Nauroz, USA

P3.10.29 Normothermic Machine Perfusion Reduces Waitlist Time in Liver Transplant: A Single Center Experience
Regina Longley, USA

P3.10.30 System-Level Barriers Reducing Access to Transplantation: Results of a Global Survey
Andrea Herrera-Gayol, Canada

P3.10.32 Optimizing Transplant Eligibility through an Integrated Obesity and Metabolic Program
Nisha Patel, USA

P3.10.33 The Ethics of Multiple Listing: Are Certain Patients at an Automatic Disadvantage?
Claire Cywes, USA

P3.10.35 Missed Opportunity? Patients with End-Stage Liver Disease Increasingly Receive Palliative Care, but Very Late
Anita Mahadevan, USA

P3.10.36 Descriptive Series of Kidney Transplant Among Amish and Mennonite Patients
Mark Wakefield, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.10.37 Comparisons of Neonatal and Maternal Outcomes and Modes of Delivery Between Kidney Transplant Recipients and General Population - A Nationwide Database Study
Hsin-Hsu Wu, Taiwan

P3.10.38 Addressing Gaps in Family Caregiver Support: An Analysis of U.S. Transplant Centers
Yadira Montoya, USA

P3.10.39 TRANSFORM: Transplant Readiness Achieved through Novel Solutions for Obesity Reduction and Management
Jamie Benken, USA

P3.10.40 The Transformative Impact of RNA Nanomedicine on Need for Solid Organ Transplantation
Nilah Ahimsadasan, Canada

P3.10.41 Diet and Diagnosis: Unveiling Secondary Oxalate Nephropathy in a Kidney Transplant Recipient
Shannon Lyons, USA

P3.10.42 From Graft to Survival: Two-Decade Trends in Bone Marrow Transplant Rejection Mortality in the USA
Roshan Afshan, USA

P3.10.43 CDC WONDER Insights: Two-Decades Trends in Infectious Disease-Related Mortality Among Organ and Tissue Transplant Recipients
Roshan Afshan, USA

P3.10.44 CMV's Impact is Not So Minimal- A Case of Post-Transplant CMV Minimal Change Disease
Renuka Tolani, USA

P3.10.45 Histopathology of Delayed Graft Function in Early Posttransplant Kidney Biopsies
Tomoki Tsukahara, USA

P3.10.46 Impact of Revascularization Time on Surgical and Histopathological Outcomes in Robotic-Assisted Living Donor Kidney Transplantation
Hafiz Umair Siddiqui, USA

P3.10.47 Development of HLA Genotype-Informed dPCR Assay to Monitor Donor-Derived cfDNA
Pascal van der Weele, Netherlands

P3.10.48 Efficacy and Safety of Immune Checkpoint Inhibitors in Kidney Transplant Recipients with Metastatic Cancer: A Systematic Review
Muhammad Ali Khan, USA

P3.10.49 Descriptive Analysis of Unstructured Donor Data for Deceased Donor Allocation
Marcus Thoreson, USA

P3.10.50 Model-Informed Precision Dosing (MIPD) of Tacrolimus in Kidney Transplantation: A RCT
Dirk Kuypers, Belgium

P3.10.51 ARES, ARtificial Intelligence for BEtter Transplant; a Federated Data Integration Architecture for Train and Validate Artificial Intelligence Prediction Models
Ignacio Revuelta, Spain

P3.10.53 Engaging Transplant Professionals with a Novel Educational Model Using Social Media Visuals
Mallika Gupta, USA

P3.10.54 Harnessing Machine Learning to Optimize Family Approaches and Increase Organ Availability for Transplantation
Jennifer Grant, USA

P3.10.55 AI-Generated Explanations in Kidney Transplantation: Accuracy vs. Readability and Implications for Patient Education
Oscar Garcia Valencia, USA

P3.10.56 Harnessing Large Language Models for Rapid and Accurate Data Extraction in Transplant Clinical Research at Scale
Luke Ni, USA

P3.10.57 Using A Novel Machine Learning Algorithm to Predict Donor Organ Quality: Lowering Costs and Overall Discard Rate
Adam Kressel, USA

P3.10.58 Identifying Risk of Readmission After Kidney Transplant Using Electronic Health Records-Based Predictive Analytics
Solaf Al-Awadhi, USA

P3.10.59 Pretransplant Clusters and Outcomes Determining Variables of Expanded Criteria Donors Controlled Donation After Circulatory Death Kidney Transplants through a Hybrid Artificial Intelligence-Based Model Combining Survival Analysis, Multiple Criteria Optimization and an Artificial Neural Network
Ignacio Revuelta, Spain

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.10.61 Identifying Profiles of Generosity Using Artificial Intelligence for Living Donation Media Campaign Planning
Amy Waterman, USA

P3.10.62 SHAP-Based Analysis of Donor-Recipient Age Matching in Kidney Transplant Survival
Jane Long, USA

P3.10.63 Bridging Support Gaps in Online Transplant Communities
Rajesh Anumolu, USA

P3.10.64 Linguistic Features of Cognitive Decline in ESKD: A Comparative Analysis of Patient Portal Messages Among Non-Transplant vs. Transplant Patients
Jasir Nawar, USA

P3.10.66 DonorNet Kidney Procurement Photos and Their Association with Kidney Utilization
Morgan Stuart, USA

P3.10.67 Improving Quality of Patient Educational Materials through a Comparative Analysis of Patient Handbooks from U.S. Transplant Centers
Tristan Mace, USA

P3.10.68 Machine Learning Prediction of Optimal Kidney Transplant Time for Patients with Diabetes
Divy Kumar, USA

P3.10.70 Enhancing Medical Student Exposure to the Field of Transplantation: Assessing Learning Outcomes of a Novel Transplant Education Program in a U.S. Medical School
Harris Whiteson, USA

P3.10.71 Trends in Transplant Nephrology Fellowship Training: Survey of US Transplant Nephrology Fellowship Programs
Kurtis Swanson, USA

P3.10.72 Organs, Health and Kindness: Three Foundational Pillars of High-Impact School-Based Organ Donation Education Programs in Canada
Breanne Spencer, Canada

P3.10.73 TRIP: Operating a Volunteer-Based Hospital Visitation Program for Transplant Patients
Ethan Staats, USA

P3.10.74 Disparities in Education on Organ Donation and Transplantation: Results of a Global Survey
Andrea Herrera Gayol, Canada

P3.10.75 Do We Deliver? Contraception Counseling Practices in Solid Organ Transplant Providers
Karen Young, USA

P3.10.76 Engaging Living Organ Donors in the Development of Data Collection Instruments
Allyson Hart, USA

P3.10.77 Sexual Health Knowledge and Practices in Post-Transplant Adolescents and Young Adults
Kaushalendra Amatya, USA

P3.10.78 Engagement of Medical Students in Multiorgan Procurement: Enhancement of Knowledge and Interest in Surgery
Sophia Gamboa, USA

P3.10.79 Social Media and Public Awareness in Mongolia
Battsetseg Gonchigjav, Mongolia

P3.10.80 From Hybrid to Fully Online: A Decade of Evolution in Donation and Transplantation Education
Joaquim Albiol, Spain

P3.10.81 The Urgent Need for an Organ Transplant Patient-Focused, Interactive Educational Tool to Facilitate Recipient Life-Time Outcomes and Well-Being
Karin Hehenberger, USA

P3.10.82 Heterogeneity in Hepatology Training in the US and Canada
Alan Hutchison, USA

P3.10.83 Advanced DCD Training: Benefits for Personal Healthcare Development and National Perspectives on DCD Programs
Brian Alvarez, Spain

P3.10.84 Organ Procurement Organization Perspectives and Experiences Facilitating Normothermic Regional Perfusion
Amanda Buster, USA

P3.10.85 The Importance of Individual Patient Stories Amplified by Social Media on Transplant Listing and Understanding
Jamie Haight, USA

P3.10.86 Enhancing Transplant Surgery Education during Surgery Clerkship: A 2+2 Model Integrating Organ Procurement for Third-Year Medical Students
Peyton Harris, USA

P3.10.87 Readability of Patient and Parent Education Materials in Solid Organ Transplant Clinic - A Single Center Study
Shaan Thomas, USA

P3.10.88 Iterative Development of an OPO-Based Abdominal Normothermic Regional Perfusion Program
Gennifer Collins, USA

P3.10.89 Thailand's First Analytical Program for Deceased Organ and Eye Donor Detection
Korntip Phonphok, Thailand

P3.10.90 Factors Associated with Prolonged Case Time in Deceased Organ Donation
Carolyn Sidoti, USA

P3.10.91 Estimating Relative Performance on Solid Organ Donation Rates Across US Counties
Jonathan Miller, USA

P3.10.92 Benefits of a Pre-Procurement Conversation with the Surgical Recovery Team: Donor Family Perspectives
Carrie Thiessen, USA

P3.10.93 Efficacy of Corticosteroid Pretreatment in the Management of Deceased Organ Donors: A Systematic Review and Meta-Analysis
Qi Zuo, Canada

P3.10.94 Knowledge and Comfort Gaps of Critical Care Specialists About Deceased Donation: Results of a Global Survey
Marcelo Cantarovich, Canada

P3.10.95 Gaps in Knowledge and Comfort in the Acceptance of Deceased Donors: Results of a Global Survey
Marcelo Cantarovich, Canada

P3.10.96 Antegrade Thoracic Aortic Cannulation with Retroperitoneal Iliac Arterial Clamping - An Alternative Surgical Technique in Deceased Donor with Hostile Abdomen
Alex Zendel, USA

P3.10.97 Characterization of Plasma Biomarkers in Brain-Dead Organ Donors
Miraf Molla, USA

P3.10.98 The Impact of Utilizing Non-Transplantable Organs for Research: The Results of a 5-Year Study
Ahmad Salehi, USA

P3.10.99 Plasma Metagenomic Sequencing in Organ Transplant Donors
Miraf Molla, USA

P3.10.100 Abdominal Normothermic Regional Perfusion - An Acceptable Approach to Organ Recovery from High BMI DCD Donors
Alex Zendel, USA

P3.10.101 Improvement of the Organ Donation: Lesson Learned from One Organ Procurement Organization's Experience
Rauf Shahbazov, USA

P3.10.102 Open Liver Biopsy Impact on Intra-Op Declines
Thomas Molony, USA

P3.10.103 Calcineurin Inhibitor Based Immunosuppression vs. Costimulation Blockade for Transplantation Patients: A Systematic Review and Meta-Analysis
Sriharsha Koduru, India

P3.10.104 Medication Adherence Before and After Conversion to LCP-Tacrolimus from Immediate Release Tacrolimus in Pediatric Solid Organ Transplant Recipients
Leandra Bitterfeld, USA

P3.10.105 Transplant Professionals' Knowledge, Attitudes, and Practices of Transgender Patient Care
Ana Rossi, USA

P3.10.106 Gift of Life: The Evolution of Organ Donation & Transplantation-Journey of Hayat -United Arab Emirates
Priya Santharaj, United Arab Emirates

P3.10.108 What We Can Do for the Future Transplant; Perspective from a Medical Student in Japan
Shingo Nagura, Japan

P3.11
Topic: Pancreas

P3.11.1 Long-Term Outcome of Pancreas Transplantation in Japan Based on the Nationwide Registry
Yoshito Tomimaru, Japan

P3.11.2 Utility of Donor Amylase and Lipase Levels in Predicting Outcomes in Pancreas Transplantation
Evronia Baselious, USA

Poster Listing

Tuesday, August 5 3:30 PM - 4:30 PM

P3.11.3 Favorable Outcomes of Pancreas Transplants from Drug Overdose Donors Supports Their Increased Utilization
Michie Adjei, USA

P3.11.4 Impact of Donor Body Mass Index on Pancreas Transplant Outcomes
Alex Jurkovich, USA

P3.11.5 Heparin Thromboprophylaxis After Pancreas Transplantation Improves Outcomes: Single-Center Experience
Mariella Ortigosa-Goggins, USA

P3.11.6 Time to Revise Eligibility Criteria Based on Fasting c-Peptide Levels and Body Mass Index in Pancreas Transplantation: Single Center Experience
Mariella Ortigosa-Goggins, USA

P3.11.7 Identifying Failure Modes of Pancreatic Islet Cells during Cold Storage Using a Multi-Omics Approach
Nabil Boutagy, USA

P3.11.8 A Longitudinal Analysis of Pancreas Transplantation Outcomes in the USA over the Past 20 Years
Reza Saidi, USA

P3.11.9 No Blood? No Problem: Blood-Free Perfusion of Human and Porcine Pancreases - A Feasibility Study
Catherine Parmentier, Canada

P3.11.10 Global Survey on Access to Transplantation: Knowledge and Comfort Gaps in the Acceptance of Pancreas and Islets from Deceased Donors
Marcelo Cantarovich, Canada

P3.11.11 Glucagon-Like Peptide 1 Receptor Agonists Use in Obese Simultaneous Pancreas-Kidney Transplant Recipients: A Single Center Experience
Mohammad Abuzeineh, USA

P3.11.12 Metabolic Outcomes of Obese Recipients of Simultaneous Pancreas and Kidney (SPK) Transplant- A Single Center Experience
Ruchi Naik, USA

P3.11.13 Clinical Significance of Pre-Transplant Serum Albumin and Mortality in Pancreas Transplant Recipients
Fawaz Al Ammary, USA

P3.11.14 One-Year HbA1c as a Predictor of Long-Term Graft Survival in SPK Transplantation: A Retrospective Analysis of UNOS Registry Data
Colin Wilson, UK

P3.11.15 Feasibility of Pancreas Transplantation from High PDRI Donors: Implications for Donor Selection
Keizo Kaku, Japan

P3.11.16 So Far, So Good: The Impact of Normothermic Regional Perfusion on Simultaneous Kidney Pancreas Outcomes
Raphael Fischer, USA

P3.11.17 Successful Simultaneous Kidney and Pancreas Transplant from a Donor on Veno-Venous ECMO
Sarah Yager, USA

P3.11.18 Innovating Pancreas Preservation: A Case Series Evaluating Pancreas Pak in Transplant Outcomes
Matthew Witt, USA

P3.11.19 Impact of NIDDK/Rosemont Criteria on Outcomes Following Total Pancreatectomy with Islet Autotransplantation: A Retrospective Cohort Analysis
Carly Darden, USA

P3.11.20 MicroRNA Containing Exosomes Released from Stressed Islets Induce Beta-Cell Differentiation and Proliferation of Adult Islet Progenitor Cells
Carly Darden, USA

P3.11.21 Pancreas Transplant Utilization: Multi-Agent AI-Driven Closed-Loop Strategy for Identifying Barriers and Establishing a Structured Optimization Framework
Oscar Garcia Valencia, USA

P3.11.22 Optimizing Stewardship: Evaluating the Appropriateness of Antimicrobial Prophylaxis in Pancreas Transplant Recipients
David Quan, USA

P3.11.23 Normothermic Regional Perfusion in DCD Pancreas Transplant, Single Center Experience
Jon Odorico, USA

P3.11.24 Robotic-Assisted Simultaneous Kidney-Pancreas Transplant without Hand Assistance
Armando Salim Munoz Abraham, USA

P3.11.25 Preventing Mycosis After Pancreas Transplantation: The Role of Microbiological Screening and Prophylactic Therapy
Kodai Shingaki, Japan

P3.11.26 Impact of Donor Substance Use on Outcomes Following Pancreas Transplantation
Sarah Huber, USA

P3.11.27 Surgical Opioid Avoidance Protocol in Pancreas Transplant Recipients
Jamie Benken, USA

P3.11.29 Surface Modification of Islets with Bissulfosuccinimidyl Suberate (BS3) Dampens Inflammation
Jagan Kalivarathan, USA

P3.11.30 Aptamer Immobilization on Islet Surface: A Strategy to Alleviate Peri-Transplant Inflammation Causing IBMIR
Jagan Kalivarathan, USA

P3.11.31 Prevalence of Insulin Use at One-Year in Kidney Transplant Recipients with Type 2 Diabetes, Not on Insulin at Evaluation: Implications for Simultaneous Kidney Pancreas Eligibility
Lavanya Kodali, USA

P3.11.32 Safety and Efficacy of Belatacept in Pancreas Transplantation: A Case Series
Giuseppe Orlando, USA

P3.11.33 The Comparative Effectiveness of Rabbit Anti-Thymocyte Globulin vs. Basiliximab in Simultaneous Kidney-Pancreas Transplantation: A Target Trial Emulation
Christie Rampersad, Canada

P3.11.34 Pancreas Graft Failure in Simultaneous Kidney-Pancreas Transplantation: Epidemiology, Mortality, and Kidney Graft Outcomes
Christie Rampersad, Canada

P3.11.35 Achieving Excellence in Simultaneous Pancreas-Kidney Transplantation: A Single-Center Analysis
Alfonso Santos, USA

P3.11.37 Effects of Modified Splenic Arteriovenous Fistula Formation at the Tail of the Transplanted Pancreas on Thrombosis Prevention in Simultaneous Pancreas-Kidney Transplantation
Jiqiu Wen, China

P3.11.38 Should Robotic Simultaneous Pancreas-Kidney Transplantation Become the New Standard for Type 2 Diabetes and Obesity? A Single-Center Retrospective Analysis
Elif Kortan, USA

P3.11.39 Outcomes of Simultaneous Kidney and Pancreas Transplantation in Patients with Type 2 Diabetes Mellitus: A Single-Center Experience
Joe Habbouche, USA

P3.11.40 Optimizing Immunosuppression for Beta Cell Replacement: Efficacy and Tolerability of Belatacept with Low-Dose Tacrolimus
Nicole Wojcik, USA

P3.11.43 Optimizing Human Islet Isolation: Insights from Donor and Isolation Procedural Factors
Qin Yang, USA

P3.11.44 Retransplantation of the Pancreas for Recurrence of Autoimmunity After Kidney-Pancreas Transplantation
George Burke, USA

P3.11.47 Diabetes Technology Utilization Amongst Pancreas Transplant Recipients
Jasmine Birch, USA

P3.14
Topic: Public Policy

P3.14.1 US Trends in Procurement of Solid Organs Intended for Research
Shalmali Dharmadhikari, India

P3.14.2 Barriers to Expanding Living Donor Paired Exchange in the USA: A Delphi Survey of Operational, Financial and Ethical Challenges
Krista Lentine, USA

P3.14.3 Financial Assistance for Living Liver Donors: Variation in Donor, Recipient, and Center Characteristics in the USA
Amit Mathur, USA

P3.14.4 Impact of the Simultaneous Heart Kidney (SHK) and Simultaneous Lung Kidney (SLuK) Eligibility Criteria and Kidney After Thoracic Safety Net Policies
Kelsi Lindblad, USA

P3.14.5 Determining the Carbon Footprint of Travel for Organ Procurement in Atlantic Canada
Felix Leathead, Canada

General Information

Access/Security

All delegates and participants will receive a name badge, available for pickup at the WTC 2025 Registration Desk, located on the Moscone South Lobby Foyer. Please wear your badge visibly at all times, as it grants access to all Plenary and Concurrent sessions, the Exhibit Hall, and Social Events. Entry to congress spaces is not permitted without a badge. A USD 60.00 fee applies for reprints of lost or misplaced badges.

Official Language

The official language of the WTC 2025 Congress is English. All sessions will be conducted in English.

Exhibit & Poster Hall

Moscone South – Exhibit Hall AB

Saturday,	**August 2**	5:30 PM - 7:00 PM (Welcome Reception)
Sunday,	**August 3**	9:30 AM - 4:30 PM 3:30 PM - 4:30 PM (Poster & DEI Reception)
Monday,	**August 4**	9:30 AM - 4:30 PM 3:30 PM - 4:30 PM (Poster Reception)
Tuesday,	**August 5**	9:30 AM - 4:30 PM 3:30 PM - 4:30 PM (Poster Reception)

Luggage Check – August 5 & 6

Moscone South – Foyer

WTC 2025 will be offering a complimentary luggage check service at the Moscone Convention Center on the last 2 days of the congress to all registered delegates.

Tuesday,	**August 5**	6:30 AM - 6:00 PM
Wednesday,	**August 6**	6:30 AM - 3:00 PM

General Information

Speaker Ready Room

Moscone South – Room 101

Friday,	**August 1**	8:00 AM - 5:00 PM
Saturday,	**August 2**	7:00 AM - 5:00 PM
Sunday,	**August 3**	7:00 AM - 5:00 PM
Monday,	**August 4**	7:00 AM - 5:00 PM
Tuesday,	**August 5**	7:00 AM - 5:00 PM
Wednesday,	**August 6**	7:00 AM - 11:00 AM

Lost Property

Please report any lost or unattended items immediately to the WTC 2025 Registration Desk. Should you lose anything while at the WTC 2025 Congress, please enquire at the Registration Desk where any recovered lost property will be held. At the end of the conference, all unclaimed lost and found items will be given to The Moscone Convention Center.

Photography

An official photographer will be present during the Congress. By registering for the WTC 2025 Congress, you agree your image may be taken. Imagery taken may be used for marketing purposes for future WTC Congresses and Events.

Refreshment & Lunch Breaks

Moscone South – Exhibit Hall AB

August 3 – 6

AM Coffee & Tea Break 9:30 AM - 10:00 AM

General Lunch Break 12:45 PM - 2:15 PM

Lunch is not provided by the WTC 2025 Congress.

Lunch will be provided by the sponsors of the Industry Supported Symposia for attendees of their symposia. (Seating and meals are available on a first-come, first-served basis.)

PM Breaks will take place during Poster Receptions 3:30 PM - 4:30 PM

General Information

Registration Desk

Moscone South – Foyer

Saturday,	**August 2**	7:30 AM - 6:30 PM
Sunday,	**August 3**	7:00 AM - 5:00 PM
Monday,	**August 4**	7:00 AM - 5:00 PM
Tuesday,	**August 5**	7:00 AM - 5:00 PM
Wednesday,	**August 6**	7:00 AM - 12:00 PM

WiFi

Wifi is available complimentary thanks to

TransMedics®

Network: WTC 2025
Password: TransMedics2025

Disclaimer

All reasonable endeavors will be made to hold the WTC 2025 Congress and to present the program as scheduled under circumstances which ensure the comfort and safety of the Congress Participants. However, the WTC and its branches, and their respective directors, officers, employees, representatives or agents, shall not be liable in any manner whatsoever to any person as a result of the cancellation of the Congress or any of the arrangements, programs or events connected therewith; nor shall any of the foregoing entities or persons be liable in any manner whatsoever for any loss, injury, damage or inconvenience which may be suffered by any person while travelling to or from, or during such person's presence in, San Francisco in connection with the Congress. Participants are advised to consider procuring their own insurance against any such occurrences.

ATC2026

AMERICAN TRANSPLANT CONGRESS

BOSTON, MA • JUNE 20–24

Breakthroughs Begin Here

Visit the ATC Team in Booth #601 to ignite your next "aha!" moment